Every score derived exclusively from peer-reviewed clinical trials and credible research institutions. 100% independent and non-profit.
A personalized supplement stack ranked by the same evidence database behind 733 supplement scores — tailored to your age, goals, and health.
No spam. Unsubscribe anytime.
We'll build a personalized supplement plan based on your answers
We built SupplementScore to fix the most broken part of wellness: the gap between what a label says and what the clinical evidence actually shows. Every score traces back to peer-reviewed research. No sponsorships, no affiliates, no ads.
Every supplement is classified by the strength and consistency of its human clinical data.
Four steps from the literature to a score you can trust.
Priority for systematic reviews, meta-analyses, and Cochrane reviews. Individual RCTs used when no meta-analysis exists. Industry-funded studies flagged and weighted lower.
Each study graded for blinding, allocation concealment, sample size, and statistical power. Effect sizes and confidence intervals recorded for every key outcome.
Rated across 6 dimensions: Efficacy, Safety, Research depth, Onset time, Cost-effectiveness, and Drug interactions. Efficacy weighted highest. Only human clinical data.
Scores evolve as new evidence is published. AI-assisted synthesis cross-referenced against Cochrane, PubMed, NIH, and WHO. Content reviewed and updated regularly.
Four stages toward hyper-personalized supplement recommendations.
The right supplement can genuinely change someone's quality of life. Better sleep. Less joint pain. More energy. Reduced anxiety. For people managing health conditions, nutrient deficiencies, or simply trying to age well, the difference between the right supplement and the wrong one can be profound. But finding honest information is nearly impossible — the supplement industry generates over $50 billion a year, and most of what you read online is written by someone trying to sell you something.
We built SupplementScore to fix that. Our goal is to use the latest advances in AI and machine learning to curate precise, personalized supplement regimens based on each individual's blood work, lab results, and eventually DNA.
We don't sell supplements. We don't accept sponsorships. We don't run affiliate links. Our goal is to keep SupplementScore free and transparent for everyone to use.
SupplementScore is an educational reference, not a medical device — not reviewed by the FDA, Health Canada, or any regulatory body. Scores reflect group-level clinical data; individual responses vary by genetics, diet, health status, medications, and pre-existing conditions. AI assists our content review and may miss nuances a clinician would catch — independently verify anything you act on. Supplement quality varies dramatically between brands; we do not test, certify, or endorse specific products. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and nothing here substitutes for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing supplements — especially if you are pregnant, nursing, or on medications. In a medical emergency, contact your local emergency services immediately.
Evidence-based reviews, safety alerts, and deep dives into supplement science. Every article is checked against the peer-reviewed literature — no sponsors, no affiliate links, no hype.
More high-quality trial evidence than almost any supplement on the market — yet wellness culture ignores it. LDL down 15 mg/dL. HbA1c down 0.4%. FDA-approved heart health claim since 1998. Here is why nobody is talking about it.
Berberine does lower blood sugar — but comparing it to GLP-1 receptor agonists misrepresents both the mechanism and the evidence. Here's what a 500mg dose actually does, and what it doesn't.
The April 2026 CDC MMWR reviewed 1,955 kava calls to U.S. poison centers. Serious outcomes peaked at 39% in 2024. Kratom co-use is driving the worst cases.
Magnesium, L-theanine, and melatonin timed correctly can meaningfully improve sleep quality — if you take them right. The trial data says timing matters more than dose.
Your liver and kidneys already detoxify you. No supplement can improve on millions of years of evolution — but the industry banks on you not knowing that.
Two new meta-analyses (Prokopidis 2023, Xu 2024) confirm creatine improves memory and cognition in healthy adults — not just athletes. The effect is real, but smaller than the marketing claims.
An estimated 48% of Americans don't get enough magnesium. Here's how to tell if you're deficient, and which form of supplement actually works for you.
High-dose turmeric extracts have triggered over 30 cases of severe hepatotoxicity. We break down who's at risk, what dose is safe, and which forms to avoid.
Optimal dosing, when to test, what deficiency looks like, and why "more is better" thinking can backfire. The VITAL trial changed what we thought we knew.
NMN and NR are sold as anti-aging miracles. The mouse data is compelling — but human trials tell a much more nuanced story. Here's what's real.
From iron and vitamin D to beetroot juice and caffeine — what the evidence actually supports for endurance performance and recovery. Legal ergogenic aids only.
A 25% reduction in cardiovascular events from 4g daily EPA — here's why the dose and purified form matter more than most fish oil capsules suggest.
A systematic review of eight randomized trials shows consistent cortisol reduction — but the benefit depends on the extract, dose, and how long you take it.
The problem isn't probiotics — it's that most brands don't contain what they advertise. Here are the three strains with real clinical evidence, and which products pass lab testing.
The skin and joint claims have more marketing than evidence behind them. Here's what hydrolyzed collagen actually does — and a cheaper alternative that works just as well.
An estimated 1 in 5 women of reproductive age are iron deficient — and the fatigue is often misdiagnosed as stress or burnout. Here's how to test, treat, and avoid the gut side effects.
The Cochrane review found zinc lozenges cut cold duration by about a day — but only if you take them fast enough, in the right form, and at a high enough dose. The details matter.
Wheat germ, aged cheese, and natto are the dietary heavyweights for spermidine. The 2016 mouse lifespan finding drove the entire supplement category; the 2025 human trials are still short, small, and focused on intermediate markers.
Published case series tie high-dose EGCG extracts to acute liver injury and transplant. Brewed green tea is safe — but the concentrated capsules are a very different story.
Electrolyte mixes have gone mainstream. We compare sodium-to-sugar ratios, cost per serving, and whether you can make the same thing at home for a fraction of the price.
The only magnesium form proven to cross the blood-brain barrier in animal studies. But do the human trials actually back up the cognitive claims? We dig into all four studies.
The supplement industry generates over $177 billion per year globally, yet the vast majority of products on store shelves have weak, mixed, or nonexistent evidence behind them. If you're just getting started and want to spend your money on things that actually work, this guide cuts through the noise. We looked at the totality of the evidence — meta-analyses, systematic reviews, randomized controlled trials — and identified the 12 supplements with the strongest and most consistent support for healthy adults.
Before the list, a few ground rules that will serve you better than any single supplement.
The first thing to check on any supplement label is the "Supplement Facts" panel, not the marketing copy on the front. Look for the actual form of the ingredient — not just "magnesium" but whether it's magnesium glycinate, magnesium oxide, or magnesium citrate. The form determines how much of the dose your body actually absorbs, which can vary from under 4% (oxide) to over 80% (glycinate). The same principle applies across most mineral supplements.
Third-party testing seals matter more than claims. Look for USP Verified, NSF Certified for Sport, or Informed Sport logos. These verify that what's on the label is what's in the bottle, in the correct doses, without contamination. A 2023 analysis of protein powders found that 40% of tested products had label inaccuracies — often lower protein content than claimed. Supplements are not FDA-pre-approved; manufacturers self-certify safety and accuracy unless tested independently.
Avoid proprietary blends. When a label says "Proprietary Blend — 1,200 mg" and lists seven ingredients underneath, you have no idea if each ingredient is at a clinically relevant dose or just a trace amount included for marketing. This practice is common in pre-workout and "nootropic" products.
1. Creatine Monohydrate — The single most studied sports supplement in existence, with dozens of published meta-analyses. At 3–5 g/day, creatine reliably raises muscle phosphocreatine stores, which improves strength, power output, and recovery across a wide range of sports. Newer evidence also supports cognitive benefits: a 2023 meta-analysis by Prokopidis and colleagues in Nutrition Reviews and a 2024 meta-analysis by Xu and colleagues in Frontiers in Nutrition both found meaningful improvements in memory and cognition, especially during sleep deprivation or mental fatigue and in older adults. The monohydrate form is the most tested and the cheapest — no need to pay extra for creatine HCl, ethyl ester, or buffered forms.
2. Omega-3 Fatty Acids (EPA/DHA) — The evidence for omega-3s in cardiovascular health is mixed but substantial. The REDUCE-IT trial (2018) showed 4 g/day of EPA reduced major cardiovascular events by 25% in high-risk patients. For general inflammation, triglyceride reduction, and joint comfort, the evidence is consistently positive across hundreds of trials. Aim for at least 1 g/day of combined EPA+DHA. Fish oil is the most cost-effective source; algae-based supplements work for vegetarians and contain the same EPA/DHA molecules.
3. Vitamin D3 + K2 — Over 40% of Americans are deficient in vitamin D, and the downstream effects touch immune function, bone density, mood regulation, and cardiovascular health. A 2022 meta-analysis in The Lancet Diabetes & Endocrinology found that supplementation in deficient adults meaningfully reduced all-cause mortality. The K2 pairing matters: vitamin D drives calcium into the bloodstream, and K2 (specifically MK-7 form) directs it to bones rather than arteries. Target 1,000–2,000 IU of D3 daily unless bloodwork suggests you need more.
4. Magnesium Glycinate or Malate — Magnesium is involved in over 300 enzymatic reactions in the body. Roughly 48% of Americans don't meet the recommended daily intake. Deficiency is associated with poor sleep quality, elevated anxiety, muscle cramps, and elevated blood pressure. Glycinate and malate forms have superior bioavailability compared to oxide, which is mostly used as a laxative. Typical effective doses range from 200–400 mg elemental magnesium daily.
5. Zinc — Zinc is critical for immune function, testosterone production, wound healing, and taste/smell. Athletes and people who sweat heavily are especially prone to depletion. A Cochrane review found zinc lozenges meaningfully shortened the duration of the common cold when started within 24 hours of symptom onset. Zinc picolinate and citrate absorb better than zinc oxide. Keep doses under 40 mg/day long-term, as excess zinc depletes copper.
6. L-Theanine — An amino acid found in green tea, L-theanine reliably promotes relaxed alertness. At 100–200 mg, it dampens excess nervous system activation without causing sedation, and the combination with caffeine (in a roughly 2:1 theanine:caffeine ratio) is one of the most robustly studied cognitive enhancer combinations in humans. Multiple RCTs confirm improvements in attention, reaction time, and reduction of caffeine-induced jitteriness.
7. Vitamin B12 (Methylcobalamin) — B12 is essential for nerve function and red blood cell formation. Vegans and vegetarians are at near-universal risk of deficiency since B12 is found almost exclusively in animal products. The methylcobalamin form is slightly better retained than cyanocobalamin in some populations. Sublingual absorption is effective and bypasses any potential issues with intrinsic factor in the gut.
8. Iron (for those deficient) — Iron supplementation is only recommended for people with confirmed deficiency or insufficiency via bloodwork. For those who are deficient — particularly menstruating women and endurance athletes — iron is among the most impactful supplements available, correcting fatigue, poor concentration, and reduced exercise performance. Do not supplement iron without testing, as excess iron is toxic and associated with oxidative stress.
9. Ashwagandha (KSM-66 or Sensoril extract) — Adaptogenic herbs are a mixed bag, but ashwagandha has an unusually clean evidence base. At 300–600 mg/day of a standardized extract, multiple RCTs show reductions in cortisol, perceived stress, and anxiety scores. A 2019 RCT by Langade and colleagues in Cureus found significant improvements in sleep quality and morning alertness at 300 mg twice daily over 10 weeks. A 2019 RCT by Lopresti and colleagues in Medicine separately documented reductions in stress and morning cortisol. Rare but real cases of drug-induced liver injury have been reported with ashwagandha, so short cycles (8–12 weeks on, 4 weeks off) and caution at higher doses are reasonable.
10. Probiotics (strain-specific) — "Probiotics" is not a single thing — it's a category of thousands of bacterial strains with wildly different effects. The strains with the strongest clinical evidence are Lactobacillus rhamnosus GG for antibiotic-associated diarrhea, Saccharomyces boulardii for traveler's diarrhea, and Bifidobacterium longum for IBS-related constipation. Unless a specific strain is matched to a specific use case, most probiotic supplements have unclear benefits.
11. Fiber (Psyllium Husk) — Often overlooked as a supplement, psyllium husk has exceptional evidence for lowering LDL cholesterol, improving glycemic control, and supporting digestive regularity. At 5–10 g/day with adequate water, effects on LDL are comparable to low-dose statins in some studies. It's cheap, widely available, and well-tolerated by most people.
12. Iodine — Iodine deficiency is the leading preventable cause of brain damage globally, and low-grade insufficiency is more common in Western countries than most people realize, particularly among those who don't consume dairy or iodized salt. The thyroid requires iodine to produce thyroid hormones that regulate metabolism, mood, and cognition. Most multivitamins contain 150 mcg, which is the RDA; kelp supplements are an alternative but can be wildly inconsistent in dose.
Steer clear of supplements that rely on animal studies with no human trial replication, products with only celebrity endorsements or before/after photos, and anything making disease treatment claims (which are illegal for supplements). "Testosterone boosters" containing undisclosed active compounds, "fat burner" stacks with stimulant cocktails, and most "anti-aging" formulas fall into this category. The more elaborate the marketing, the weaker the evidence tends to be.
Poor sleep is one of the most underestimated drivers of poor health outcomes. Chronic sleep restriction — even mild, like getting 6 hours instead of 8 — causes measurable impairments in immune function, glucose metabolism, cardiovascular risk markers, and cognitive performance. Yet the most commonly used sleep aids are either habit-forming (benzodiazepines, Z-drugs) or too blunt (diphenhydramine, the antihistamine in most OTC sleep products, which suppresses deep sleep stages).
A thoughtful stack of evidence-backed supplements can meaningfully improve sleep quality without dependence, next-day grogginess, or the structural sleep disruption caused by pharmaceuticals. Here is what the science supports, how to time each compound, and how to cycle the stack to preserve effectiveness.
Before reaching for supplements, it helps to know what you're optimizing. A healthy night's sleep cycles through light sleep, slow-wave sleep (SWS, also called deep sleep), and REM sleep roughly every 90 minutes. SWS is when the body does most of its physical repair, immune consolidation, and glymphatic brain clearance. REM sleep handles emotional processing and memory consolidation. Most sleep medications suppress either SWS, REM, or both. The goal of the stack below is to reduce sleep onset latency (time to fall asleep), improve SWS depth, and avoid suppressing any sleep stage.
Magnesium is involved in the regulation of GABA receptors — the same inhibitory receptors that benzodiazepines target, but through a gentler, physiological pathway. Adequate magnesium helps dampen excess neurological excitation that delays sleep onset. In a double-blind RCT of elderly adults published in the Journal of Research in Medical Sciences (2012), magnesium supplementation significantly improved insomnia severity, sleep efficiency, sleep time, and early morning awakening compared to placebo. A 2021 umbrella review in the journal Nutrients confirmed these findings across multiple populations.
Dose and timing: 300–400 mg of elemental magnesium (as glycinate or threonate) taken 30–60 minutes before bed. Glycinate is well-tolerated and less likely to cause digestive upset than citrate or malate at these doses. Magnesium L-threonate (a newer form) has some preliminary evidence for crossing the blood-brain barrier more effectively, but costs significantly more and the extra benefit is unproven.
L-theanine, an amino acid isolated from tea leaves, increases alpha-wave activity in the brain — the pattern associated with relaxed wakefulness and the mental state just before natural sleep onset. Unlike sedatives, it does not force sedation; it facilitates the natural transition into sleep by reducing anxiety and ruminative thinking without blunting cognitive function.
A 2019 double-blind RCT published in Nutrients (Hidese et al.) randomized 30 healthy adults to 200 mg L-theanine or placebo for four weeks. The theanine group showed significant reductions in sleep latency, improved sleep quality scores on validated questionnaires, and reduced daytime sleepiness without any reported adverse effects. Another RCT in boys with ADHD found similar sleep quality improvements at the same dose.
Dose and timing: 100–200 mg taken 30–45 minutes before bed. This is a well-tolerated compound with no known dependency potential. It can be used every night without cycling.
Glycine is a non-essential amino acid that plays a dual role in sleep: it acts as an inhibitory neurotransmitter in the central nervous system and also lowers core body temperature — a critical signal the brain uses to initiate and maintain deep sleep. Core body temperature must drop roughly 1–1.5°C for sleep onset and SWS maintenance. Glycine appears to facilitate this process through peripheral vasodilation.
A series of Japanese clinical trials (Bannai et al., 2012; Sleep and Biological Rhythms, and a follow-up in Frontiers in Neurology) found that 3 g of glycine taken before bed reduced time to first reach slow-wave sleep, improved performance on next-day cognitive tasks, and reduced self-reported fatigue after sleep restriction. The effect was notable enough that participants were performing comparably to rested controls despite restricted sleep schedules.
Dose and timing: 3 g taken 30 minutes before bed. Glycine is cheap, tastes sweet, and mixes easily in water. There is no known dependency risk, and it appears safe for nightly use. People with existing renal issues should check with a physician, as glycine is metabolized in part by the kidneys.
Melatonin is perhaps the most misused supplement in the category. Typical U.S. pharmacy doses run 5–10 mg, yet the physiological rise of melatonin at natural sleep onset is approximately 0.1–0.3 mg. Multiple studies confirm that 0.5 mg is as effective as 5 mg for reducing sleep latency, and that high doses can disrupt natural melatonin receptor sensitivity over time, potentially worsening sleep quality with chronic use.
The real use case for melatonin is circadian rhythm correction, not sedation. It's ideal for: jet lag (taking low-dose melatonin at the destination's nighttime accelerates circadian re-entrainment), shift work, or delayed sleep phase disorder where the body's clock is shifted late. It is not particularly effective for maintaining sleep once you're asleep, which is why many people find it works for falling asleep but doesn't prevent 3am waking.
Dose and timing: 0.3–0.5 mg taken 60–90 minutes before desired sleep time for circadian correction. If using for travel, take it at the destination's 10 pm for two to three days. Avoid doses above 1 mg for routine nightly use.
The staggered timing allows melatonin to begin signaling the circadian clock before the other compounds take effect. Magnesium takes slightly longer to have a calming effect than the amino acids, so it goes in earlier.
Magnesium, glycine, and L-theanine all have no known tolerance issues and can be used nightly. Melatonin should be reserved for periods of genuine circadian disruption rather than used nightly for sedation — two to three weeks on, two to three weeks off is a sensible pattern if you feel you need ongoing support. If you're using the stack for more than 8 weeks without improvement, the problem is likely behavioral (inconsistent sleep/wake schedule, light exposure, temperature) rather than nutritional, and no supplement will fix that.
Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs) suppresses REM sleep, leaves a 6–8 hour antihistamine hangover, and builds tolerance in as few as three days. Valerian root has extremely inconsistent evidence — some RCTs show modest benefit, others show none, and standardization of active compounds across products is poor. Passionflower and chamomile are pleasant and have mild anxiolytic effects but are unlikely to meaningfully move clinical sleep metrics on their own.
Walk into any health food store or scroll through wellness accounts online, and you'll be told your body is full of "toxins" — accumulated waste that your organs can't handle on their own. The solution, you'll be told, is a $49.99 cleanse kit, a juice fast, or a daily capsule of something with "detox" in the name. The global detox supplement market was valued at approximately $3.2 billion in 2024 and is projected to grow.
There's just one problem: the concept is physiologically incoherent, the products don't work, and the word "toxin" in a supplement context is almost always scientifically meaningless.
The word "toxin" has a precise meaning in biology: it refers to a poisonous substance produced by a living organism (bacteria, plants, animals). Botulinum toxin is a toxin. Tetrodotoxin from puffer fish is a toxin. What detox supplement marketers mean by "toxins" is something far vaguer — usually a mix of metabolic waste products, environmental pollutants, heavy metals, or "bad energy," depending on how unscientific the marketing gets.
Here is what your body actually does with genuine metabolic waste and environmental compounds: The liver contains two phases of detoxification enzymes (Phase I cytochrome P450 enzymes and Phase II conjugation enzymes) that transform fat-soluble compounds into water-soluble ones so they can be excreted. The kidneys then filter about 200 liters of blood per day, removing urea, creatinine, drugs, and their metabolites. The lungs exhale carbon dioxide — a genuine metabolic waste product — with every breath. The lymphatic system moves waste from tissues to nodes for processing. Your skin secretes minor amounts of metabolic byproducts through sweat.
This is a sophisticated, redundant, constantly running system that took hundreds of millions of years to evolve. No tea, no capsule, and no juice fast improves it.
A 2015 systematic review in the Journal of Human Nutrition and Dietetics searched for clinical evidence supporting commercial detox diets and products. The researchers found no convincing evidence that any marketed "detox" regimen reduced concentrations of environmental pollutants, heavy metals, or metabolic waste products in the body beyond what occurs naturally. They concluded that "the term 'detox' is used in a commercial context to imply the elimination of toxic or harmful substances from the body... despite the absence of evidence to suggest that any such accumulation occurs in healthy individuals."
The European Food Safety Authority (EFSA) has rejected health claims for dozens of "detox" and "cleanse" products submitted for regulatory review. When manufacturers have been required to define exactly which toxins their product removes and provide clinical measurement of that removal, they have consistently been unable to do so.
In the United States, the FDA has issued warning letters to multiple companies for making illegal disease claims under the guise of "detox" language. Selling a product as treating or preventing a specific disease requires drug approval. Framing those same claims as "detox" became a regulatory workaround — but the FDA has been increasingly aggressive about products that imply treatment while maintaining supplement classification.
When you look at the actual ingredients in most detox supplements, they fall into a few categories:
Medical detoxification is a real thing, but it refers to specific clinical scenarios: alcohol withdrawal management (which can be life-threatening without supervision), opioid detox protocols, chelation therapy for confirmed heavy metal poisoning (lead, mercury, arsenic — diagnosed by blood tests, administered intravenously under medical supervision), and dialysis for kidney failure patients. None of these happen in a capsule you buy at a pharmacy. All require diagnosis and clinical oversight.
If you have genuine concerns about heavy metal exposure — you work with industrial chemicals, live near a Superfund site, have a history of eating large predatory fish frequently — blood and urine tests can actually measure metal levels. If they're elevated, a physician can prescribe an appropriate chelation protocol. No supplement company will tell you to get tested first because their business depends on you believing you have a problem they can solve.
Beyond the financial cost, detox culture carries real risks. It normalizes the idea that the body is fundamentally inadequate and needs constant external cleansing — which is false and psychologically damaging in the context of eating behavior. Many "detox" programs are thinly disguised caloric restriction regimens that produce temporary weight loss (mostly water and glycogen depletion), which reverses within days of returning to normal eating. The more concerning risk is people with actual symptoms — liver disease, kidney dysfunction, heavy metal exposure — being reassured by a supplement that they're "cleansing" while delaying appropriate medical care.
Your liver doesn't need a supplement. It needs you to limit alcohol, maintain a healthy weight, avoid unnecessary medications, and treat it like the extraordinary organ it actually is.
Kava (Piper methysticum) is a plant from the Pacific Islands. For thousands of years, Pacific communities have ground its roots and steeped them in cold water to make a calming ceremonial drink. The active compounds, called kavalactones, reduce anxiety and produce a mild euphoria. Traditional root-only preparations have a long record of apparently safe use.
Over the last decade, kava has moved into Western supplement culture as an anxiety remedy and an alcohol alternative. Kava bars have opened across the United States, and capsules and concentrated extracts are sold in wellness shops and online. The problem: the Western supplement market has industrialized and concentrated a substance whose safety depends heavily on how it is prepared. In April 2026, the CDC published a detailed look at what has happened since — and the numbers are striking.
On April 3, 2026, the CDC's Morbidity and Mortality Weekly Report (MMWR) published an analysis of kava-related calls to America's Poison Centers from January 2000 through June 2025 (Towers et al., MMWR 75(12);2026). The authors reviewed 1,955 kava exposure calls across 25+ years. The headline finding: the share of calls rated as a "serious medical outcome" rose from about 12% in 2000 to a peak of 39% in 2024, then 32% in the first half of 2025. A "serious medical outcome" means the person needed medical treatment or had notable clinical effects — not that they died.
Call volume itself has climbed sharply in recent years, likely because kava bars and concentrated extracts have grown popular. A second pattern in the data: many of the worst calls involved co-use with kratom. In the first half of 2025, roughly 30% of kava calls also involved kratom, up from near zero in earlier years. Kratom has its own hepatotoxicity signal, and the combination appears to drive a disproportionate share of serious outcomes.
Importantly, the MMWR dataset did not identify any cases of acute liver failure from kava alone. Elevated liver enzymes — an early warning sign of liver stress — appeared in about 1.7% of kava-only calls and about 6.3% of kava-plus-kratom calls. That is higher than expected for a "natural" product, but it is different from the transplant-level liver failure cases that made headlines in Europe 20 years ago. Those European cases are real and are discussed below, but they came from a different pattern of use (concentrated extracts, often with other drugs or alcohol) and they are not what the 2026 CDC data describe.
The CDC authors recommended that healthcare providers ask patients directly about kava and kratom use when evaluating unexplained liver enzyme elevations, because patients often do not volunteer supplement use.
Western consumers are often unaware of a key distinction. Traditional kava uses only the root, prepared as a cold-water extraction. The kavalactone dose is modest and fairly consistent, and the process leaves behind certain plant compounds found in the stem, leaves, and peelings that are linked to liver toxicity.
Most Western commercial kava products — capsules, concentrated extracts, and powders marketed as "full-spectrum" — are made differently. Early investigations into kava-associated liver injury in Germany and Switzerland in the early 2000s (which led to temporary bans in several European countries) found that many implicated products mixed "noble" and "tudei" kava varieties, used above-ground plant parts, and concentrated kavalactones well above the levels delivered by traditional drinks.
Flavokavain B, a chalcone compound present in kava leaves and stem bark but at very low levels in root preparations, has been identified in lab and animal studies as a likely contributor to liver toxicity. It can trigger programmed cell death in liver cells at concentrations reachable with concentrated extracts. Traditional root-only preparations contain very little flavokavain B; whole-plant or above-ground-part extracts contain substantially more.
The result: people buying kava supplements online cannot usually tell whether a product uses root-only noble kava at traditional strength, or a concentrated whole-plant extract that may carry a very different risk. Most labels do not disclose this clearly.
Certain groups face sharply higher risk from kava and should avoid it:
Genetic variation in CYP2D6, a liver enzyme involved in kavalactone metabolism, may help explain why some people develop liver injury at doses others tolerate. That individual variability makes population-level risk hard to predict.
Germany, France, Switzerland, and Canada issued bans or strong warnings on kava products in the early 2000s following reports of liver failure. Germany lifted its ban in 2014 after its Federal Institute for Risk Assessment (BfR) concluded that the risk was tied mainly to non-traditional extracts, and that water-based root extracts had a different risk profile. The UK Medicines and Healthcare products Regulatory Agency (MHRA) still maintains restrictive guidance.
The U.S. FDA issued a consumer advisory in 2002 noting rare but severe liver injury. The agency has not banned kava but continues to monitor adverse events through its MedWatch system. The 2026 CDC MMWR escalates official concern given the growth of kava bars, concentrated extracts, and kratom co-use.
If you use kava supplements or go to kava bars, the most important steps are: avoid daily use, avoid combining with alcohol, kratom, or sedative medications without medical guidance, and watch for early signs of liver stress — unusual fatigue, nausea, yellowing of skin or eyes (jaundice), dark urine, or pain in the right upper abdomen. If any of those show up, stop use and see a doctor. If you use kava regularly, ask your doctor about checking liver enzymes (AST, ALT, bilirubin).
Kava's anxiety-reducing effect is real and the plant carries a cultural legitimacy that deserves respect. But the Western supplement market has concentrated and industrialized a substance whose safety depends on preparation method, dose, and what else you are taking — and it has done so without enough warning to the consumer.
Creatine monohydrate has been a fixture in sports supplements for decades. In the last five years, research has expanded well beyond muscle — into the brain. Creatine is not just a fuel source for muscle contractions. It also plays an important role in brain energy metabolism, where phosphocreatine (a stored form of energy) helps keep ATP (the cell's main energy currency) available during demanding mental tasks. Two recent meta-analyses — Prokopidis and colleagues in Nutrition Reviews (2023) and Xu and colleagues in Frontiers in Nutrition (2024) — have pulled together the human trial data on creatine and cognition. The findings have implications for a much wider group than the typical creatine user.
The brain is an expensive organ. It uses about 20% of the body's energy while making up only 2% of body weight. Neurons rely on ATP for almost every function — running ion pumps, sending signals across synapses, making neurotransmitters, and general cellular housekeeping. During intense mental work — hard problem-solving, sustained attention, or holding several items in mind at once — local ATP demand can spike fast. The creatine-phosphocreatine system helps meet that demand faster than the body's slower main energy pathway (oxidative phosphorylation) can on its own.
Unlike muscle, the brain makes some of its own creatine using two enzymes called AGAT and GAMT. But that internal supply is limited, and supplementation can still push brain creatine higher. Magnetic resonance spectroscopy (an MRI-based technique that can measure brain chemistry) has shown that taking creatine raises brain creatine levels by about 5–10% in healthy adults. The increase is larger in vegetarians and vegans, who get less creatine from their diet to begin with.
The 2023 Prokopidis meta-analysis pooled 16 randomized controlled trials (492 healthy participants) testing creatine on memory. It found a small but statistically significant improvement in memory performance with creatine, with a standardized mean difference (SMD — a standard effect-size measure) of about 0.30. Older adults aged roughly 66–76 showed larger effects than younger adults. The 2024 Xu meta-analysis added more trials focused on general cognition and found similar results, with effects most consistent in older adults and in conditions of mental stress.
The classic physical loading protocol (20 g/day for 5 days) was not meaningfully better than a maintenance dose (3–5 g/day) for cognitive outcomes. Tissue saturation builds more slowly on the lower dose, but reaches similar levels within about 4 weeks.
Beyond short-term cognition, preclinical and early human evidence suggests creatine may help protect neurons against damage from traumatic brain injury (TBI), loss of blood flow (ischemia), and certain degenerative processes. The proposed mechanisms include:
In children with traumatic brain injury, a small open-label study by Sakellaris and colleagues (2006 and 2008 follow-up) reported that creatine supplementation (0.4 g/kg/day for 6 months) shortened the duration of post-traumatic headache, dizziness, and fatigue compared with standard care. Larger controlled trials in adults are still underway. In Parkinson's disease, the NIH-funded Phase 3 NET-PD LS-1 trial (Kieburtz and colleagues, 2015) found creatine at 10 g/day safe and well-tolerated but did not slow clinical progression. Some researchers have since argued the dose may have been too low for a large-body, long-half-life pool like the brain.
A less expected finding is that creatine may boost the effect of antidepressants. A 2012 RCT by Lyoo and colleagues in the American Journal of Psychiatry reported that adding 5 g/day of creatine to SSRI therapy in women with major depressive disorder produced a faster and larger response than SSRI alone. The proposed mechanism involves creatine fixing an energy shortfall in the prefrontal cortex seen in depression on phosphorus-31 MRS imaging.
A 2023 narrative review in Translational Psychiatry concluded that the evidence for creatine as an antidepressant add-on is preliminary but promising, with particular interest in treatment-resistant cases. Larger trials are still needed before clinical practice changes, but the signal adds to the picture of creatine as neurologically active, not just a muscle supplement.
Creatine monohydrate has an exceptional long-term safety profile. Over three decades of research have not shown kidney damage in healthy people at standard doses. A common source of confusion is serum creatinine — a breakdown product of creatine used to estimate kidney function — which does tend to rise slightly on blood panels when someone takes creatine. That rise reflects the extra creatine in the body, not kidney injury. Actual kidney function markers (such as estimated GFR from cystatin C) remain normal, as shown in systematic reviews including Dolan and colleagues in Nutrition Reviews (2019).
Few supplement categories have generated more excitement — or more investor capital — in the last decade than nicotinamide mononucleotide (NMN) and its precursors. Backed by compelling mouse data, an elegant aging theory, and high-profile scientific advocates, NMN became the poster child for the longevity supplement movement. Bottles sell for $60–$120 per month, with marketing that implies they are essentially slowing biological aging itself.
After more than a dozen human clinical trials, the picture looks considerably less exciting than the mouse data suggested. Understanding why requires distinguishing between a biomarker and a health outcome — a distinction that matters enormously in medicine and that the supplement industry routinely exploits.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the body, involved in hundreds of metabolic reactions — most critically in mitochondrial energy production, DNA repair, and the activation of sirtuins (a family of proteins implicated in cellular stress resistance and longevity). NAD+ levels decline with age: a 50-year-old may have roughly half the NAD+ of a 20-year-old in certain tissues.
The theory is straightforward: if NAD+ decline contributes to aging, and if NMN (a dietary precursor to NAD+) raises NAD+ levels, then NMN should slow aging-related deterioration. In mice, this logic held up remarkably well. NMN supplementation in aged rodents improved insulin sensitivity, physical endurance, eye function, energy metabolism, muscle wasting, and bone density — essentially reversing multiple age-related phenotypes. Some of the most influential studies came from David Sinclair's lab at Harvard, whose work generated enormous media coverage and public interest.
The problem is that mice are not humans, and a biomarker change is not a health outcome.
As of early 2024, at least 12 published randomized controlled trials in humans have tested NMN or NR (nicotinamide riboside, a closely related NAD+ precursor). The consistent finding across nearly all of them is: yes, oral NMN and NR reliably raise blood NAD+ levels. A typical trial sees whole-blood NAD+ increase 40–100% over baseline within two to four weeks of supplementation at doses of 300–1000 mg/day. The biomarker moves. Definitively and consistently.
What the trials have not demonstrated, in any robust or replicable way, is that this rise in NAD+ translates into meaningful health outcomes:
The fundamental issue is one of the most important lessons in evidence-based medicine: a change in a biomarker is not the same as a change in health. Medical history is littered with cautionary examples. Hormone replacement therapy was adopted based on favorable biomarker changes in cardiovascular risk factors — until large RCTs showed it actually increased cardiovascular events in certain populations. CETP inhibitors raised HDL cholesterol dramatically in trials — and failed to reduce cardiovascular events. Multiple diabetes drugs reduced HbA1c effectively while increasing mortality risk.
NAD+ may be similar. Raising NAD+ in blood or peripheral tissues does not necessarily mean that NAD+ is reaching the tissues where it matters most (the brain, the heart, the liver), because NAD+ itself cannot cross cell membranes — it must be synthesized intracellularly from precursors. Whether supplemental NMN reaches target tissues in meaningful quantities, and whether the cells there can actually use it to improve function, remains genuinely uncertain.
It's also possible that NAD+ decline in aging is a consequence rather than a cause. Aging involves a cascade of interconnected processes; NAD+ levels fall partly because of increased consumption by CD38 (an enzyme dramatically upregulated in aging tissues and chronic inflammation) and PARP enzymes (activated by increasing DNA damage). Supplementing NAD+ precursors without addressing the upstream causes of NAD+ drain may be like refilling a bucket with a hole in the bottom.
David Sinclair's 2019 book "Lifespan" popularized the NAD+ theory for a mass audience and generated enormous commercial interest. Sinclair himself disclosed at the time that he was taking NMN and other supplements and had financial interests in longevity-related companies. Several of the most influential pro-NMN animal studies came from his lab, and some later attracted criticism for reproducibility challenges. This is not to impugn individual researchers — the science of aging is genuinely complex and fast-moving — but the gap between mouse results and media extrapolation was extraordinarily wide and was enthusiastically exploited by a supplement industry that had every financial incentive to do so.
Several prominent aging researchers, including those at the National Institute on Aging, have publicly cautioned that the human evidence does not yet support the commercial claims being made about NMN. A 2023 review in Cell Metabolism noted that while NMN research in preclinical models is legitimately promising, "translating these findings to clinical benefit in humans has proved far more difficult than anticipated."
NMN and NR are likely safe at marketed doses — no serious adverse effects have been reported in trials. This makes the decision to take them personal and financially, not medically, risky. If you want to experiment, the honest assessment is: there is a reasonable theoretical basis, there is consistent evidence that NAD+ levels rise, and there is currently insufficient human evidence that this produces any measurable improvement in aging-related outcomes. You are paying $60–$120/month for a biomarker change whose health significance is unproven.
The things that robustly and repeatedly improve aging-related outcomes in human studies are considerably less glamorous: regular aerobic exercise (the most potent known NAD+ booster, incidentally, through activation of NAMPT), caloric moderation and time-restricted eating, smoking cessation, alcohol reduction, high-quality sleep, and management of chronic inflammatory conditions. None of these require a monthly subscription.
Watch this space. The human trial data is still accumulating, and it is possible that the right dose, the right population, or the right combination of interventions will eventually produce the results the mouse data suggested. But we're not there yet, and the supplement industry priced its products as if we were already.
Omega-3 fatty acids are among the most extensively studied supplements in the world, with a trial database spanning decades and thousands of publications. But the question of which form to take — fish oil, algal oil, or krill oil — generates disproportionate confusion and marketing-driven misinformation. Supplement companies have strong financial incentives to claim their particular form is superior. The actual evidence tells a more nuanced story.
The key is understanding what you're actually trying to get: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), the two long-chain omega-3s with the most clinical evidence. The source — fish, algae, or krill — is largely a delivery vehicle question. What matters is bioavailability, dose, purity, and your individual circumstances.
Conventional fish oil concentrates EPA and DHA from oily fish (anchovies, sardines, mackerel) through molecular distillation. It is the most studied form by an enormous margin and is the basis for every major cardiovascular and anti-inflammatory omega-3 trial. The REDUCE-IT trial, ASCEND trial, and VITAL trial — the three largest omega-3 cardiovascular trials — all used fish-derived EPA and/or DHA.
Standard fish oil comes in the triglyceride (TG) or ethyl ester (EE) form. Triglyceride-form fish oil has better bioavailability — approximately 70% higher absorption than ethyl ester in some comparative studies — because it more closely resembles the form in which fats naturally occur in food. Many cheaper fish oil products are in the ethyl ester form, though re-esterified triglyceride (rTG) concentrates exist that offer high EPA+DHA concentrations with good bioavailability.
The main practical concern with fish oil is oxidation. Fish oil is unstable and oxidizes when exposed to heat, light, and air. Oxidized fish oil produces aldehydes and other byproducts with potentially pro-inflammatory effects — the opposite of the intended benefit. A 2015 Norwegian study found that over 50% of retail fish oil products tested exceeded recommended peroxide value limits, with many smelling rancid by the time consumers opened them. Buying from reputable manufacturers with third-party oxidation testing (TOTOX values) is therefore not a minor consideration.
Here is the piece most marketing obscures: fish do not make EPA and DHA. They accumulate these fatty acids by eating microalgae. Algal oil is not a "plant-based alternative" to fish oil — it is the original source that fish oil is derived from, one step removed. Microalgae-derived DHA and EPA are molecularly identical to those in fish oil.
Algal oil has been thoroughly validated as bioequivalent to fish oil across multiple studies. A head-to-head comparison published in Lipids found that algal DHA raised blood DHA levels equivalently to cooked salmon. For vegetarians, vegans, and those with fish allergies, algal oil is a complete replacement — not a compromise. It also eliminates concerns about oceanic contaminants (mercury, PCBs, dioxins) since it is produced in controlled fermentation environments.
The main drawback is cost: algal oil typically costs 2–3 times more per gram of EPA+DHA than fish oil. For EPA specifically, algal sources have historically been more limited, though several manufacturers now offer high-EPA algal formulations.
Krill oil is extracted from Antarctic krill (Euphausia superba) and differs from fish oil in one meaningful structural way: a portion of the EPA and DHA is bound to phospholipids rather than triglycerides. This phospholipid carrier was theorized to improve absorption and brain delivery, and krill oil also naturally contains astaxanthin (a carotenoid antioxidant) that confers some oxidative stability.
The bioavailability argument for krill is real but smaller than commonly claimed. A 2015 meta-analysis in Lipids in Health and Disease found that krill oil raised EPA+DHA levels comparably to fish oil when doses were matched by EPA+DHA content — meaning the absorption advantage largely disappears when you account for the fact that krill oil products often contain less EPA+DHA per capsule. At equivalent actual doses, the differences in blood levels are modest (roughly 10–15% in some studies).
More critically, krill oil has no large independent cardiovascular outcome trials of its own. All the major clinical evidence underpinning omega-3 cardiovascular recommendations was built with fish oil. Krill costs significantly more per gram of EPA+DHA. The astaxanthin content is generally too low to be pharmacologically significant at standard krill doses. For most people, the premium over high-quality fish oil is difficult to justify based on current evidence.
Collagen supplements have become one of the fastest-growing segments of the supplement industry, driven by marketing claims around skin anti-aging, joint repair, hair thickness, and gut health. Global sales topped $9 billion in 2024 and are projected to nearly double by 2030. The marketing premise is appealing: collagen is the most abundant structural protein in the human body, it declines with age, and supplementing it should logically replace what's lost.
The biology, however, is more complicated than the premise suggests — and the trial data is considerably more interesting (and more limited) than the marketing implies.
Collagen is a protein made up of amino acids, primarily glycine, proline, and hydroxyproline. When you ingest collagen — whether from a supplement, bone broth, or any protein source — your digestive system breaks it down into individual amino acids and small peptides before it enters the bloodstream. It does not travel to your skin or joints as collagen. The body reassembles collagen where it's needed from these amino acid building blocks, using vitamin C as a critical cofactor.
This means that, from a first-principles perspective, collagen supplements should be no more effective than any high-quality protein source providing the same amino acid profile. A chicken breast or a serving of Greek yogurt provides plenty of glycine, proline, and hydroxyproline. This is the core skeptical argument against collagen supplementation.
The rebuttal — and where the research gets more nuanced — is that hydrolyzed collagen supplements are processed into specific small peptides (di- and tripeptides) that may be absorbed partially intact before full digestion, and that these peptides appear to have signaling effects on fibroblasts (collagen-producing skin cells) and chondrocytes (cartilage cells) beyond simple amino acid delivery. Whether this mechanism drives meaningful real-world outcomes is what the trials have been testing.
The strongest and most replicated evidence for collagen is in skin elasticity (how well skin bounces back) and hydration. A 2021 systematic review and meta-analysis in the International Journal of Dermatology (de Miranda et al.) pooled 19 studies covering 1,125 participants on oral hydrolyzed collagen for skin outcomes. The review found small but statistically meaningful improvements in skin elasticity and hydration versus placebo, over 8–24 weeks, at doses of 2.5–10 g/day. A separate 2023 meta-analysis by Pu et al. in Nutrients (26 RCTs, 1,721 participants) reached a similar conclusion.
Wrinkle reduction has also been reported, though effect sizes were smaller and more variable. A 2014 double-blind RCT in Skin Pharmacology and Physiology (Proksch et al.) found that 2.5 g/day of a specific collagen peptide (Verisol) reduced the volume of eye-area wrinkles by about 20% after 8 weeks versus no change on placebo, with the effect holding at 12 weeks. These are not dramatic cosmetic transformations — they are measurable but modest changes in how skin behaves under instruments.
Important caveats: many trials in this space are funded by collagen manufacturers, which introduces potential bias. The specific collagen peptide product matters — different hydrolysates have different peptide profiles, and results from one product cannot be assumed to apply to a generic "collagen supplement." Blinding is also challenging in some studies given the distinct taste and texture of collagen powders.
The evidence for collagen in joint health is moderately positive, mainly in osteoarthritis and activity-related joint discomfort. A 2008 Penn State study (Clark et al., industry-funded but with independent statistics) randomized 147 athletes to 10 g/day of hydrolyzed collagen or placebo for 24 weeks. The collagen group showed greater reductions in joint pain during activity and at rest than the placebo group.
A broader picture came from Liu and colleagues' 2023 meta-analysis (19 RCTs, 1,461 participants) in Nutrients, which found statistically significant reductions in joint pain scores with hydrolyzed collagen in both osteoarthritis patients and athletes, with the largest benefits appearing after 3–6 months of use. A separate line of evidence involves undenatured type II collagen (UC-II): a 2016 RCT by Lugo et al. in the Journal of the International Society of Sports Nutrition found that UC-II at just 40 mg/day produced larger reductions in knee pain and stiffness than 1,500 mg of glucosamine plus 1,200 mg of chondroitin.
The proposed mechanism for UC-II is different from hydrolyzed collagen: it works through oral tolerance — basically training the immune system to calm its attack on joint collagen. This is a separate pathway from simply delivering amino acids. It suggests that the specific kind of collagen used matters, not just the milligram count on the label.
Claims about collagen "healing the gut lining" or improving leaky gut are largely unsupported by human clinical evidence. Glycine has some anti-inflammatory properties that are being studied in gastrointestinal contexts, but direct collagen supplementation for gut health has minimal trial data. Hair thickness claims are similarly thin — one small industry-funded study showed some improvement in hair growth rate, but replication is lacking.
A common belief about dietary supplements is that "natural" means safe — and that supplements will not affect prescription drugs. Neither is true. Supplements are active compounds. They can change how drugs are absorbed, broken down, or cleared from the body. Those changes have caused hospitalizations, treatment failures, and, in some cases, deaths.
The problem is made worse because most people do not tell their doctors or pharmacists what supplements they take, and most clinicians do not ask. A 2007 national survey analyzed by Kennedy et al. in the Archives of Internal Medicine found that roughly 69% of U.S. adults using prescription drugs plus supplements had not discussed the supplements with a doctor. Follow-up studies through the 2010s (Tarn and colleagues, and the 2020 NHANES analysis by Gahche and colleagues) show the same pattern. Below are five of the most clinically important and commonly encountered interactions.
St. John's Wort (Hypericum perforatum) is the most dangerous supplement for drug interactions. It is a strong inducer of two of the body's main drug-processing systems — CYP3A4 (a liver enzyme family) and P-glycoprotein (a transporter that moves drugs across cell membranes). "Inducing" these systems means the body breaks down affected drugs much faster than intended, which lowers blood levels and can wipe out the drug's effect.
Drugs affected include SSRIs and SNRIs (common antidepressants — combining can trigger serotonin syndrome, a life-threatening surge of serotonin), oral contraceptives (dozens of documented contraceptive failures and unintended pregnancies in Europe after St. John's Wort use), cyclosporine (used after organ transplant to prevent rejection — St. John's Wort has caused acute rejection), HIV antiretrovirals such as indinavir and efavirenz, digoxin (a heart drug), and warfarin. The FDA, the UK MHRA, and the European Medicines Agency have all issued formal warnings. This is not theoretical — it has caused deaths and lost organs.
High-dose fish oil (above 3 g/day of combined EPA+DHA) has real blood-thinning effects. EPA in particular reduces the production of thromboxane A2, a signal that normally makes platelets stick together. In most healthy people this is neutral or mildly beneficial. In anyone taking blood-thinning drugs, it adds to the effect and can push bleeding risk into dangerous territory.
This risk is dose-dependent. At 1 g/day, the risk is generally low and the combination is often managed clinically. At 4 g/day (the dose used in large cardiovascular trials), the interaction is large enough that trials routinely monitor INR (a warfarin blood test) in participants. Anyone on blood thinners should tell their prescriber about fish oil and have clotting tests checked if using higher doses. Note: the 2022 STRENGTH and OMEMI trials also linked 4 g/day omega-3 use to a small increase in atrial fibrillation, which is a separate concern from bleeding.
Minerals with a double positive charge — magnesium, calcium, zinc, and iron — can bind to certain drugs in the gut and form compounds that the body cannot absorb. This process is called chelation. The drugs most affected are fluoroquinolone antibiotics (ciprofloxacin, levofloxacin), tetracycline antibiotics (doxycycline), and levothyroxine (synthetic thyroid hormone, used by tens of millions of people with hypothyroidism).
For the antibiotics above, taking magnesium, calcium, iron, or zinc within about 2 hours can cut absorption by 30–90%. During a serious infection, that can mean the antibiotic fails. For levothyroxine, calcium and iron can cut absorption by up to 30–40% in controlled studies. Many hypothyroid patients take calcium with their thyroid pill at breakfast and wonder why their TSH (the main thyroid blood test) stays high. The fix is simple: levothyroxine should be taken on an empty stomach, 30–60 minutes before any other food, supplement, or drink other than water. The interaction is real, it is easy to avoid, but it is often not explained by the prescriber.
Warfarin works by blocking the body's use of vitamin K to make clotting factors. Its whole mechanism depends on vitamin K being at a steady level. Any supplement that adds significant vitamin K — especially vitamin K2 in the MK-7 form, which has a long half-life of about 72 hours and builds up in tissue — pushes against warfarin. The result is a lower INR, a less effective blood thinner, and a higher chance of clots and stroke.
Standard multivitamins and most food sources of vitamin K1 are manageable as long as intake is steady. The common culprits are vitamin K2 supplements (now popular for bone and heart health) and green "superfood" powders, which can be high in K1. The key rule for anyone on warfarin is consistency: sudden changes in vitamin K intake — starting, stopping, or swapping amounts — will destabilize the INR. Changing a vitamin K supplement without telling your prescriber is genuinely dangerous.
Grapefruit is technically a food, but bergamot — a close citrus relative used in some "cholesterol-lowering" supplements — belongs in the same warning. Both contain compounds called furanocoumarins that strongly and long-lastingly block CYP3A4 in the gut wall. Unlike St. John's Wort, which speeds up drug breakdown, grapefruit slows it down. That means CYP3A4-cleared drugs build up to higher-than-intended levels.
Affected drugs include simvastatin and lovastatin (two statins; atorvastatin and pravastatin are processed differently and are much less affected), nifedipine and felodipine (calcium channel blockers for high blood pressure), cyclosporine, and several psychiatric medications. A single 200 mL glass of grapefruit juice can block gut CYP3A4 for more than 24 hours. Bergamot supplements sold for cholesterol often contain the same furanocoumarins unless specifically processed to remove them — yet they are sold next to, and sometimes as alternatives to, statins. That combination can drive statin blood levels high enough to cause rhabdomyolysis (severe muscle breakdown that can damage the kidneys).
Magnesium is one of the most commonly recommended supplements, and for good reason: it is involved in over 300 enzymatic reactions in the body, roughly 48% of Americans do not meet the recommended daily intake, and deficiency is associated with poor sleep, anxiety, muscle cramps, elevated blood pressure, and impaired glucose regulation. But "magnesium" on a supplement label is not a single thing — it is a mineral that must be bound to a carrier molecule, and that carrier determines how much you actually absorb, where it acts, and what side effects you can expect.
Walking into a pharmacy and choosing between magnesium oxide, glycinate, citrate, malate, threonate, and taurate without guidance is genuinely confusing. Here is what the evidence says about the most clinically relevant forms.
Magnesium oxide is the cheapest form and the most prevalent in low-cost multivitamins and generic supplement products. A 500 mg tablet of magnesium oxide contains approximately 300 mg of elemental magnesium — a high percentage by weight, which makes it look efficient on labels. The problem is bioavailability: magnesium oxide has only about 4% bioavailability in most studies, meaning the vast majority passes through the gut unabsorbed.
What magnesium oxide is effective at is laxation. The unabsorbed magnesium draws water into the colon through osmosis, which is why magnesium oxide is the active ingredient in most osmotic laxatives (Phillips' Milk of Magnesia, for example). As a magnesium supplement for systemic effects — sleep, anxiety, muscle function, cardiovascular health — it is a poor choice. Many people take magnesium oxide, notice nothing, and conclude magnesium "doesn't work for them" when they were simply taking a largely inert form for systemic purposes.
Magnesium citrate has bioavailability of approximately 25–30%, significantly higher than oxide. It is the most common recommendation for general magnesium supplementation and is a good all-purpose choice. The citrate form is well-tolerated, relatively inexpensive, and has good evidence across a range of outcomes including blood pressure reduction, muscle cramp prevention, and general magnesium repletion.
At higher doses (above 400–500 mg elemental magnesium), citrate can cause loose stools in some people — a useful signal that your dose exceeds what the gut can absorb in one sitting. For people seeking a general magnesium supplement and who do not have digestive sensitivity, citrate is usually the starting recommendation. Split dosing (morning and evening) improves tolerance and absorption at higher target doses.
Magnesium glycinate is magnesium bound to glycine, an amino acid with its own inhibitory neurotransmitter properties (glycine acts on NMDA receptors and in the spinal cord). This combination makes magnesium glycinate particularly well-suited for sleep support and anxiety management, as both the magnesium and the glycine contribute to CNS calming through complementary mechanisms.
Bioavailability is high — estimated at 50–80% in some studies, though direct head-to-head human bioavailability comparisons are limited — and it is the most gentle on the digestive system of any common magnesium form. The near-absence of GI side effects makes it suitable for people who experience loose stools from citrate. At 300–400 mg elemental magnesium per night, glycinate is generally considered the gold standard form for sleep-specific applications.
The trade-off is cost: glycinate is typically 2–3 times more expensive per gram of elemental magnesium than citrate. For people using magnesium strictly for sleep or anxiety, this premium is arguably justified. For people replenishing a dietary deficit without specific CNS goals, citrate is a more economical choice.
Magnesium L-threonate is a newer, patented form developed by researchers at MIT. Its distinguishing claim is its ability to cross the blood-brain barrier and raise brain magnesium concentrations more effectively than other forms. This was demonstrated in preclinical studies (rats) where threonate significantly increased brain magnesium levels while other forms did not. Subsequent human trials showed modest improvements in cognitive flexibility, short-term memory, and quality of sleep in older adults.
The clinical evidence in humans is limited — two published trials, both from the same research group and with relatively small sample sizes. While the preclinical rationale is strong, independent replication in larger trials is needed before threonate can be confidently recommended over glycinate for brain-specific applications. It is also the most expensive magnesium form by a significant margin — often 4–5 times the cost of glycinate.
The practical situation: if you specifically want cognitive benefits from magnesium supplementation (not just sleep or muscle function), threonate is the most theoretically rational choice. If your goal is sleep, anxiety reduction, or general repletion, glycinate provides similar CNS benefit at lower cost.
Magnesium malate is magnesium bound to malic acid, a compound that the body uses inside the Krebs cycle (the energy-making process in mitochondria). On paper, that makes it a reasonable pick for people looking for energy support or help with muscular endurance. Absorption is good and it is generally easy on the stomach. The human evidence base, though, is small. The most-cited study is Russell and colleagues' 1995 placebo-controlled crossover trial in the Journal of Rheumatology (24 patients with fibromyalgia, 4 weeks of blinded treatment followed by a 6-month open-label extension). During the blinded phase, 300 mg of malic acid plus about 150 mg of elemental magnesium per day did not beat placebo. Benefits only emerged during the open-label extension at higher doses. Bottom line: malate is a reasonable form, but the fibromyalgia claim rests on weak evidence and should be described that way.
Ashwagandha (Withania somnifera) has become the wellness industry's favorite adaptogen — a category-defining supplement that promises to reduce cortisol, combat stress, improve sleep, boost testosterone, enhance cognitive performance, increase endurance, and support thyroid function, all in one capsule. Google Trends shows a nearly tenfold increase in searches since 2019. It is now the fifth most commonly used natural product in the United States according to NIH survey data.
The honest assessment is more complicated than either the enthusiasts or the skeptics suggest. Ashwagandha has real clinical evidence behind specific effects at specific doses in specific populations. It also has a rapidly expanding list of claims that significantly outpace that evidence. Understanding which is which requires separating the extract quality question, the mechanism question, and the outcome question.
Ashwagandha is a root from the nightshade family (Solanaceae) used for over 3,000 years in Ayurvedic medicine. The primary active compounds are withanolides, a class of steroidal lactones that appear to modulate stress response pathways. The root also contains alkaloids, saponins, and iron. The term "adaptogen" has no regulatory or scientific definition — it is a marketing category meant to suggest the plant "helps the body adapt to stress," a claim vague enough to cover almost any effect.
Critically, ashwagandha is not a single standardized compound — it is a complex botanical extract with significant variation between products. The KSM-66 and Sensoril branded extracts used in most clinical trials are standardized to specific withanolide percentages (5% for KSM-66, 10% for Sensoril). Generic ashwagandha powders have wildly variable withanolide content. This means the clinical trial data on KSM-66 and Sensoril cannot be assumed to apply to unlabeled, unstandardized products at GNC, Amazon, or your local health food store.
The most replicated finding in ashwagandha clinical trials is a reduction in perceived stress scores and self-reported anxiety, with accompanying reductions in serum cortisol in several studies. A 2012 double-blind, placebo-controlled trial published in the Indian Journal of Psychological Medicine randomized 64 adults with chronic stress to 300 mg of KSM-66 twice daily for 60 days. The ashwagandha group showed a 28% reduction in serum cortisol levels, a 69% reduction in insomnia scores, and statistically significant improvements on every validated stress and anxiety scale used (PSS, GHQ-28, DASS).
These results have been broadly replicated. A 2019 study published in Medicine found that 240 mg/day of a concentrated ashwagandha extract for 60 days significantly reduced anxiety and morning cortisol levels vs. placebo. A 2021 RCT in the Journal of Clinical Medicine found improvements in stress, sleep quality, and overall well-being in 150 mg/day KSM-66 groups over 30 days. The stress/anxiety signal across multiple independent trials from different groups is the most credible finding in the ashwagandha literature.
Multiple RCTs have tested ashwagandha for sleep. A 2021 meta-analysis in PLOS ONE by Cheah and colleagues pooled five trials and found a statistically significant improvement in overall sleep quality (SMD of about −0.59), with meaningful benefit on sleep efficiency, total sleep time, and sleep latency. The authors described the effects as small to moderate, with a larger benefit in people who had clinical insomnia at baseline. Most of the benefit appears to come through the anxiety-reducing mechanism — by lowering pre-sleep cognitive arousal and cortisol, ashwagandha makes falling asleep easier for people whose insomnia is anxiety-driven.
This is meaningfully different from how the compound is marketed ("deep sleep," "restorative sleep"), which implies a direct pharmacological action on sleep architecture. The evidence suggests it helps mostly by reducing the psychological noise that prevents sleep in stressed individuals, not by acting as a sedative or directly reshaping sleep architecture like melatonin or glycine.
Testosterone: Several trials have found modest increases in testosterone (ranging from 10–17% over baseline) in men using ashwagandha, particularly in combination with resistance training. These are statistically significant in small trials but clinically modest — well below the threshold that would produce noticeable anabolic effects. The mechanism is unclear; some researchers propose cortisol reduction secondarily improves testosterone, as the two hormones are metabolically linked. Marketing that frames ashwagandha as a testosterone booster dramatically overstates this finding.
Cognitive function: Several small trials have found improvements in attention, information processing speed, and memory with ashwagandha supplementation. However, most of these trials use populations with baseline cognitive impairment or significant stress loads, and effects in healthy well-rested adults are much less clear. A 2021 RCT in adults without cognitive pathology found no significant cognitive improvement at 300 mg KSM-66 twice daily over 8 weeks.
Athletic performance: A 2015 trial found ashwagandha improved VO2 max and muscle strength/recovery in elite cyclists and elite strength athletes. Other trials in recreational exercisers show more modest effects. The effects appear most pronounced in individuals under high training stress, which again traces back to the cortisol-mediated mechanism rather than direct performance enhancement.
Ashwagandha is generally well-tolerated at studied doses. However, a growing number of case reports have linked high-dose ashwagandha to liver injury — autoimmune hepatitis-like presentations requiring hospitalization. As of 2024, ICSR (Individual Case Safety Reports) in the FDA's MedWatch database and published case series had identified approximately 30 suspected cases of ashwagandha-associated hepatotoxicity, with some requiring liver transplant evaluation. The mechanism is poorly understood; it may involve immune-mediated reactions in genetically susceptible individuals rather than direct hepatotoxicity.
These cases are rare relative to the enormous number of people taking ashwagandha globally. But they represent a non-zero risk that has grown as doses have escalated and products have proliferated. Most cases involved doses above 500 mg/day for extended periods, often of products that were not the standardized KSM-66 or Sensoril extracts studied in trials.
Additional cautions: ashwagandha is contraindicated in pregnancy (traditional use as an abortifacient exists in Ayurvedic literature). It should be used cautiously with thyroid medications, as several trials show thyroid-stimulating effects (T3/T4 increases) that could amplify or complicate thyroid drug therapy. The standard recommendation is to cycle use — 8–12 weeks on, 4 weeks off — to avoid chronic exposure.
Ashwagandha is a legitimately effective supplement for stress reduction and anxiety in clinically stressed adults, at 300–600 mg/day of a standardized extract (KSM-66 or Sensoril), for 8–12 week cycles. It is not a testosterone booster, not a universal cognitive enhancer, and not a performance supplement with evidence comparable to creatine. The liver injury signal, while rare, is real and warrants caution at higher doses and in people with pre-existing liver conditions. The gap between what ashwagandha demonstrably does and what the market tells you it does is wide enough to qualify as the most overhyped supplement of the moment — not because the evidence is poor, but because it has been stretched far beyond its actual scope.
Vitamin D occupies a strange position in supplement science: it is both one of the most important micronutrients in human health and one of the most frequently misunderstood. Deficiency is pervasive — over 40% of American adults have serum 25(OH)D levels below 20 ng/mL, the threshold most labs flag as deficient — yet the question of how much to supplement remains genuinely contested among researchers.
Vitamin D status is measured as serum 25-hydroxyvitamin D [25(OH)D]. The Endocrine Society defines deficiency as below 20 ng/mL, insufficiency as 20–29 ng/mL, and sufficiency as 30–100 ng/mL. Some researchers and clinicians argue that 40–60 ng/mL is the true optimal range for immune function and disease prevention, citing epidemiological data showing lowest all-cause mortality at those levels. However, this remains debated — randomized controlled trials have generally used supplementation to bring deficient people into the 30–50 ng/mL range, with less evidence for benefits above 50 ng/mL in people not deficient to begin with.
For deficient adults, the Endocrine Society recommends 1,500–2,000 IU/day to maintain levels above 30 ng/mL. The Institute of Medicine's Recommended Dietary Allowance is 600 IU for adults under 70 and 800 IU for those over 70 — but these numbers were designed to prevent frank deficiency, not optimize health. Most experts agree that 1,000–2,000 IU/day is appropriate for adults with limited sun exposure, while those with confirmed deficiency may require 4,000–6,000 IU/day short-term to restore levels. Vitamin D3 (cholecalciferol) is more effective at raising blood levels than D2 (ergocalciferol) and should be the default choice.
Always pair vitamin D supplementation with vitamin K2 (MK-7 form, 90–200 mcg/day). Vitamin D increases calcium absorption; K2 ensures that calcium is directed to bone rather than arterial walls. This pairing is especially important at doses above 2,000 IU/day.
Classic vitamin D deficiency produces bone pain, muscle weakness, fatigue, and in severe cases rickets or osteomalacia. But subclinical insufficiency (20–30 ng/mL) produces subtler effects: increased susceptibility to respiratory infections, mood disruption, slower muscle recovery, and impaired immune surveillance. Seasonal affective disorder (SAD) is strongly correlated with low vitamin D in winter months, though supplementation's effect on mood is modest in adequately-nourished adults.
A 25(OH)D blood test costs $30–$50 and provides actionable information. Testing is particularly worthwhile for: people with darker skin (melanin reduces cutaneous vitamin D synthesis), those living above 37° latitude, people who work indoors year-round, anyone with obesity (vitamin D is sequestered in adipose tissue), people with malabsorption conditions (Crohn's, celiac), and anyone on corticosteroids or anticonvulsants. Without testing, 1,000–2,000 IU/day is a reasonable maintenance dose for most healthy adults. Avoid megadosing (>10,000 IU/day) without medical supervision, as vitamin D is fat-soluble and can accumulate to toxic levels.
The idea that bacteria in your gut could influence your emotions would have seemed fringe science a decade ago. Today it is one of the most active areas of psychiatric and gastroenterological research. The gut-brain axis — the bidirectional communication network between the enteric nervous system and the central nervous system — is now understood to be a genuine physiological pathway, not a metaphor.
Approximately 90% of the fibers in the vagus nerve run from the gut to the brain, not the other way around. The gut produces roughly 90–95% of the body's serotonin, the neurotransmitter most associated with mood regulation. While gut-derived serotonin does not cross the blood-brain barrier directly, it plays crucial roles in regulating gut motility, and changes in gut serotonin signaling appear to influence vagal tone and downstream central nervous system activity. Animal studies have demonstrated that germ-free mice (raised without gut bacteria) show dramatically elevated stress responses and anxiety-like behaviors, responses that can be partially reversed by recolonizing their guts with specific bacterial strains.
The term "psychobiotic" was coined in 2013 by researchers Ted Dinan and John Cryan to describe live organisms that, when ingested in adequate amounts, produce a mental health benefit. Since then, over 30 human RCTs have tested the effects of probiotic supplementation on mood, anxiety, and depression. The results are promising but require careful interpretation.
A 2019 meta-analysis in the British Journal of Nutrition (Liu et al.) pooled 34 RCTs and found that probiotic supplementation lowered depression and anxiety rating-scale scores compared with placebo. Effect sizes were moderate (pooled SMD ≈ 0.24 for depression, ≈ 0.10 for anxiety in healthy adults; larger in clinically distressed groups). The clearest benefits showed up in people with elevated baseline depression or anxiety, not in already-healthy adults. The best-studied mood strains include Lactobacillus helveticus R0052 + Bifidobacterium longum R0175 (Messaoudi 2011), Bifidobacterium longum 1714, and a handful of multi-strain blends containing L. acidophilus and B. bifidum.
Beyond vagal signaling, gut bacteria influence the brain through several other pathways. They produce short-chain fatty acids (SCFAs) like butyrate that cross the blood-brain barrier and have anti-inflammatory and neuroprotective effects. Gut bacteria also modulate the HPA (hypothalamic-pituitary-adrenal) axis, the body's primary stress response system, influencing cortisol production. Additionally, certain strains produce GABA precursors and other neuroactive compounds that may influence anxiety circuits directly.
This research does not yet translate into a clear clinical recommendation for using probiotics as a primary mental health treatment. The strain specificity problem is significant: most commercial probiotics contain strains that have not been studied for mood effects. The most studied psychobiotics are only available in a few specialized products. Diet matters enormously — a probiotic cannot meaningfully change gut microbiome composition if the rest of the diet is fiber-poor and ultra-processed. Fermented foods (yogurt, kefir, sauerkraut, kimchi) provide a broader array of bacterial species and may be more impactful than any single-strain supplement. If you're exploring probiotics for mood support, look specifically for products containing researched strains, not just high CFU counts.
Iron deficiency is the world's most common nutritional deficiency, affecting an estimated 2 billion people globally. Iron deficiency anemia produces fatigue, shortness of breath, cold intolerance, brain fog, and reduced exercise capacity. For people who are genuinely deficient, correcting iron status can be transformative. Yet a surprising number of people take iron supplements without understanding the factors that determine whether that iron actually gets absorbed — and the answer is rarely "just take it with water."
Non-heme iron (the form in most supplements and plant foods) is absorbed at only 2–20% under normal conditions. Heme iron (from meat) absorbs at 15–35%. Absorption of non-heme iron is exquisitely sensitive to what else is in your stomach at the time. Calcium — even in moderate amounts from dairy — blocks iron absorption by up to 60%. Coffee and tea contain polyphenols and tannins that reduce non-heme iron absorption by 40–90%. Phytates in whole grains and legumes form insoluble complexes with iron, further reducing uptake. Most people taking iron supplements with breakfast (coffee + cereal + milk) are absorbing almost none of it.
Vitamin C dramatically improves non-heme iron absorption — 100 mg of vitamin C taken with iron can increase absorption by 2–4 fold by converting ferric iron (Fe³⁺) to the more bioavailable ferrous form (Fe²⁺) and chelating it to keep it soluble in the higher-pH environment of the small intestine. Take iron with a glass of orange juice or a vitamin C supplement, on an empty stomach, and separate from calcium, coffee, and high-fiber foods by at least one hour. The best time is mid-morning, away from breakfast and lunch.
Ferrous sulfate is the most commonly prescribed form and is highly bioavailable, but causes significant GI side effects (constipation, nausea, dark stools) in many people. Ferrous bisglycinate (iron glycinate) is a chelated form with comparable or slightly lower elemental iron absorption per milligram, but dramatically fewer GI side effects — making it far more tolerable for everyday supplementation. Ferric forms (ferric citrate, ferric sulfate) are generally less bioavailable and not recommended as first-line supplements. Liquid iron formulations can reduce GI irritation by allowing flexible dosing and avoiding high local iron concentrations in the gut.
Unlike most water-soluble vitamins, iron accumulates in the body. Excess iron is a pro-oxidant that damages cells and is associated with increased cardiovascular risk and liver disease. Hemochromatosis (hereditary iron overload) affects roughly 1 in 200 people of Northern European descent and can be worsened catastrophically by supplementation. Before taking iron, confirm deficiency through serum ferritin and hemoglobin. A ferritin below 30 ng/mL typically indicates depleted stores even if hemoglobin is still normal. Retest after 3 months of supplementation to confirm response.
The U.S. multivitamin market generates over $8 billion annually. An estimated one in three Americans takes a multivitamin every day. In 2022, the U.S. Preventive Services Task Force (USPSTF) published its updated recommendation: multivitamin supplementation provides no meaningful benefit for reducing cardiovascular disease or cancer in healthy adults, and there is insufficient evidence to recommend it for overall mortality. For many, this was a headline that deserved more nuance than it received.
The 2022 USPSTF statement reviewed evidence across 84 studies and concluded that for multivitamins the current evidence is insufficient to judge whether benefits outweigh harms for preventing cardiovascular disease or cancer in generally healthy, non-pregnant adults (an "I statement," not a recommendation against). The Task Force recommended against using beta-carotene or vitamin E supplements for this purpose because of net harm at supplemental doses. That conclusion applies specifically to primary disease prevention in otherwise healthy people eating a reasonably varied diet. It does not apply to people with documented deficiencies, those on calorie-restricted diets, people with malabsorption disorders, older adults with reduced gastric acid and dietary variety, or people on medications that deplete specific nutrients.
For several populations, a multivitamin remains a reasonable low-cost insurance policy. Older adults (65+) frequently have inadequate intake of B12, vitamin D, and zinc due to reduced appetite, lower gastric acid production, and decreased outdoor activity. Strict vegetarians and vegans are at high risk for B12, iron, zinc, and iodine insufficiency. People on long-term metformin therapy deplete B12. Bariatric surgery patients have impaired absorption of multiple micronutrients and require lifelong supplementation. Pregnant women benefit from folate, iron, and iodine above dietary levels. For these groups, a basic multivitamin or targeted supplementation is well-supported.
Even when supplementation is warranted, most multivitamins are poor products. They typically use cheap, poorly-absorbed mineral forms (magnesium oxide, zinc oxide, ferrous sulfate) at doses too low to correct deficiency, while including high doses of fat-soluble vitamins that accumulate. The iron and calcium in many multivitamins compete for absorption. Many contain vitamin K1 instead of the more bioactive K2 form. Premium multivitamins that use chelated minerals and active vitamin forms (methylcobalamin for B12, methylfolate for folate, cholecalciferol for D3) are significantly more effective — and significantly more expensive. If you take a multivitamin, the form of each ingredient matters as much as the presence of it.
For a healthy adult eating a varied diet, a daily multivitamin is unlikely to prevent disease or meaningfully extend life. The USPSTF conclusion is correct in that context. But "not beneficial for primary disease prevention in healthy adults" is a far more specific claim than "waste of money for everyone." If you're in a higher-risk group for specific deficiencies, targeted supplementation — or a high-quality multivitamin — remains sensible. If you're not, spending the same money on vegetables is probably the better investment.
Turmeric is one of the best-selling supplements in the world. The marketing is compelling: thousands of years of Ayurvedic use, impressive anti-inflammatory effects in cell studies, a bright golden color that signals health. There's just one problem: the active compound — curcumin — is so poorly absorbed by the human body that taking a standard turmeric supplement is roughly equivalent to not taking it at all.
Curcumin comprises approximately 2–5% of turmeric root by weight. More importantly, it is highly insoluble in water, rapidly metabolized in the gut wall and liver, and quickly excreted. Studies of standard curcumin powder in humans find peak plasma concentrations so low they are often undetectable at clinically relevant doses. A landmark 2007 review in Molecular Pharmaceutics (Anand et al.) concluded that native curcumin shows poor bioavailability in humans — "major reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination." This is the compound found in the vast majority of turmeric and curcumin supplements on store shelves.
Researchers and manufacturers have developed several approaches to improve curcumin absorption. Piperine (black pepper extract) co-administration increases curcumin bioavailability by roughly 2,000% (about 20-fold) in humans (Shoba et al. 1998) by inhibiting intestinal glucuronidation — but note this was a short-term study at high doses. Phospholipid complexes (Meriva form) improve absorption 5–20 fold. Nanoparticle formulations, lipid-based systems, and the BCM-95 and Longvida branded extracts all achieve meaningfully higher plasma concentrations than standard curcumin. The human trial evidence for anti-inflammatory and joint benefits comes almost exclusively from these enhanced-bioavailability forms, not from plain curcumin powder.
The supplement industry's response has been to sell plain turmeric powder and cheap curcumin extracts at high margins while citing the positive research on bioavailable formulations. A bottle labeled "Curcumin 500 mg" rarely specifies which form; "with BioPerine" (piperine) is the bare minimum. Without a specific enhanced-bioavailability designation, most curcumin supplements should be assumed to have poor absorption.
Even with bioavailable forms, the clinical evidence for curcumin is more modest than headlines suggest. The strongest evidence is for mild-to-moderate osteoarthritis joint pain, where several RCTs using Meriva or BCM-95 show effects comparable to low-dose NSAIDs with fewer GI side effects. Evidence for curcumin's effects on CRP and other inflammatory markers is reasonably consistent in people with elevated baseline inflammation. Claims about curcumin for cancer prevention, Alzheimer's prevention, or cardiovascular protection are based on in vitro and animal data and have not been confirmed in human trials at clinically relevant doses.
If you want to experiment with curcumin, look specifically for: Meriva (phospholipid complex), BCM-95 or Biocurcumax, Longvida (lipid nanoparticle), CurcuWIN, or a standard curcumin product with at least 5 mg of piperine per dose. Expect to pay more than for plain turmeric powder. If the label says only "turmeric extract" or "curcumin" with no further specification, assume poor bioavailability and treat health claims accordingly.
The weight loss supplement market generates over $33 billion per year in the United States alone. It is also the supplement category most associated with hospitalizations, severe adverse events, and deaths. Unlike most supplement categories where the primary concern is inefficacy, weight loss supplements have a documented track record of serious harm — both from declared ingredients at excessive doses and from undisclosed adulterants that contaminate "natural" products.
2,4-Dinitrophenol (DNP) is an industrial chemical that uncouples cellular respiration, causing cells to produce heat instead of ATP. It produces rapid, substantial fat loss. It also kills people. DNP causes hyperthermia, profuse sweating, rapid heart rate, cataracts, agranulocytosis, and death. There is no safe margin between an effective dose and a lethal one. DNP has never been approved for human use and has been illegal for sale as a dietary supplement since 1938. Yet it continues to appear regularly in weight loss products sold online and in gyms. Between 2011 and 2022, the FDA documented at least 19 deaths in the United States attributable to DNP-containing products. Most victims were young men and women who purchased what they believed were "natural" fat burners.
1,3-Dimethylamylamine (DMAA) is a synthetic stimulant originally marketed as a geranium extract (a false claim). It was widely used in pre-workout and weight loss products until the FDA banned it following multiple deaths, including two soldiers who died during exercise after consuming DMAA-containing products. Despite the ban, DMAA and its analogs (DMBA, DMHA, AMP citrate) continue to appear in products under misleading botanical names. These compounds cause dangerous increases in heart rate and blood pressure, carry risks of hemorrhagic stroke, and interact badly with caffeine — which is almost always co-present in the same products.
Weight loss supplements have the highest rate of pharmaceutical drug contamination among all supplement categories. The FDA's "Tainted Supplements" database documents hundreds of weight-loss products found to contain undisclosed pharmaceutical compounds — primarily sibutramine (a withdrawn appetite suppressant linked to cardiovascular events), phenolphthalein (a laxative withdrawn over cancer risk), and occasionally fluoxetine (an antidepressant). A 2018 analysis in JAMA Network Open (Tucker et al.) found that 776 adulterated supplements appeared in FDA warnings from 2007–2016. Sexual-enhancement products were the largest category (45.5%), followed by weight-loss products (40.9%); sibutramine was detected in 84.9% of tainted weight-loss samples.
Of the legal, commonly marketed weight loss ingredients, caffeine + green tea extract (EGCG) has the most consistent evidence for modest thermogenic effects, with a meta-analysis showing approximately 1.3 kg of additional weight loss over 12 weeks compared to placebo. Fiber supplements (psyllium, glucomannan) modestly reduce caloric absorption and improve satiety. Protein supplementation reduces overall caloric intake by increasing satiety. None of these produce dramatic results. If a product promises dramatic results, contains proprietary blends with unspecified doses, or is sold primarily through influencer marketing, treat it with serious skepticism. The supplement industry's worst actors concentrate in this category.
In 2022 and 2023, "berberine is nature's Ozempic" became one of the fastest-spreading supplement claims on social media, driven largely by TikTok content that reached hundreds of millions of views. Sales of berberine supplements increased by an estimated 700% in 18 months. The comparison to semaglutide (Ozempic/Wegovy) is provocative, somewhat grounded in mechanism, and substantially misleading about magnitude and clinical reality.
Berberine is an alkaloid found in several plants including Berberis vulgaris, goldenseal, and Oregon grape root. It has been used in traditional Chinese and Ayurvedic medicine for over 2,500 years, primarily for gastrointestinal infections and diabetes-like conditions. Its primary metabolic mechanism is activation of AMPK (adenosine monophosphate-activated protein kinase), an enzyme that acts as a cellular energy sensor and plays a central role in glucose and lipid metabolism. This is a genuinely important mechanism that explains why berberine has real effects on blood sugar regulation.
Multiple RCTs and several meta-analyses have confirmed that berberine at 500 mg three times daily reduces fasting blood glucose, post-meal blood glucose, HbA1c, and LDL cholesterol in people with type 2 diabetes or metabolic syndrome. A 2015 meta-analysis in the Journal of Ethnopharmacology (Lan et al., 27 RCTs, n = 2,569) found that berberine produced glycemic reductions (fasting glucose, post-meal glucose, HbA1c) comparable to oral hypoglycemics, with a head-to-head pilot vs. metformin showing similar HbA1c reductions (Yin 2008). These are real, meaningful effects in people with impaired glucose metabolism.
The "nature's Ozempic" framing is misleading because semaglutide (Ozempic/Wegovy) produces an average of 10–15% body weight loss over 68 weeks in clinical trials. Berberine trials in overweight adults show weight loss in the range of 1.5–3 kg over 12 weeks. These are categorically different magnitudes of effect. Semaglutide acts on GLP-1 receptors throughout the gut and brain, powerfully suppressing appetite and slowing gastric emptying. Berberine does not meaningfully activate GLP-1 receptors and has no comparable appetite-suppressing mechanism. The comparison invites people to believe they are getting a comparable benefit to a prescription weight loss drug when they are not.
Most berberine trials are small, short (12 weeks), and were conducted in Chinese populations with type 2 diabetes. Generalizability to healthy Western adults seeking weight loss is uncertain. Berberine has poor and highly variable oral bioavailability (typically under 5%), raising questions about which metabolites actually drive effects. GI side effects — diarrhea, constipation, nausea — are common at therapeutic doses (1,500 mg/day). Berberine inhibits CYP3A4 and P-glycoprotein, meaning it can alter blood levels of many medications including cyclosporine, some antibiotics, and anticoagulants. It is contraindicated in pregnancy due to potential effects on fetal bilirubin.
Berberine is a legitimate, evidence-backed supplement for blood sugar regulation and lipid management in people with metabolic syndrome or prediabetes. It is not nature's Ozempic. It produces modest weight loss, not transformative weight loss, and through mechanisms entirely different from GLP-1 agonists. If you have elevated fasting glucose or HbA1c, berberine is worth discussing with your doctor as an adjunct to lifestyle changes. If you're hoping it will produce the dramatic weight loss seen with semaglutide, the evidence does not support that expectation.
Omega-3 fatty acids — particularly DHA (docosahexaenoic acid) — are structural components of the brain and retina, and critical for neurodevelopment in infancy and childhood. The question of whether children need omega-3 supplements, how much, and from what source is one of the most common nutrition questions parents ask. The answers are more nuanced than most supplement labels suggest.
DHA accounts for approximately 97% of the omega-3 fatty acids in the brain and 93% of those in the retina. It is incorporated into neuronal cell membranes throughout prenatal development and the first years of life, and continues to accumulate in the brain through adolescence. Adequate DHA availability during these windows is associated with better visual acuity in infants, improved cognitive development, and reduced risk of attention and behavioral problems. Severe deficiency during critical developmental windows produces lasting neurological effects.
The key question is not whether DHA is important — it clearly is — but whether most children in developed countries are getting enough from diet alone. Fatty fish (salmon, sardines, mackerel) are rich sources of DHA. Children who eat fish two to three times per week likely have adequate DHA status. Children who rarely eat fish — and surveys suggest that's the majority of American children — may have DHA intakes below recommended levels.
The evidence for omega-3 supplementation in children is mixed and depends on context. In children with confirmed low omega-3 status or specific conditions, benefits are clearer. A 2018 systematic review and meta-analysis in Neuropsychopharmacology (Chang et al., 7 RCTs, n = 534 youth with ADHD) reported small but statistically significant improvements in ADHD clinical symptom scores (Hedges' g = 0.38) and attention (g = 1.09) with n-3 PUFA supplementation, with the strongest effects in children with low baseline omega-3 levels. A 2012 Cochrane review (Gillies et al.) reached a more cautious conclusion, finding little overall benefit for parent- or teacher-rated ADHD symptoms. For general cognitive development in healthy children with adequate dietary DHA, supplementation benefits are less clear.
There is no universally agreed pediatric RDA for DHA, but health authorities generally recommend: 100–150 mg DHA/day for toddlers (1–3 years), 150–200 mg/day for ages 4–8, and 200–250 mg/day for ages 9–13. Most children's fish oil gummies contain 50–100 mg DHA per serving — often at the low end or below these targets. Check the label for actual EPA+DHA content per serving, not just "fish oil" milligrams (which includes fat that is not EPA or DHA). Algae-based DHA supplements are the best option for vegetarian children and avoid the heavy metal concerns associated with some fish-derived products. Mercury contamination in fish oil supplements is rare when products are purified, but look for brands that test for heavy metals and publish results.
Two to three servings of fatty fish per week is the dietary goal for school-age children and largely meets DHA needs. When dietary intake is consistently low, a pediatric omega-3 supplement with 150–250 mg DHA (not just "fish oil") per serving is a reasonable, safe addition. Fish oil is well-tolerated in children at these doses with minimal side effects beyond occasional fishy aftertaste — which flavored or enteric-coated products can largely eliminate. Consult your pediatrician before adding supplements to a child's regimen, particularly if the child is on any medications.
Magnesium is required for over 300 enzymatic reactions in the human body, including ATP synthesis, DNA repair, protein synthesis, and the regulation of neurotransmitters. It is the fourth most abundant mineral in the body and the second most abundant intracellular cation. It is also the micronutrient that approximately 48% of Americans fail to consume in adequate amounts, according to NHANES data — a number that rises to over 70% in older adults. Despite this prevalence, magnesium deficiency is rarely discussed, poorly understood, and frequently missed by standard blood tests.
The most common magnesium blood test measures serum magnesium (the magnesium circulating in blood plasma). The problem: serum magnesium represents only about 1% of total body magnesium; the remaining 99% is stored in bones, muscles, and soft tissue. The body vigorously maintains serum magnesium within a narrow range by drawing from intracellular and bone stores — meaning serum magnesium can appear normal even when tissue magnesium is severely depleted. A serum magnesium test can miss subclinical deficiency in the majority of cases. More sensitive tests include RBC (red blood cell) magnesium levels and the magnesium retention test (a urinary excretion test after IV magnesium), but these are rarely ordered in routine care.
Because magnesium is involved in so many physiological processes, deficiency produces a wide and nonspecific symptom profile that is easily attributed to other causes. Common presentations include: muscle cramps and spasms (especially nocturnal leg cramps), poor sleep quality and difficulty maintaining sleep, anxiety and irritability, fatigue not explained by anemia or thyroid dysfunction, headaches and migraines, elevated resting heart rate, constipation, and heightened sensitivity to noise and light. In clinical deficiency, cardiac arrhythmias and neuromuscular excitability (tetany) can occur. The subclinical range is associated with elevated blood pressure, elevated CRP, impaired insulin sensitivity, and increased risk of cardiovascular disease in epidemiological studies.
Modern agricultural practices have reduced the magnesium content of soil substantially over the past century, and consequently the magnesium content of many crops. USDA data show that leafy vegetables, once reliable magnesium sources, contain 20–38% less magnesium than they did in the 1940s. Ultra-processed food diets are inherently low in magnesium. Alcohol, caffeine, and diuretics all increase urinary magnesium excretion. Proton pump inhibitors (PPIs) impair magnesium absorption in the gut — a known but frequently undercommunicated risk of long-term PPI use. Metabolic syndrome and type 2 diabetes are both associated with increased urinary magnesium wasting.
Magnesium glycinate (chelated to glycine) is the best-tolerated and most bioavailable form for most people, with minimal laxative effect at doses up to 400 mg elemental magnesium. Magnesium citrate is also well-absorbed and somewhat less expensive, with mild laxative effects at higher doses. Magnesium oxide — the cheapest and most common form in multivitamins — has approximately 4% bioavailability and is primarily useful as a laxative, not a mineral supplement. The RDA is 310–420 mg elemental magnesium per day depending on age and sex. Supplement 100–200 mg in the evening; magnesium's muscle-relaxing and mild GABAergic effects support sleep quality when taken before bed.
Unlike pharmaceuticals, dietary supplements in the United States are not required to demonstrate safety or efficacy before reaching store shelves. The FDA regulates supplements under DSHEA (Dietary Supplement Health and Education Act of 1994), which places the burden of proof on the FDA to demonstrate that a product is unsafe after it reaches the market — not on manufacturers to prove it is safe before. The result is a market where quality varies enormously, mislabeling is common, and contamination with undisclosed pharmaceuticals is a documented problem at scale.
A 2015 New York Attorney General investigation tested herbal supplements from four major retailers (GNC, Target, Walgreens, Walmart) using DNA barcoding and found that the majority did not contain the primary labeled botanical, or contained unlisted species. The earlier peer-reviewed DNA-barcoding study by Newmaster et al. (BMC Medicine 2013, PMID 24120035) tested 44 products from 12 companies and found that about 59% had substitutions or fillers. Tucker et al. (JAMA Network Open 2018;1(6):e183337, PMID 30646238) catalogued pharmaceutical adulteration across the FDA's Tainted Products database, which has documented over 1,000 supplements containing undisclosed drugs — a list that represents only what has been tested, a fraction of the market.
Third-party certification programs provide independent verification that a supplement contains what its label claims, in the correct amounts, without undisclosed contaminants. The main trustworthy programs are:
A product with none of these seals is not necessarily low quality — some small manufacturers do rigorous internal testing — but it carries meaningfully more uncertainty. A product making aggressive health or performance claims with no third-party certification should be treated with skepticism.
Certain patterns reliably predict low quality or outright fraud. Proprietary blends that list ingredients without individual doses prevent consumers from knowing if any ingredient is at a clinically relevant amount — and often mean most ingredients are present only in trace quantities. Products with elaborate "matrix," "complex," or "formula" names applied to combinations of 15+ ingredients are almost never backed by evidence for the blend. Prices dramatically below market rate for a given ingredient (e.g., high-dose NMN at a fraction of established brand prices) often indicate underdosing or substitution. Products sold exclusively through social media with no retail presence, no registered manufacturing address, and no verifiable lot numbers are high-risk.
Check the FDA's Tainted Supplement database at fda.gov/food/dietary-supplement-products-ingredients/tainted-products-marketed-dietary-supplements-dbr before purchasing any weight loss, sexual enhancement, or bodybuilding supplement — these categories account for over 90% of documented adulterations. Use ConsumerLab or the NSF certified products database to check whether a product has been independently tested. Look for a lot number, manufacture and expiration dates, and a U.S. manufacturing address on every bottle. If a supplement does not have these basics, do not buy it. For high-cost supplements (NMN, CoQ10, specialized omega-3s), it is worth spending a few minutes on a brand's website to find their certificate of analysis (COA) — a test report that documents potency and purity for a specific batch.
Reviewed against 10 peer-reviewed and regulatory sources.
For athletes dealing with tendon pain, joint wear, or slow soft-tissue recovery, collagen has emerged as one of the more scientifically credible nutritional interventions in recent years. Unlike many sports supplements, the evidence for collagen in musculoskeletal applications is built on a mechanistic rationale that holds up under scrutiny — and a growing body of randomized trials that support specific use cases, particularly for tendons and cartilage.
Understanding the evidence requires distinguishing between the two main types of therapeutic collagen and the very different mechanisms through which each is theorized to work.
Type I collagen is the most abundant collagen in the human body, comprising roughly 90% of total collagen. It is the primary structural protein in tendons, ligaments, bones, and skin. Hydrolyzed type I collagen — the powdered supplement form — is derived from animal connective tissue (bovine, porcine, or marine sources) and broken into small peptides (primarily Pro-Hyp and Hyp-Gly dipeptides) that can be absorbed intact and have demonstrated signaling effects on fibroblasts, the cells responsible for maintaining tendon and ligament structure.
Type II collagen is the main collagen in articular cartilage. Supplements using undenatured type II collagen (UC-II) work through a completely different mechanism: oral tolerance. When native (undenatured) type II collagen fragments pass through gut-associated lymphoid tissue, they train the immune system to reduce its inflammatory attack on cartilage collagen. This mechanism is supported by studies in rheumatoid and osteoarthritis patients and explains why UC-II is effective at doses as low as 40 mg/day — far below what would be needed for simple amino acid delivery.
Mixing up these types is one of the most common consumer errors. A generic "collagen peptide" powder is primarily hydrolyzed type I/III and is not equivalent to UC-II for cartilage-specific applications.
The most compelling athletic use case for hydrolyzed collagen is tendon synthesis and injury prevention. A landmark 2017 study by Shaw et al., published in the American Journal of Clinical Nutrition, demonstrated that 15 g of gelatin (the cooked form of collagen) consumed 1 hour before intermittent exercise significantly increased collagen synthesis markers in blood and in engineered ligament tissue compared to placebo or a lower 5 g dose. Crucially, co-administration of vitamin C was required — the collagen synthesis pathway depends on vitamin C as a cofactor for the hydroxylation of proline and lysine.
This study provided the mechanistic basis for a practical protocol: consuming 15–20 g of hydrolyzed collagen with 50 mg of vitamin C approximately 30–60 minutes before exercise or rehabilitation work on tendons and ligaments. Subsequent research has supported this framework. A 2019 RCT in athletes with chronic Achilles tendinopathy found that collagen supplementation combined with a loading exercise program produced significantly greater reductions in pain and improvements in tendon stiffness compared to placebo plus exercise alone over 24 weeks.
The timing specificity matters: you want elevated collagen precursor levels in the blood during the exercise-stimulated window when tendon cells are most responsive to anabolic signaling.
For osteoarthritis and activity-related joint discomfort, both hydrolyzed type I collagen (at 10 g/day) and UC-II (at 40 mg/day) have clinical support. A head-to-head comparison by Crowley et al. (Int J Med Sci 2009, PMID 19847319) in 52 patients with knee osteoarthritis found UC-II 40 mg/day superior to a combination of glucosamine (1,500 mg) and chondroitin (1,200 mg) for reducing WOMAC pain, stiffness, and functional scores at 90 days — a notable finding given the dominant market position of glucosamine/chondroitin products. A subsequent larger trial by Lugo et al. (Nutr J 2016, PMID 26822714) replicated this pattern.
For athletes without existing joint pathology seeking to maintain joint health under high training loads, the evidence is less robust but mechanistically plausible. The prevailing sports nutrition view is that 10 g/day of hydrolyzed collagen is a low-risk, reasonably evidenced intervention for joint maintenance in high-impact athletes.
Reviewed against 6 peer-reviewed sources.
The longevity supplement market has exploded into a multi-billion dollar industry, fueled by compelling preclinical data, high-profile scientific advocates, and the deep human desire to slow biological aging. NMN, resveratrol, and spermidine now fill pharmacy shelves alongside more established vitamins, each promising to extend healthspan, reverse biological age, or activate ancient cellular repair pathways. The marketing is sophisticated, the science sounds credible, and the prices are high.
A sober assessment of the human clinical trial data reveals a consistent pattern: the mouse results that launched these supplements were genuinely exciting; the translation to humans has been, so far, disappointing.
Nicotinamide mononucleotide (NMN) and its close relative nicotinamide riboside (NR) raise blood NAD+ levels reliably and consistently in human trials — this part is not in dispute. What is disputed is whether this biomarker change translates into any measurable health benefit. As of early 2026, over a dozen published RCTs have tested these compounds in humans. The findings have been uniformly underwhelming for clinical outcomes: no significant improvements in insulin sensitivity (the primary endpoint in a major Washington University trial), no cognitive improvements in healthy adults, no consistent changes in muscle function, body composition, or inflammatory markers.
One small Japanese trial (n=42) found improvements in walking speed in men over 65, and this remains the most frequently cited positive finding. It has not been replicated. The honest evidence-based position is: NMN raises a biomarker whose health significance is unproven, at a cost of $60–120/month, with no demonstrated clinical benefit in healthy humans at marketed doses.
Resveratrol burst into public consciousness in the mid-2000s when David Sinclair's lab at Harvard reported it activated sirtuins (longevity-associated proteins) and extended lifespan in yeast, worms, and flies. In obese mice, high-dose resveratrol improved metabolic markers and extended lifespan. The media coverage was extraordinary. Supplements appeared almost immediately.
The subsequent decade of human research has been systematically deflating. GlaxoSmithKline acquired Sirtris Pharmaceuticals (a resveratrol-focused company co-founded by Sinclair) for $720 million in 2008, then shut it down in 2013 after clinical trials failed to show benefit. Multiple human trials have found no significant effects on lifespan markers, cardiovascular risk factors, insulin sensitivity, or inflammation in healthy adults. A landmark 2014 study in JAMA Internal Medicine found that resveratrol intake (measured by urinary metabolites) in an elderly Italian cohort was not associated with longer lifespan, less cancer, less cardiovascular disease, or less inflammation — if anything, higher resveratrol was associated with slightly worse outcomes.
The bioavailability problem is severe: resveratrol is rapidly metabolized in the gut and liver, with less than 1% of an oral dose reaching systemic circulation in its active form. The doses used in positive mouse studies, when scaled to human body weight, would be unrealistically large. Modified forms (micronized, liposomal) improve bioavailability modestly but have not produced compelling clinical results.
Spermidine is a polyamine found naturally in wheat germ, soybeans, aged cheese, and mushrooms. Its proposed longevity mechanism — autophagy induction (the cellular "self-cleaning" process that degrades damaged proteins and organelles) — is mechanistically sound and supported by strong preclinical data. In animal models, spermidine supplementation has extended lifespan across multiple species and improved cardiovascular and cognitive function.
In humans, the story is far shorter. A small proof-of-concept trial by Wirth et al. (Cortex 2018, PMID 29427839) found modest memory improvements with spermidine in older adults with subjective cognitive decline; the larger SmartAge follow-up by Schwarz et al. (Lancet Healthy Longevity 2022, PMID 34756517) using 0.9 mg/day of a wheat-germ extract for 12 months in 100 participants did not find significant improvement in the primary memory endpoint versus placebo. The wheat germ-based products used in these trials provide spermidine at levels achievable through dietary means for someone eating a varied plant-rich diet. Whether isolated supplementation beyond dietary levels provides meaningful additional benefit in healthy adults remains unproven.
The contrast between the hype around these three compounds and the evidence for other interventions is stark. Regular aerobic exercise is the most consistently and robustly documented intervention for extending healthspan in humans — it activates AMPK, reduces mTOR activity, induces autophagy, raises NAD+ through NAMPT activation, and has cardiovascular, metabolic, and cognitive benefits in hundreds of large RCTs. Caloric restriction and time-restricted eating have human trial data supporting improvements in multiple aging-associated biomarkers. Smoking cessation remains the single highest-impact modifiable longevity intervention available to smokers.
None of these require a monthly subscription. The supplement industry has been extraordinarily effective at monetizing the aspiration for convenient biological shortcuts in a space where the science is genuinely preliminary and the consumer verification burden is essentially zero. Watch the spermidine and NMN spaces — larger trials are ongoing and results could shift the picture. But as of now, paying premium prices for these compounds means paying for potential, not proven benefit.
Reviewed against 6 peer-reviewed sources.
Every autumn, zinc supplement sales spike dramatically as consumers stock up for cold season. The marketing is confident: zinc boosts immunity, shortens colds, and keeps you healthy through winter. The actual clinical evidence is considerably more nuanced — and highly dependent on the specific form of zinc, the dose, the timing, and the specific outcome being measured. Getting this wrong means buying expensive supplements with the wrong mechanism for the application you intend.
Zinc is an essential trace mineral involved in over 300 enzymatic reactions and is critical for the development and function of virtually every immune cell type — neutrophils, NK cells, T lymphocytes, B lymphocytes, and macrophages all require zinc. Deficiency impairs both innate and adaptive immunity significantly. Even mild zinc deficiency, which is common in the elderly, vegetarians, people with gut malabsorption, and those with high sweat loss, is associated with increased infection susceptibility and impaired vaccine responses.
This clear biological role has led to widespread marketing of zinc for "immune support." But the clinically important questions are more specific: Does supplemental zinc prevent infections? Does it reduce duration or severity of infections once contracted? And which form of zinc actually gets to the right place to do this?
The strongest evidence base for zinc and acute illness comes from Cochrane reviews on zinc lozenges for the common cold. Singh & Das's 2013 Cochrane review (updated 2015) pooled 18 RCTs and found that zinc supplementation started within 24 hours of symptom onset shortened cold duration. An updated 2024 Cochrane review by Nault et al. (PMID 38719213) reanalysed 34 trials and found low-certainty evidence that zinc may reduce cold duration by about 2 days on average, with substantial heterogeneity between trials. High-quality individual trials using zinc acetate or zinc gluconate lozenges at 75–100 mg of elemental zinc per day consistently show the largest effect.
The critical detail is the form: ionic zinc (from zinc acetate or zinc gluconate lozenges that dissolve slowly in the mouth) is required to produce this effect. The proposed mechanism is direct inhibition of rhinovirus replication in the nasal and throat mucosa — an effect that requires ionic zinc to be present in the upper respiratory tract mucous membranes, not merely absorbed into the bloodstream. Zinc that is swallowed as a tablet and absorbed through the gut does not produce the same effect because it does not contact the local infection site in ionic form.
For prevention, the evidence is weaker. Some trials show a reduction in cold incidence with regular zinc supplementation in zinc-deficient populations, but the prevention evidence in healthy zinc-sufficient adults is inconsistent.
The vast majority of zinc supplements sold for "immune support" are zinc tablets or capsules — zinc citrate, zinc picolinate, zinc bisglycinate — designed for systemic absorption. These are appropriate for correcting zinc deficiency, supporting long-term immune function in deficient individuals, and general nutritional supplementation. They are not appropriate as a treatment for acute cold symptoms, where you need ionic zinc in contact with upper respiratory mucosa.
Zinc lozenges must be used correctly to work: they should dissolve slowly in the mouth (not chewed or swallowed whole), should be started within 24 hours of symptom onset, and should be dosed every 2–3 hours while awake (not just once or twice daily). Most cold zinc products on pharmacy shelves are either the wrong form, the wrong dose, or used at the wrong timing. The efficacy data in Cochrane reviews applies specifically to zinc acetate or zinc gluconate lozenges providing at least 75 mg of elemental zinc per day, dissolved slowly in the mouth.
The RDA for zinc is 8 mg/day for women and 11 mg/day for men. The tolerable upper intake level is 40 mg/day for adults. Chronic intake above this can cause copper deficiency (zinc and copper compete for absorption), impair immune function (the opposite of the intended effect), and reduce HDL cholesterol. This means high-dose zinc supplementation for "immune boosting" is counterproductive if sustained — the dose required for lozenge efficacy in acute infections (75+ mg/day in ionic form) is appropriate only for short-term use during illness, not as a daily supplement.
For long-term immune support, the appropriate strategy is ensuring you are not deficient — zinc-rich foods (oysters, beef, pumpkin seeds, lentils, chickpeas) or a moderate-dose supplement (15–25 mg elemental zinc per day) if dietary intake is inadequate. High-risk groups include strict vegans and vegetarians (phytates in plant foods reduce zinc absorption significantly), elderly individuals, people with inflammatory bowel disease, and those taking long-term medications that deplete zinc.
Reviewed against 6 peer-reviewed sources.
Melatonin has become the most commonly used sleep supplement in children in the United States. Survey data suggests that 1 in 5 school-age children and adolescents now take melatonin at least occasionally, and it has become many parents' first resort for bedtime struggles, sleep onset difficulties, and night waking. The perceived safety — it's natural, it's a hormone the body makes anyway, it's widely available without prescription — has led to its adoption well ahead of the evidence for its safety and efficacy in pediatric populations.
The American Academy of Pediatrics (AAP) and sleep medicine specialists have raised significant concerns about this pattern. Those concerns deserve careful examination.
Melatonin is a hormone produced by the pineal gland in response to darkness. It signals to the brain and body that night has arrived, helping to initiate the circadian shift toward sleep. Crucially, melatonin is a circadian signal, not a sedative — it shifts the timing of sleep onset rather than increasing sleep pressure or duration. This distinction matters enormously: melatonin is most useful when the problem is sleep timing (difficulty falling asleep at the desired time) and is much less useful for maintaining sleep or for children who simply don't feel tired at bedtime due to insufficient sleep pressure.
In children with circadian rhythm difficulties — particularly those with autism spectrum disorder (ASD) or ADHD, where melatonin rhythm disruption is common — melatonin supplementation has a reasonable evidence base. Multiple RCTs in children with ASD have found that low-dose melatonin (0.5–3 mg) improved sleep onset latency and total sleep time with minimal side effects over 3–6 month periods. This is the population where clinical use is most defensible.
Consumer melatonin products designed for adults typically contain 3–10 mg per dose. In adults, even these doses are pharmacologically excessive — research consistently shows that the effective circadian signal dose for adults is 0.5–1 mg, not 5–10 mg. In children, the gap is even wider. Pediatric pharmacologists generally recommend starting at 0.5 mg and rarely exceeding 3 mg in children, with timing of administration (30–60 minutes before desired sleep onset) being critical.
The products most parents reach for — gummy melatonin supplements specifically marketed with children's branding — frequently contain 1–5 mg per gummy, with inconsistent actual content. Cohen et al. (JAMA 2023, PMID 37097570) analysed 25 melatonin gummy products sold in the US and found that 22 of 25 had quantified melatonin content deviating from the label (range 74–347% of labeled amount); one "melatonin" product contained no detectable melatonin. A separate analysis by Erland & Saxena (J Clin Sleep Med 2017, PMID 28095978) of 31 products found content ranging from −83% to +478% of label and detected serotonin in a quarter of them. Parents giving children "1 gummy" may be administering several times the effective pediatric dose, and CDC surveillance documented a rise in pediatric melatonin-related poison control calls of roughly 530% between 2012 and 2021 (Lelak et al., MMWR 2022, PMID 35653308).
Melatonin itself does not cause physiological addiction in the pharmacological sense. However, behavioral dependency is a well-documented clinical concern: children who receive melatonin every night may not develop the natural ability to self-regulate sleep onset, become reliant on the external signal, and struggle to fall asleep without it when the supplement is discontinued. Sleep medicine specialists uniformly emphasize that sleep hygiene and behavioral interventions (consistent schedules, appropriate light exposure, no screens before bed) should be the first-line approach, with melatonin as a short-term adjunct, not a nightly indefinite intervention.
The AAP's 2023 position: while melatonin can be appropriate for specific clinical uses in children with sleep disorders — particularly in ASD and ADHD — there is insufficient evidence to support long-term nightly use in otherwise healthy children with behavioral sleep difficulties. Parents should consult a pediatrician before giving melatonin to children under 3, use the lowest effective dose, set a defined treatment duration (weeks, not indefinitely), and pair it with consistent behavioral sleep strategies.
Reviewed against 6 peer-reviewed and regulatory sources.
Protein supplements are the largest and most thoroughly studied segment of the sports nutrition market. The question of which protein source is "best" generates endless debate in gyms and online communities, usually driven by brand loyalty, dietary ideology, or marketing rather than evidence. The scientific reality is more useful: different protein sources have different characteristics that matter differently depending on your goals, timing, and dietary context.
Understanding protein quality requires grasping a few key concepts before comparing sources: protein digestibility, amino acid profile, leucine content, and absorption kinetics.
The gold standard for measuring protein quality has shifted from the older Protein Digestibility Corrected Amino Acid Score (PDCAAS) to the Digestible Indispensable Amino Acid Score (DIAAS), which the FAO now recommends. Both scores measure how well a protein source provides all essential amino acids relative to human requirements, adjusted for digestibility. DIAAS is considered more accurate because it measures ileal (small intestinal) digestibility rather than total digestibility, giving a more accurate picture of what actually becomes bioavailable.
By DIAAS, animal proteins (whey, casein, eggs, dairy) generally score above 1.0 (exceeding requirements), while most plant proteins score below 1.0 due to lower digestibility and/or limiting amino acids. Soy protein is the notable exception among plant proteins, scoring near or above 1.0 in most analyses.
Whey protein is the watery fraction left after milk is curdled to make cheese. It has the highest leucine content of any commonly used protein supplement (roughly 10–11% of amino acid composition), rapid digestion and absorption kinetics, and a DIAAS above 1.0. Leucine is the critical trigger for muscle protein synthesis (MPS) through mTOR activation — the leucine threshold for maximizing MPS per meal appears to be approximately 2.0–3.0 g, which is reliably achieved with a 20–25 g serving of whey.
Three forms exist: whey concentrate (typically 70–80% protein, retains some lactose and fat, cheapest), whey isolate (>90% protein, minimal lactose, more expensive, preferable for lactose-sensitive individuals), and hydrolyzed whey (pre-digested peptides, fastest absorption, most expensive, with modest evidence of faster but equivalent peak MPS compared to isolate). For most people, concentrate or isolate is the evidence-supported choice. Hydrolyzed whey's faster absorption provides marginal benefit primarily in very narrow post-exercise windows.
Casein makes up roughly 80% of milk protein and forms curds in the stomach, resulting in slow, sustained amino acid release over 5–7 hours compared to whey's 1–2 hour peak. This kinetic difference makes casein well-suited for specific applications: pre-sleep consumption to support overnight muscle protein synthesis, and situations where a single meal or supplement needs to sustain amino acid availability over extended periods.
A landmark 2012 study by Res et al., published in Medicine & Science in Sports & Exercise, found that 40 g of casein protein consumed before sleep increased overnight MPS rates and next-morning whole-body protein balance compared to placebo. This finding has been replicated multiple times and represents one of the more useful timing applications in protein supplementation — particularly for athletes in high training loads who cannot meet protein needs during waking hours alone.
For maximizing overall muscle protein synthesis across a day, whey's higher leucine content and faster kinetics make it the default recommendation around training. Casein provides a useful complement for overnight recovery.
Plant protein supplements have improved substantially as the market has grown. Standalone soy protein isolate has the best amino acid profile of plant options and is bioequivalent to whey in muscle protein synthesis outcomes in several head-to-head trials when dose is matched by leucine content. Pea protein isolate, while lower in methionine, has a reasonable leucine content and reasonable DIAAS score; a 2015 study found comparable muscle thickness gains to whey after 12 weeks of resistance training in young men.
The key limitation of plant proteins individually is often a limiting amino acid — pea protein is low in methionine; rice protein is low in lysine. Blended plant protein formulas (pea + rice, or pea + hemp) are designed to complement these limitations and typically produce amino acid profiles closer to completeness than single-source plant proteins. If using a plant protein, a blend or a higher dose (25–35 g) to compensate for lower leucine density per gram of protein is advisable.
Most adults eating varied diets with adequate total calories meet protein requirements without supplementation. The populations most likely to benefit from protein supplementation are: older adults (sarcopenia risk is significant over 65; protein needs increase to approximately 1.2–1.6 g/kg/day with adequate leucine per meal being more important), athletes in caloric restriction or very high training volumes, vegans who find it challenging to meet complete protein needs through whole foods, and people recovering from injury or surgery.
The timing mythology of a narrow "anabolic window" has been significantly revised by research — total daily protein intake matters far more than precise timing for most people. Distribute protein reasonably across meals (each meal containing at least 25–40 g with a leucine-sufficient profile), meet total daily targets (1.6–2.2 g/kg for active individuals), and protein supplements become a convenient tool rather than a mandatory one.
Reviewed against 6 peer-reviewed sources.
The liver supplement category is among the most crowded and most misleading in the supplement market. Products promising to "detox," "cleanse," or "support liver health" line pharmacy shelves, most of them containing proprietary blends of botanical ingredients backed by minimal to no clinical evidence. But within this noise, two compounds stand out for having genuine evidence in specific clinical contexts: N-acetyl cysteine (NAC) and silymarin from milk thistle.
Understanding these compounds requires separating what they demonstrably do from what they are marketed to do.
N-acetyl cysteine is a precursor to glutathione, the body's primary endogenous antioxidant. NAC is, unambiguously, one of the most evidence-backed compounds in all of medicine — but primarily for specific high-risk applications, not general liver "support."
Its most established use is as an antidote for acetaminophen (paracetamol) overdose. Acetaminophen is metabolized partly into a toxic intermediate (NAPQI) that depletes hepatic glutathione and causes liver necrosis in overdose. Intravenous NAC is standard emergency medicine, reducing mortality from acetaminophen overdose dramatically when given within 24 hours. This mechanism has led to interest in NAC for chronic low-grade acetaminophen-induced liver stress in regular users.
For non-alcoholic fatty liver disease (NAFLD), the evidence is emerging but not yet conclusive. A 2010 RCT in Hepatitis Monthly by Khoshbaten et al. (PMID 22312426) found that 1,200 mg/day of NAC over 3 months significantly reduced liver enzymes (ALT, AST) in NAFLD patients compared to standard care with vitamin C. Subsequent small trials and a 2018 meta-analysis in Clinical Nutrition ESPEN similarly found improvements in ALT with NAC in NAFLD. These are meaningful signals, though trials are relatively small and longer-term outcome data (on cirrhosis progression, for example) is lacking.
NAC at 600–1,800 mg/day is generally well-tolerated. The main practical consideration: NAC has mucolytic (mucus-thinning) properties that make it useful in pulmonary conditions but can cause GI discomfort at higher doses. It also has emerging evidence in psychiatric conditions (OCD, addiction) where oxidative stress and glutamate pathways are implicated — the mechanistic rationale extends well beyond the liver.
Milk thistle (Silybum marianum) seeds contain silymarin, a flavonolignan complex with well-documented hepatoprotective properties in laboratory and animal studies: it inhibits free radical production, stabilizes hepatocyte cell membranes, promotes liver cell regeneration, and has anti-fibrotic effects. The pharmacology is legitimate.
In humans, the evidence is most supportive for alcoholic liver disease and viral hepatitis. Multiple trials have shown that silymarin supplementation (140–420 mg/day of standardized extract, equivalent to 420–700 mg milk thistle) reduces liver enzymes in alcoholic hepatitis and chronic hepatitis patients. A 2005 Cochrane review identified 13 RCTs and found benefits primarily in alcoholic liver disease, though methodological quality was variable.
For NAFLD, the data is moderately positive. A 2017 meta-analysis in Phytotherapy Research pooled 8 RCTs and found significant reductions in ALT, AST, and fasting blood glucose in NAFLD patients taking silymarin compared to placebo — effect sizes were modest but consistent. The limitation is that most trials use surrogate markers (liver enzymes, liver fat on imaging) rather than hard endpoints (cirrhosis, liver failure, mortality). Whether silymarin prevents disease progression in NAFLD patients is not established.
For healthy individuals using alcohol occasionally and seeking "liver protection," the evidence is weak. The liver is extraordinarily capable of regeneration and detoxification at moderate alcohol exposures, and the hepatoprotective effects of silymarin are most pronounced in established disease states, not as prevention in healthy livers under normal stress.
Products containing dandelion root, artichoke leaf, burdock, turmeric combinations, activated charcoal, and similar botanical blends for "liver detox" have essentially no clinical evidence. The liver does not require external "detoxification" assistance in healthy individuals — it performs continuous detoxification biochemistry as its primary function. The commercial use of "detox" language has no physiological basis and is primarily a marketing construct.
The compounds with the best evidence in specific liver conditions remain NAC (for glutathione depletion scenarios and emerging NAFLD evidence) and silymarin-standardized milk thistle (for alcoholic liver disease and as an adjunct in NAFLD). Neither should be viewed as a substitute for addressing the underlying causes of liver stress: alcohol reduction, weight loss in NAFLD, medication review, and metabolic syndrome management.
Reviewed against 6 peer-reviewed sources.
Testosterone booster supplements represent one of the largest and most lucrative segments of the men's health supplement market — and one of the most systematically unsupported by clinical evidence. Products claiming to "naturally boost testosterone," "optimize hormonal health," and "restore peak male vitality" generate billions in annual sales, backed primarily by aggressive marketing, selective use of preclinical data, and deeply embedded cultural anxieties about masculinity and aging.
Three ingredients appear most frequently in these products: tribulus terrestris, tongkat ali (Eurycoma longifolia), and fenugreek. Each has a body of research behind it. That research consistently tells the same story.
Tribulus terrestris is the most common ingredient in testosterone booster supplements globally. Its proposed mechanism — increasing luteinizing hormone (LH) secretion from the pituitary, which signals the testes to produce more testosterone — is theoretically plausible and based on animal studies in rodents. In rats, tribulus extracts have shown modest increases in testosterone-dependent behaviors and androgen receptor sensitivity.
In humans, the results are unambiguous: no effect on testosterone. The 2005 double-blind placebo-controlled trial by Neychev & Mitev in the Journal of Ethnopharmacology (PMID 16023808) — the most cited human trial on tribulus — randomized 21 young men to 450 mg/day of tribulus or placebo for 4 weeks and found no significant difference in total or free testosterone, luteinizing hormone, or androstenedione. A 2014 systematic review in the Journal of Dietary Supplements by Qureshi et al. pooled available human data and reached the same conclusion. Subsequent longer trials of tribulus in resistance-trained men have likewise found no effect on testosterone, body composition, or performance.
The dose needed to produce testosterone effects in rats, when scaled to human body weight, would be many times higher than any commercially available product provides. The preclinical data simply does not translate.
Tongkat ali is a Southeast Asian medicinal plant with a more nuanced evidence picture than tribulus. Several human trials have found modest increases in testosterone, particularly in populations with low baseline testosterone due to stress, aging, or late-onset hypogonadism. A 2012 pilot study published in Phytotherapy Research found that 200 mg/day of a standardized extract (Physta) for 4 weeks in 76 men with late-onset hypogonadism symptoms increased total testosterone from below-normal to low-normal range in a meaningful proportion of participants. A 2013 study in the same journal found similar effects in 63 men under chronic stress, with accompanying reductions in cortisol.
The critical context: these benefits appear primarily in men whose testosterone is below normal due to stress or aging — populations where even modest increases may produce subjective benefit. In healthy young men with normal testosterone levels, tongkat ali does not significantly raise testosterone further. The effect may be more accurately characterized as stress reduction (cortisol lowering) secondarily improving testosterone, rather than direct androgenic stimulation. The marketing does not make this distinction.
Fenugreek's proposed testosterone mechanism is different: its saponins (particularly protodioscin) inhibit aromatase and 5-alpha reductase, enzymes that convert testosterone to estrogen and DHT respectively. By reducing testosterone breakdown, the theory goes, more testosterone remains in circulation. A 2011 industry-funded trial found increases in both total and free testosterone in men taking a fenugreek extract over 8 weeks, alongside improvements in strength training performance. Several subsequent trials have found improvements in libido and sexual function.
The testosterone increases reported in fenugreek trials are consistently modest — on the order of 6–12% over baseline — and their clinical significance is unclear. For comparison, clinically meaningful testosterone replacement therapy produces increases of 300–500%. The strength and libido improvements may be attributable to other mechanisms (fenugreek has hypoglycemic effects that could improve training performance through blood sugar regulation) rather than specifically to testosterone elevation. Independent replication from groups without financial conflicts of interest is limited.
The irony is that the most powerful natural interventions for maintaining healthy testosterone levels are lifestyle factors that most supplement purchasers are already aware of but find less marketable than a capsule: resistance training (consistently the most potent natural testosterone stimulus, with acute increases of 15–25% and chronic improvements in baseline); adequate sleep (testosterone is primarily synthesized during sleep, and a week of sleep restriction to 5 hours per night reduces testosterone by 10–15%); body fat reduction (adipose tissue contains aromatase, and reducing body fat in overweight men reliably increases testosterone); zinc and vitamin D repletion in deficient individuals (both are required cofactors for testosterone synthesis); and stress management (chronic cortisol elevation suppresses LH and testosterone).
None of these come in a proprietary blend. The testosterone booster market survives not because its products work, but because its promises are compelling and the gap between desire and verification is wide.
Reviewed against 7 peer-reviewed sources.
Pregnancy is the period in which supplement decisions carry the highest stakes of any in human life. Getting the essential nutrients right prevents neural tube defects, supports fetal brain development, prevents maternal anemia, and reduces preterm birth risk. Getting it wrong — taking the wrong supplements, the wrong doses, or categories that are contraindicated — can cause fetal harm, miscarriage, or toxicity with consequences that are irreversible. The gap between evidence-based supplementation and popular supplement culture is wider in pregnancy than almost anywhere else.
Folate/Folic Acid: The most critical pregnancy supplement, and ideally one started before conception. Folate is essential for neural tube closure, which occurs in the first 28 days of pregnancy — often before a woman knows she is pregnant. The recommended dose is 400–800 mcg/day of folic acid (or methylfolate for women with MTHFR variants who have impaired folic acid conversion). Women with prior neural tube defect pregnancies or certain medical conditions require 4–5 mg/day under medical supervision. This is one of the most robustly evidence-based supplementation recommendations in medicine — neural tube defect rates dropped approximately 70% in countries that implemented mandatory folic acid fortification.
DHA (Omega-3): DHA is essential for fetal brain and retinal development, with active brain accumulation occurring primarily in the third trimester. Most prenatal vitamins do not contain adequate DHA. The WHO recommends at least 200 mg/day of DHA in pregnancy. The DOMInO trial by Makrides et al. (JAMA 2010, PMID 20959535), the largest RCT on pregnancy DHA to date, supplemented 800 mg/day of DHA from mid-pregnancy and found no significant effect on early childhood cognition (Bayley MDI at 18 months) but a reduction in very-early preterm birth; a 2018 Cochrane review by Middleton et al. (PMID 30480773) pooled 70 trials and concluded omega-3 in pregnancy reduces preterm birth and low birth weight but does not reliably improve later neurodevelopmental scores. Algal DHA avoids the mercury contamination risk of fish and is bioequivalent to fish-derived DHA.
Iron: Iron requirements roughly double in pregnancy due to expanded blood volume and fetal needs. Approximately 50% of pregnant women globally develop iron deficiency anemia. The WHO recommends 30–60 mg of elemental iron daily throughout pregnancy. Iron supplements cause GI side effects (constipation, nausea) in many women — ferrous bisglycinate is significantly better tolerated than ferrous sulfate with similar efficacy, though more expensive. Taking iron with vitamin C improves absorption; taking it with calcium, dairy, or tea reduces it substantially.
Iodine: Often overlooked, iodine is essential for fetal thyroid development and neurological maturation. Iodine deficiency is the world's leading preventable cause of intellectual disability. Many prenatal vitamins do not contain adequate iodine (150 mcg/day recommended; many products contain 0–50 mcg). Check your prenatal vitamin label specifically for iodine content.
Vitamin D: Most prenatal vitamins contain 400 IU, but optimal vitamin D status in pregnancy (serum 25-OH-D above 40–50 ng/mL) typically requires 1,500–2,000 IU/day for most women. Vitamin D deficiency in pregnancy is associated with gestational diabetes, preeclampsia, and poorer neonatal bone development. Testing levels and supplementing to sufficiency is the evidence-based approach.
Vitamin A above 10,000 IU/day: Preformed vitamin A (retinol, retinyl acetate, retinyl palmitate) is teratogenic at high doses, causing characteristic patterns of fetal malformation involving the skull, brain, and heart. Most prenatal vitamins contain vitamin A as beta-carotene (which the body converts only as needed and is safe), but check that any additional vitamin A supplementation does not push total preformed vitamin A above 10,000 IU/day. Avoid supplements marketed for skin, hair, or beauty that may contain high preformed vitamin A doses.
Herbal supplements: The majority of herbal supplements have not been tested for safety in pregnancy. Several have documented risks. Blue cohosh and black cohosh can stimulate uterine contractions. Dong quai and licorice root have hormonal effects. St. John's Wort has CYP enzyme effects affecting drug metabolism. Echinacea's safety in the first trimester is uncertain. High-dose ginger above 1,000 mg/day raises concerns. The general principle is: avoid herbal supplements unless specifically reviewed and approved by your obstetrician.
High-dose herbs in "detox" or "cleanse" products: These often contain multiple herbal ingredients at undisclosed or excessive doses and are never appropriate in pregnancy.
Prebiotics and probiotics: Generally considered safe during pregnancy for specific strains with safety data (Lactobacillus rhamnosus GG, Lactobacillus acidophilus). Novel or unvalidated strains should be avoided.
Look for: at least 400–800 mcg folate (methylfolate preferred for universal coverage), at least 27 mg iron (ferrous bisglycinate for tolerability), 200+ mg DHA, 150 mcg iodine, 600–1,000 IU vitamin D (supplementing additional separately is often needed), choline (very few prenatals contain adequate choline at 450 mg/day — it is critical for fetal brain development and often completely absent from prenatal formulas).
Reviewed against 11 peer-reviewed and regulatory sources (safety-category rigor).
The term "adaptogen" was coined in 1947 by Soviet pharmacologist Nikolai Lazarev and developed further by Israel Brekhman in the 1960s to describe a class of compounds that non-specifically increase resistance to biological stress. The concept arose from Soviet military research into performance enhancement under extreme conditions. Decades later, the term has been adopted wholesale by the wellness industry as marketing language for a diverse range of botanical supplements, most of which don't meet the original pharmacological criteria and many of which lack meaningful clinical evidence.
Within this category, two compounds stand out as having genuine mechanistic rationale and the most robust human clinical evidence: ashwagandha (Withania somnifera) and Rhodiola rosea. Understanding what these plants actually do requires understanding the biology of stress they target — the HPA axis.
The hypothalamic-pituitary-adrenal (HPA) axis is the body's primary hormonal stress response system. When the brain perceives a stressor, the hypothalamus releases corticotropin-releasing hormone (CRH), which signals the pituitary to release ACTH, which signals the adrenal glands to produce cortisol. Cortisol mobilizes energy, suppresses immune function and inflammation, and prepares the body for immediate demands. This acute response is adaptive and life-sustaining.
Chronic stress, however, produces persistent HPA activation, sustained elevated cortisol, progressive HPA dysregulation, and downstream effects including impaired sleep, anxiety, impaired memory and concentration, suppressed immune function, disrupted sex hormone production, and elevated cardiovascular risk. Adaptogens, at least the well-studied ones, appear to work primarily by modulating HPA axis reactivity — reducing cortisol output under stress conditions, improving HPA negative feedback, and supporting the recovery phase after acute stress.
Ashwagandha's primary active compounds are withanolides, steroidal lactones that modulate stress response pathways. Multiple RCTs using standardized extracts (KSM-66 or Sensoril) have found consistent reductions in serum cortisol (14–28% below baseline in controlled studies), reduced PSS (Perceived Stress Scale) scores, and improvements in GAD-7 anxiety scores in clinically stressed populations. The signal for stress and anxiety is the most replicated and credible finding in the adaptogen literature.
Important context: the benefits are most pronounced in individuals with elevated baseline stress and cortisol — the effect appears to be normalizing rather than uniformly cortisol-suppressing. In healthy, unstressed individuals, ashwagandha's effects are considerably more modest. This is actually consistent with the original adaptogen concept of non-specific stress resistance rather than pharmacological suppression of a normal physiological response.
The safety caveat: a growing number of case reports of ashwagandha-associated hepatotoxicity in susceptible individuals has emerged. The mechanism is likely immune-mediated rather than directly toxic, and cases primarily involve higher doses (>500 mg/day) and non-standardized products. Cycling — 8–12 weeks on, 4 weeks off — is the standard recommendation to minimize prolonged exposure risk.
Rhodiola rosea is a root used in traditional medicine across Scandinavia, Russia, and Central Asia for centuries, particularly for fatigue, cold weather performance, and mental endurance. Its primary active compounds are rosavins and salidroside, which appear to modulate catecholamine release (dopamine, norepinephrine, serotonin) in addition to HPA axis effects, providing a somewhat different neurochemical profile from ashwagandha.
The clinical evidence for Rhodiola is strongest for burnout and fatigue-related conditions. A 2009 RCT by Olsson et al. (Planta Medica 75(2):105–112, PMID 19016404) randomized 60 adults with stress-related fatigue to standardized Rhodiola rosea extract SHR-5 (576 mg/day) or placebo for 28 days. The Rhodiola group showed significant improvements in fatigue (Pines Burnout Scale), attention (concentration test), and morning salivary cortisol response — with particularly notable improvements in cognitive function and mental fatigue measures. A 2012 systematic review by Hung et al. in Phytomedicine concluded Rhodiola shows a signal for physical and mental fatigue under stress conditions but noted variable trial quality.
For acute cognitive performance under stress (exam pressure, shift work, sleep deprivation), Rhodiola has a reasonably consistent evidence base across several trials. The effect is more stimulant-like in onset than ashwagandha's more gradual HPA modulation — some users describe a faster-onset sense of mental clarity and reduced fatigue. This appears related to salidroside's effects on monoamine neurotransmitter systems.
The cycling recommendation for adaptogens is not an arbitrary convention — it reflects genuine uncertainty about long-term HPA axis effects. The HPA axis has elaborate negative feedback mechanisms that prevent chronic cortisol oversuppression. Chronically blunting cortisol responses through prolonged adaptogen use may theoretically alter HPA sensitivity and feedback set points. There is limited human data on adaptogen effects with continuous use beyond 12–16 weeks. The practical protocol most herbalists and researchers recommend is: 8–12 weeks of active use, 2–4 weeks off, repeat as needed. This approach minimizes unknown long-term risks while preserving the short-term benefits in high-stress periods.
Reviewed against 6 peer-reviewed sources.
The supplement industry operates under a regulatory framework that would be unacceptable in any other category of health product. Unlike pharmaceuticals, dietary supplements in the United States are not required to demonstrate safety or efficacy before being sold. They are not required to prove that the label accurately reflects the contents. They are not required to be tested for contamination. The FDA's authority is largely reactive — it can take action after harm is demonstrated, not preventively before a product reaches shelves.
Third-party testing organizations exist precisely because of this gap. What their results reveal about the supplement industry is disturbing enough that every supplement user should understand it.
ConsumerLab.com, one of the most comprehensive independent supplement testing organizations, has conducted over 5,000 product tests over two decades. Their published data consistently shows that approximately 20–30% of products tested in any given category fail for at least one of the following: incorrect ingredient amounts (over or under label claim), contamination with heavy metals (lead, arsenic, cadmium, mercury), contamination with undeclared ingredients, failing disintegration or dissolution testing, or undisclosed contaminants including pesticide residues.
The failure rates are not uniformly distributed. Herbal supplements and botanical extracts fail at higher rates than isolated vitamins and minerals. Products from smaller manufacturers without formal quality systems fail more often than products from established manufacturers with pharmaceutical-grade facilities. Products sold on Amazon's third-party marketplace fail at higher rates than products sold through traditional retail, partly because authenticity verification in that channel is weak and counterfeiting is documented.
The most alarming finding category is adulteration of supplements with undisclosed pharmaceutical drugs. The FDA's database of tainted products marketed as dietary supplements has, as of 2025, catalogued over 1,000 products found to contain undeclared drug ingredients. The most common categories are: sexual enhancement supplements (commonly adulterated with sildenafil, tadalafil, or analogs); weight loss supplements (contaminated with sibutramine, which was withdrawn from the market due to cardiovascular deaths, and various stimulant analogs); and muscle-building supplements (contaminated with anabolic steroids, SARMs, or designer hormone analogs).
This is not trace contamination from manufacturing cross-contamination — it is intentional adulteration. Consumers purchasing "all-natural" sexual enhancement supplements may be taking pharmacologically significant doses of PDE5 inhibitors without knowing it, with serious implications for anyone taking nitrates (for heart disease) where the drug combination can cause fatal hypotension. The FDA's MedWatch system receives thousands of serious adverse event reports from supplement products annually, and many of the most serious cases involve adulterated products in these categories.
Three certification programs represent the gold standard for verified supplement quality, each with somewhat different focuses:
USP Verified: The United States Pharmacopeia's verification program tests that a product contains the declared ingredients at the stated amounts, is free from harmful levels of contaminants, will properly break down and release its ingredients in the body, and is manufactured under proper quality control. USP is the most rigorous and broadly credible program for general supplement quality.
NSF International: NSF's Certified for Sport program is specifically designed for athletes subject to anti-doping regulations. It tests for 270+ athletic-banned substances in addition to general quality markers. A supplement with NSF Certified for Sport can be used by competitive athletes with reasonable confidence it will not cause a positive anti-doping test. NSF's general dietary supplement certification covers quality and contaminant testing without the banned substance screen.
Informed Sport / Informed Choice: UK-based program with similar scope to NSF Certified for Sport, widely used in professional sports globally. Products are batch-tested, meaning each manufactured lot is tested before sale, not just the formula once at certification.
The limitation: these certifications are voluntary, expensive, and available to only a fraction of the thousands of products on the market. A product without a certification seal is not necessarily unsafe — many reputable manufacturers maintain excellent quality without pursuing formal certification. But in higher-risk categories (sports performance, weight loss, sexual enhancement, herbal combinations), third-party certification is the only way a consumer can have reasonable confidence in what they are taking.
Reviewed against 9 peer-reviewed and regulatory sources.
For a decade, "gut health" was synonymous with probiotics. The science has moved well past that. The field now recognizes that the gut microbiome — the roughly 38 trillion microorganisms residing in the human intestine — is a dynamic ecosystem that interacts with the immune system, the nervous system, and metabolic function in ways that no single probiotic strain can meaningfully influence on its own.
The emerging hierarchy in gut health research places prebiotics and dietary diversity at the foundation, probiotics as a potentially useful but limited tool, and postbiotics as a newer category with growing mechanistic evidence.
Prebiotics are fibers and compounds that selectively nourish beneficial gut bacteria. The best-studied prebiotics include inulin and fructooligosaccharides (FOS), found in chicory root, garlic, and leeks; galactooligosaccharides (GOS), produced from lactose; and resistant starch from cooked-and-cooled potatoes and unripe bananas. The Stanford-led 17-week randomized trial by Wastyk et al. (Cell, 2021) directly compared a high-fiber diet to a high-fermented-food diet in healthy adults; the fermented-food arm consistently increased microbiota diversity and reduced inflammatory markers, while the fiber arm produced individualized responses tied to baseline microbiome diversity. Most intervention studies showing benefit use 5–20 g/day of a specific prebiotic fiber.
Postbiotics are the bioactive metabolites produced when gut bacteria ferment fiber. Short-chain fatty acids (SCFAs) — particularly butyrate, propionate, and acetate — are the best understood. Butyrate is the primary energy source for colonocytes, maintains the gut barrier, and has demonstrated anti-inflammatory properties in preclinical and early human research. You cannot supplement SCFAs effectively in pill form — the strategy that works is consuming fermentable fiber that your microbiome converts to SCFAs in situ.
The interventions with the clearest human evidence for gut health are: increasing dietary fiber to 25–35 g/day from diverse sources, consuming fermented foods daily (yogurt, kefir, kimchi, sauerkraut, miso), avoiding unnecessary antibiotic use, and using specific probiotic strains for specific indications rather than generic "probiotic" products. The gut microbiome responds measurably to dietary changes within 48–72 hours — for better or worse.
Reviewed against 4 peer-reviewed sources.
Fish oil is one of the most widely consumed supplements globally and one of the most frequently mislabeled and oxidized. Independent surveys of retail fish oil products in the US, UK, New Zealand, and Australia have repeatedly found that a substantial share of tested products exceed at least one voluntary oxidation threshold — sometimes before the consumer ever opens them. Rancid fish oil doesn't just smell bad; oxidized lipids may attenuate the cardiovascular benefits and could potentially cause harm.
Omega-3 fatty acids are highly unsaturated, which makes them biologically active and also chemically unstable. Exposure to heat, light, and oxygen triggers lipid peroxidation, measured via peroxide value (PV), anisidine value (AnV), and the combined TOTOX score (2×PV + AnV). The Global Organization for EPA and DHA Omega-3s (GOED) sets voluntary thresholds (PV ≤ 5, AnV ≤ 20, TOTOX ≤ 26). The Albert et al. New Zealand survey published in Scientific Reports (2015) tested 32 retail fish oil products and reported that the majority exceeded at least one of these voluntary oxidation limits.
Look for third-party certification. IFOS (International Fish Oil Standards) is the most rigorous fish oil-specific certification, testing for oxidation, potency, contaminants, and heavy metals. IFOS 5-star certified products are the benchmark.
Check the form. Triglyceride (TG) form fish oil is absorbed 70% better than ethyl ester (EE) form, which is the cheap industrial form used in many products. Re-esterified triglyceride (rTG) form is the best absorbed.
Dose reality check. Many products advertise "1,000 mg fish oil" but contain only 300 mg of EPA+DHA. Aim for at least 1,000–2,000 mg of combined EPA+DHA daily from the Supplement Facts panel. Refrigerate after opening and use within 90 days.
Reviewed against 4 peer-reviewed and standards sources.
Vitamin B12 deficiency is estimated to affect roughly 10–20% of adults over 60, with the proportion rising in subgroups taking proton pump inhibitors (PPIs), metformin, or following strict vegetarian diets. It often presents with vague, progressive symptoms easily attributed to normal aging: fatigue, forgetfulness, numbness and tingling in the extremities, and low mood. Most cases are preventable and reversible if caught early.
B12 absorption from food requires stomach acid to release B12 from protein. Age-related atrophic gastritis reduces stomach acid production in a meaningful share of adults over 50. Long-term PPI use and metformin therapy each independently lower B12 absorption through different mechanisms. The American Family Physician 2017 review by Langan and Goodbred lists screening criteria including PPI use beyond 12 months, metformin use beyond 4 months, vegan or strict vegetarian diet, prior gastric or small-bowel surgery, and age over 75. Wolffenbuttel et al.'s 2020 NHANES analysis (Netherlands Journal of Medicine) showed that elevated methylmalonic acid (MMA) — a more sensitive marker than serum B12 — was more strongly tied to functional decline than serum B12 alone.
Early B12 deficiency elevates homocysteine and methylmalonic acid (MMA) before serum B12 falls below the standard laboratory reference range — meaning standard blood tests can miss it. Neurological effects — subacute combined degeneration of the spinal cord — can be irreversible if deficiency persists for years. Macrocytic anemia, cognitive decline, and peripheral neuropathy are the classic advanced presentations.
The most sensitive tests are serum methylmalonic acid and holotranscobalamin (active B12). Anyone over 50, anyone on long-term PPI or metformin therapy, and all vegans should be tested. Sublingual methylcobalamin at 1,000 mcg/day is effective even in people with impaired intrinsic factor, as passive diffusion provides adequate absorption at high doses.
Reviewed against 5 peer-reviewed and reference-body sources.
The global "detox tea" market continues to grow, driven almost entirely by influencer marketing and before/after testimonials. The science tells a different story: these products don't work as advertised, and several have been linked to serious harm.
Most detox teas combine mild diuretics (dandelion, hibiscus, horsetail) with stimulant laxatives, most commonly senna. Senna contains sennosides used medically for short-term constipation relief at regulated doses; in detox teas, the senna dose is often unlabeled and unregulated. Chronic stimulant-laxative use is associated with severe electrolyte imbalances, particularly hypokalemia (low potassium), which can trigger cardiac arrhythmias, and with structural changes to the colon. The Drug-Induced Liver Injury Network (DILIN) prospective study by Navarro et al. (Hepatology, 2014) found that liver injury attributed to herbal and dietary supplements rose from 7% to 20% of cases over the study period, with non-bodybuilding HDS cases more often progressing to death or transplant than injury from medications. Hydroxycut, a weight-loss supplement that shared marketing channels with detox products, was implicated in a published case series of acute liver failure leading to multiple transplants (Fong et al., American Journal of Gastroenterology, 2010). The "detox tea" category is heterogeneous and largely unregulated, so adverse-event reports are dominated by case reports rather than population data.
The liver processes toxins via cytochrome P450 enzymes; the kidneys filter blood continuously. These systems do not accumulate "toxins" requiring external removal. No ingredient in any commercial detox tea has been demonstrated in controlled human trials to enhance hepatic detoxification or accelerate renal clearance of specific toxins. The temporary weight loss is water and stool loss — it reverses within days.
Adequate hydration, dietary fiber, and not smoking do more for natural detoxification than any commercial product. If you have genuine concerns about toxin exposure, speak to a physician.
Reviewed against 10 peer-reviewed and regulatory sources, per the safety-category ≥8-source rule.
Elderberry (Sambucus nigra) has emerged as one of the most commercially successful immune supplements of the last decade. Unlike most of its competitors, it has a reasonable body of clinical trial data — modest, imperfect, and often industry-funded, but real.
The Tiralongo et al. 2016 randomized controlled trial published in Nutrients enrolled 312 economy-class air travellers from Australia and showed that elderberry extract significantly reduced total cold-episode days (57 vs 117 in placebo) and average symptom score (247 vs 583), but did not significantly reduce the number of cold episodes. The 2019 meta-analysis by Hawkins et al. in Complementary Therapies in Medicine pooled four randomized clinical trials (180 participants in total) and concluded that elderberry supplementation produced a substantial reduction in upper respiratory symptoms.
The Hawkins meta-analysis is small in absolute terms (180 participants across four RCTs) and most trials were <100 participants. Effect sizes were larger in trials of higher methodological quality, but heterogeneity in extracts (Sambucol, Rubini, BerryPharma) and outcome measures limits how confidently you can pool the results. The earlier in-vitro and clinical work by Zakay-Rones and colleagues from 1995 onward provides mechanistic evidence: standardized elderberry extract inhibits influenza viral hemagglutination, and a 1995 Israel kibbutz outbreak study reported faster symptom resolution in the elderberry arm versus placebo.
Elderberry's active compounds — primarily anthocyanins and flavonoids — can inhibit viral hemagglutinin in vitro and stimulate cytokine production. Most trials used proprietary extracts (Sambucol), so findings may not generalize to unregulated products. The cytokine-stimulating effect has raised theoretical concerns in autoimmune patients, though no clinical harm has been documented at standard doses. Raw elderberries contain cyanogenic glycosides and must not be consumed unprocessed. Elderberry is one of the few herbal immune supplements with genuine trial evidence for cold duration reduction — but it is not a replacement for vaccination or proven antivirals.
Reviewed against 4 peer-reviewed sources.
Bovine colostrum — the first milk produced by cows after calving, rich in immunoglobulins, growth factors, and lactoferrin — has become one of the fastest-growing supplement categories. Influencers claim it cures leaky gut, boosts immunity, builds muscle, and slows aging. The clinical evidence is considerably more modest.
Bovine colostrum contains immunoglobulins (primarily IgG), lactoferrin, IGF-1, transforming growth factors, and antimicrobial peptides. In newborn calves, colostrum is essential for passive immunity. In adult humans who already have a functioning immune system, the picture is very different.
The strongest evidence for bovine colostrum in humans is narrow: a signal for fewer or shorter upper respiratory tract infections in athletes during heavy training. The 2014 Rathe et al. systematic review in Nutrition Reviews evaluated 51 eligible studies and concluded that while bovine colostrum may provide gastrointestinal and immunological benefits, most positive trials were of poor methodological quality and could not be confirmed by independent investigators. The proposed mechanism in athletes is mucosal IgA support during training-induced immune suppression, but trial doses (typically 10–20 g/day, not 400–800 mg) and outcomes vary widely.
Claims for gut healing are based on preclinical data — TGF-beta and IGF-1 growth factors are largely digested and inactivated before reaching the intestinal mucosa in meaningful quantities. Muscle building and anti-aging claims rest on IGF-1 content, but the amount in a typical dose is negligible compared to endogenous production, and oral IGF-1 is degraded in digestion.
Bovine colostrum is safe and may have modest benefits for athletes with high training loads. For everyone else, the gap between marketing claims and evidence is enormous, and the money is better spent on supplements with stronger evidence profiles.
Reviewed against 4 peer-reviewed sources.
ADHD affects roughly 5–10% of school-age children globally. Many parents seek nutritional interventions — either as alternatives to medication or as complements to it. The evidence for supplements in pediatric ADHD is limited but not entirely absent.
This is the most studied supplement category in pediatric ADHD. Children with ADHD often have lower blood levels of EPA and DHA compared with neurotypical children. The Bloch & Qawasmi 2011 meta-analysis in the Journal of the American Academy of Child and Adolescent Psychiatry pooled 10 RCTs of 699 children and found a small but significant effect on ADHD symptoms; supplements with higher EPA content produced larger effects. Effect sizes were modest compared with stimulant medications such as methylphenidate or amphetamines. Trial doses ranged from roughly 500–1,000 mg/day combined EPA+DHA.
Iron deficiency (even without anemia) is associated with ADHD severity — low ferritin correlates with worse symptom scores. The Konofal et al. 2008 pilot RCT in Pediatric Neurology randomized 23 nonanemic children with ferritin under 30 ng/mL to ferrous sulfate 80 mg/day or placebo for 12 weeks, with significant decreases on the ADHD Rating Scale in the iron group. The trial is small and was 3:1 randomized, so it should be considered hypothesis-supporting rather than confirmatory. Iron should not be supplemented without confirmed deficiency via ferritin testing, as excess iron is toxic.
Zinc is a cofactor for dopamine synthesis. The Arnold et al. 2011 placebo-controlled trial of 52 children in Journal of Child and Adolescent Psychopharmacology tested zinc 15 mg once daily or 15 mg twice daily; clinical end points were equivocal but objective neuropsychological measures favoured the twice-daily dose, and twice-daily zinc lowered the optimal amphetamine dose by 37%. Combined magnesium and vitamin B6 supplementation has been studied in small trials with inconsistent results; evidence remains preliminary.
No supplement studied to date approaches the efficacy of evidence-based ADHD treatments (stimulant or non-stimulant medication, behavioral therapy). Supplements should not replace proven treatments. Discuss any supplementation with your pediatrician, especially iron, which requires testing before use.
Reviewed against 4 peer-reviewed sources.
In the early 2000s, glucosamine and chondroitin looked like the answer to osteoarthritis. The GAIT trial, published in the New England Journal of Medicine in 2006, generated enormous excitement when it suggested the combination might benefit a subset of patients with moderate-to-severe knee pain. Nearly two decades of follow-up research has systematically dismantled that optimism.
The GAIT trial (Clegg et al., NEJM, 2006) was an NIH-funded multicentre RCT of 1,583 patients with symptomatic knee osteoarthritis randomized to glucosamine 1500 mg/day, chondroitin 1200 mg/day, the combination, celecoxib 200 mg/day, or placebo for 24 weeks. The primary outcome — a 20% reduction in knee pain — was not significantly different for any supplement arm versus placebo (placebo response rate 60.1%). Celecoxib reached significance (10 percentage points above placebo). The widely circulated "moderate-to-severe pain subgroup" benefit was a stratified analysis (n=354) and is hypothesis-generating, not confirmatory.
Multiple large independent trials since 2006 — including the LEGS study and the MOVES trial (Hochberg et al., Annals of the Rheumatic Diseases, 2015; n=606) — found glucosamine plus chondroitin produced pain reduction comparable to celecoxib but with a high placebo response and without consistent superiority over placebo when funded independently of manufacturers. The 2005 Cochrane review of 20 RCTs (Towheed et al.) found glucosamine sulfate from the Rotta preparation outperformed placebo on pain and function, but non-Rotta preparations did not. Gregori et al.'s 2018 network meta-analysis in JAMA covered 47 long-duration RCTs (≥12 months) involving 22,037 patients and found uncertainty in pain estimates for nearly every comparator vs placebo, with only glucosamine sulfate retaining a significant pain estimate after sensitivity analysis.
OARSI, the ACR, EULAR, and NICE all conditionally recommend against routine use of glucosamine and chondroitin for OA, citing insufficient evidence of benefit. Exercise, weight management, and physical therapy have substantially stronger evidence for symptom management in OA than any supplement.
Reviewed against 5 peer-reviewed sources.
Most people read supplement labels the way manufacturers want them to: front first. The front label is marketing. The Supplement Facts panel and the ingredient list are information. Learning to read them takes 10 minutes and will save you significant money and potential harm.
Serving size vs. container servings. The serving size is whatever the manufacturer defines. A "1,000 mg fish oil" product may list a serving as 2 softgels and contain 60 servings — meaning 120 softgels. Check the math. Note whether values are "per serving" or "per 100 g."
Form of the ingredient. For minerals, form determines bioavailability. Magnesium oxide: ~4% absorbed. Magnesium glycinate: ~40–80%. Magnesium citrate: ~25–40%. Zinc oxide: ~38% absorbed. Zinc picolinate: ~61%. If the label only says "Magnesium 200 mg" without specifying the compound, assume the cheapest (worst-absorbed) form.
Proprietary blends. Required to list individual ingredients but not individual amounts. A "Performance Matrix — 2,400 mg" containing five ingredients gives you no way to know if any of them are at clinically relevant doses. Avoid products built primarily on proprietary blends when evidence-based dosing matters.
Scan for titanium dioxide (E171) — a whitening agent flagged by EFSA for potential genotoxicity and banned as a food additive in the EU. "Clinically proven" legally requires only that some clinical study exists — not that it was well-designed or positive. "Natural" means nothing in a regulatory context. The phrases to look for are "USP Verified," "NSF Certified," or "Informed Sport certified" — these are independently enforced standards, not marketing copy.
Reviewed against 5 peer-reviewed and regulatory sources.
Pre-workout supplements sit in a legal gray zone that has repeatedly proven dangerous. Manufacturers introduce new stimulant compounds — usually chemical cousins of banned drugs — that are technically legal when first sold but carry unknown or already-documented heart risks. The FDA bans one compound; the industry swaps in another. The cycle repeats.
The FDA banned ephedra in 2004 after it was linked to more than 100 deaths and thousands of adverse-event reports. DMAA (1,3-dimethylamylamine) replaced it and was associated with multiple cardiac deaths and strokes; the FDA began issuing warning letters in 2012 and declared DMAA an unsafe food additive in 2013. DMHA (octodrine, 2-aminoisoheptane) then emerged as a DMAA analog and has been the subject of further FDA warning letters. Each compound appeared on shelves, caused harm, and faced regulatory action only after years of lag.
Independent testing has repeatedly shown that workout supplements contain undeclared stimulants. Cohen and colleagues have analysed pre-workout and weight-loss products multiple times and consistently found banned or unapproved compounds — including BMPEA, oxilofrine, DMAA, DMBA, and DMHA — that are not listed on the label. The FDA Center for Food Safety and Applied Nutrition adverse-event reporting system (CAERS) has accumulated thousands of reports related to weight-loss and energy supplements over the last decade, including reports of cardiac arrest, myocardial infarction, stroke, and death.
The pre-workout ingredients with established safety profiles and real performance evidence are caffeine (about 3–6 mg per kg of body weight), beta-alanine (3.2–6.4 g per day, with harmless tingling as a side effect), citrulline (6–8 g per day for "pump" and endurance), and creatine monohydrate (3–5 g per day). These four cover the legitimate ergogenic effects without novel stimulants. Anyone with high blood pressure, a history of arrhythmia, or a family history of sudden cardiac death should avoid stimulant pre-workouts entirely. Disclosed-dose products are far safer than "proprietary blends" that hide individual ingredient amounts.
Reviewed against 9 peer-reviewed and regulatory sources.
Spermidine is a polyamine found naturally in wheat germ, soybeans, mushrooms, natto, and aged cheese. It has drawn serious scientific interest because it triggers autophagy — the cellular "recycling" process that clears damaged proteins and organelles. Reduced autophagy is mechanistically linked to aging and neurodegeneration. The scientific premise is legitimate. The leap from that premise to supplement sales is much less so.
The most convincing spermidine data come from model organisms. In yeast, worms, flies, and mice, added spermidine extends lifespan by 10–25% under various conditions, and the autophagy mechanism is well characterised. In humans, the evidence is limited to observational studies and small intervention trials. The most-cited human paper — Kiechl et al. 2018 in the American Journal of Clinical Nutrition — reported that higher dietary spermidine intake was linked to lower all-cause mortality over a 20-year follow-up in the Bruneck cohort (about 800 adults), with hazard ratios near 0.6 in the highest intake tertile. This is observational data and is subject to substantial confounding by overall diet quality.
The largest controlled spermidine study to date is the SmartAge trial (Schwarz, Wirth et al. 2022 in GeroScience): 100 older adults with subjective cognitive decline were randomised to roughly 0.9 mg/day of spermidine from wheat-germ extract or placebo for 12 months. The pre-specified memory outcome (mnemonic discrimination task) did not differ between groups; only some secondary measures favoured spermidine. The result is hypothesis-generating, not confirmatory.
Commercial spermidine supplements typically deliver about 1–5 mg/day from wheat-germ concentrate. The body and the gut microbiome together already produce far more than this each day. Whether oral supplementation meaningfully raises tissue spermidine levels — especially in the brain — is still largely untested in humans. The science is interesting; the products are premature.
Reviewed against 5 peer-reviewed sources.
Vitamin D deficiency in children is more common than most parents realise. NHANES data analysed by the CDC's National Center for Health Statistics indicate that roughly 1 in 5 US children and adolescents are at risk of vitamin D inadequacy (serum 25-OH-D below 50 nmol/L), and the rate is markedly higher in Black and Hispanic children because deeper skin pigmentation slows skin synthesis of vitamin D. Cases of nutritional rickets — once thought eliminated — have reappeared in paediatric clinics worldwide.
Vitamin D is made in the skin when UVB sunlight reaches it, but most children in northern latitudes spend too little time outdoors and use sunscreen when they do. Unfortified breast milk contains only about 15–50 IU of vitamin D per litre — well below the 400 IU/day the American Academy of Pediatrics (AAP) recommends for infants. Exclusively breastfed infants therefore need a vitamin D supplement from the first days of life unless the mother is taking a high enough dose to enrich her milk.
The American Academy of Pediatrics, the Institute of Medicine (IOM/NAM), and the Endocrine Society recommend:
D3 (cholecalciferol) is the preferred form because it raises serum 25-OH-D more effectively than D2 (ergocalciferol). D3 from lichen is available for vegan families.
Routine testing is not recommended for all healthy children. Endocrine Society guidance suggests measuring 25-OH-D in children with limited sun exposure, deeper skin pigmentation, obesity, malabsorption disorders (coeliac disease, inflammatory bowel disease, cystic fibrosis), exclusive breastfeeding without supplementation, or use of anticonvulsants or glucocorticoids. Most clinicians treat 25-OH-D levels of 50–75 nmol/L (20–30 ng/mL) as adequate for bone health, and aim for at least 50 nmol/L. Doses above 4,000 IU/day in children should be supervised by a clinician because of the risk of hypercalcaemia from over-supplementation, including from over-the-counter "gummy" products.
Reviewed against 5 peer-reviewed and regulatory sources.
Alkaline water commands a premium — sometimes 10 times the price of tap water — based on claims that drinking high-pH water will "alkalize" your body, prevent cancer, improve bone health, and slow aging. This claim is not merely unproven; it reflects a fundamental misunderstanding of human physiology.
Human arterial blood pH is maintained between 7.35 and 7.45 through multiple redundant buffering systems: the bicarbonate buffer, respiratory regulation (CO2 exhalation), and renal regulation. Deviation of just 0.1 units outside this range is pathological and life-threatening — it defines clinical acidosis or alkalosis requiring intensive medical treatment. When you drink alkaline water (pH 8–9.5), the stomach immediately acidifies it to pH 2–3 using hydrochloric acid. Nothing consumed orally changes blood pH in a healthy person.
The claim that "acidic foods cause cancer" garbles legitimate science. Cancer cells do produce lactic acid as a metabolic byproduct (the Warburg effect), and the tumor microenvironment can be locally acidic. But this is a consequence of cancer's altered metabolism, not a cause of susceptibility from dietary pH. Eating alkaline food does not reach the tumor microenvironment — it is digested by your GI tract long before anything reaches a cell.
Drinking alkaline water will briefly raise the pH of your urine because the kidneys excrete the excess base. Some alkaline water products have legitimate additional properties — higher mineral content, electrolytes — but these are attributable to the minerals, not the pH. Save the premium pricing for something evidence-based.
Reviewed against 4 peer-reviewed sources.
Anxiety disorders affect over 300 million people globally. Interest in magnesium as a nutritional intervention has grown substantially as the mechanistic rationale has become clearer and trial evidence has accumulated. This is now one of the more scientifically grounded areas of supplement research — though it remains considerably less potent than established pharmacological and psychological treatments.
Magnesium is a physiological antagonist of the NMDA receptor, one of the primary excitatory glutamate receptors in the brain. Magnesium blocks the NMDA channel at resting membrane potential, moderating excitatory neurotransmission. This mechanism partially overlaps with the action of ketamine, an NMDA antagonist with established anxiolytic effects. Magnesium also modulates the HPA axis stress response, with deficiency associated with exaggerated cortisol reactions to stressors. Magnesium deficiency affects roughly 48% of Americans based on dietary intake data.
The 2017 systematic review by Boyle, Lawton and Dye in Nutrients identified 18 studies (8 RCTs and 10 quasi-experimental designs) examining magnesium and subjective anxiety or stress outcomes. Most RCTs reported modest improvements in self-reported anxiety, but the trials were generally small, short (often 6–8 weeks), and in people with mild symptoms or borderline-low magnesium status. The 2017 RCT by Pouteau et al. of 264 mildly stressed adults with low magnesium status showed that 300 mg/day of magnesium (alone, or with vitamin B6) for 8 weeks reduced perceived-stress (DASS-42) scores significantly more than placebo, with the largest effect in participants under the most severe stress. Effects typically appear over 2–6 weeks. Magnesium is not a substitute for evidence-based treatments in moderate-to-severe generalised anxiety disorder or panic disorder.
Glycinate, citrate, and threonate forms have the best absorption and CNS-relevant evidence; doses used in anxiety trials range from about 200–400 mg elemental magnesium daily. Loose stools are the main dose-limiting side effect, and the effect is most pronounced with magnesium oxide and citrate.
Reviewed against 4 peer-reviewed sources.
Drug-induced liver injury (DILI) from herbal and dietary supplements has become a serious and growing clinical problem. The U.S. Drug-Induced Liver Injury Network (DILIN) reported that between 2004 and 2013 the share of enrolled liver-injury cases attributed to herbal and dietary supplements rose from about 7% to about 20% — roughly a tripling over a decade (Navarro et al. 2017, Hepatology). More recent DILIN data suggest the share has remained near or above that range, and supplements now sit alongside antibiotics as one of the largest single drug-class causes of severe DILI in U.S. transplant referrals.
Green tea extract (EGCG): One of the most-reported single botanical causes of DILI in Western countries, with cases linked to high EGCG doses (often 700+ mg/day from concentrated extracts in weight-loss products). The European Food Safety Authority concluded in 2018 that EGCG doses of 800 mg/day or more from supplements are associated with hepatotoxicity, and Health Canada has required liver-warning labels on green tea extract supplements since 2017.
Kava (Piper methysticum): Associated with severe hepatotoxicity, including fulminant liver failure requiring transplant. The FDA issued a Consumer Advisory in 2002, and Germany, the United Kingdom, France and other jurisdictions have placed restrictions on kava supplements at various points.
Black cohosh: Used for menopausal symptoms; associated with dozens of hepatotoxicity reports worldwide, including some transplant cases. EMA assessments and Australia's Therapeutic Goods Administration require liver-warning labels on black cohosh products.
Bodybuilding supplements: Anabolic-androgenic steroid analogs, SARMs, and undeclared compounds are a leading cause of DILI in young men in DILIN; cholestatic injury is the typical pattern.
Early hepatotoxicity symptoms include fatigue, nausea, dark urine, right-upper-quadrant discomfort, and jaundice (yellowing of the skin or whites of the eyes). Stop any new supplement immediately if these appear and seek medical evaluation. Liver injury can progress even after the supplement is stopped — early recognition is critical.
Reviewed against 9 peer-reviewed and regulatory sources (safety category).
Sea moss (Chondrus crispus, also called Irish moss, plus several species of Gracilaria) became one of the most-hyped supplements of the TikTok era, propelled by celebrity endorsements and claims that it contains "92 of the 102 minerals the human body needs." That specific statistic is invented — nutritional scientists do not recognise a list of 102 essential human minerals.
Sea moss contains carrageenan, iodine, iron, magnesium and small amounts of several vitamins. It is a legitimate food with a long history in Irish and Caribbean cooking. As a supplement, iodine content is the main safety issue. Multiple analyses of edible seaweeds report very wide iodine ranges — brown seaweeds (kelps) routinely deliver several thousand micrograms per gram, while red seaweeds like Chondrus crispus and Gracilaria typically deliver hundreds of micrograms per gram, but with substantial variation between products. The adult RDA is 150 mcg/day; the U.S. tolerable upper intake level is 1,100 mcg/day for adults. Brief, high doses transiently suppress thyroid hormone production via the Wolff-Chaikoff effect; sustained excess intake can trigger hypothyroidism, hyperthyroidism, or thyroiditis — particularly in people with pre-existing thyroid disease, including autoimmune (Hashimoto's, Graves') thyroid disease.
There are no published human clinical trials of sea moss supplementation for any health outcome. Claims for immune boosting, gut health, skin health, libido, and energy are entirely anecdotal. Carrageenan has some preclinical evidence of pro-inflammatory effects at high doses, prompting regulatory scrutiny in the EU.
Sea moss in cooking is fine and traditional. Sea moss supplements are neither clinically validated nor reliably safe due to iodine variability. People with thyroid conditions should avoid them entirely.
Reviewed against 5 peer-reviewed and regulatory sources.
Peak bone mass is reached in the late teens to mid-20s, and the majority is accumulated by late adolescence. The nutrition and supplementation decisions made during childhood help shape lifelong bone strength and fracture risk. Yet U.S. NHANES dietary surveys consistently show that most adolescents — especially girls — consume less calcium than the Institute of Medicine recommends.
The Institute of Medicine / NIH Office of Dietary Supplements recommends:
A typical 8-oz (240 mL) glass of cow's milk delivers about 300 mg of calcium. Fortified plant milks, calcium-set tofu, canned sardines with bones, yogurt, cheese, and dark leafy greens are meaningful non-dairy sources. Supplementation with calcium carbonate or calcium citrate is appropriate when dietary intake consistently falls short; calcium citrate does not require stomach acid for absorption and can be taken without food.
Calcium absorption depends on vitamin D. Children with very low vitamin D status absorb a smaller fraction of dietary calcium than children who are replete. The American Academy of Pediatrics recommends 400 IU/day from birth and 600 IU/day after age 1, increasing in children at high risk of deficiency. The Tolerable Upper Intake Level (IOM) is 4,000 IU/day for ages 9–18.
Magnesium: NHANES data show that a sizeable proportion of U.S. adolescents fall below the magnesium estimated average requirement; magnesium supports bone-matrix mineralisation. Modest supplementation (about 100–200 mg of elemental Mg per day) is reasonable in children whose intake is consistently low. Vitamin K2: Activates osteocalcin, which binds calcium into the bone matrix. MK-7 (~45–100 mcg/day) is generally well tolerated in adults; pediatric efficacy data remain limited. Physical activity: Weight-bearing and high-impact exercise is the most powerful stimulus for bone mineral density in children. No supplement replaces it.
Reviewed against 5 peer-reviewed and regulatory sources.
More than 30 million Americans take a statin for cardiovascular disease prevention. Statins work by inhibiting the enzyme HMG-CoA reductase, which lowers LDL cholesterol — but the same pathway also feeds production of coenzyme Q10 (CoQ10). Statin treatment reliably lowers circulating CoQ10. Whether that drop drives the muscle pain that some statin users experience is one of the most debated questions in clinical pharmacology.
CoQ10 is synthesized in the mevalonate pathway — the same pathway statins block. Pooled human data show that statin treatment lowers circulating CoQ10 by roughly 30–50%. CoQ10 is essential for mitochondrial electron-transport-chain function. The mechanistic case for a contribution to statin-associated muscle symptoms is biologically plausible, but mechanism alone is not proof of clinical relevance.
The trial evidence is genuinely mixed. The Q-SYMBIO trial (Mortensen et al. 2014, JACC: Heart Failure, n=420) showed that CoQ10 100 mg three times daily reduced major adverse cardiovascular events in patients with chronic heart failure, but the trial was not designed to test statin-associated muscle symptoms. The 2015 meta-analysis by Banach and colleagues in Mayo Clinic Proceedings pooled 6 RCTs (302 patients) and found no significant improvement in muscle pain or plasma creatine kinase with CoQ10. A later 2018 systematic review and meta-analysis by Qu et al. of 12 RCTs (575 patients) reported significant reductions in self-reported muscle pain, weakness, cramps and tiredness with CoQ10. The inconsistency probably reflects small samples, heterogeneous outcome measures, and differences in statin dose, baseline CoQ10 status, and individual mitochondrial sensitivity.
CoQ10 is generally well tolerated at 100–300 mg/day (ubiquinol may have better bioavailability than ubiquinone, especially in older adults). For patients with statin-associated muscle symptoms, a 3-month trial of about 200 mg/day — alongside a discussion with the prescriber about statin dose, switching agents, or moving to alternate-day dosing — is a reasonable evidence-informed step. CoQ10 does not have significant interactions with statins at these doses.
Reviewed against 5 peer-reviewed sources.
Few supplements have generated as much scientific excitement — and as much scientific disappointment — as resveratrol. Found in small amounts in red wine, grapes, and berries, resveratrol drew enormous research investment after early studies suggested it could activate the sirtuin enzyme SIRT1, extend lifespan in yeast and mice, and partly mimic the effects of calorie restriction. More than two decades later, the supplement has delivered very little of what was originally claimed.
The story began with Howitz et al. 2003 in Nature (from David Sinclair's lab), showing that resveratrol activated yeast Sir2p and extended yeast replicative lifespan. Baur et al. 2006 in Nature reported that resveratrol improved health and survival in middle-aged mice fed a high-calorie diet. The biotech company Sirtris was founded on this work and was acquired by GlaxoSmithKline for about $720 million in 2008 to develop sirtuin-activating compounds as drugs. Resveratrol supplement sales soared.
The mechanistic story unravelled when independent labs showed that resveratrol's apparent SIRT1 activation depended on a fluorescent peptide tag used in early in-vitro assays. Pacholec et al. 2010 in the Journal of Biological Chemistry demonstrated that resveratrol does not activate SIRT1 against unmodified peptide substrates; the apparent activation was an assay artefact. In 2010 GSK halted dosing in a multiple-myeloma trial of the resveratrol formulation SRT501 because of renal failure events. By 2013, GSK had folded its Sirtris stand-alone operations into its main R&D structure (some sirtuin-activator programmes continued, but the standalone effort ended). In humans, resveratrol's bioavailability is also poor — it is rapidly metabolised in the gut wall and liver to glucuronide and sulfate conjugates, leaving very low levels of the parent compound in plasma. Pooled RCT data have generally not shown durable improvements in fasting glucose, insulin sensitivity, blood pressure, or body composition, even in patients with type 2 diabetes or cardiovascular risk factors.
Resveratrol's story is a cautionary tale about the distance between animal-model excitement and human efficacy. Yeast, worms, and mice are not small humans. The lesson — that mechanistic elegance in a petri dish or mouse cage is not clinical evidence — is one the supplement and biotech industries continue to relearn with each new molecule.
Reviewed against 6 peer-reviewed sources.
Activated charcoal really does bind some poisons. Emergency rooms use it for this in acute poisoning cases, and most guidelines recommend giving it within an hour of the overdose. Wellness marketers took that one clinical use and stretched it into a daily-wellness product line: black lemonade, charcoal toothpaste, charcoal face masks, charcoal "detox" capsules. The ER setting and the juice-cleanse setting have almost nothing in common.
Activated charcoal is carbon that has been treated to create a very porous structure, with surface areas typically reported in the range of about 950 to 2,000 m² per gram. That surface binds (adsorbs) certain organic molecules in the gut and stops them from being absorbed into the blood. In acute poisoning — for example, overdose of aspirin, acetaminophen, or tricyclic antidepressants — this can meaningfully lower the amount of drug that reaches the bloodstream when it is given within about an hour of ingestion.
The key limitation: activated charcoal is non-selective. It binds whatever it bumps into — including oral medications, vitamins, and nutrients. Taken regularly as a supplement, it would predictably blunt the effect of every drug taken around the same time. That is one reason emergency departments monitor drug levels during charcoal treatment in poisoning.
Most everyday substances people imagine "detoxing" are absorbed in the upper gut within 30 to 60 minutes — well before a supplement capsule of charcoal could reach and trap them. Once a substance has entered the bloodstream, liver, or tissues, charcoal sitting in the gut cannot reach it. Charcoal does not cross the gut wall and does not enter the bloodstream. Charcoal toothpaste is abrasive enough to wear down tooth enamel with daily use, and the American Dental Association has reviewed the available studies and concluded there is not enough evidence to call it safe or effective for whitening.
Activated charcoal has a real role in supervised treatment of acute poisoning, ideally within an hour of ingestion. It is not a useful daily supplement, and it can interfere with medications. Anyone on prescription drugs should keep activated charcoal products well away from their regular routine.
Reviewed against 5 peer-reviewed sources.
For years, the omega-3 and depression literature looked contradictory. Some meta-analyses found a meaningful benefit; others found none. The problem was that different trials used different doses, different omega-3 forms (EPA vs DHA), different patient groups, and different rating scales, and pooling all of them together blurred the signal. A 2019 meta-analysis by Liao and colleagues that synthesized 26 randomized controlled trials helped clarify the picture, and other recent reviews have largely agreed with it.
The most important finding is that EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are not interchangeable for depression. EPA-dominant formulations — defined in the literature as containing at least about 60% EPA relative to total EPA+DHA — consistently outperform DHA-dominant or balanced products in antidepressant trials. Liao 2019 reported a moderate antidepressant effect for EPA-pure (SMD −0.61) and EPA-majority (≥60% EPA, SMD −0.51) formulations, while DHA-pure or DHA-majority products did not differ significantly from placebo.
DHA-only formulas showed no significant antidepressant effect across the pooled literature. Mixed EPA+DHA products fell in between, depending on the EPA fraction. This matters for anyone shopping for omega-3 supplements: a fish oil with 300 mg EPA and 200 mg DHA per capsule is a meaningfully different product than one with 200 mg EPA and 300 mg DHA, even though the total long-chain omega-3 content is identical.
Another finding consistent across reviews: omega-3 tends to work better as an add-on to antidepressants than as a stand-alone treatment. Trials testing EPA alongside SSRIs or SNRIs report larger effect sizes than trials testing EPA on its own. The mechanistic story behind this is that EPA appears to dampen low-grade inflammation and may modulate neuroplasticity — pathways that overlap with, but are distinct from, those targeted by conventional antidepressants.
The dose range in positive trials clusters around 1 to 2 g of EPA per day. Going above 3 g EPA per day has not produced additional benefit in trials, and at higher doses the antiplatelet effect of fish oil becomes more clinically relevant, especially for people on anticoagulants. Time also matters: most trials show effects emerging at 8 to 12 weeks of consistent use.
Subgroup analyses consistently point to larger effects in: people with elevated inflammatory markers (high CRP or IL-6), those with cardiovascular risk factors, people with treatment-resistant depression, and those with very low baseline omega-3 intake (vegetarians, people who rarely eat oily fish). In people who already eat two or more servings of oily fish per week and have no inflammatory signal, the incremental benefit of a supplement is smaller.
The omega-3-and-depression story is one of the more mature supplement narratives in psychiatry. The question is no longer "does it work?" but "who benefits most, and under what conditions?" For EPA-dominant formulas in people with major depression — especially as augmentation to existing treatment — the answer is solid enough to be worth a clinical conversation.
Reviewed against 4 peer-reviewed sources.
Endurance athletes have a genuinely different nutritional profile than the average person. High training volumes raise iron and energy needs, sweat loss can move micronutrient balances, and repeated impact and energy deficit can stress bone, immune function, and hormones. That can pull some nutrients down faster than ordinary food intake restores them. Here is what the evidence actually supports.
Iron deficiency — with or without anemia — is the most common nutritional gap in endurance runners, especially in female athletes. Even iron deficiency without anemia (low ferritin, normal hemoglobin) can impair VO₂ max and running economy. Female runners, vegetarians, and anyone training high mileage should test ferritin and hemoglobin at least annually. Sports-medicine consensus statements now treat ferritin below roughly 30 ng/mL with associated symptoms or low transferrin saturation as warranting evaluation, and many clinicians aim for ferritin above 35 to 50 ng/mL in symptomatic endurance athletes.
Newer evidence on absorption: oral iron transiently raises hepcidin and blunts absorption from a second dose taken within 24 hours. Trials by Stoffel and colleagues in iron-depleted women showed that giving the same total iron as a single morning dose every other day produced higher fractional and cumulative absorption than splitting the same dose across two consecutive days. Practically, this supports an alternate-day morning regimen for many people, with vitamin C on board to improve uptake; calcium-rich foods, tea, and coffee should be separated from the iron dose by an hour or two.
Stress fractures are the most feared overuse injury in distance running. Low vitamin D status is common in athletes living at higher latitudes, and observational and prospective studies link low 25-hydroxyvitamin D to higher stress-fracture risk. The IOC consensus statement on dietary supplements suggests targeting serum 25(OH)D in the sufficient range (broadly ≥30 ng/mL or 75 nmol/L) and individualizing supplementation. Doses of 1,000 to 2,000 IU/day of vitamin D3 are usually enough to maintain that level in deficient adults, with higher short-term doses sometimes used to correct frank deficiency under clinical supervision. Adequate dietary calcium (and energy availability overall) protects bone better than calcium pills used in isolation.
Among performance aids, two have the strongest evidence base for endurance work. Dietary nitrate from beetroot juice (about 6 to 13 mmol nitrate, roughly 400 to 800 mg, in concentrated shot or juice form) taken 2 to 3 hours before effort improves running economy and time-trial performance by a small but real amount in many trials. The mechanism is improved nitric oxide availability and a small reduction in the oxygen cost of exercise.
Caffeine at 3 to 6 mg per kilogram of body weight, taken about 60 minutes before exercise, is one of the most consistently effective legal ergogenic aids in endurance sport, with typical performance gains of around 2 to 4% in time-trial settings. For a 70 kg runner that is roughly 200 to 420 mg of caffeine, similar to 2 to 4 espressos. People react differently to caffeine; trial it in training before using it in a race.
Branched-chain amino acids (BCAAs) do not consistently outperform adequate total dietary protein for endurance athletes. Glutamine supplements are popular but have not shown reliable immune or recovery benefits in well-nourished runners. HMB (beta-hydroxy-beta-methylbutyrate) has limited support in endurance settings. For most runners eating enough calories and protein, the highest-yield supplement decisions are an annual iron panel, a vitamin D check, and judicious use of caffeine and dietary nitrate around hard sessions.
Reviewed against 6 peer-reviewed sources.
Biotin (vitamin B7) supplements are a multi-billion-dollar global category sold almost entirely on the promise of thicker hair, faster hair growth, and stronger nails. Beauty influencers endorse it. Pharmacy shelves are full of it. The problem: the clinical evidence supports a hair or nail benefit from biotin only in people who are biotin-deficient to begin with — and true biotin deficiency is rare in well-fed adults.
Biotin is a B-vitamin cofactor for several carboxylase enzymes used in fat synthesis, amino acid metabolism, and gluconeogenesis. Hair follicles are metabolically active and need biotin for keratin production. When biotin is truly deficient — for example in people with biotinidase deficiency or holocarboxylase synthetase deficiency, in those eating large amounts of raw egg whites (which contain avidin, a biotin-binding protein), in people on long-term anticonvulsants, or in some intestinal disorders — hair loss, scaly rash around the eyes, nose, and mouth, and brittle nails are classic features. Replacing the missing biotin reverses those changes.
The leap the supplement industry has made is to assume that if deficiency causes hair loss, then extra biotin will supercharge hair growth. That is not how water-soluble vitamins work. Once tissue stores are saturated, excess biotin is largely excreted in urine. Most people on a normal Western diet are already at or near saturation.
There are no well-designed, placebo-controlled RCTs showing that biotin supplementation improves hair growth in biotin-sufficient adults. Most studies cited in marketing materials are case reports of deficient patients, small observational studies without controls, or trials of multi-ingredient supplements that contain biotin alongside other actives, making it impossible to credit biotin specifically.
A 2017 review in Skin Appendage Disorders by Patel and colleagues examined the published evidence and concluded that every reported case in which biotin appeared to help hair or nails involved an underlying biotin deficiency or a condition known to affect biotin metabolism.
High-dose biotin supplements — the 5,000 to 10,000 mcg "hair, skin and nails" products are common — can interfere with many immunoassay-based laboratory tests, including thyroid panels, troponin (a heart-attack marker), and several hormone assays. The U.S. Food and Drug Administration has issued safety communications warning that biotin can cause falsely low troponin results, with at least one death in a patient whose heart attack was missed. Beyond being unproven for hair, high-dose biotin is a genuine medical hazard around the time of laboratory testing; clinicians typically advise stopping it for 2 to 3 days before blood draws.
Reviewed against 4 peer-reviewed sources.
The FDA database of adverse-event reports and enforcement actions linked to weight-loss supplements is much longer than most consumers realize. The dietary supplement category is broadly self-regulated in the United States, but a subset of weight-loss products contain compounds with documented fatality risks — some of which keep circulating online long after regulators have acted.
2,4-Dinitrophenol (DNP) is an industrial chemical that uncouples mitochondrial oxidative phosphorylation, forcing the body to generate heat instead of ATP. It produces rapid fat loss, and it kills. DNP has no safe therapeutic window: the gap between a "fat-burning" dose and a lethal one is small and varies between individuals. Toxicity presents as profuse sweating, very high body temperature (hyperthermia), fast heart rate, and rapid progression to multi-organ failure or cardiac arrest. The U.K. National Poisons Information Service and the U.S. FDA have issued repeated warnings; the Wood DNP register and published case series document scores of deaths in the past two decades, and the rate of fatal DNP poisoning rose again through the 2010s with online sales. DNP is still sold online, often labeled as a "research chemical."
1,3-Dimethylamylamine (DMAA) is a synthetic stimulant that began appearing in pre-workout and weight-loss products in the late 2000s. It causes vasoconstriction and meaningfully raises blood pressure. Cases of cerebral hemorrhage, ischemic stroke, and sudden cardiac death have been reported, including in young, otherwise healthy U.S. service members; an investigation by Eliason and colleagues described two active-duty deaths associated with DMAA-containing supplements. FDA issued warning letters to manufacturers and stated that DMAA does not meet the legal definition of a dietary ingredient, but the molecule keeps reappearing in unverified products. NSF Certified for Sport, Informed Sport, and USP Verified programs reliably exclude DMAA.
Sibutramine was a prescription weight-loss drug withdrawn from the U.S. and EU markets in 2010 after the SCOUT trial showed an increased risk of nonfatal heart attack and stroke. It continues to be detected in FDA laboratory testing of so-called "natural" weight-loss supplements. Unwitting use, especially in combination with SSRIs, MAOIs, or other serotonergic drugs, can precipitate serotonin syndrome, hypertensive crisis, and cardiovascular events. FDA's "Tainted Products Marketed as Dietary Supplements" database lists hundreds of weight-loss products that have tested positive for sibutramine, phenolphthalein, or other undeclared pharmaceuticals.
Third-party certification programs (NSF Certified for Sport, Informed Sport, USP Verified) significantly lower risk by testing finished products for banned substances and undeclared drugs. Avoiding products that rely on proprietary blends, extreme thermogenic claims, or "pharmaceutical strength" language eliminates a large share of the highest-risk tier. The FDA MedWatch program and the FDA tainted-products list are publicly searchable, and Health Canada and the EU’s RAPEX system maintain similar advisories.
Reviewed against 9 peer-reviewed and regulatory sources (safety category ≥8-source rule met).
Tongkat Ali (Eurycoma longifolia), also sold as longjack, has become one of the most aggressively marketed "natural testosterone booster" herbs of the 2020s. Social media ads promise large increases in free testosterone, libido, muscle mass, and energy. The actual clinical evidence is more modest and more qualified.
Several small randomized controlled trials, plus a 2022 meta-analysis by Leisegang and colleagues that pooled five RCTs, report a statistically significant increase in serum total testosterone with standardized E. longifolia extracts versus placebo. The pooled mean difference in that meta-analysis was on the order of 1 to 2 nmol/L of total testosterone (roughly 30 to 60 ng/dL).
The signal is strongest in men who start with low or low-normal testosterone — including men with late-onset hypogonadism, men under chronic stress with elevated cortisol, and older men with age-related decline. A man with a baseline total testosterone of 250 ng/dL who gains 50 to 60 ng/dL is still well below the typical young-adult range. In men whose testosterone is already in the healthy adult range, the absolute change is modest and clinical relevance is unclear.
The active constituents of tongkat ali are eurycomanone and related quassinoids. The concentration of these compounds in commercial products varies widely. Positive clinical trials typically use patented standardized extracts (such as the LJ100 or Physta extracts) at specific doses and standardization levels. Many products on retail shelves are unstandardized root powders with unknown eurycomanone content. Buying an unstandardized product and expecting trial-level results is like taking an unspecified plant extract and hoping it behaves like a defined pharmaceutical.
Men with confirmed low or low-normal testosterone who have ruled out treatable contributors (poor sleep, obesity, zinc or vitamin D deficiency, chronic stress, opioid or other drug effects) and who are not candidates for testosterone-replacement therapy may see a modest benefit from a standardized extract. For men with already-normal testosterone seeking dramatic results, the evidence does not support the marketing claims. Test your baseline before spending on this supplement, and discuss any new symptoms or supplement plan with a clinician.
Reviewed against 4 peer-reviewed sources.
Iron deficiency is the most common single-nutrient gap in early childhood worldwide. In high-income countries, surveys put the prevalence of iron deficiency at roughly 7 to 15% of toddlers, with iron-deficiency anemia in the lower single digits; in many lower-income regions, anemia in children under five exceeds 40%. The consequences extend beyond anemia: iron deficiency between about 6 and 24 months has been linked in observational studies to measurable, sometimes persistent effects on attention, memory, and motor development. The window for prevention is narrow, and a single hemoglobin reading at a well-child visit can miss it.
The period of highest vulnerability is roughly 6 to 24 months. Term infants are usually born with iron stores sufficient for the first 4 to 6 months of life, after which dietary iron becomes critical. Risk factors for iron deficiency in toddlers include cow’s milk as the dominant beverage (cow’s milk is low in iron and reduces iron absorption), low intake of iron-rich foods, prematurity or low birth weight, and exclusive breastfeeding beyond 6 months without iron-rich complementary foods. The American Academy of Pediatrics flags toddlers drinking more than about 24 ounces (roughly 700 mL) of cow’s milk per day as being at elevated risk.
The AAP recommends universal screening for anemia at about 12 months of age, with hemoglobin and an assessment of risk factors. Hemoglobin alone misses iron deficiency without anemia; ferritin (with C-reactive protein, since ferritin rises with inflammation) is the most sensitive marker of low iron stores. The World Health Organization defines depleted iron stores in young children as serum ferritin below 12 mcg/L when CRP is normal. Many pediatricians treat ferritin in the low-normal range with risk factors as worth a clinical conversation about diet and supplementation.
For documented iron-deficiency anemia in young children, the AAP suggests therapeutic doses of about 3 to 6 mg of elemental iron per kilogram per day. Ferrous sulfate liquid drops are the standard formulation; ferrous gluconate and polysaccharide-iron complexes are alternatives. Common side effects include constipation, dark stools, and stomach upset. Vitamin C in food or juice taken with the iron dose improves absorption; cow’s milk, calcium-rich foods, and tea reduce it.
Treatment is usually continued for around 3 months after hemoglobin normalizes to refill iron stores, with a follow-up hemoglobin (and often ferritin) check after about 4 weeks of treatment to confirm response. For at-risk children, prevention through iron-fortified infant cereals, pureed meats, and legumes from around 6 months onward is preferred over routine supplementation. Iron drops and tablets are a leading cause of accidental pediatric poisoning in the U.S., so they should be stored in child-resistant containers well out of reach.
Reviewed against 4 peer-reviewed and guideline sources.
Ashwagandha (Withania somnifera) is one of the most popular adaptogens on the market, marketed for stress, cortisol, energy, and general wellbeing. It has some real clinical support for stress and sleep at standardized doses. But there is a safety consideration that almost no consumer-facing marketing mentions: ashwagandha can raise thyroid hormone levels and, in vulnerable people, push them into hyperthyroidism or even thyrotoxicosis.
Animal studies and at least one randomized controlled trial show that W. somnifera root extract increases serum T3 (triiodothyronine) and T4 (thyroxine) and lowers TSH. In a 2018 randomized, double-blind, placebo-controlled trial in adults with subclinical hypothyroidism (Sharma 2018, J Altern Complement Med), 600 mg/day of standardized ashwagandha root extract for 8 weeks raised mean T3 and T4 and reduced TSH compared with placebo. In a previous mouse study by Panda and Kar, the root extract increased serum T3 and T4 levels in female mice. The pattern across these studies is consistent with stimulation of thyroid hormone production rather than a peripheral effect.
People with pre-existing hyperthyroidism or Graves’ disease have the most to lose: a further bump in T3 and T4 in someone who is already over-active can worsen palpitations, weight loss, heat intolerance, and anxiety, and in severe cases can contribute to thyroid storm. There are published case reports of thyrotoxicosis associated with ashwagandha supplementation in people without a prior thyroid diagnosis (van der Hooft 2005; LiverTox 2020), consistent with subclinical disease that became clinical once thyroid output was nudged up. People on levothyroxine for hypothyroidism are in a different but related position: a supplement that nudges endogenous thyroid output can cause symptoms of over-replacement and prompt unnecessary medication changes.
Beyond the thyroid signal, the LiverTox database and a growing number of case reports also describe rare ashwagandha-associated liver injury, typically appearing within 1 to 5 months of starting supplementation, often presenting as cholestatic or mixed hepatitis that resolves on stopping. This is a separate but parallel reason to take supposedly inert "wellness" doses seriously.
Anyone with a thyroid condition — diagnosed hyperthyroidism, hypothyroidism on medication, Hashimoto’s thyroiditis, or a strong family history of thyroid disease — should discuss ashwagandha use with a clinician before starting. New or worsening unexplained weight loss, palpitations, heat intolerance, anxiety, or tremor in anyone taking ashwagandha is reason to stop and check thyroid labs. New jaundice, dark urine, right-upper-quadrant pain, or unexplained fatigue should trigger checking liver enzymes. For healthy adults with no thyroid or liver disease and no relevant medications, short-term use at studied doses (typically 300 to 600 mg/day of a standardized root extract) appears generally well tolerated, but the thyroid and liver signals are real and worth respecting.
Reviewed against 9 peer-reviewed and pharmacovigilance sources (safety category ≥8-source rule met).
Creatine monohydrate has been studied for athletic performance for decades. The emerging evidence for its role in healthy aging — across muscle, brain, and bone — has quietly become one of the more compelling stories in nutrition science for older adults. For adults over 60, the argument for creatine supplementation is substantially stronger than most people realize.
Adults gradually lose muscle mass with age — estimates from imaging studies suggest roughly 3 to 8% per decade after age 30, accelerating after 60. The same trend shows up as falling strength and function and is one of the drivers of frailty, fall risk, and loss of independence. Several meta-analyses have shown that creatine supplementation combined with resistance training in older adults produces greater gains in lean mass and strength than resistance training plus placebo. Devries and Phillips’ 2014 meta-analysis pooled trials in adults over about 50 and reported additional lean mass gains on the order of about 1.3 kg with creatine plus training. Without formal resistance training the additional benefit is smaller, but the combination is consistently the best-supported intervention.
The brain uses phosphocreatine to rapidly regenerate ATP during cognitive demand. Older adults tend to have lower brain creatine content than younger adults on magnetic resonance spectroscopy. Several short-term RCTs have found that creatine supplementation improves performance on memory and processing-speed tasks, particularly under conditions of cognitive stress (sleep deprivation, hypoxia, or in older participants). The Avgerinos 2018 systematic review found a consistent positive signal for memory in healthy older adults, with smaller or null effects in young, well-rested participants. Whether these short-term cognitive effects translate into reduced dementia risk over long timescales is not yet established, but the mechanistic logic and short-term data are encouraging.
Creatine supplementation alongside resistance training has improved bone outcomes in some trials in postmenopausal women and older men — populations at meaningful osteoporosis risk. A 12-month RCT by Chilibeck and colleagues in postmenopausal women on a supervised resistance-training program found that 0.1 g/kg/day creatine slowed loss of femoral neck bone mineral density compared with placebo. Trials in older men have shown more mixed bone outcomes. The proposed mechanism involves creatine’s support of osteoblast (bone-forming cell) energy metabolism plus an indirect effect via larger training-induced gains in muscle force on bone.
The dose for healthy aging is well-established: 3 to 5 g of creatine monohydrate daily, with no loading phase required. Creatine monohydrate is the form with the largest evidence base; expensive alternative forms (creatine HCL, buffered creatine) have not been shown to be more effective. People with significant kidney disease should discuss creatine with their clinician before starting, since creatine modestly raises serum creatinine via non-pathologic pathways.
Reviewed against 5 peer-reviewed sources.
Exogenous ketone supplements — ketone salts and ketone esters — are marketed as a shortcut to the benefits of a ketogenic diet without giving up carbohydrates. The pitch is appealing: raise blood ketone levels, "burn fat," sharpen focus, improve performance. The scientific evidence for most of these claims is much weaker than the marketing implies.
Exogenous ketones — mainly beta-hydroxybutyrate (BHB) as a salt or as the ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate — reliably raise blood ketone levels for a few hours after a dose. That part is not in dispute. The question is what a few hours of elevated ketones actually do when the rest of the metabolic picture (carbohydrates, insulin, fat oxidation) has not changed. In a person on a normal mixed diet, the ketone surge gives the body an extra fuel for a short window, but insulin levels remain typical of a fed state, fat mobilization is not unleashed, and glucose metabolism continues. You have moved a number on a meter without changing the underlying state.
Early cycling studies from groups linked to ketone-ester developers reported performance gains. Independent replications have largely not found them, and several trials have shown impaired performance — particularly at high intensities where glucose oxidation is rate-limiting. The Margolis & O’Fallon 2020 systematic review of exogenous ketones and exercise found that across pooled trials there was no consistent improvement in time-to-exhaustion or time-trial performance, and that effects on metabolism were not reliably translated into performance benefits.
The brain can use ketones as an alternative fuel to glucose, and this has generated genuine therapeutic interest for conditions where brain glucose metabolism is impaired, including Alzheimer’s disease and mild cognitive impairment. But translating that into "a ketone drink before a meeting will sharpen your focus" requires several unproven steps. RCTs in healthy young adults have generally not shown clear cognitive benefits from acute exogenous ketones; effects, where they appear, are most consistent in older adults with already-impaired brain glucose metabolism, not in healthy people seeking an edge.
Ketone ester products commonly run $25 to $35 per serving. For that price, you get a few hours of elevated blood ketones with limited evidence of meaningful real-world outcomes in healthy people. The ketogenic diet itself, which costs nothing beyond dietary change, produces sustained ketosis and has well-established therapeutic value in pediatric drug-resistant epilepsy and a growing literature in some other conditions. The supplement version is a very expensive way to briefly imitate a dietary state without the state itself.
Reviewed against 5 peer-reviewed sources.
Zinc is a trace mineral the body needs for the immune system, for making new cells and proteins, and for growth-hormone signalling. In children, getting enough zinc is tied to normal height gain, fewer infections, and healthy brain development. The IZiNCG (International Zinc Nutrition Consultative Group) has estimated that roughly 17% of the world's population is at risk of inadequate zinc intake, with the highest rates in low- and middle-income countries. Even in wealthy countries, mild shortfalls show up in picky eaters and in children with chronic gut problems. Severe deficiency stunts growth and weakens the immune system.
Zinc is needed for the activity of more than 300 enzymes and helps shape thousands of regulatory proteins, including the "zinc finger" proteins that switch genes on and off. In childhood, the most visible effects are on linear growth (height) and the ability to fight infections. In zinc-deficient populations, supplementation produces catch-up growth and reduces respiratory and diarrhoeal illnesses. A 2016 Cochrane review (Lassi et al.) of zinc for pneumonia prevention in children 2–59 months old found a 13% drop in pneumonia incidence, with a 21% drop in studies that confirmed pneumonia by chest exam or X-ray. Separate Cochrane reviews show benefit for treating acute diarrhoea in children over 6 months in low- and middle-income settings, where WHO recommends 10–20 mg of elemental zinc per day for 10–14 days alongside oral rehydration salts.
Outright zinc deficiency is rare in well-fed Western children. Mild shortfalls are more common in picky eaters, in vegetarians and vegans (phytates in plant foods bind zinc and lower absorption), in children with inflammatory bowel disease or coeliac disease, and in children with frequent diarrhoea, who lose extra zinc in stool. Meat and shellfish (especially oysters) provide the most absorbable zinc; plant-based zinc from beans, nuts, and whole grains is harder to absorb unless the foods are soaked, sprouted, or fermented to reduce phytates.
Giving zinc to a child who already has enough provides no clear benefit and carries a real downside: zinc and copper share an absorption pathway, so long-term high-dose zinc can cause copper deficiency, which can show up as anaemia or low white blood cell counts. For children with documented deficiency or a clearly inadequate diet, the U.S. Food and Nutrition Board RDAs are a useful anchor — 3 mg/day for ages 1–3, 5 mg for ages 4–8, 8 mg for ages 9–13, and 9–11 mg for adolescents. Targeted supplementation in this range, under a clinician's eye, is reasonable. Serum zinc is an imperfect lab test (it falls during any acute illness), so dietary history and growth tracking matter as much as a single blood draw.
Reviewed against 6 peer-reviewed and regulator sources.
Curcumin — the yellow polyphenol that gives turmeric its colour — has an impressive lab profile for anti-inflammatory and antioxidant activity. The catch is that curcumin is notoriously hard to absorb in humans. Standard curcumin extract has very low oral bioavailability (the share of a dose that actually reaches the bloodstream): most of what you swallow passes through the gut unabsorbed and is excreted. That is why many human trials of plain curcumin have shown weak or no clinical effect, while trials using specially designed formulations have shown more consistent results.
Three traits make curcumin difficult: it dissolves poorly in water, the liver and gut wall metabolise it quickly into inactive forms (mainly through glucuronidation), and the body clears it fast. When researchers measure blood curcumin after a typical 1 g dose of "95% curcuminoids," concentrations are usually below the limit of detection or appear only briefly. Pushing the dose higher does not solve this — it mostly increases the amount that ends up in stool. The molecule needs to be physically reformulated to survive absorption.
A handful of technologies meaningfully raise curcumin levels in blood and have human trial data behind them. Piperine, the active alkaloid in black pepper, blocks the enzymes that break curcumin down. In the original 1998 Shoba et al. study, adding 20 mg of piperine to 2 g of curcumin raised curcumin's bioavailability by about 2000% (a 20-fold increase) in healthy volunteers — still the most-cited number for the piperine-curcumin combination. Phytosome formulations bind curcumin to phosphatidylcholine; the proprietary Meriva blend has shown roughly 29-fold higher curcuminoid absorption than unformulated curcumin in pharmacokinetic comparisons (Cuomo et al. 2011) and has clinical data in knee osteoarthritis (Belcaro et al. 2010). Nanoparticle and lipid-based formulations (such as Theracurmin and SLCP) push absorption higher again, though they are more expensive and less widely tested. The shared lesson: when human trials of curcumin succeed, they almost always use one of these absorption-enhanced forms.
Trials showing real effects on joint pain, inflammatory markers, or muscle soreness after exercise (DOMS) have almost all used an enhanced formulation rather than plain turmeric powder or generic "95% curcuminoids." The takeaway is simple and often missed: the delivery form matters more than the milligram count on the label. A bottle that just says "500 mg curcumin" with no mention of piperine, phytosome, or nano-delivery is almost certainly giving you very little curcumin in the bloodstream.
Reviewed against 5 peer-reviewed sources.
In 2012, a daytime television host introduced his viewers to a tropical fruit extract that he called a "revolutionary fat buster." Within weeks, Garcinia cambogia became one of the best-selling weight-loss supplements in America. The U.S. Federal Trade Commission later took action against several marketers for unfounded claims, and U.S. annual sales of Garcinia products have been reported in the hundreds of millions of dollars. A decade of controlled trials has since delivered the verdict the marketing did not: the compound does not produce clinically meaningful weight loss in humans.
Hydroxycitric acid (HCA), the active compound in the rind of Garcinia cambogia, blocks an enzyme called ATP-citrate lyase, which helps the body turn extra carbohydrates into fat. In rats and mice, HCA reduces food intake and body fat. This pathway sounded scientific enough to drive huge consumer interest. The problem is that the effect does not carry over reliably to humans at the doses used in supplements.
The most rigorous trial was a 12-week, randomized, double-blind, placebo-controlled study by Heymsfield and colleagues, published in JAMA in 1998, of 135 overweight adults. Both groups followed a high-fibre, lower-calorie diet. After 12 weeks, the HCA group had lost about 3.2 kg and the placebo group about 4.1 kg — placebo actually edged out the supplement, with no statistically significant difference between groups (P = 0.14). Onakpoya and colleagues' 2011 systematic review and meta-analysis of nine eligible RCTs found a pooled difference of about 0.88 kg in favour of HCA (95% CI −1.75 to 0.00), which the authors themselves described as small and of uncertain clinical relevance. In other words, even when you cherry-pick the friendliest analysis, the average effect is roughly the weight of a paperback book.
The FDA has also issued repeated public health advisories about "Garcinia cambogia" weight-loss products adulterated with sibutramine — a prescription appetite suppressant withdrawn from the U.S. market in 2010 because it raised the risk of heart attack and stroke — and with other undisclosed pharmaceutical drugs (these alerts are catalogued in the FDA's Tainted Products Marketed as Dietary Supplements database). Independent product testing has also found many Garcinia products contain less HCA than the label claims. So even if HCA did work as advertised, there is no reliable guarantee a given bottle contains what it says.
The Garcinia cambogia story is a clean template for how supplement marketing can outrun the science: a plausible mechanism in animals, a celebrity TV endorsement, hundreds of millions of dollars in sales, and rigorous trials that fail to find the promised effect. The industry moved on to the next mechanism-sounds-good ingredient; the clinical evidence did not move with it.
Reviewed against 4 peer-reviewed and regulator sources.
Electrolyte products — sports drinks, tablets, powders, and concentrated drops — are sold to athletes as essential for performance and recovery. The actual exercise physiology literature is more nuanced. Electrolyte replacement matters a lot in some situations and not at all in others. Most marketing skips that distinction.
Exercise under about an hour, in cool or temperate conditions, with average sweat rates does not run electrolyte stores low enough to hurt performance. Plain water is fine. Electrolyte replacement becomes genuinely useful in four situations: endurance exercise lasting more than 60–90 minutes; exercise in hot and humid conditions with heavy sweating; multi-day events or training blocks with little time to refuel; and individual athletes who are prone to cramping and have documented high sodium losses in sweat.
Sodium is the electrolyte lost in the largest amounts through sweat. Sweat sodium varies a lot from person to person — recent reviews and ACSM consensus put it in the rough range of 230–1700 mg per litre (10–70 mmol/L), with most athletes near 400–1100 mg/L. Falling sodium — not plain dehydration — is the main driver of exercise-associated hyponatremia (dangerously low blood sodium). It most often shows up in slower, longer events when athletes drink too much plain water and dilute their blood. The 2015 Third International Exercise-Associated Hyponatremia Consensus Statement (Hew-Butler et al.) recommends drinking to thirst rather than to a fixed schedule. ACSM guidelines (Sawka et al. 2007) suggest that during prolonged exercise (more than 2 hours), drinks providing roughly 0.3–0.7 g/L of sodium are reasonable for most athletes; heavy and salty sweaters at the upper end of that range may benefit from somewhat more.
Sweat also contains potassium (typically about 150–230 mg/L) and small amounts of magnesium (about 1–10 mg/L) — far less than sodium. In normal training, food easily covers these losses. Potassium is widely distributed across whole foods (bananas, potatoes, beans, avocado, dairy, leafy greens), and deficiency from exercise alone is uncommon in athletes who eat enough overall. Magnesium can be a baseline gap for some athletes — exercise raises magnesium turnover — but is better addressed through diet or a standalone magnesium supplement than through small, variable amounts in a sports drink.
Most mainstream sports drinks provide roughly 50–110 mg of sodium per 240 ml (8 oz) serving — well below the per-hour sodium intake that endurance athletes might benefit from in hot conditions. Their main payload is sugar (typically 6–8% carbohydrate as glucose, sucrose, or fructose), which is useful for endurance work but largely irrelevant for a 30–45 minute gym session. For serious endurance athletes, purpose-built electrolyte products with higher, clearly stated sodium content are better targeted to actual sweat losses than the supermarket sports drinks marketed at recreational exercisers.
Reviewed against 5 peer-reviewed sources.
CBD (cannabidiol) products are now one of the most visible wellness categories in U.S. retail, and anxiety relief is the headline claim on most labels. Industry analysts have estimated annual U.S. CBD sales at several billion dollars. Demand is driven by personal testimonials, a plausible neuroscience story, and very aggressive marketing. The actual clinical-trial evidence for CBD in anxiety is thinner, less consistent, and more complicated than the industry suggests.
The strongest evidence for CBD in anxiety-related conditions comes from three places. First, pharmaceutical-grade CBD (Epidiolex) is FDA-approved for several rare childhood epilepsy syndromes, where it is genuinely effective. Second, a handful of small but well-designed trials of high-dose oral CBD have shown acute anxiety-reducing effects in social anxiety disorder; the most cited is Bergamaschi et al. (2011), in which a single oral dose of 600 mg CBD significantly reduced anxiety during a simulated public-speaking test in 24 treatment-naive patients with social anxiety. Third, animal models consistently show anti-anxiety effects through the endocannabinoid system. The problem is the gap between those findings and what shoppers actually buy.
Most retail CBD products supply 10–50 mg of CBD per dose. The positive human anxiety trials used 300–600 mg. Whether the lower doses scale down proportionally is not established. Reviews (e.g., Blessing et al. 2015) describe CBD's dose-response curve as roughly bell-shaped (often called an inverted-U), meaning too little and too much both look worse than an intermediate dose — and the intermediate dose in the published anxiety trials sits well above what is in a typical gummy.
Oral CBD bioavailability — the share of the dose that actually reaches the bloodstream — is roughly 6–20% and varies a lot between people and with food (a fatty meal can multiply absorption several-fold). That means a 25 mg gummy may put only about 1.5–5 mg into systemic circulation — a small fraction of the doses used in clinical trials. Sublingual tinctures (held under the tongue) absorb a bit better; vaporised CBD reaches the bloodstream most efficiently but carries lung-related risks of its own. An "effective oral dose" for everyday anxiety, if there is one, has not yet been pinned down in adequately powered trials.
CBD sits in a regulatory grey zone in most markets. Independent testing has repeatedly found mislabelled retail CBD: in Bonn-Miller et al. (2017) — a JAMA research letter analysing 84 products purchased online — only about 31% were accurately labelled, with most under-labelled or over-labelled, and roughly one in five contained detectable THC. In the U.S., there is no pre-market FDA approval for CBD-content claims on these products. For a consumer spending $60–$120 a month on CBD for anxiety, the evidence that the product contains what it says, at a dose with a real shot at working, is not strong.
Reviewed against 5 peer-reviewed and regulator sources.
Vitamin K2 (menaquinone) is built and works differently from the better-known vitamin K1 (phylloquinone) in leafy greens. K2 comes mainly from fermented foods such as Japanese natto, certain aged cheeses, and some animal liver and egg yolk; gut bacteria also make small amounts. Over the past fifteen years K2 has grown into a supplement category in its own right, driven by a clean mechanistic story about vascular calcification — and a randomized-trial track record that has been slower to arrive.
K2 is a cofactor for an enzyme that activates matrix Gla protein (MGP), one of the most potent known natural inhibitors of vascular calcification. When MGP stays inactive ("uncarboxylated"), calcium is more likely to deposit in artery walls, hardening the plaque that builds up in atherosclerosis — a process linked to cardiovascular events even after accounting for cholesterol. K2 also activates other vitamin K-dependent proteins, including osteocalcin (which helps direct calcium into bone). The biological logic in shorthand: K2 helps keep calcium out of arteries and into bones at the same time.
The Rotterdam Study — a Dutch prospective cohort of 4,807 adults followed from 1990–2000 (Geleijnse et al., 2004) — found that the highest tertile of dietary menaquinone intake was associated with a 57% lower risk of coronary heart disease mortality compared with the lowest tertile (relative risk 0.43, 95% CI 0.24–0.77), and with significantly less severe aortic calcification. The Dutch Prospect-EPIC cohort (Gast et al., 2009) reported similar results: higher dietary K2 was linked to a lower incidence of coronary heart disease in postmenopausal women. These are among the stronger diet-outcome associations in cardiovascular epidemiology. The catch: most K2 in the diet comes from fermented foods (natto, aged cheeses) and organ meats — eating patterns that often travel with other lifestyle factors, leaving room for residual confounding.
Several RCTs have tested K2 against surrogate (intermediate) cardiovascular markers rather than heart attacks or deaths. Daily MK-7 (the long-chain form, menaquinone-7) at 180–360 mcg consistently reduces circulating inactive MGP, confirming biological activity. The clearest cardiovascular surrogate trial is Knapen et al. (2015), in which 244 healthy postmenopausal women took 180 mcg/day MenaQ7 (MK-7) or placebo for three years; the supplement group showed significantly less worsening of carotid-femoral pulse wave velocity and Stiffness Index β — measures of arterial stiffness — particularly in women whose arteries were already stiffer at baseline. Smaller Dutch and German trials have hinted at slowed progression of coronary artery calcification, with mixed results. What is still missing: adequately powered, multi-year trials measuring hard endpoints — heart attacks, strokes, cardiovascular death — that would justify treating K2 like a proven cardiovascular drug.
The verdict: K2 has a plausible mechanism and respectable observational support. The randomized-trial evidence is encouraging on intermediate markers, but not yet definitive for the outcomes patients actually care about. For adults concerned about vascular calcification, or those taking calcium supplements (which may modestly raise calcification risk), 100–200 mcg/day of MK-7 is a low-risk, potentially high-upside addition while better trial data accumulate. K2 has known interactions with vitamin K antagonist anticoagulants (warfarin), so anyone on those drugs should not start a K2 supplement without their prescriber's sign-off.
Reviewed against 5 peer-reviewed sources.
By most industry estimates, Amazon now accounts for roughly 30–40% of all U.S. dietary supplement sales — the single largest point of purchase in the category. It is also, by the assessment of independent researchers and trade-group investigations that have repeatedly test-purchased from the platform, one of the least reliable places to buy them. The issue is not Amazon's own private-label products. It is the third-party marketplace, the opacity of Fulfilled-by-Amazon (FBA) inventory commingling, and the structural incentives that have let counterfeit supplements flourish on the platform for more than a decade.
Under FBA, Amazon stores third-party inventory in its warehouses. By default, Amazon may use "commingled" (or "virtual") inventory, meaning units from many sellers — authorized distributors and unauthorized resellers alike — can sit in the same bin and ship interchangeably. A shopper who orders a brand-name supplement may receive a unit drawn from another seller's stock, which can include counterfeit product, expired stock, or product stored outside recommended conditions. Industry trade-group investigations (notably by the Council for Responsible Nutrition) and federal civil suits have documented counterfeit supplements — often from overseas manufacturers with no documented quality controls — entering the FBA supply chain and reaching shoppers who believed they were getting authentic product.
Peer-reviewed analyses have repeatedly found that supplements sold on online U.S. marketplaces contain wrong ingredients, the wrong dose, or undisclosed pharmaceutical drugs. Cohen and colleagues (JAMA 2014) re-purchased 27 supplements after FDA recalls; two-thirds of supplements still on the market 6+ months after recall still contained at least one banned drug. Cohen et al. (2018, Drug Testing and Analysis) bought 12 brain-and-body sport supplements online and detected the unapproved stimulants β-methylphenethylamine and oxilofrine in many of them. Cohen et al. (2021, Clinical Toxicology) found the unapproved drug phenibut, sold as a "dietary supplement," on multiple U.S. retail sites including Amazon. The U.S. FDA has also added more than 1,100 unique products to its Tainted Products Marketed as Dietary Supplements_CDER database, many sold through online marketplaces.
For supplements where product integrity matters — anything you take daily, anything for a child or pregnancy, and anything tested in workplace or sport drug-testing programs — buying directly from the brand's own website removes the marketplace intermediary entirely. Buying from authorized distributors with clear supply-chain accountability is the next best option. On Amazon itself: confirm the "Sold by" line is the brand name (not a third-party reseller), check that the brand has formally opted out of FBA commingling (some brands now publish this), and look for independent third-party certification — NSF Certified for Sport, USP Verified, or Informed Sport — on the bottle in hand, not just on the listing photo (which can be manipulated). NSF Certified for Sport in particular tests every lot for contaminants and banned substances, which addresses both the counterfeiting and the "mystery contents" problem at once.
Reviewed against 9 peer-reviewed and regulator sources (safety category — extra rigor).
Teen multivitamin sales run into the hundreds of millions of dollars a year in the U.S., driven mainly by parental worry rather than measured deficiency. The underlying nutritional science is narrower than the marketing. A teenager eating a varied omnivorous diet has no clearly established cognitive or long-term health benefit from a daily multivitamin (MVI). There is a small downside: a daily pill can give false reassurance about a diet that genuinely needs attention. The real exceptions — adolescent girls with heavy menstrual bleeding, strict vegans, intensively training athletes, and teens with diagnosed absorption disorders such as coeliac disease or Crohn's — are specific enough to name.
Adolescence is a stretch of fast growth and big appetite, driven by growth spurts and hormonal change. A teen who eats enough calories from a reasonably varied diet is also taking in a lot of naturally occurring vitamins and minerals. National dietary surveys (NHANES in the U.S., similar surveys in Canada and the U.K.) consistently show that most adolescents in wealthy countries meet or exceed the recommended intake for most vitamins and minerals from food alone — with a handful of common exceptions noted below. Generic multivitamins give the same dose of every nutrient regardless of individual need; the doses that exceed what the diet already covers are largely excreted unchanged.
Adolescent girls have the highest risk of specific shortfalls. Iron deficiency is common after menarche because menstruation is the body's only major route for losing iron; average menstrual blood loss is around 30–40 mL per cycle, with about 10% of women losing more than 80 mL (a definition of menorrhagia, where iron loss can outpace diet). A serum ferritin (iron-storage) test is more informative than a generic MVI. Calcium and vitamin D matter most during peak bone-mass accretion — roughly ages 9–18, with the steepest gain around 11–14 (Weaver et al., 2016 NOF position statement). Teens who get fewer than three servings of dairy or fortified plant milk a day, or who live in low-sunlight climates, are the ones who should target these specifically. Folate is important for adolescent girls of reproductive age, since the neural tube closes before most pregnancies are recognised; the U.S. CDC recommends 400 mcg/day folic acid for all who could become pregnant.
Teen vegans and vegetarians face higher risk of vitamin B12 deficiency (B12 is essentially absent from plant foods) and sometimes lower iron and zinc absorption due to phytates in grains, legumes, and seeds. B12 supplementation — or reliably fortified foods — is essential for vegan teens; it is the one supplement where deficiency without action is predictable rather than speculative. Adolescent athletes training intensively have elevated needs for iron, vitamin D, and total calories — targeted testing and food planning generally serve them better than a generic MVI. The American Academy of Pediatrics has long taken the same line: routine multivitamin supplementation is not recommended for healthy children eating a varied diet.
Reviewed against 6 peer-reviewed and regulator sources.
The pairing of L-theanine and caffeine is one of the most-studied cognitive "stacks" in the nootropic world, with more than a dozen randomized controlled trials in healthy adults. The pattern across the literature is reasonably consistent: the combination supports attention, accuracy on demanding tasks, and subjective focus, while taking the edge off the jitteriness and anxiety some people get from caffeine alone. It is one of the few cognitive combinations where the mechanism, the pharmacokinetics, and the behavioural outcomes line up.
Caffeine is an adenosine receptor antagonist. By blocking adenosine — a sleep-promoting molecule that builds up the longer you are awake — caffeine reduces tiredness and raises alertness and reaction speed. At higher doses, it can also push up anxiety, heart rate, and the kind of jitteriness that hurts fine-grained performance. L-theanine is an amino acid found almost only in tea (Camellia sinensis), where it naturally sits next to caffeine. EEG studies show L-theanine increases alpha-wave activity associated with "relaxed alertness," and animal work suggests it modulates GABA and glutamate signalling — softening the excitatory side of caffeine without making the user sleepy.
The most replicated finding across the literature: the combination of L-theanine and caffeine outperforms either compound alone on tasks that demand sustained attention, rapid visual information processing, and short-term memory. The combination also tends to produce lower self-rated anxiety and fewer jitteriness ratings than caffeine alone, despite similar alertness gains. In Haskell et al. (2008), 250 mg L-theanine + 150 mg caffeine improved Rapid Visual Information Processing accuracy and reduced "mental fatigue" ratings more than either substance alone. In Owen et al. (2008), 100 mg L-theanine + 50 mg caffeine improved both speed and accuracy on an attention-switching task and made participants less distractible. Dodd et al. (2015) reported faster reaction times on an attention task with the combination at 200 mg L-theanine + 75 mg caffeine. The doses across the literature vary, but the "cleaner-feeling caffeine" pattern is fairly consistent.
There is no single official ratio, but most studied combinations land in the 1:1 to 2:1 L-theanine-to-caffeine-by-weight range. Common effective combinations include 100 mg caffeine with 100–200 mg L-theanine, or 50–75 mg caffeine with 100–150 mg L-theanine for people who are caffeine-sensitive. Onset is generally 30–45 minutes after dosing and peaks around 60–90 minutes, matching caffeine's pharmacokinetics. A cup of brewed green tea naturally provides a small dose of both — roughly 25–50 mg caffeine and 5–25 mg L-theanine per cup, depending on type and brew time — at lower absolute amounts than supplement-grade formulations. Caffeine doses for cognitive effect are well below the 400 mg/day generally considered safe for healthy adults by EFSA and the U.S. FDA, but should still be tapered (or skipped) by anyone with arrhythmia, anxiety disorders, or pregnancy concerns. Tolerance to the alertness effect develops within 1–4 weeks of regular daily use; an occasional break or pre-task-only use keeps the effect crisper.
Reviewed against 5 peer-reviewed and regulator sources.
Saw palmetto (Serenoa repens) berry extract is one of the most widely used herbal products for the urinary symptoms of benign prostatic hyperplasia (BPH) — the non-cancerous enlargement of the prostate that becomes increasingly common in men over 50. Industry analysts have estimated global saw palmetto sales in the hundreds of millions of dollars annually. Three successive Cochrane systematic reviews (Wilt et al. 2002, MacDonald et al. 2009, Tacklind et al. 2012), spanning two decades of cumulative randomized trial evidence, have consistently found that saw palmetto is no more effective than placebo for BPH symptoms. This is a story about how early encouraging data, a plausible mechanism, and strong commercial interests can sustain a market that better-quality science has steadily undermined.
Small trials from the 1980s and 1990s reported statistically significant improvements in urinary flow and symptom scores with saw palmetto in men with BPH. The proposed mechanism — modest inhibition of 5-alpha-reductase, the enzyme that converts testosterone to DHT (the hormone that drives prostate growth) — sounded biologically plausible, since prescription 5-alpha-reductase inhibitors like finasteride do reduce BPH symptoms. These early positive signals drove the adoption of saw palmetto as a mainstream "men's health" supplement.
The first Cochrane review (Wilt et al. 2002) found a modest positive signal but flagged serious methodological problems with the available trials — short duration, small samples, weak blinding. As better-quality trials accumulated, the picture changed. The STEP trial (Bent et al. 2006, NEJM) — 225 men randomized to saw palmetto 160 mg twice daily or placebo for one year — found no difference between groups on AUA Symptom Index or urinary flow. The CAMUS trial (Barry et al. 2011, JAMA) — a 369-man, NCCAM/NIDDK-funded multi-centre study with escalating doses of standard, double, and triple the usual dose of saw palmetto extract over 72 weeks — found no improvement compared with placebo on the AUA Symptom Index or any secondary outcome (group difference 0.79 points favouring placebo, P = 0.91 in the saw palmetto direction). The 2012 Cochrane review (Tacklind et al.), pooling 32 RCTs in 5,666 men, concluded that saw palmetto, even at double and triple doses, did not improve urinary flow measures or prostate size. In short: no benefit on peak urinary flow rate, no benefit on symptom scores, no benefit at any dose tested.
BPH symptoms fluctuate naturally, so many men feel better on a new pill simply because they happened to start it during a less-bad stretch — a textbook setup for placebo and regression-to-the-mean effects. The supplement industry has largely continued to market the 1990s mechanism story without surfacing the subsequent Cochrane conclusions. For men with symptomatic BPH, evidence-based options include alpha-blockers (tamsulosin, alfuzosin, silodosin), 5-alpha-reductase inhibitors (finasteride, dutasteride), combination therapy, and behavioural changes (timed voiding, evening fluid restriction, limiting alcohol and caffeine), all of which outperform saw palmetto in head-to-head and placebo-controlled trials.
Reviewed against 4 peer-reviewed sources.
Intermittent fasting — usually a 16:8 schedule (16 hours fasted, an 8-hour eating window) — is now mainstream. Most fasting guides skip the practical question: which supplements are safe to take while fasted, which should wait, and which actually break a fast in a way that matters?
"Breaking a fast" is fuzzier than the internet suggests. The strict definition focuses on insulin: anything that triggers a meaningful insulin rise ends the fasted state. A looser definition is anything with calories. The practical version most people care about: anything that pulls in enough calories or stimulates the gut enough to defeat the goal of the fast — whether that goal is metabolic flexibility, digestive rest, or ketosis.
The following do not meaningfully raise insulin or shift fasting metabolism: water, calorie-free electrolytes (sodium, potassium, magnesium in plain forms), creatine monohydrate, plain caffeine, and most fat-soluble vitamins (A, D, E, K) in capsule form. Pure creatine monohydrate is calorie-free and does not raise insulin in healthy adults. Magnesium glycinate, zinc, vitamin C, and B vitamins taken with plain water all carry negligible calories and will not interfere with fasting goals.
Protein supplements — whey, casein, collagen, BCAAs — all stimulate insulin and belong inside the eating window. Fish oil capsules contain a small amount of fat (about 10–15 calories per serving) and technically break a strict fast, though that dose is too small to matter for most goals. MCT oil raises insulin and ketone production in ways that may help or hurt depending on the goal — hold it for the eating window if strict ketosis is the target. Gummy vitamins contain sugar and calories. Probiotic capsules survive stomach acid better when taken with food, so the eating window is the better home for them anyway.
A practical setup: take fat-soluble vitamins (D3, K2, omega-3) with the first meal of the eating window, since dietary fat improves their absorption. Take magnesium 30–60 minutes before bed for sleep support, regardless of fasting. Creatine works any time. Protein supplements stay inside the eating window. Iron is best taken on an empty stomach; 30 minutes before opening the eating window is a reasonable compromise that protects absorption without ending the fast for long.
Reviewed against 5 peer-reviewed sources.
The advice to take probiotics with antibiotics is so common it has become reflexive. The catch: timing and strain choice decide whether they help, do nothing, or actively slow the gut's recovery once the antibiotic course ends.
Antibiotics are not selective weapons. A course of broad-spectrum antibiotics like amoxicillin-clavulanate or ciprofloxacin can cut microbial diversity by 25–50% within 24 hours of the first dose. That ecological collapse is the underlying cause of antibiotic-associated diarrhea (AAD), which affects 5–30% of antibiotic users, and of Clostridioides difficile infection. The CDC estimates roughly 250,000 hospitalized C. diff cases per year in the US, with community-associated infections climbing as well.
A landmark 2018 Cell paper by Suez and colleagues at the Weizmann Institute found something counterintuitive. After antibiotics, the group taking a multi-strain probiotic showed the slowest return to a normal gut microbiome — significantly delayed and incomplete reconstitution — while a comparison group given autologous fecal microbiome transplant recovered within days. The probiotic strains colonized and crowded out the returning native bacteria. The takeaway: probiotics taken purely for post-antibiotic "recovery" may delay the very recovery they are sold to support.
The case for taking probiotics during the antibiotic course (not after) is strong. The 2017 Cochrane review by Goldenberg and colleagues pooled 31 randomized trials and 8,672 patients and found probiotic co-administration cut the risk of C. difficile-associated diarrhea by about 60% on average, and by roughly 70% among patients at higher baseline risk (number needed to treat ~12). The most studied strains are Lactobacillus rhamnosus GG and Saccharomyces boulardii. Optimal timing for bacterial strains is at least 2 hours away from the antibiotic dose. S. boulardii, a yeast rather than a bacterium, is not killed by antibacterial drugs and can be taken at the same time.
For long-term microbiome recovery after the course ends, dietary diversity — fermented foods, prebiotic fiber, varied plant intake — appears to outperform routine probiotic supplementation. Prebiotics provide the substrate that native bacteria use more efficiently than imported probiotic strains.
Reviewed against 5 peer-reviewed sources.
Plant-based diets carry real health upsides but also create predictable nutritional gaps. A handful of nutrients are either absent from plants, present in poorly absorbed forms, or only available in amounts no realistic diet provides. These are the supplements with the strongest case — and the doses that match the evidence.
Vitamin B12 is made only by microbes and reaches us through animal foods. Vegans who do not supplement will become deficient over time, and prolonged B12 deficiency can cause irreversible nerve damage. Either methylcobalamin or cyanocobalamin works for maintenance — head-to-head studies show similar results when adequate doses are used. Two practical regimens have strong evidence: 50–100 mcg daily, or 1,000–2,000 mcg twice weekly. The high-dose weekly approach works because of passive diffusion (about 1% of any oral dose is absorbed regardless of intrinsic factor), so it is reliable even for older adults with reduced absorption.
Most D3 supplements come from lanolin (sheep wool, not vegan). Vegan D3 from lichen is bioequivalent and widely available — target 1,000–2,000 IU daily, adjusted by bloodwork. Conversion of plant-based ALA to EPA and DHA is poor in humans: less than ~8% to EPA and under ~4% to DHA, with conversion to DHA often well below 1%. Algal oil supplements deliver DHA (and now usually EPA) directly. Roughly 200–300 mg of DHA per day from algal oil is a reasonable minimum for general health.
Non-heme iron from plants absorbs at 2–20%, versus 15–35% for heme iron from animal foods. Iron bisglycinate is gentler on the gut than ferrous sulfate at equivalent elemental doses. Phytates in legumes and grains reduce zinc absorption, so the NIH suggests vegetarians need roughly 50% more dietary zinc than omnivores. Vegans who avoid dairy and seafood are at real risk of iodine inadequacy — 150 mcg daily of potassium iodide (or kelp standardized to a known iodine content) is a reliable solution. Calcium citrate absorbs well at any meal and does not require stomach acid, making it preferable to calcium carbonate for older adults or anyone on acid-suppressing medication.
Creatine and carnosine (or its precursor beta-alanine) are higher in omnivores than vegetarians and respond well to supplementation. Creatine monohydrate at 3–5 g/day raises muscle creatine stores in vegans more than in omnivores at baseline and improves performance and possibly cognition. Choline is also commonly under-consumed on plant-based diets — soybeans, quinoa, and supplements (250–500 mg/day) close the gap.
Reviewed against 6 peer-reviewed sources.
Tribulus terrestris is one of the most consistently stocked supplements in gym retail — sold as a "natural testosterone booster" and marketed aggressively to men. The problem is straightforward: when tested in healthy men with a placebo control, it does not raise testosterone.
The testosterone story traces back to Eastern European athlete anecdotes from the 1970s and 1980s, plus animal studies suggesting that saponin compounds in the plant might stimulate luteinizing hormone (LH) production. Rats fed tribulus did show effects. The mistake was assuming the same mechanism would carry over to healthy human men. Rats and humans regulate the hypothalamic-pituitary-gonadal axis very differently, and compounds that move LH in rodents often do nothing to it in humans. This rodent-to-human translation failure is one of the most common sources of false supplement claims.
Multiple double-blind, placebo-controlled trials in healthy young men have used tribulus at 450–1,500 mg/day for 4–12 weeks and found no significant change in serum testosterone, LH, FSH, or any other androgen marker. A 2025 systematic review by Camargos and colleagues in Nutrients pooled 10 clinical trials covering 483 men and concluded the evidence for raising testosterone is not robust; only two studies found small intra-group changes (60–70 ng/dL), and those were in men with hypogonadism. There is some weak evidence for modest improvements in self-rated libido or erectile function, independent of any testosterone change — not enough for clinical recommendation.
Dietary supplements do not need to prove efficacy before they are sold in the US. Manufacturers cite rodent studies, traditional use, and mechanistic hypotheses — none of which substitute for human clinical evidence. Consumers reasonably but mistakenly assume that nationwide retail availability implies proof of effect.
Reviewed against 5 peer-reviewed sources.
Protein powder is one of the most widely used supplements in the world. Most users assume that a product sold legally at retail — especially at premium prices — has been tested for safety. That assumption is incorrect, and the contamination data is genuinely concerning.
The Clean Label Project's 2018 report tested 134 best-selling protein powders across 52 brands. Roughly 70% had detectable lead, 74% had detectable cadmium, and 55% had detectable BPA (bisphenol A, an endocrine disruptor). Plant-based powders — especially brown rice and pea protein — carried five times more cadmium on average than whey, and roughly 75% of plant-based products had detectable lead versus around 10% of whey-based products. Several products exceeded California's Proposition 65 daily safety limits in a single serving. Two servings per day — common in heavy users — can push cumulative exposure into a regulatory gray zone over time.
The Clean Label Project's 2025 follow-up report ("Protein Study 2.0") tested 160 products across 70 brands and showed the problem has not gone away: organic and plant-based products again averaged the highest heavy-metal contamination, and chocolate-flavored products carried roughly four times more lead than vanilla on average. Industry trade groups have disputed the methodology, but FDA and Health Canada both recognize that protein powders — especially brown-rice based — are a documented dietary source of inorganic arsenic, lead, and cadmium.
Manufacturing concentrates not only protein but also any heavy metals from the source material. Brown rice protein is the worst offender for inorganic arsenic because rice plants take up arsenic from irrigation water at higher rates than most grains, a finding documented by Meharg and colleagues and reinforced by FDA monitoring. Cocoa is the largest dietary source of cadmium and lead in chocolate-flavored products. BPA can enter from older lined processing equipment or from plastic packaging. The FDA does not routinely test supplements for heavy metals before they reach the market — manufacturers are responsible under the Dietary Supplement Health and Education Act, but there is no required pre-market verification.
Choose products with NSF Certified for Sport, Informed Sport, or USP Verified seals — these programs include heavy-metal testing. Check the Clean Label Project's searchable product database. If heavy-metal exposure is the primary concern, whey or casein generally test cleaner than plant-based blends, and vanilla flavors generally test cleaner than chocolate. Limit habitual intake: food sources of protein do not carry the same concentration risk, and most adults can hit protein goals without daily two-scoop powder use.
FDA, Health Canada, and the European Food Safety Authority all flag pregnant and breastfeeding women, infants, and young children as the highest-risk groups for chronic heavy-metal exposure, because lead and cadmium accumulate in tissues over time and prenatal lead exposure has neurodevelopmental effects at any measurable blood level. People in these groups should be especially careful about routine plant-based or organic protein-powder use without third-party metals testing.
Reviewed against 9 peer-reviewed and regulatory sources (safety-category rigor).
Turkey tail (Trametes versicolor, also written Coriolus versicolor) has been used in traditional Chinese medicine for centuries and is now one of the most heavily marketed medicinal mushroom supplements in Western retail. The marketing often implies — or outright says — that turkey tail can prevent or treat cancer. That claim goes well beyond what the science supports.
Turkey tail contains two polysaccharide complexes: polysaccharide-K (PSK, sold in Japan as Krestin) and polysaccharide-peptide (PSP). PSK has been used in Japan since 1977 as an adjunct to standard cancer therapy — alongside surgery and chemotherapy, not in place of them. A 2017 network meta-analysis of 23 trials in 10,684 patients found that PSK added to chemotherapy significantly improved 1- to 5-year overall survival in colorectal and gastric cancers, with no increase in side effects. A separate 2007 individual-patient meta-analysis of curative gastric-cancer resections (8,009 patients) reported a hazard ratio of 0.88 (95% CI 0.79–0.98) for survival with PSK. This is real evidence — but for purified PSK specifically, in cancer patients, alongside chemotherapy, in mostly Japanese populations.
What this evidence does not support: turkey tail supplements preventing cancer in healthy people, replacing conventional therapy, or off-the-shelf retail products that have not standardized PSK content being equivalent to the pharmaceutical PSK extract used in Japan. Most US retail turkey tail supplements do not verify PSK content or replicate the dosing schedules used in trials. The 2012 Bastyr/NIH-NCI funded phase 1 trial by Torkelson and colleagues (n=11, 9 completers) tested 3, 6, or 9 g/day after radiation in breast cancer patients. The 6 g/day dose increased natural killer cell activity, but the study was tiny, designed to assess safety, and not powered to show clinical benefit.
Turkey tail is generally well tolerated at typical supplement doses. Patients undergoing chemotherapy, immunotherapy, or transplant immunosuppression should consult their oncology team before adding any immune-modulating supplement, since interactions with cancer regimens are theoretically possible.
Reviewed against 6 peer-reviewed sources.
Docosahexaenoic acid (DHA) is a long-chain omega-3 fatty acid. It makes up roughly 97% of the omega-3 in the brain and about 93% of the omega-3 in the retina. The fetal brain accumulates DHA fastest during the third trimester and the first two years of postnatal life — the critical window for neural migration, myelination, and synaptogenesis (the wiring of brain cells).
The fetus depends entirely on maternal DHA crossing the placenta. The placenta actively concentrates DHA into fetal circulation above maternal blood levels — but only when maternal intake is adequate. Maternal DHA status in the third trimester predicts neonatal visual acuity, early cognitive scores, and language development. The 2018 Cochrane review by Middleton and colleagues pooled 70 randomized trials in 19,927 women. It found that omega-3 supplementation during pregnancy lowered the risk of preterm birth (before 37 weeks) by about 11% and the risk of early preterm birth (before 34 weeks) by about 42%, and reduced the proportion of low-birthweight infants. The review concluded the evidence was strong enough that routine omega-3 supplementation in pregnancy should be considered.
The FAO/WHO and most expert bodies recommend at least 200 mg of DHA per day during pregnancy and lactation. The Cochrane review identified an optimum dose of 500–1,000 mg of long-chain omega-3s daily (with at least 500 mg DHA) starting around 12 weeks. Most pregnant women in Western countries consume only 50–100 mg DHA per day. Standard prenatal vitamins often skew toward plant-based ALA, which is converted to DHA at less than 4% efficiency in humans — not enough to close the gap.
Fatty fish low in mercury — salmon, sardines, anchovies, herring, Atlantic mackerel, trout — can safely be eaten 2–3 times per week per FDA/EPA "Advice About Eating Fish" (updated 2024). Higher-mercury species (shark, swordfish, king mackerel, tilefish, bigeye tuna) should be avoided in pregnancy. For women who don't eat fish, algal oil DHA bypasses the mercury issue entirely: algae produce DHA directly with no marine-food-chain heavy metal accumulation, and an EPA-plus-DHA algal oil at 200–500 mg/day is bioequivalent to fish oil for raising blood DHA.
Breast milk DHA content closely tracks maternal intake. Mothers who eat little fish produce milk with DHA levels that may be inadequate for optimal neural development. The 200–300 mg/day DHA recommendation continues throughout breastfeeding.
The 2021 ADORE trial (Carlson et al., EClinicalMedicine) randomized 1,100 pregnant women to 200 mg or 1,000 mg of DHA per day. The high-dose arm cut early preterm birth (<34 weeks) by roughly half in women with low baseline DHA, suggesting individualized higher doses may benefit a subset of women. ACOG and ISSFAL now both endorse a minimum of 200 mg DHA in pregnancy as a routine recommendation.
Reviewed against 6 peer-reviewed and regulatory sources.
N-acetylcysteine (NAC) is best known as the hospital antidote for acetaminophen overdose. Over the past two decades, a growing body of psychiatric research has tested NAC as an add-on therapy for OCD, addiction, and depression — with results that have made it one of the more serious nutraceutical candidates in psychiatry.
NAC works through two relevant pathways. As a cysteine donor, it replenishes glutathione, the brain's main antioxidant. More importantly for psychiatric effects, NAC modulates the cystine-glutamate antiporter, which regulates extracellular glutamate. Disrupted glutamate signaling is implicated in addiction, OCD, and treatment-resistant depression.
A 2012 double-blind RCT (Afshar et al., Journal of Clinical Psychiatry) tested NAC at 2,400 mg/day as an SSRI add-on in patients with treatment-refractory OCD. At 12 weeks, the NAC group showed significantly larger reductions in Y-BOCS scores (the standard OCD severity scale) than placebo. A 2024 meta-analysis (Hinkle et al., Frontiers in Psychiatry) pooled six randomized trials of NAC augmentation in adult OCD (n=195). It concluded NAC at 2,000–3,000 mg/day may benefit moderate-to-severe OCD and is generally well tolerated, but called for larger trials to confirm. Of five clear adjunctive trials, four showed significant Y-BOCS reductions; one 20-week study did not. The evidence is best characterized as promising but not definitive.
Multiple RCTs have found NAC reducing craving and use in cannabis and cocaine dependence. A 2012 RCT by Gray et al. in cannabis-using adolescents (1,200 mg twice daily for 8 weeks) doubled the odds of cannabis-negative urine drug screens compared to placebo. Larger follow-up trials in adults have been more mixed, with effects most evident in specific subgroups. Mechanism: chronic drug use disrupts the cystine-glutamate exchanger, and NAC appears to restore it.
Several RCTs have found NAC producing antidepressant effects, particularly in bipolar depression and in cases with elevated inflammatory markers. A 2008 trial by Berk and colleagues showed NAC 1,000 mg twice daily reduced depressive symptoms in bipolar disorder over 24 weeks. Evidence is not strong enough for first-line use but supports adjunct trials in treatment-resistant cases. Most psychiatric NAC research uses 1,800–3,000 mg/day in divided doses. The most common side effect is gastrointestinal upset; nausea, heartburn, and diarrhea typically resolve with food. Anyone taking NAC alongside psychiatric medications, blood thinners, or nitroglycerin should clear it with their prescribing physician.
Reviewed against 5 peer-reviewed sources.
Browse any major supplement brand and you'll see a familiar visual language: earth tones, leaf icons, and words like "clean," "pure," "natural," "sustainably sourced," and "eco-friendly." None of those terms are regulated for dietary supplements. They function as marketing signals, not verified facts.
The FDA has no formal definition of "natural" for dietary supplements. Any manufacturer can put "all natural" on a product that contains titanium dioxide (a synthetic whitening pigment) and magnesium stearate (a synthetic flow agent) without any regulatory consequence. "Sustainably sourced" similarly has no legal definition or third-party verification requirement. A "sustainably sourced ashwagandha" claim might mean a real regenerative-farming partnership — or it might mean the company bought from a broker who said responsible sourcing was happening, with no audit trail to prove it.
In 2015 the New York Attorney General's office, working with a Clarkson University DNA-barcoding lab, tested 78 store-brand herbal supplement samples across GNC, Target, Walgreens, and Walmart. About 21% of the products contained DNA from the labeled plant; many contained only fillers (rice, houseplant, asparagus) or unlisted substitute species. The DNA-barcoding methodology was later disputed by industry groups (and the underlying journal paper was retracted in 2024 over methodology concerns), but the agreements that followed — including GNC's commitment to DNA-test active herbal ingredients — remain in force. The broader point stands: independent verification is the exception, not the rule.
USDA Organic certification does apply to supplements when an organic claim is made — products labeled "organic" must contain at least 95% organically produced ingredients, grown without prohibited synthetic pesticides, GMOs, or irradiation. This is one of the few environmentally meaningful certifications with regulatory teeth. Note that "organic" does not mean "low in heavy metals" — the Clean Label Project has repeatedly found that organic protein powders test higher for cadmium and lead on average. "Clean label" itself is a marketing term, not a regulatory category.
Certifications worth looking for: USP Verified, NSF Certified for Sport, Informed Sport (all three include identity, potency, contaminant, and banned-substance testing); USDA Organic for production methods; Rainforest Alliance, Fair Trade USA, and B Corporation for broader environmental and social claims. Everything else labeled "natural" or "sustainable" is unverified marketing language until proven otherwise.
Reviewed against 6 regulatory and peer-reviewed sources.
NSAIDs — ibuprofen, naproxen, diclofenac — work fast for joint pain. They also carry meaningful gastrointestinal and cardiovascular risks with chronic daily use. Boswellia serrata (Indian frankincense) has a different mechanism and a clinical evidence base that makes it a legitimate option for people who need long-term joint pain relief and want to limit NSAID exposure.
NSAIDs block cyclooxygenase enzymes (COX-1 and COX-2), which reduces prostaglandin production. Blocking COX-1 also strips away the prostaglandins that protect the stomach lining, which is why long-term NSAID use causes ulcers and bleeding. Daily NSAID use is associated with a several-fold increase in serious GI complications and a measurable increase in cardiovascular event risk. Boswellic acids — especially AKBA (3-O-acetyl-11-keto-β-boswellic acid) — work on a different pathway: they inhibit 5-lipoxygenase (5-LOX), the enzyme that makes leukotrienes. Leukotrienes drive cartilage breakdown in osteoarthritis and synovial inflammation. Inhibiting 5-LOX does not damage gastric mucosal protection, so the GI safety profile is much friendlier.
A 2020 systematic review and meta-analysis by Yu and colleagues in BMC Complementary Medicine and Therapies pooled seven randomized controlled trials in 545 osteoarthritis patients. Boswellia significantly reduced pain and stiffness and improved joint function compared with placebo, with the recommended treatment duration of at least 4 weeks. A 2024 multi-center RCT (Vishal et al., Frontiers in Pharmacology) of a standardized 30%-AKBA Boswellia extract found measurable knee osteoarthritis benefit within 5 days, sustained for 15 days after discontinuation. A 2024 sub-group meta-analysis of standardized Aflapin showed clinically meaningful benefit at low doses (100 mg/day) in 90-day trials.
Boswellia generally takes 4–8 weeks to show full benefit — this is a chronic-management option, not a rescue medication for an acute flare. Look for products standardized to at least 30% boswellic acids with declared AKBA content, or a branded form (Aflapin, ApresFlex, 5-Loxin, Boswellin Super) backed by published RCTs. Take with a fat-containing meal for better absorption. Reasonable starting doses range from 100–250 mg of standardized AKBA-enriched extract to 300–400 mg three times daily of total Boswellia extract, depending on the product.
Boswellia is generally well tolerated. Mild GI upset is the most common side effect. Theoretical interactions exist with anticoagulants (additional anti-platelet effect) and CYP3A4-metabolized drugs — check with a pharmacist if you take blood thinners or have a complex medication list. Stop use 1–2 weeks before surgery.
Reviewed against 6 peer-reviewed sources.
Selective androgen receptor modulators (SARMs) are drug compounds first developed to treat muscle loss and bone disease. The plan was to get the muscle-building effects of steroids with fewer side effects. None of them are FDA-approved for any human medical use. Yet they are sold openly online and in gyms, often labeled as "research chemicals" or "not for human consumption" to dodge drug law. Buyers are taking unapproved drugs with documented risks of liver failure, heart attack, and stroke.
SARMs were designed to switch on androgen receptors in muscle and bone while leaving the prostate and liver mostly alone. In theory, that means anabolic benefits without the worst side effects of testosterone and other synthetic androgens. In practice, the selectivity is incomplete. Recreational doses are far higher than what trials studied. Products are not pharmaceutical grade. And long-term safety data in healthy people barely exists, because no SARM ever completed FDA approval. The trials needed to prove safety were never done.
Published case reports and case series describe SARM-related drug-induced liver injury (DILI), severe hypogonadism with testosterone suppression that sometimes requires medical treatment, ischemic stroke in young athletes, and cardiac events including myocarditis (Flores 2020 PMID 33134761; Barbara 2020 PMID 32754621; Bedi 2021 PMID 34239744). A 2023 review in Therapeutic Advances in Drug Safety summarized the published literature and found cholestatic liver injury was the single most common pattern reported (Hilkens 2023 PMID 38028932). The FDA issued consumer warnings against SARMs in body-building products in October 2017 and again in 2021, citing risks of liver toxicity, heart attack, and stroke (FDA 2017; FDA 2021). FDA enforcement actions and product testing have repeatedly found SARMs in products labeled only as “workout” or “testosterone support,” sometimes at concentrations far above any studied dose, and sometimes containing SARMs not listed on the label at all (Van Wagoner 2017 PMID 28114673). Selling SARMs in human dietary supplements is illegal under the Dietary Supplement Health and Education Act (DSHEA), because SARMs are unapproved drugs, not dietary ingredients. The federal SARMs Control Act — reintroduced most recently in 2024 — would explicitly schedule SARMs as controlled substances if enacted.
If you develop yellowing of the eyes or skin (jaundice), dark urine, severe fatigue, racing heart, testicular shrinkage, or major mood changes, see a doctor right away. Tell them you used a SARM — many clinicians have not seen these cases and will not ask. A reasonable first work-up is liver enzymes (AST, ALT, alkaline phosphatase, bilirubin), a lipid panel, and a full hormone panel (testosterone, LH, FSH, estradiol). Recovery of the hypothalamic-pituitary-gonadal axis after SARM use can take months and sometimes does not fully return to baseline.
Reviewed against 9 peer-reviewed and regulatory sources (safety-category rigor).
Shilajit is a blackish-brown sticky tar that seeps out of cracks in high-altitude mountain rocks. It forms over centuries as plant matter is squeezed and partly broken down between layers of stone. In Ayurvedic medicine it is classified as a rasayana, or rejuvenating substance. In the modern Western supplement market it is sold as a testosterone booster, energy aid, and anti-aging product at $50–$100 per month. The human evidence does not support most of those claims.
Purified shilajit contains fulvic and humic acids (40–60% of content), dibenzo-alpha-pyrones, and a large number of trace minerals in ionic form (Carrasco-Gallardo 2012 PMID 22216264). The human trials are small, mostly funded by ingredient manufacturers, and inconsistent. A 2010 Andrologia RCT (Biswas 2010 PMID 19854048) tested processed shilajit in 60 infertile men and reported improved sperm count and motility — a result in a clinical population, not in healthy men. A follow-up open-label study in 28 oligospermic men found modest testosterone, FSH, and LH changes after 90 days of 100 mg twice daily (Pandit 2016 PMID 26395129). A 2019 Journal of the International Society of Sports Nutrition trial in healthy resistance-trained men (Keller 2019 PMID 30290359) reported small improvements in muscle strength but did not measure testosterone as a primary outcome. There is no high-quality RCT showing shilajit raises testosterone in healthy eugonadal men. The total clinical database is too small to support most of the marketing claims.
Raw or poorly purified shilajit can contain meaningful amounts of heavy metals — arsenic, lead, mercury, and cadmium — that reflect the geology of the rock it seeped out of (Wilson 2011 PMID 21470302). Purification quality varies a lot between brands, and unlike most plant-based supplements, shilajit has no formal pharmacopeial standard. The U.S. Pharmacopeia heavy-metal limits for dietary supplements (USP General Chapter <232>) cap daily oral lead at 5 µg and arsenic at 15 µg; older Indian Ayurvedic preparations including some shilajit products have exceeded those limits in independent surveys (Saper 2008 PMID 18728265). Independent third-party testing — or a USP- or NSF-verified product — is important before use.
Marketing claims for shilajit — testosterone boosting, energy, anti-aging — outpace the clinical evidence by a wide margin. The contamination risk gives a second reason for caution if you cannot verify how a product was tested.
Reviewed against 6 peer-reviewed sources.
The infant probiotic market has grown quickly. The pitch is that giving babies live bacteria helps their developing gut microbiome and improves health. The pediatric research has a few well-studied uses with real evidence — and a much larger pool of marketing claims that the evidence does not support. The two are worth keeping separate.
A baby's gut is essentially sterile at birth. It is then colonized by bacteria from the birth canal, the mother's skin, breast milk, and the environment. Babies born by C-section miss vaginal exposure and show different bacterial mixes in the gut for at least the first few years (Dominguez-Bello 2010 PMID 20566857). Breastfeeding is the strongest natural shaper of the early microbiome. Breast milk delivers human milk oligosaccharides (HMOs) that selectively feed Bifidobacterium species, especially B. infantis.
The clearest pediatric probiotic evidence is for Lactobacillus reuteri DSM 17938 in colic. An individual-patient-data meta-analysis of four RCTs in 345 infants (Sung 2018 PMID 29279326) found that DSM 17938 roughly doubled the chance of treatment success (≥50% reduction in crying/fussing time at day 21) in breastfed infants. The benefit in formula-fed infants was much smaller and not statistically significant. For necrotizing enterocolitis (NEC) in preterm infants, a 2023 Cochrane review of 60 trials in over 11,000 infants found that probiotics reduced severe NEC and all-cause mortality (Sharif 2023 PMID 37196077), and several NICU programs now use specific multi-strain protocols. The American Academy of Pediatrics has stopped short of recommending universal NICU probiotics, citing variability in products and the FDA warning that followed the 2023 death of a preterm infant given a non-pharmaceutical-grade probiotic (FDA 2023 Safety Communication).
Giving probiotics to all infants to "boost immunity" or "support development" is not supported by good evidence. Parents should be cautious about products that do not name a specific strain or cite infant clinical trials — the genus and species are not enough; the strain identifier (e.g., DSM 17938, BB-12, Bb-02) matters. Safety note: very premature infants (<32 weeks gestation), infants with central lines, and immunocompromised infants carry a small but real risk of probiotic sepsis. Use probiotics in those groups only under neonatal medical supervision and with a pharmaceutical-grade product.
Reviewed against 5 peer-reviewed and regulatory sources.
This is not a motivational essay. It is a direct comparison of effect sizes. When you place the measured biological effects of regular exercise next to the measured effects of any supplement — including the best-supported ones — exercise wins on the outcomes that actually matter, usually by a wide margin.
A pooled analysis of accelerometer-measured activity in 116,221 adults (Saint-Maurice 2020 PMID 32219361) found that meeting U.S. physical activity guidelines (~150 minutes moderate-to-vigorous activity per week) was associated with about a 30% lower risk of all-cause mortality. The 2024 Lancet Global Health analysis of 196 countries (Strain 2024 PMID 38942499) confirms a similar dose-response. The best-supported cardiovascular supplement — pharmaceutical-grade icosapent ethyl (purified EPA) at 4 g/day in the REDUCE-IT trial (Bhatt 2019 PMID 30415628) — cut major adverse cardiovascular events by 25% in a high-risk statin-treated population. The dose far exceeds what typical fish-oil capsules deliver. Exercise produces a larger absolute risk reduction across a much broader population, at zero financial cost.
A 1-year aerobic exercise RCT in 120 older adults (Erickson 2011 PMID 21282661) found a roughly 2% increase in hippocampal volume — reversing the typical age-related decline of about 1–2% per year. No supplement has shown structural brain-volume gains in a controlled human trial. Regular moderate-intensity exercise also lowers C-reactive protein (CRP), IL-6, and TNF-alpha through multiple mechanisms; the best-studied anti-inflammatory supplement (fish oil) shows consistently smaller effect sizes (Tabrizi 2020 PMID 32227340). The Diabetes Prevention Program (Knowler 2002 PMID 11832527) found that a structured lifestyle program (diet plus 150 min/week activity, ~7% weight loss) reduced new type 2 diabetes by 58% over 2.8 years — better than metformin (31%) and better than any supplement that has ever been tested for that endpoint.
A 2024 BMJ network meta-analysis of 218 RCTs in 14,170 adults (Noetel 2024 PMID 38355154) found that walking, jogging, and strength training produced moderate-to-large reductions in depression symptoms — on par with cognitive behavioral therapy and SSRIs. Ashwagandha, the best-evidenced supplement for anxiety, shows effect sizes that are meaningfully smaller than aerobic exercise produces. The right framing: supplements are add-ons to a physically active life, not replacements for one.
Reviewed against 6 peer-reviewed sources.
The nootropics market — worth several billion dollars a year — sells everything from lion's mane to racetams to "focus stacks" of a dozen herbs. The pitch is that these compounds make a healthy brain work better. For most of them, the evidence in healthy adults is somewhere between thin and nonexistent.
Most positive nootropic trials are run in people with cognitive impairment — older adults with mild cognitive impairment (MCI), Alzheimer's disease, or sleep deprivation. The size of any benefit in those groups does not transfer to healthy young or middle-aged adults with normally functioning brains. A 2016 review in Evidence-Based Complementary and Alternative Medicine (Suliman 2016 PMID 27656235) catalogued the natural-nootropic literature and found that while several compounds showed benefit in impaired populations, replicated cognitive-enhancement evidence in healthy adults was largely absent. A 2024 umbrella review of dietary supplements for cognition in healthy adults reached the same conclusion (Lampousi 2024 PMID 38395036).
Bacopa monnieri has genuine evidence for delayed verbal recall after 8–12 weeks of supplementation in older adults (Stough 2008; Kongkeaw 2014 PMID 24252493 — meta-analysis of 9 RCTs). It is slow-acting, not an acute focus aid, and its marketing as an instant cognitive enhancer is not supported by the data. Ginkgo biloba: the GEMS trial (DeKosky 2008 PMID 19017911) randomized 3,069 older adults to 240 mg/day or placebo for a median 6.1 years. Ginkgo did not reduce all-cause dementia or Alzheimer's incidence (HR 1.12, 95% CI 0.94–1.33). Cognitive trajectory analyses from the same cohort found no slowing of decline (Snitz 2009 PMID 20040554). Phosphatidylserine: the FDA describes its qualified health claim for cognitive function as supported by very limited and preliminary evidence; clinical evidence in healthy young adults is nearly absent. Lion's mane: positive trials are mostly in older adults with MCI; healthy-adult cognitive evidence is small and short.
The honest short list: caffeine (the most consistent cognitive-performance compound known), L-theanine combined with caffeine for sustained attention, and creatine monohydrate for working memory under sleep deprivation or fatigue (Avgerinos 2018 PMID 29704637 — meta-analysis). Sleep, exercise, and stress management produce cognitive effects that are an order of magnitude larger than any supplement.
Reviewed against 6 peer-reviewed sources.
High blood pressure (hypertension) affects nearly half of U.S. adults. Several supplements commonly used by people with hypertension — potassium, magnesium, CoQ10, hawthorn, licorice root, and St. John's wort — can interact with blood pressure medications. Some interactions are mild. A few are dangerous. Most patients do not tell their doctor what supplements they take, and most clinicians do not ask. The result is preventable harm.
ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, telmisartan) raise blood potassium because they reduce aldosterone, the hormone that drives potassium excretion. Adding potassium supplements — or potassium-based salt substitutes such as “NoSalt” — on top of these drugs can cause hyperkalemia, an elevated blood potassium that can trigger fatal cardiac arrhythmias. The risk multiplies when potassium-sparing diuretics (spironolactone, eplerenone, amiloride) are also in use. Patients on these drug classes should not take potassium supplements without lab monitoring and physician oversight (Raebel 2012 PMID 22555185).
Licorice root contains glycyrrhizin, which inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 2. This produces a mineralocorticoid excess–like state — the body acts as if it has too much aldosterone, which raises blood pressure, lowers potassium, and can cause weakness, edema, and cardiac arrhythmia (Sigurjónsdóttir 2003 PMID 12624617; EFSA 2014 Compendium of Botanicals). The European Food Safety Authority and the Scientific Committee on Food set 100 mg/day glycyrrhizin as a level above which adverse effects become more likely, and clinical pseudoaldosteronism has been reported at sustained intakes of about 100–200 mg/day. Licorice and its extracts are common in “adrenal support,” “cortisol balance,” and herbal stomach formulas where it is not always prominent on the label. Deglycyrrhizinated licorice (DGL) is the safer form for people on antihypertensives.
Magnesium supplementation has a small blood-pressure-lowering effect and is generally safe with antihypertensives; the main caution is hypermagnesemia in patients with reduced kidney function or those on potassium-sparing diuretics. Hawthorn (Crataegus) extracts have additive effects with antihypertensives and with digoxin and may produce excessive blood-pressure reduction (Tassell 2010 PMID 22228951). CoQ10 (ubiquinone) produces a modest blood-pressure reduction in some trials — the 2007 Rosenfeldt meta-analysis (PMID 17287847) reported pooled systolic BP reductions of about 16 mmHg, but a more conservative 2016 Cochrane review (Ho 2016 PMID 26935713) found the evidence insufficient to support a clear effect. CoQ10's structural similarity to vitamin K means it can reduce the anticoagulant effect of warfarin and may require INR monitoring (Engelsen 2003 PMID 12625571). St. John's wort induces CYP3A4 and P-glycoprotein and can lower blood levels of calcium-channel blockers (e.g., nifedipine, verapamil) and several other antihypertensives, reducing their effect (Russo 2014 PMID 24033819).
Bring every supplement bottle to your next blood-pressure visit, including herbal teas. Ask your pharmacist to run an interaction check — pharmacists are usually faster and more accurate than apps. If you take an ACE inhibitor, ARB, or potassium-sparing diuretic, do not add potassium supplements or potassium-based salt substitutes without your clinician's say-so.
Reviewed against 9 peer-reviewed and regulatory sources (safety-category rigor).
Medicinal mushrooms are everywhere now — lion's mane, reishi, chaga, cordyceps, and turkey tail show up in coffee blends, gummies, and expensive multi-mushroom powders. Each species has a different mix of bioactive compounds and a different evidence base. Marketing treats them as interchangeable wellness products. The clinical research does not.
Lion's mane (Hericium erinaceus) contains hericenones and erinacines, compounds that increase nerve growth factor (NGF) in laboratory and animal studies. The clinical evidence in humans is small but consistent in older adults with mild cognitive impairment (MCI). A 16-week double-blind RCT in 50 Japanese adults with MCI (Mori 2009 PMID 18844328) gave 3 g/day of lion's mane or placebo and reported higher cognitive-function scores in the supplement group, with the benefit fading after the supplement was stopped. A 2019 RCT in 31 older Japanese adults reported improvements in cognitive function on the MMSE-J after 12 weeks of erinacine A–enriched lion's mane (Saitsu 2019 PMID 31553601). Healthy-young-adult evidence is much thinner. Quality matters: products made from mycelium grown on grain substrate are mostly grain starch with little of the active compounds; look for fruiting-body extracts with beta-glucan content above 25% and disclosed alpha-glucan (starch) below 5%.
Reishi (Ganoderma lucidum) has older clinical work on neurasthenia — a 2005 RCT in 132 patients found a polysaccharide extract reduced fatigue and improved well-being (Tang 2005 PMID 15857210). Sleep-quality data is weaker than commonly stated; most positive trials are small or use proprietary extracts. The polysaccharide fraction modulates innate immunity in laboratory and animal models, and reishi is sometimes used as an adjunct in oncology supportive care — a 2016 Cochrane review (Jin 2016 PMID 27045603) found very low–quality evidence that Ganoderma may augment chemotherapy response and modestly improve quality of life, but cautioned against using it as a primary cancer treatment.
Cordyceps is marketed for athletic performance. A small RCT in trained adults (Hirsch 2017 PMID 28316263) reported modest improvements in tolerance to high-intensity exercise after chronic Cordyceps militaris supplementation; effects on VO₂max have been small and inconsistent across trials. Chaga (Inonotus obliquus) has extensive in vitro and animal data but essentially no controlled human trials. Marketing is well ahead of evidence. Chaga also contains high levels of oxalates — case reports of oxalate-related acute kidney injury have been published in patients who consumed chaga at gram-scale daily doses (Kikuchi 2014 PMID 24558428), so people prone to kidney stones or with chronic kidney disease should avoid it.
Reviewed against 6 peer-reviewed sources.
In 2021–2022, a single popular podcast discussion of the theoretical testosterone-boosting mechanism of Fadogia agrestis — a shrub native to West and Central Africa — drove a huge spike in Google searches, product launches, and sales. Within months, fadogia appeared in dozens of testosterone-support supplements sold in the U.S. This is how supplement trends now work: one influential mention, no human data, full commercial roll-out.
Fadogia agrestis has been studied almost entirely in rodents. The interest comes from a 2005 paper in the Asian Journal of Andrology (Yakubu 2005 PMID 16110341) reporting that an aqueous stem extract raised serum testosterone in male rats in a dose-dependent way. That single rat study, plus a small number of follow-on rodent papers from the same Nigerian research group, makes up most of the mechanistic literature that supplement companies cite. As of 2026, there are no published randomized controlled trials of Fadogia agrestis in humans on PubMed — no pharmacokinetic studies, no dose-finding studies, no safety studies, no efficacy studies in any human population. Commercial human supplementation built on rat data, with no intervening clinical work, skips the basic research pipeline that exists to protect consumers.
The same rodent literature that fueled enthusiasm also reported harm at higher doses. The original Yakubu 2005 paper noted histological changes in testicular tissue at the highest dose tested. A 2008 paper from the same group reported alterations in serum biochemistry consistent with liver and kidney injury after 28 days of high-dose extract (Yakubu 2008 PMID 18801104). Doses used in commercial supplement protocols (often 600 mg/day or higher) have not been validated against the rodent toxicity range. The podcast discussion that triggered the trend acknowledged the lack of human data; the supplement labels that followed did not.
Reviewed against 5 peer-reviewed and authoritative sources.
Pediatric melatonin use in the United States has climbed sharply over the past decade. A 2023 cross-sectional survey found that about 1 in 5 U.S. children aged 5–9 had used melatonin in the previous 30 days, and about 1 in 5 preteens (ages 10–13) used it daily (Hartstein 2024 PMID 38109115). Most of this growth has come from gummy products that look like candy and are framed as "natural." The safety picture is more complicated than the marketing suggests.
A 2023 JAMA letter (Cohen 2023 PMID 37039797) analyzed 25 melatonin gummy products sold at major U.S. retailers. 22 of the 25 contained a quantity of melatonin that was more than 10% off the stated label dose — the threshold the U.S. Pharmacopeia considers acceptable. Actual melatonin content ranged from 74% to 347% of the labeled dose. One product labeled 1.5 mg per gummy contained nearly 9 mg. Five of the products also contained CBD, which was not always disclosed on the label. This matters in children because the natural nocturnal rise in endogenous melatonin is on the order of 0.05–0.1 mg over the course of the night. Commercial dosing starts at 0.5–1 mg, already 5–20 times physiological levels — and a mislabeled gummy at 6× the stated dose can take a child far above any studied range.
CDC and AAPCC data show pediatric melatonin ingestion calls to U.S. Poison Control Centers rose 530% between 2012 and 2021 — from 8,337 to 52,563 calls (Lelak 2022 PMID 35679177). About 83% of those calls were for children aged 5 and under. Over the 10-year period, more than 4,000 children were hospitalized after a melatonin ingestion, with two pediatric deaths reported. The trajectory of calls closely tracks the growth in gummy products. AAPCC has continued to flag melatonin as a top-five reason for pediatric exposure calls in 2023–2024 (AAPCC 2024 Annual Report).
The American Academy of Pediatrics and the American Academy of Sleep Medicine both recommend that behavioral sleep interventions — consistent bedtimes, wind-down routines, dark and cool rooms, screen-free time before bed — be tried first for childhood insomnia (Bruni 2023 European consensus PMID 36739840). For children with autism spectrum disorder or attention-deficit/hyperactivity disorder where behavior strategies are not enough, short-term, low-dose melatonin (0.5–1 mg as a starting dose, ideally an immediate-release tablet rather than a gummy) under pediatric supervision can be reasonable. Effects of long-term pediatric melatonin use on puberty and growth are not yet well studied, which is the main reason expert groups urge caution.
Reviewed against 6 peer-reviewed and surveillance sources.
Berberine has become one of the most-discussed metabolic supplements in recent years, helped along by viral comparisons to metformin (the standard first-line type-2-diabetes drug). The evidence for berberine's effects on blood sugar, HbA1c, and LDL cholesterol is real. What gets less attention — and is clinically important — is what berberine does to the gut microbiome.
A 2008 RCT in Metabolism compared berberine (500 mg three times daily) with metformin in 36 adults newly diagnosed with type 2 diabetes (Yin 2008 PMID 18397984). The two groups showed similar reductions in fasting glucose, postprandial glucose, and HbA1c after 3 months. A 2012 meta-analysis of 14 RCTs (Dong 2012 PMID 23118768) reported pooled HbA1c reductions of about 0.7–0.9%, fasting glucose ~1.0 mmol/L, and postprandial glucose ~2.2 mmol/L — effect sizes in the same range as first-line oral diabetes medications. A larger and more recent meta-analysis pooling 27 RCTs (Lan 2015 PMID 25579796) confirmed similar effects on lipids, with LDL cholesterol reductions of 0.4–0.7 mmol/L. Mechanistically, berberine activates AMP-activated protein kinase (AMPK), increases LDL-receptor expression by stabilizing its mRNA, and lowers PCSK9 expression (Kong 2004 PMID 15531889; Pisciotta 2012 PMID 22939542).
Berberine has roughly 1% oral bioavailability — it is barely absorbed into the bloodstream (Liu 2016 PMID 27703510). This is not a limitation; it is the mechanism. Berberine works largely in the gut: it inhibits the disaccharidase enzymes that release glucose from carbohydrates, reduces intestinal glucose transport, and reshapes the composition of the gut microbiome. So berberine's microbiome effects are not a side effect — they are a central feature of how the drug works.
Berberine is a broad-spectrum antimicrobial. In rodent and human studies it shifts microbial community structure substantially: it decreases some Firmicutes populations and certain Lactobacillus species, alters short-chain fatty acid producers, and can enrich Akkermansia or specific Ruminococcaceae depending on the host (Zhang 2020 PMID 32346077; Sun 2020 PMID 32694566 Sci Rep). The same antimicrobial activity that helps lower glucose can also reduce taxa most people consider beneficial. Because the data come from small short-term studies, it is reasonable to cycle (e.g., 8–12 weeks on, 4 weeks off) and to monitor digestive symptoms. People taking metformin, sulfonylureas, insulin, or other glucose-lowering drugs should not add berberine without physician oversight — the effects are additive and hypoglycemia has been reported.
Reviewed against 7 peer-reviewed sources.
Colloidal silver is a suspension of silver particles in water. It has been sold since the early 1900s as an antibiotic, antiviral, and immune booster. It does not work for any of these uses in people. It does cause a permanent, irreversible condition called argyria that turns the skin a blue-grey color. And it is still on store shelves despite a 1999 FDA final rule that found no over-the-counter colloidal silver product is generally recognized as safe or effective for treating any disease.
Silver does kill germs in the right setting. Silver-coated catheters, silver sulfadiazine creams for burns, and silver-containing wound dressings are used in hospitals for surface infection control. Swallowing colloidal silver is a different story. The amount that reaches the bloodstream is far below what would kill bacteria or viruses inside the body. The silver is absorbed, gets stored in skin and other tissues, and does no antimicrobial work where you need it.
Argyria happens when silver builds up in the skin. Sunlight then turns those silver deposits into silver sulfide, which is blue-grey. Discoloration usually starts in sun-exposed areas first — face, hands, arms, and the gum line — and gets darker with more use. It does not fade when the supplement is stopped. Many cases appear in the peer-reviewed literature, including patients with skin and nail discoloration after long-term self-treatment (Kim 2009; Kwon 2009; Slater 2022; Simon 2020), a child with cystic fibrosis who used colloidal silver for mucus clearance (Baker 2007), and a 70-year-old man who developed seizures, not just a color change, after self-medicating (Hu 2023). Dermatologists keep seeing new cases — almost all from supplement use, not workplace exposure.
The U.S. EPA's oral reference dose for silver is 5 micrograms per kilogram per day — about 350 micrograms per day for a 70-kg adult, set to avoid argyria. A typical "immune-support" teaspoon of a 10 ppm colloidal silver product delivers roughly 50 micrograms per dose; many products on the market contain hundreds to thousands of micrograms per recommended serving, putting daily users above the EPA limit within one dose. A 2017 systematic review in Environmental Health (Fewtrell 2017) also flagged unresolved genotoxicity concerns from particulate silver in mammalian studies, on top of the well-established argyria risk.
In 1999 the FDA issued a final rule (21 CFR 310.548) stating that over-the-counter drug products containing colloidal silver or silver salts are not generally recognized as safe or effective for any disease. Despite that, colloidal silver still sells as a "dietary supplement" using vague structure-function claims (such as "supports immune health") that side-step the disease-treatment language the FDA banned. During the COVID-19 pandemic, the FDA and FTC sent joint warning letters to companies marketing colloidal silver as a COVID treatment — a reminder that these claims simply migrate to whichever health worry is in the news.
Psyllium husk is derived from the seeds of Plantago ovata — a humble desert plant native to India, Pakistan, and the eastern Mediterranean — and is the active ingredient in Metamucil. It is quietly one of the most thoroughly studied dietary supplements in existence. More than 100 randomized controlled trials have tested its effects on cholesterol, blood sugar, blood pressure, bowel function, satiety, and body composition. It has an FDA-authorized health claim, recommendations from the American Heart Association, the American Diabetes Association, and the American College of Gastroenterology, and a safety profile that is almost unrivaled for a supplement with measurable clinical effects.
And yet — scroll TikTok, open any wellness newsletter, walk into a GNC — and it is the creatine tubs, ashwagandha capsules, and NMN bottles that get the attention. Psyllium gets a dusty shelf next to the stool softeners. This article argues that the quiet, boring fiber on the bottom shelf is one of the highest-leverage supplements most people aren't taking.
Psyllium is off-patent, cheap, and commoditized. A bag lasts months and costs less than a single serving of a trendy greens powder. There is no margin to fund influencer campaigns, no proprietary blend to trademark, and no Netflix documentary coming. Its obscurity in wellness culture says more about marketing incentives than about the science.
Psyllium has been used medicinally for at least 2,500 years. It appears in Ayurvedic texts (where it is called isabgol), in classical Persian medicine, and in European pharmacopoeias by the 16th century. In the United States, it entered mainstream awareness in 1934 when Procter & Gamble launched Metamucil, marketing it as a gentle laxative. For decades it was treated as a simple bulking agent and nothing more.
The shift began in the 1980s, when controlled trials started showing that psyllium did something no other laxative did: it consistently lowered LDL cholesterol. By 1998, the FDA had reviewed enough evidence to authorize a formal health claim — only the second soluble fiber (after oat beta-glucan) to achieve this. Today more than a thousand PubMed-indexed studies reference psyllium.
The magic of psyllium is physical, not chemical. When mixed with water, its mucilaginous outer layer absorbs 10–40× its weight in liquid and forms a thick, viscous gel. That gel does four clinically measurable things as it moves through the gut:
Crucially, psyllium is only partially fermented. Unlike inulin or pure beta-glucan, most of the gel remains intact all the way through the small intestine, giving it time to bind bile acids and blunt glucose absorption before the colonic bacteria get to it. This is why it is unusually effective across multiple organ systems from a single dose.
The FDA authorized a soluble-fiber heart-health claim for psyllium in 1998 after reviewing 67 human trials. A 2018 meta-analysis in the American Journal of Clinical Nutrition (Jovanovski et al.) pooled 28 randomized controlled trials covering 1,924 participants and found psyllium lowered LDL by an average of 13 mg/dL and non-HDL cholesterol by 16 mg/dL. Effects are dose-responsive and show up within 3–4 weeks.
For perspective, a low-dose statin (rosuvastatin 5 mg, atorvastatin 10 mg) typically lowers LDL by 30–40 mg/dL, so psyllium is not a drug replacement. But 15 mg/dL is roughly half of what a low-dose statin does — delivered without muscle pain, liver monitoring, or a prescription. For primary prevention in people who don't need a statin yet, or as an add-on to diet and a statin, this is a meaningful effect. It is more than you will get from red yeast rice capsules, berberine, garlic, or any other OTC "natural cholesterol" product with anything close to the same evidence base.
Because psyllium gel slows gastric emptying and physically impedes glucose absorption in the small intestine, it flattens the post-meal glucose spike. A 2015 meta-analysis by Gibb et al. in the American Journal of Clinical Nutrition pooled 35 trials and found that in people with type 2 diabetes, psyllium lowered fasting glucose by ~37 mg/dL (~2.0 mmol/L) and HbA1c by ~0.4 percentage points. Effects scaled with baseline glycemic impairment: psyllium did almost nothing in euglycemic (non-diabetic) subjects, a modest amount in pre-diabetic subjects, and the most in poorly controlled diabetics.
This is why the American Diabetes Association's Standards of Care specifically endorses viscous fiber supplementation as a nutrition strategy. For someone with pre-diabetes or newly diagnosed T2D, 10–15 g of psyllium daily (split before meals) is one of the cheapest, most evidence-backed interventions available outside of diet and exercise.
Meta-analyses consistently show a small but statistically significant blood pressure effect from psyllium — about −2.0 mmHg systolic and −1.5 mmHg diastolic at 10–15 g/day, larger in hypertensive subjects. This is smaller than DASH-style dietary changes and smaller than any anti-hypertensive drug, but it is a free bonus on top of the lipid and glucose benefits.
Psyllium is one of the very few agents that works for both constipation and diarrhea — because its effect is mechanical, not stimulant. In constipation, the gel holds water and increases stool bulk, triggering the stretch reflex that drives peristalsis. In diarrhea-predominant IBS, the same gel absorbs excess water and slows transit, firming the stool.
A 2014 Cochrane-style review of laxatives for chronic constipation rated psyllium among the highest for efficacy and by far the best for long-term safety — unlike stimulant laxatives (senna, bisacodyl), it does not cause tolerance, rebound constipation, or electrolyte disturbances. The American College of Gastroenterology gives psyllium a strong recommendation for chronic idiopathic constipation and a conditional recommendation for IBS.
Psyllium's viscous gel slows gastric emptying, extending fullness after meals. Trials show modest but real weight loss (−2 to −4 kg over 8–12 weeks) when taken before meals in overweight subjects, independent of any deliberate calorie restriction. It is not a weight-loss drug — but as a preload before meals it reduces calorie intake by a small, repeatable amount, which compounds over time.
Perhaps the most damning comparison for wellness culture is not the effect sizes but the evidence base itself. Here is how psyllium stacks up against supplements that get 100× more attention:
Not all fibers do the same things. The key property for cholesterol and glucose effects is viscosity — how thick a gel the fiber forms. Here is how common fiber supplements compare:
A few simple rules separate "it worked" from "it did nothing" or "it made me bloated":
The safety profile is remarkable — psyllium has been consumed in gram doses daily by millions of people for decades. The most common adverse effects are gas, bloating, and a feeling of abdominal fullness in the first week, almost always self-limiting if you titrate up slowly. True allergic reactions are rare but documented (bakery and healthcare workers with chronic inhalation exposure are at highest risk).
Do not take psyllium if you have: known swallowing difficulty, a history of esophageal stricture, suspected or diagnosed bowel obstruction, severe gastroparesis, or are recovering from recent GI surgery. Patients on lithium or narrow-therapeutic-index drugs should consult their physician about timing.
You want plain, pharmaceutical-grade Plantago ovata husk — either as loose powder or as capsules. Things to look for on the label:
Psyllium has a larger, higher-quality evidence base than almost any supplement marketed for metabolic health. At 10–15 g/day it meaningfully lowers LDL cholesterol, blunts post-meal glucose, nudges blood pressure down, normalizes bowel function, and costs pennies per serving. If we rebuilt the supplement aisle around evidence rather than marketing, psyllium would be the first thing most people were told to try.
Magnesium is the fourth most abundant mineral in your body and a helper in more than 300 enzyme reactions. Low intake is common — NHANES intake data show roughly 45–48% of U.S. adults eat less magnesium than the Estimated Average Requirement, with higher rates in older adults. Low intake has been linked to muscle cramps, poor sleep, anxiety, higher blood pressure, and worse glucose control. The form of magnesium you take matters less than many ads suggest, but a few real differences are worth knowing.
Magnesium oxide is mostly elemental magnesium by weight (about 60%), but the body absorbs only about 4% of it (Firoz & Graber 2001). It works mainly as a laxative or antacid. For fixing low magnesium status, oxide is the weakest choice, even though it dominates the cheapest multivitamins.
Magnesium citrate dissolves easily in water and is one of the better-absorbed forms in head-to-head studies (Walker 2003, Lindberg 1990). It has a mild osmotic laxative effect, which helps with constipation. Citrate is the most cost-effective all-rounder for general use: affordable, reasonably absorbed, and well-studied.
Magnesium glycinate (also called magnesium bisglycinate) pairs magnesium with the amino acid glycine. It is generally well tolerated and causes less diarrhea than citrate or oxide at similar doses. Direct trial evidence that glycinate beats other forms for sleep or anxiety is thin, but Schuchardt and Hahn's 2017 review notes that the type of magnesium salt matters less than the dose and your starting status. Glycinate is a sensible choice if other forms upset your gut.
L-threonate was designed to raise magnesium in the brain. Animal studies in rats showed clear cognitive gains. Human data are limited to one small RCT — Liu 2016 (PMID 26519439), 44 adults aged 50–70 with cognitive complaints, 12 weeks of MMFS-01 (magnesium L-threonate) — which reported gains in a composite cognitive score versus placebo. Threonate runs $50–$80 a month and is the most expensive form. Larger trials have not been published.
Magnesium malate combines magnesium with malic acid, a small molecule used in cellular energy production. Limited trials have looked at malate in fibromyalgia, with mixed results. Absorption is similar to citrate. It is a reasonable option, but the muscle-specific advantage is more theoretical than proven.
For most adults, magnesium citrate or glycinate at 200–400 mg/day of elemental magnesium is an effective, affordable way to correct a common dietary gap. Doses above 350 mg/day from supplements (the IOM tolerable upper intake) can cause loose stools, so split the dose with meals.
Liquid apple cider vinegar (ACV) has a small, genuinely interesting evidence base for blood sugar after meals and, in one trial, mild weight loss. The effect sizes are small. ACV pills take that thin evidence and apply it to a completely different delivery vehicle without retesting the same endpoints. They also bring problems liquid does not have: large dose-to-dose differences in actual acetic acid content and documented esophageal burns when a capsule sticks and dissolves on the way down.
The most-cited human trial of liquid ACV is Kondo 2009 (PMID 19661687) — a 12-week, double-blind RCT in 155 obese Japanese adults split into three groups. Daily intake of a 500 mL drink containing 15 mL or 30 mL of vinegar (about 750 or 1,500 mg of acetic acid) lowered body weight by roughly 1.0–1.7 kg compared with placebo. The drop was statistically significant but small enough to be clinically trivial. Blood-sugar trials are mostly short and small, and a 2024 umbrella review (Hadi et al.) concluded effects on fasting glucose and HbA1c are inconsistent and based on low-quality evidence. This is the ceiling of the evidence the pill industry leans on.
The proposed mechanisms for ACV — acetic acid slowing gastric emptying and blunting starch digestion — depend on acetic acid actually contacting the upper GI tract. Encapsulated pills dissolve in the stomach after most carb absorption is already underway, removing the timing the liquid form depends on. As of April 2026, no published clinical trial has shown that ACV capsules reproduce the metabolic effects that liquid vinegar sometimes shows. The pills bolt an untested delivery format onto an already weak evidence base.
Vinegar in any form is acidic enough (pH around 2.5–3.0) to erode dental enamel and irritate the esophagus. Hill 2005 (PMID 15983536) tested 8 ACV tablet brands and found wide variation in tablet size, pH, and labeled vs. measured acid content — with serious doubt that ACV was even the actual ingredient in some brands. The same paper documents an esophageal injury case caused by an ACV tablet that lodged in the esophagus and burned the lining as it dissolved. High intakes have also been linked to low blood potassium (hypokalemia) in case reports, especially relevant for people on diuretics, digoxin, or insulin.
The bottom line: ACV pills add no proven benefit over the already-limited liquid form and bring real safety concerns — including unpredictable dosing and the risk of an esophageal burn. They are not worth buying.
In February 2004, after years of growing adverse-event reports and the deaths of professional athletes, the FDA banned ephedra alkaloids in dietary supplements — the first outright ingredient ban under DSHEA. By the time of the ban the agency had received more than 16,000 adverse-event reports linked to ephedra, including dozens of strokes and heart attacks. The Shekelle 2003 RAND/AHRQ meta-analysis (PMID 12672771) confirmed both modest weight loss (about 0.9 kg/month above placebo) and a 2- to 3-fold higher risk of psychiatric, autonomic, GI, and cardiac symptoms. What the ban did not remove was the commercial demand. In the two decades since, the weight-loss and pre-workout aisles have cycled through a long line of chemically related stimulants, each a step removed from ephedra and each with a thinner safety record than the one before it.
Citrus aurantium (bitter orange) and its main alkaloid p-synephrine became the first big ephedra replacement. p-Synephrine is structurally similar to ephedrine and acts on adrenergic receptors, though its effect on heart rate and blood pressure is generally smaller. Case reports and pharmacovigilance reviews have linked bitter-orange "fat burners" to high blood pressure, QT prolongation, ischemic stroke, and at least one fatal arrhythmia — almost always in combination with caffeine and other stimulants (Stohs 2017; FDA Consumer Update 2004). Bitter orange remains legal in dietary supplements in the U.S.
DMAA reached the market in the mid-2000s under the misleading claim that it was an extract of geranium. Independent analytical work showed DMAA is a synthetic amphetamine-like stimulant, not a natural plant constituent (Cohen 2012, Arch Intern Med). The FDA started issuing warning letters in 2012 and reported more than 100 adverse-event filings linking DMAA to heart attacks, hemorrhagic strokes, seizures, and at least 5 deaths. The U.S. Department of Defense pulled DMAA products from on-base stores in 2012 after two soldiers died during exertion. DMAA still surfaces under names such as methylhexanamine, geranamine, and "geranium oil extract."
As each new stimulant faces regulatory action, manufacturers swap in the next analog: DMHA (1,5-dimethylhexylamine), DMBA (1,3-dimethylbutylamine), octodrine, beta-methylphenethylamine (BMPEA), oxilofrine, deterenol, higenamine. A 2021 analytical study by Cohen and colleagues (PMID 33755516) tested 17 weight-loss and sports supplements labeled as containing deterenol and found 9 prohibited stimulants, with up to 4 different stimulants combined in a single product — cocktails that have never been tested in humans for safety. The pattern is the same: sympathomimetic activity, minimal human safety data, real cardiovascular risk.
The downstream public-health signal is visible in U.S. emergency rooms. Geller and colleagues (NEJM 2015, PMID 26465986) estimated 23,000 ED visits per year from supplement-related adverse events, with weight-loss and energy products causing 71.8% of supplement-related visits for palpitations, chest pain, or rapid heart rate — mostly in adults aged 20–34.
Practical takeaway: treat any energy, weight-loss, or pre-workout product with a proprietary blend or unfamiliar amine name with strong skepticism. The absence of a banned name does not mean the absence of a banned mechanism.
Nicotinamide mononucleotide (NMN) is a building block your body uses to make NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in DNA repair, mitochondrial energy production, and circadian rhythm. NAD+ does fall with age, and that is real. Whether taking NMN reverses that in any meaningful way in humans — and whether the reversal actually improves how you feel, function, or live — is where the science is still well short of the marketing.
Mouse studies show NMN can reverse parts of vascular aging, improve muscle endurance, raise insulin sensitivity, and extend lifespan in some models. These findings drove the commercial market. The problem: mice convert NMN to NAD+ more efficiently than humans, and longevity findings rarely translate cleanly across species. Dose extrapolation from mouse to human is notoriously unreliable.
As of April 2026, fewer than 20 completed RCTs of NMN in humans are published. The two most-cited:
Igarashi 2022 (PMID 35927255) randomized 42 healthy older Japanese men to 250 mg/day NMN or placebo for 6 or 12 weeks. NMN raised blood NAD+ and produced nominally significant improvements in gait speed and left-hand grip strength. The authors note these need to be confirmed in larger trials. Body composition did not change.
Yoshino 2021 (PMID 33888596), published in Science, was a 10-week placebo-controlled trial of 25 postmenopausal women with prediabetes who were overweight or obese. The dose was 250 mg/day (not the 600 mg figure that has circulated in media). The primary endpoint — muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp — improved with NMN versus placebo. A published comment (Brenner 2021, PMID 34326206) flagged a baseline imbalance in liver fat between groups, which the authors addressed without reversing the conclusion. The trial does not show benefit in healthy adults or men.
What no human trial has shown: longer life, lower rates of dementia, heart disease, or cancer, or any of the aging-related outcomes the marketing implies. NMN reliably raises NAD+ in blood — but moving a biomarker is not the same as a clinical benefit.
Quality NMN runs $80–$150 per month. At that price you are paying for early-stage science and a story. Nicotinamide riboside (NR) is a related NAD+ precursor with a larger human trial base and is usually 30–50% cheaper. Neither has proven longevity benefits in humans. Until larger, longer trials with clinical endpoints are completed, NMN remains speculative for most people.
Few pediatric supplement categories have been tested as thoroughly as omega-3s for attention-deficit/hyperactivity disorder (ADHD). The literature now spans dozens of randomized trials, several meta-analyses, and an updated 2023 Cochrane review. The short version: early meta-analyses showed a small benefit on parent-rated symptoms, but the most recent Cochrane synthesis — which includes more and better trials — finds no meaningful effect when looking at the highest-quality data.
Bloch and Qawasmi 2011 (PMID 21961774), JAACAP, pooled 10 randomized trials in 699 children with ADHD and reported a small but statistically significant benefit (standardised mean difference around 0.3). Higher EPA doses were correlated with stronger effect. The authors framed the size as roughly a quarter of what stimulant medications produce.
The 2023 update of the Cochrane review (Gillies, Leach & Perez Algorta 2023, PMID 37058600) included 37 trials and more than 2,374 participants. With more data and stricter risk-of-bias filtering, it found high-certainty evidence that PUFA supplementation has no effect on parent-rated total ADHD symptoms (SMD −0.08, 95% CI −0.24 to 0.07), inattention, or hyperactivity/impulsivity compared with placebo. Side-effect rates were similar to placebo. This is a significant downgrade from the earlier 2012 Cochrane (Gillies 2012, PMID 22786509), which had already concluded "little evidence" of benefit.
How to reconcile? The earlier positive signal was driven by smaller, methodologically weaker trials, often lacking adequate blinding. As more rigorous trials were added the effect shrank toward zero. Children with documented low omega-3 status may still benefit, but supplementation cannot be expected to meaningfully improve ADHD symptoms in the average pediatric population.
Omega-3s do not replace stimulant medication. No trial has shown fish oil matches methylphenidate or amphetamine derivatives on core ADHD endpoints. Using fish oil as a primary treatment in a child who would benefit from medication delays effective care.
If you choose to try fish oil as an adjunct, 1–2 grams of combined EPA+DHA daily from a fish-oil or algal-oil product (plant-based ALA from flax does not convert efficiently to EPA/DHA) is safe and well-tolerated in children. Use a third-party tested product (USP, NSF, or IFOS) for purity. Discuss it with the child's pediatrician, especially if they are on other medications. Frame it as a low-cost trial, not a substitute for evidence-based ADHD care.
Taurine is an amino sulfonic acid found in high concentrations in the heart, skeletal muscle, brain, and retina. Unlike most amino acids, it is not built into proteins but works as a free molecule in bile acid conjugation, calcium signaling, antioxidant defense, and cell volume regulation. Adults make some taurine from cysteine and methionine, but most circulating taurine comes from food — meat and seafood — so vegans and strict vegetarians tend to run lower blood levels.
Singh et al. 2023 (PMID 37289866), published in Science (not Nature Aging, as is sometimes reported), measured taurine across the human lifespan and found about an 80% drop between young adulthood and old age, with similar declines in mice and monkeys. In mice, taurine supplementation extended median lifespan by roughly 10–12% and improved several markers of biological aging — bone density, muscle function, immune cell composition, and DNA damage. The human observational arm showed lower taurine correlated with multiple age-related diseases. The authors emphasized that randomized clinical trials are needed before drawing causal conclusions in humans.
The cardiovascular evidence for taurine pre-dates the 2023 lifespan paper and is more solid. Waldron et al. 2018 (Curr Hypertens Rep, PMID 30006901), a meta-analysis of 7 RCTs in 103 participants, found taurine at doses of 1–6 g/day for periods ranging from 1 day to 12 weeks reduced both systolic and diastolic blood pressure by approximately 3 mmHg on average (range 0–15 mmHg systolic, 0–7 mmHg diastolic), with no adverse events reported. A Japanese epidemiological study (Yamori 2010, J Biomed Sci) found inverse associations between dietary taurine intake and cardiovascular mortality, which has been cited as one of several explanations for Japan's relatively low rate of coronary disease.
Taurine has a strong safety profile. The European Food Safety Authority's 2009 opinion on taurine in energy drinks concluded that exposure to taurine at the doses found in those products (around 0.06 g/kg body weight per day, or about 4 g/day for a 70-kg adult) was unlikely to raise safety concerns. EFSA's earlier Scientific Committee on Food set a no-observed-adverse-effect level of 1,000 mg/kg/day in animal studies. Energy drinks contain taurine at about 1–2 g per can — their stimulant effects are from caffeine, not taurine. At 1–3 g/day, taurine is a low-cost supplement with real emerging evidence on blood pressure and cardiac function, though the longevity claim still needs confirmation by adequately powered human RCTs.
The supplement industry depends on convincing you that you need more pills than you actually do. A beginner walking into a supplement store sees hundreds of products. Most are duplicates, are based on weak evidence, or are not relevant to anyone without a specific deficiency. The smarter starting question is simple: what nutritional gap am I trying to close?
Most marketing is goal-driven: "build muscle," "lose fat," "boost energy." Evidence-based supplementation starts with documented shortfalls. In U.S. and Western European adults, three gaps show up across surveys: vitamin D (NHANES 2005–2006: 41.6% of US adults below 20 ng/mL serum 25-OH-D, Forrest 2011, PMID 21310306), magnesium (about 45–48% of US adults eat less than the Estimated Average Requirement per the most recent NHANES analyses), and the long-chain omega-3 fatty acids EPA and DHA (very low intake in anyone who does not eat oily fish two or more times per week). These three form a defensible core starter stack.
Vitamin D3: 1,000–2,000 IU/day for most adults without lab testing; 3,000–5,000 IU/day if a serum 25-OH-D shows deficiency, then re-test in 8–12 weeks. The Endocrine Society's tolerable upper limit is 4,000 IU/day for healthy adults without supervision. Take with a meal containing fat. Supports bone, immune, and (likely) muscle function.
Magnesium: 200–400 mg/day of elemental magnesium as citrate or glycinate. The IOM tolerable upper intake from supplements is 350 mg/day in adults; loose stools at higher doses are common. Supports sleep, blood pressure, and muscle function (DiNicolantonio 2018, PMID 29387426).
Omega-3 (EPA + DHA): 1–2 g/day of combined EPA + DHA from fish oil or algal oil. Plant-based ALA from flaxseed converts poorly to EPA/DHA in humans (under 10%) and is not equivalent. Use a third-party-tested product (USP, NSF, or IFOS) for purity.
Protein powder is convenient food, not a supplement — useful only if you can't hit your protein target from meals. Pre-workout stimulants are unnecessary and habit-forming. Testosterone boosters, fat burners, and detox products have no convincing evidence of meaningful effect. A standard multivitamin is a low-priority catch-all that adds little when the core three are already covered.
Creatine monohydrate is the most evidence-backed performance supplement available. The International Society of Sports Nutrition's updated 2017 position stand (Kreider et al., JISSN, PMID 28615996) summarizes hundreds of trials supporting safety and efficacy for strength, lean mass, and high-intensity exercise performance. The standard dose is 3–5 g/day; a loading phase is optional. It is also cheap (cents per day for monohydrate). Add it once the core stack is in place.
The global testosterone-booster supplement market topped $1.5 billion in 2024, per industry trackers like Grand View Research, and is still growing. These products — sold to men for muscle building, libido, energy, and "male vitality" — are one of the supplement industry's most profitable categories and one of its least evidence-supported.
Common ingredients in testosterone-booster supplements include fenugreek extract, ashwagandha root, zinc, vitamin D, D-aspartic acid, Tribulus terrestris, and proprietary blends of herbs and amino acids. Most have been studied in human trials. The results are consistently underwhelming.
Balasubramanian and colleagues 2019 (J Sex Med, PMID 30770069) analyzed the top 5 best-selling testosterone boosters on Amazon at the time. Across those products they identified 19 unique active ingredients. A literature review of the 10 most common ingredients turned up 191 studies — only 19% of which used human subjects. Of the 37 human studies, only 30% reported an actual increase in testosterone, 3% reported a decrease, 46% reported no effect, and 22% were indeterminate. After filtering disingenuous Amazon reviews with ReviewMeta.com, claims of improved libido fell 91%, claims of improved strength/endurance fell 93%, and reports of "improved sports ability" fell 89%.
Fenugreek: Some trials suggest a modest reduction in the conversion of testosterone to DHT via 5-alpha reductase inhibition, which could nudge free testosterone up. Effect sizes are small and clinical relevance is unclear. Fenugreek does not raise total testosterone production.
Ashwagandha: May reduce cortisol, which can secondarily support testosterone in chronically stressed men. Effects are modest and most visible in men with elevated stress or sub-normal baseline testosterone.
D-Aspartic Acid: A small 2009 trial (Topo et al., Reprod Biol Endocrinol) showed a short-term increase. Larger, better-controlled trials including Willoughby and Leutholtz 2013 (PMID 24074738) and follow-ups have failed to replicate any testosterone-raising effect in healthy resistance-trained men.
Tribulus terrestris: Multiple RCTs — including a 5-week trial in elite rugby league players (Rogerson 2007, J Strength Cond Res) — have found no significant testosterone-raising effect. Its reputation rests on animal data and decades-old anecdote.
Beyond not working, some testosterone-booster products have been found to contain undeclared anabolic steroids on independent lab testing. The FDA maintains an updated "Tainted Products Marketed as Dietary Supplements" database (Tainted Sexual Enhancement and Bodybuilding categories). Choosing a supplement does not give you the purity controls of an FDA-approved pharmaceutical. Anyone with symptoms suggestive of low testosterone should ask their primary-care doctor for a morning total-testosterone blood test before spending on these products.
Kava (Piper methysticum) is a Pacific Island plant. People in Fiji, Tonga, Samoa, and Vanuatu have used the root for centuries as a ceremonial and social drink. The classic recipe is simple: grind the fresh or dried root only, mix with cold water, strain, and drink the cloudy suspension. This water-based form of kava has a long safety record in places where rates of liver disease are not raised.
That picture changed in the early 2000s. Liver injury reports linked to concentrated kava extracts sold in capsules and tinctures led to action in several countries. Germany suspended kava products in 2002 (the BfR has updated its risk assessment several times since). Health Canada issued a stop-sale advisory in 2002. Switzerland and France withdrew kava products. The U.S. Food and Drug Administration (FDA) issued a Consumer Advisory the same year, warning of severe liver injury. Most of these reports were tied to the concentrated extracts, not to traditional water-based kava.
Water-based kava extracts the kavalactones — the calming compounds — while leaving most other plant chemistry behind. Acetone and ethanol extracts pull out more compounds, including ones that water does not. Two extra compounds get the most attention from researchers:
The leading hypothesis: cost-cutting in supplement manufacturing (using aerial parts and harsh solvents) likely explains why concentrated kava extracts caused harm that traditional water-based kava did not.
The anxiety evidence is real. A 2013 randomized controlled trial (n=75, 6 weeks) by Sarris and colleagues found kava significantly reduced anxiety scores versus placebo, with no clinically meaningful rise in liver enzymes during the trial. The 2003 Cochrane review by Pittler and Ernst pooled 11 RCTs and found kava was better than placebo for anxiety with a moderate effect size. So the question is not "does kava work?" but "which form, at what dose, and at what risk?"
This is one of the safety questions where regulators do not all agree. The World Health Organization's 2007 review concluded that root-only, water-based kava poses an "acceptably low level of risk." Germany's BfR is more cautious and continues to flag uncertainty even for root-only products. The FDA's advisory remains in place. When two authoritative sources disagree, the safer move is to assume the stricter one applies to you, especially if you take other medications or drink alcohol.
Urolithin A is a small molecule made by certain gut bacteria when you eat polyphenols found in pomegranates, berries, walnuts, and some teas. The molecule itself does not come from food directly — your gut microbes have to convert plant compounds called ellagitannins into it. That bacterial step is why urolithin A is unusual: two people can eat the same pomegranate and end up with very different blood levels.
Researchers got interested in urolithin A because of mitophagy — the housekeeping process that clears out broken mitochondria, the small "power plants" inside our cells. Mitophagy slows down with age and may play a role in muscle weakness, fatigue, and some metabolic diseases. Urolithin A appears to switch mitophagy back on in lab studies.
The mitophagy story is legitimate biology. A 2019 randomized trial published in Nature Metabolism (Andreux et al., n=60 healthy older adults, ages 61–85, 28 days) found that 500 mg or 1,000 mg per day of urolithin A produced a clear molecular signature of better mitochondrial health in muscle and blood, with no safety problems. A 2022 randomized trial in Cell Reports Medicine (Liu et al., 4 months) found 1,000 mg per day improved muscle strength in middle-aged and older adults compared with placebo. These are well-conducted trials, not marketing papers.
The problem is the gap between what has been shown and what is sold. Marketing pages call urolithin A an "anti-aging supplement," "longevity molecule," and "mitochondria recharger." Those phrases go far beyond what two short-duration trials in older adults can support. Urolithin A has not been shown to extend human lifespan, prevent any age-related disease, or produce benefits in young, healthy adults. The strength gains in human trials are real but modest — on the order of 10–15% on a single endurance task, not a transformation. The benefits in younger, fitter people are unstudied.
Roughly 30–40% of adults make significant urolithin A on their own when they eat ellagitannin-rich foods. The rest carry a different mix of gut microbes and produce little or none. Supplementing with the finished molecule sidesteps that gap, but it also means most "natural" claims about getting urolithin A from a glass of pomegranate juice only work for a minority of people. There is no cheap, widely available test to find out which group you are in.
The leading urolithin A product, Mitopure (Timeline/Amazentis), costs about $60–$100 per month for the 500–1,000 mg/day doses used in trials. For most people that is a steep price for a likely small benefit, especially if you are under 60 and exercising regularly. Resistance training and protein intake remain the proven paths to muscle strength at any age, and they are free.
Bottom line: urolithin A is interesting science with a narrow, real benefit in older adults — not the universal longevity drug the marketing implies.
Children's gummy vitamins are the fastest-growing slice of the supplement aisle. The U.S. children's gummy market is now estimated above $2 billion annually, and the global gummy-vitamin category (kids and adults combined) is well over $6 billion. The reason is simple: kids who refuse tablets will eat what is essentially candy. But three problems hide on most labels — a sugar problem, a dosing problem, and a list of nutrients that gummies physically cannot deliver well.
A typical kids' gummy vitamin has 2–5 grams of added sugar per daily serving. Over a year that is roughly 730–1,825 grams — about 1.6 to 4 pounds of added sugar that does no nutritional work the vitamin itself could not do without it.
For context, the American Heart Association says children ages 2–18 should keep added sugars under 25 grams per day, and children under 2 should have no added sugar at all. A 5-gram gummy hands a 4-year-old 20% of their entire daily added-sugar budget before breakfast. For a toddler under 2, any gummy puts them over the recommended amount.
Independent testing groups, including ConsumerLab and U.S. Pharmacopeia (USP) verification programs, have repeatedly found gummy formats are among the least accurate vitamin formats. Three reasons:
FDA recall and warning-letter records also document gummy products with significantly more or less of a labeled vitamin than claimed.
For most healthy kids in the U.S. and Canada, daily multivitamins are not actually needed if the child eats reasonably varied food. The American Academy of Pediatrics says routine multivitamins are not required for typically developing kids on a balanced diet. Where gaps exist, target them directly:
If your child will only take a gummy, look for one with under 1 gram of added sugar (xylitol- or erythritol-sweetened options exist) and a USP Verified or NSF mark on the label. Keep xylitol products well out of reach of dogs — xylitol is highly toxic to them.
Glycine is the simplest amino acid your body uses. It's the main amino acid in collagen and gelatin, your body makes it on its own, and you can buy a kilogram of pure glycine powder online for less than the price of a single bottle of melatonin gummies. The catch is that nobody is paying influencers to talk about a $3-a-month amino acid — which is part of why glycine is one of the most under-rated sleep tools available.
A series of small, placebo-controlled trials by Yamadera, Inagawa, and Bannai (Ajinomoto / Tokyo) tested 3 grams of glycine taken about 30–60 minutes before bed. Across these studies, glycine produced:
These are small studies (typically 10–30 participants) from one research group, so they're best read as "promising and consistent" rather than "definitive." They are also notably cleaner methodologically than the trials behind most heavily marketed sleep supplements.
Glycine has two jobs in the brain. It acts as an inhibitory neurotransmitter in the spinal cord and brainstem (via glycine receptors), and it acts as a co-agonist at NMDA glutamate receptors elsewhere. The sleep effect appears to come from a third route: glycine drops core body temperature by widening blood vessels in the hands and feet, releasing heat. A falling core temperature is one of the body's natural signals to start sleep. The 2015 Kawai paper traced this effect to NMDA receptors in the suprachiasmatic nucleus, the brain's master clock.
Importantly, glycine does not sedate you the way antihistamines (Benadryl/diphenhydramine) or "PM" cold medicines do. It supports the body's own sleep-onset signaling rather than blunting wakefulness.
For most adults with mild trouble falling asleep, 3 grams of glycine is one of the cheapest, safest first things to try — well ahead of melatonin gummies for occasional use.
Walk into any supplement store and you'll see "morning," "evening," "pre-workout," "intra-workout," and "post-workout" formulas of essentially the same ingredients. The implication is that timing is everything. The evidence says otherwise: timing matters for a handful of specific things and is mostly noise for the rest. Daily consistency matters far more than the exact hour.
Caffeine. Caffeine peaks in the blood about 30–60 minutes after you take it, and its half-life in most adults is 4–6 hours (longer in slow metabolizers, shorter in heavy users). Two timing rules:
Iron. Best absorbed on an empty stomach with water or with vitamin C (which boosts absorption of non-heme iron). Coffee, tea, milk, and calcium supplements all sharply reduce iron absorption when taken at the same time. If iron upsets your stomach, take it with a small meal — you'll absorb a little less but you'll keep taking it.
Fat-soluble vitamins (A, D, E, K). Take them with a meal that includes some fat. The actual time of day matters very little, but skipping food can cut absorption substantially.
Magnesium and glycine for sleep. If you're using these specifically to help sleep, take them in the evening. Magnesium glycinate or threonate 1–2 hours before bed; glycine 30–60 minutes before. Used for general health, time of day matters less.
Levothyroxine and thyroid medications. Not a supplement, but worth flagging since people on thyroid meds often add supplements. Take levothyroxine on an empty stomach 30–60 minutes before food. Calcium, iron, and magnesium supplements should be taken at least 4 hours apart from levothyroxine.
For multivitamins, fish oil, B vitamins, vitamin C, zinc, probiotics, creatine, and most herbal supplements, the evidence shows that consistency drives the outcome — not the specific time of day.
The "anabolic window" idea — that you must consume protein within 30 minutes after a workout or lose your gains — was overstated in early research. Schoenfeld and Aragon's review concluded that total daily protein intake (around 1.6–2.2 g/kg body weight for trained lifters) is the dominant driver of muscle protein synthesis. Hitting that total over the day matters far more than nailing a 30-minute post-workout window.
Creatine is the same story. A small 2013 trial by Antonio and Ciccone suggested a slight edge for post-workout dosing over pre-workout, but the difference was small and other trials don't reliably reproduce it. Take 3–5 g per day at any time you'll remember it.
Pick a time you will actually take your supplements every day — usually anchored to a meal you don't skip. For most people that's breakfast or dinner. Add evening-only items (sleep magnesium, glycine, melatonin) to your nighttime routine. The marginal benefit of perfectly optimized timing is dwarfed by the benefit of taking the supplement at all.
Homeopathy was created in 1796 by a German physician named Samuel Hahnemann. It rests on two ideas:
Both ideas contradict basic chemistry, physics, and pharmacology. The reason homeopathy cannot work is not a matter of opinion. It is a matter of how matter works.
Homeopathic products are sold at "potencies" like 30C or 200C. The "C" stands for centesimal — a 1-in-100 dilution. A 30C product has been diluted 1:100 thirty times in a row. The dilution factor is 10-60.
How small is 10-60? Avogadro's number is about 6 × 1023. That's how many molecules of water are in 18 grams of water (one mole). At 12C, you have already diluted past Avogadro's number, meaning the average dose at 12C contains less than one molecule of the original substance. At 30C the math is staggering: to hold a single molecule of starting substance, you would need a sphere of solvent roughly the size of the Sun. By 200C, you would need a sphere larger than the observable universe.
In other words, a typical 30C homeopathic pill is statistically pure sugar pill or pure water — nothing else.
The standard reply to the dilution problem is that water "remembers" the molecules that were once dissolved in it. The idea was published in 1988 in Nature by French immunologist Jacques Benveniste. Nature's editor John Maddox — together with researcher Walter Stewart and stage magician James Randi — visited the Benveniste lab and re-ran the experiments under blinded conditions. The effect disappeared. Their report, "'High-dilution' experiments a delusion," was published in the same journal a few weeks later. (The original paper was not formally retracted, but no other lab has reliably reproduced the effect since.)
"Water memory" has no physical mechanism. Hydrogen bonds in liquid water rearrange in roughly a picosecond — a trillionth of a second. Any "memory" would be erased before it could affect biology.
The clinical record matches what the physics predicts: homeopathic remedies perform no better than placebo. The most thorough review came from Australia's National Health and Medical Research Council (NHMRC) in 2015. After examining about 1,800 homeopathy studies covering 68 health conditions, the NHMRC concluded there is no good-quality evidence that homeopathy is effective for any of them. Cochrane reviews of individual homeopathic uses (for hay fever, asthma, ADHD, chronic pain, and others) have reached similar conclusions. Apparent benefits in uncontrolled reports are explained by placebo response, regression to the mean (symptoms tend to fade on their own), and the natural course of self-limiting illness.
A sugar pill is harmless. The risk in homeopathy is what a person doesn't take instead. Homeopathic asthma "remedies" used in place of inhalers, homeopathic teething gels (some past products contained variable amounts of belladonna and were the subject of FDA warnings and a recall), and homeopathic alternatives to childhood vaccines have all been linked to harm. The U.S. FDA tightened its enforcement guidance on over-the-counter homeopathic products in 2019–2022, signaling that "homeopathic" labeling does not exempt a product from the same safety standards as other drugs.
Phenibut (β-phenyl-γ-aminobutyric acid) is not really a supplement. It is a prescription medication in some countries that has been quietly sold online to people in countries where it is not approved at all. Despite being marketed as a "calming nootropic" or "natural anxiety aid," phenibut is pharmacologically closer to a benzodiazepine than to any vitamin or herb — and it carries the kinds of risks you would expect from that comparison.
Phenibut was developed in the Soviet Union in the 1960s and is still prescribed in Russia, Ukraine, Belarus, and Latvia for anxiety, sleep disorders, and certain post-stroke and post-traumatic conditions. It has never been approved by the U.S. FDA, Health Canada, the UK MHRA, or Australia's TGA. In the United States it sits in a gap: not approved as a drug, never properly classified as a dietary supplement either — but also not federally scheduled, which has let online sellers offer it for years.
Phenibut is a GABA-B receptor agonist, like the prescription muscle relaxant baclofen. It also weakly activates GABA-A receptors and modulates voltage-gated calcium channels at higher doses. Adding the phenyl ring lets it cross the blood-brain barrier in a way that ordinary GABA cannot. At 250–750 mg, users typically describe feelings of calm, reduced social anxiety, and mild euphoria. At higher doses the effects look more like alcohol or benzodiazepines: heavy sedation, slurred speech, slowed breathing, and impaired coordination.
Phenibut's most documented harm is rapid physical dependence. Case reports describe tolerance building within just a few days of daily use, and clinically significant withdrawal after as little as one to two weeks of regular dosing. Withdrawal symptoms include severe rebound anxiety, insomnia, tremor, hallucinations, and psychosis. Unlike caffeine withdrawal, phenibut withdrawal can be medically serious. Hospitalized patients are typically managed with long-acting benzodiazepines (similar to alcohol or benzodiazepine withdrawal) and slow phenibut tapers over weeks.
A 2020 MMWR report by Graves and colleagues analyzed phenibut exposures reported to U.S. poison control centers between 2009 and 2019. Calls increased sharply over the decade. Many cases were severe enough to be coded as "major" outcomes — including respiratory depression, agitated delirium, and intensive-care admissions. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and the World Health Organization Expert Committee on Drug Dependence have both flagged phenibut as a substance of growing concern.
Phenibut is not a benign anxiety aid. It is a centrally active GABAergic drug with a rapid dependence profile and a withdrawal syndrome serious enough to require hospitalization. Because it acts on the same receptor families as alcohol and benzodiazepines, mixing it with either dramatically raises the risk of respiratory depression. There is no safe casual-use protocol for phenibut. Anyone who has been taking it daily should not stop abruptly; a medically supervised taper is the safer way out.
If you are looking for the calming, social-anxiety-reducing effects people describe with phenibut, the safer evidence-based options are: short-term cognitive behavioral therapy, prescription SSRIs/SNRIs, or, for situational use under a clinician's care, beta blockers. Glycine, magnesium, and L-theanine have far smaller effects but no comparable risk profile.
Exogenous ketone products — ketone esters and ketone salts that raise blood ketone levels directly without dietary restriction — are sold for weight loss, "fat burning," mental clarity, and athletic performance. They cost $5–$10 per serving, taste sharp and salty, and the weight-loss claim does not hold up to the trials.
Ketogenic diets cause weight loss for several reasons: people eat fewer calories (high-fat, high-protein diets are filling), they lose water as glycogen stores empty, and there are some minor metabolic differences in how the body burns fuel. Exogenous ketones recreate only the elevated blood ketone level. They do not cut your calorie intake or empty your glycogen.
More importantly, ketones are themselves a fuel. Beta-hydroxybutyrate provides about 4.7 kcal per gram. Drinking exogenous ketones adds calories and signals to your body that fuel is plentiful, which actually turns down the breakdown of stored fat (lipolysis). That's the opposite of what a fat-loss product should do.
A 2018 trial by Stubbs and colleagues in Obesity showed a single ketone ester drink reduced the hunger hormone ghrelin and self-rated appetite for a few hours after consumption. That short-term blunting of hunger has not translated into actual weight loss in any controlled trial. A 2018 study in the Journal of Physiology by Myette-Côté et al. showed that exogenous ketone drinks taken before a meal reduced free fatty acid availability and lipolysis — consistent with the mechanism concern above.
No randomized trial of exogenous ketones for weight loss has shown a meaningful reduction in body weight or fat mass compared with placebo. The closest thing to a fat-loss benefit comes from short-term studies showing modestly reduced food intake at the next meal — an effect that disappears over a full day.
Athletic-performance claims are a separate question. The 2016 Cox et al. study in Cell Metabolism reported that ketone ester drinks improved cycling time-trial performance in elite athletes. But several follow-up trials — including Evans et al. 2019 in Medicine & Science in Sports & Exercise on 10-km running and Leckey et al. 2017 on cycling — found no benefit, and in some cases worse performance because the drinks caused GI distress. The current picture: maybe a small benefit for steady-state endurance in trained athletes using ketone esters (not salts), with no benefit for high-intensity work and no benefit for the average exerciser.
Bottom line: exogenous ketones are not a fat-loss supplement. They are an extra calorie source that suppresses your body's own fat breakdown. The only reliable interventions for fat loss remain a sustained calorie deficit and exercise.
Vitamin A is one of the clearest examples of how context changes everything in pediatric nutrition. In countries where many children are vitamin A deficient, periodic high-dose supplementation is one of the most cost-effective public-health programs ever run. In well-fed children in the U.S., Canada, and Europe, the same vitamin can cause real harm if you stack supplements on top of an already adequate diet.
The Cochrane review by Imdad and colleagues (2017) pooled 47 trials with more than 1.2 million children ages 6 months to 5 years in low- and middle-income countries. Periodic vitamin A supplementation reduced all-cause childhood mortality by about 12% (relative risk 0.88) and reduced diarrhea-related deaths and measles complications more sharply — in some severely deficient settings, vitamin A roughly halves measles mortality. The World Health Organization and UNICEF still run vitamin A programs in many high-deficiency countries on this basis.
That picture does not transfer to children in the U.S., Canada, or most of Europe, where the average diet already provides enough vitamin A.
Vitamin A as retinol is fat-soluble and stored in the liver. Unlike vitamin C or B vitamins, your body cannot easily flush the excess. Children in high-income countries get vitamin A from many sources at once: fortified milk and cereals, eggs, dairy, butter, fish, and (sometimes) liver pâté. Adding a daily multivitamin with retinol on top can push total intake past the safe upper limit.
The U.S. National Academies set the following pediatric numbers (in mcg RAE — retinol activity equivalents):
For comparison, a 100 g serving of beef liver can contain about 6,000–9,000 mcg RAE — ten times a toddler's UL in one meal. Many children's multivitamins also list 100–200% of the RDA as preformed retinol. A child who eats liver pâté on Saturday plus a daily multivitamin can chronically exceed the upper limit without anyone noticing.
Chronic vitamin A toxicity in children can show up as irritability, headaches, bone pain, hair loss, dry skin, and elevated pressure inside the skull (a condition called pseudotumor cerebri or idiopathic intracranial hypertension), which can damage vision. Severe cases cause liver injury. Acute toxicity — usually from a single very large dose, or from accidental overdose of a concentrated drop product — causes nausea, vomiting, blurred vision, and bulging fontanelle in infants. Any child with these symptoms after recent vitamin A use needs medical evaluation.
Beta-carotene is a plant pigment your body converts to vitamin A on demand. The conversion slows down when stores are full, so beta-carotene from carrots, sweet potatoes, and leafy greens does not cause toxicity. (Very high beta-carotene intake can turn skin slightly orange — a harmless pigment effect, not poisoning.) Multivitamins that supply vitamin A as beta-carotene rather than retinol are a safer choice for children who already eat a varied diet.
Most healthy U.S./Canadian children do not need a vitamin A supplement. If your child takes a multivitamin, check the label: prefer "beta-carotene" over "retinyl palmitate" or "retinyl acetate," and don't stack multiple vitamin-A-containing supplements. Save high-dose retinol for children with documented deficiency or specific medical conditions, under a clinician's care.
Most of your immune system lives next to your gut. Roughly 70–80% of the body's antibody-producing immune cells sit in tissue along the intestines (called gut-associated lymphoid tissue, or GALT). What happens to the bacteria in your gut shows up in places that don't seem related — including how often you catch a cold. Researchers call this two-way communication the "gut-lung axis," and it is one of the few areas of probiotic research where the trial evidence has held up over time.
The flagship study is the Cochrane review by Hao and colleagues. The 2015 update pooled 13 randomized trials with about 3,720 participants and found probiotics reduced the proportion of people who got at least one upper respiratory tract infection (URTI) by roughly half (relative risk about 0.53) and shortened average URTI duration by about 1.9 days. The 2022 Cochrane update by Zhao et al. added more trials and reached a slightly more cautious conclusion: probiotics likely do reduce URTI episodes, with moderate-certainty evidence, though the effect size is smaller than the 2015 review suggested when only the highest-quality trials are included.
Targeted meta-analyses agree that benefit is real but variable: largest in children in daycare, older adults in long-term care, and endurance athletes during heavy training (all groups with elevated respiratory infection rates), and smaller in healthy young adults whose baseline rate of colds is already low.
The leading mechanisms are not fully proven but are plausible:
"Probiotics" is not a single product. Effects depend on the specific strain, the dose, and whether the bacteria are alive when you swallow them. The most consistent respiratory evidence is for:
Generic store-brand "acidophilus" capsules have weaker and less consistent evidence. Look for products that list specific strains (with the strain code, e.g., LGG, BB-12) and a CFU count of at least 1–10 billion per daily dose, plus a "best by" date and storage instructions you can actually follow (refrigeration or shelf-stable).
Probiotics are not a substitute for vaccines, hand-washing, or masking when you are sick. They are a modest, low-risk add-on most useful for people in higher-exposure settings — daycare-age children, older adults, and athletes in heavy training cycles. For a healthy adult who catches one or two colds a year, the absolute benefit is small, though the safety profile of most well-known strains is excellent.
Women's nutritional needs are not just smaller versions of men's needs. Menstrual cycles, pregnancy, and menopause each shift what your body actually requires. Generic "women's multivitamins" — which usually differ from standard multivitamins only in marketing and iron content — ignore most of these shifts. Useful supplementation works one life stage at a time.
Folate or folic acid: The single most important supplement for women who could become pregnant. 400–800 mcg/day before conception and in early pregnancy cuts the risk of neural tube defects (such as spina bifida) by roughly 70%. The FDA requires folic acid fortification of grains for this reason, but a daily supplement still matters for anyone planning a pregnancy or not using reliable birth control. Methylfolate (5-MTHF) is the better form for the roughly 10% of women with MTHFR variants that slow folic acid conversion.
Iron: Monthly blood loss makes iron deficiency the most common nutrient deficiency in premenopausal women worldwide. Test ferritin before supplementing — too much iron causes its own problems. The RDA is 18 mg/day for premenopausal women; higher therapeutic doses need a doctor's supervision.
Vitamin D: As for all adults, 1,000–2,000 IU/day is reasonable given how common deficiency is.
A prenatal vitamin is the foundation. Common additions: DHA (200–300 mg/day) for fetal brain growth, choline (450 mg/day, often under-dosed in prenatals), and iodine (150 mcg/day, important for fetal brain development). Keep retinol-form vitamin A under 770 mcg RAE/day — the IOM upper limit in pregnancy — because excess can cause birth defects. Beta-carotene does not carry the same risk.
As estrogen falls, bone loss speeds up and heart-disease risk rises. Calcium: aim for 1,200 mg/day total from food plus supplements, paired with vitamin D. Calcium citrate is absorbed better than carbonate when stomach acid is low or when taken without food. Magnesium: helps with sleep (often disrupted by hormone changes), bone health, and blood pressure. Black cohosh: a 2012 Cochrane review found no clear benefit for hot flashes overall, though some short-term trials show modest relief. It is not hormone replacement therapy and should be avoided by women with hormone-sensitive cancers.
Bone health stays the priority — calcium and vitamin D remain the best-supported choices. Vitamin B12 absorption drops with age as stomach acid declines, so 500–1,000 mcg/day or, in confirmed deficiency, B12 injections may be needed. Omega-3 fatty acids matter more after menopause because estrogen's protective effect on the heart is gone.
Melatonin owns the sleep supplement aisle, but it is only one of several compounds with real human data. Melatonin mostly works on timing — when you fall asleep — not on depth or quality. If your problem is not sleep onset but bedtime anxiety, light sleep, or 3 a.m. wake-ups, other supplements may help more.
About half of US adults take in less magnesium than the RDA from food, and magnesium quietly supports GABA — the brain's main calming signal. Magnesium glycinate (bound to glycine, itself a mild sleep helper) is the best-tolerated form for brain effects. A 2022 systematic review by Arab and colleagues looked across 9 studies in adults and concluded that low magnesium status tracks with poorer sleep, but the few randomized trials gave mixed results. The honest read: it may help, especially if you are short on magnesium, and the safety profile is good. Dose: 200–400 mg elemental magnesium (as glycinate), 30–60 minutes before bed.
L-theanine is an amino acid in green tea. It promotes alpha brain waves — the pattern of relaxed alertness — and lowers anxiety without sedating you. In sleep studies it shortens time to fall asleep and improves how restful sleep feels, without the morning fog of sedatives. Its dual action on glutamate (calming) and GABA (boosting) pairs well with melatonin. Dose: 100–200 mg, 30–60 minutes before bed. Side effects at this dose are rare.
Glycine is a non-essential amino acid that gently lowers core body temperature — one of the body's natural sleep cues — and tunes NMDA receptors in a way that supports deeper sleep. In Japanese trials, 3 g at bedtime improved sleep quality, reduced next-day fatigue, and improved cognitive performance the following day in adults with poor sleep. It is cheap, well tolerated, and underused. Best taken as a powder dissolved in water.
Phosphatidylserine (PS) is most useful for people whose sleep problems come from high evening cortisol — the wired-but-tired pattern where stress hormones stay elevated past bedtime. PS lowers cortisol and ACTH by roughly 20–30% at doses of 400–600 mg/day. It is less useful for ordinary insomnia, but worth a try for stress-driven sleep loss.
A practical stack for most people: low-dose melatonin (0.3–1 mg) plus magnesium glycinate (300 mg) and L-theanine (200 mg), about 45 minutes before bed. Add glycine (3 g) if sleep quality — not falling asleep — is the main issue. Save phosphatidylserine for stress-driven insomnia. Start with one compound at a time so you can tell what is actually working before stacking them.
Supplement labels often treat "folate" and "folic acid" as the same thing. They are not. The difference matters for pregnancy, heart health, and mental health, and the supplement industry has been slow to reflect it clearly.
Folic acid is a synthetic form of folate. To do anything in the body, it has to be converted in several steps into 5-methyltetrahydrofolate (5-MTHF) — the active form that travels in your blood and reaches the brain. The enzyme that drives the final step, called MTHFR, works less well in people who carry common MTHFR gene variants. The most studied variant, C677T, drops enzyme activity by about 35% in people with one copy and roughly 70% in people with two copies.
MTHFR variants are among the most common gene differences in people. About 40–60% of US adults carry one copy of the C677T variant, and roughly 10–15% carry two copies. A second variant, A1298C, is also common. Together, these variants affect about 10–20% of people's ability to fully process folic acid — meaningful given how widely folic acid is added to grains and supplements.
For most people, food folate plus low-dose folic acid is enough. For people with two MTHFR variant copies, standard folic acid may not raise active folate as well, and unconverted folic acid can build up in the blood. Methylfolate (5-MTHF) skips the MTHFR step entirely and reliably raises plasma folate in variant carriers. In multiple trials, methylfolate beats folic acid at lowering high homocysteine — a marker of heart-disease risk — in this group.
Folate is needed to make serotonin, dopamine, and norepinephrine. In people with MTHFR variants, impaired folate metabolism has been linked to higher rates of depression and poorer response to antidepressants. Adding L-methylfolate (prescription Deplin at 7.5–15 mg/day, or lower OTC doses of 5-MTHF) improved SSRI response in randomized trials of treatment-resistant depression. It remains one of the most underused nutrient strategies in psychiatry.
If you are pregnant or planning to be, both folic acid and 5-MTHF protect against neural tube defects — but methylfolate is the safer pick if you know (or suspect) you carry MTHFR variants. For everyday use, methylfolate costs only slightly more and is reasonable for anyone unsure of their MTHFR status. Genetic testing (23andMe, AncestryDNA, or targeted MTHFR panels) can identify your status for under $50.
The "detox" wellness category is now multi-billion dollars a year, built on a premise that basic human physiology does not support. Your liver, kidneys, skin, and lungs already form a highly effective system for clearing waste — one that has been refined over millions of years. No supplement, foot pad, or juice cleanse on the market meaningfully boosts that system in healthy people. The evidence here is not close.
Detox foot pads are sticky patches you wear on the soles of your feet overnight. Sellers claim they pull toxins through the skin and turn brown as proof. Lab analyses tell a simpler story: the brown color comes from wood vinegar (bamboo vinegar) and tourmaline reacting with the moisture in your sweat. The darkening responds to humidity, not to anything biological. When researchers tested used pads against unused ones, they found no increase in heavy metals, environmental pollutants, or metabolic waste.
One pattern shows up over and over in detox marketing: vendors will not name a specific toxin. Pressed for details, they offer vague phrases — "environmental toxins," "accumulated waste," "heavy metals," "free radicals." Real chelation therapy is a hospital treatment for confirmed heavy-metal poisoning, using prescription chelators matched to a specific metal documented by blood tests. None of that is what a supplement company is selling. In the wellness aisle, "toxin" is a marketing word, not a medical one.
Multi-day juice cleanses claim to rest the digestive system and flush out toxins. The liver does not need a rest — it processes waste continuously, and a few nutrients in whole food (especially in cruciferous vegetables) actually turn up the enzymes the liver uses to do that work. The weight people lose on juice cleanses is mostly water and stored carbohydrate, not fat, and almost all of it returns within a few days. No randomized trial has shown that any commercial cleanse removes a measurable toxin.
Real toxic exposures — lead, mercury, acetaminophen overdose — are medical emergencies treated in a hospital with specific, evidence-based drugs. If you suspect heavy-metal exposure, ask a physician for blood and urine testing. If something is confirmed, treatment will be prescription chelation under medical supervision, not a supplement. Over-the-counter "heavy metal detox" products have no clinical evidence that they remove meaningful amounts of any specific toxin.
Kratom (Mitragyna speciosa) is a Southeast Asian plant whose ground leaves are sold in the United States as a "botanical supplement." You will find it in capsules, powders, and shots at gas stations, convenience stores, smoke shops, and online. The marketing pitches it for energy, mood, and opioid withdrawal. What is usually missing from the label: kratom's two main alkaloids, mitragynine and 7-hydroxymitragynine, act on the same brain receptors as opioid drugs.
7-hydroxymitragynine (7-HMG) binds mu-opioid receptors with greater affinity than morphine in laboratory studies, and rats will self-administer it like an opioid. The effects you feel are dose-dependent in the same pattern as a classic opioid: pain relief at low doses, euphoria and sedation at higher doses, and breathing suppression at toxic doses. The DEA proposed Schedule I status for kratom's main alkaloids in 2016 but withdrew the proposal after public pushback. As of 2026, kratom is still federally legal, though the FDA lists it as a "drug of concern."
Physical dependence builds with regular use, often within a few weeks. Withdrawal — documented in hundreds of case reports and multiple observational studies — includes muscle aches, insomnia, anxiety, irritability, sweating, nausea, and cravings. The pattern looks like opioid withdrawal, though usually milder. The FDA has received thousands of adverse event reports tied to kratom, and the CDC has linked kratom to dozens of overdose deaths, most involving other drugs. Even when kratom alone is hard to isolate as the cause, the signal is real.
U.S. poison centers logged 3,484 kratom-related calls between 2014 and 2019, with the rate climbing each year, according to American Association of Poison Control Centers (AAPCC) data. Reports include seizures, liver injury, and dozens of deaths in older adults whose cases involved drug interactions. Drug-induced liver injury cases tied to kratom have been published in hepatology journals on multiple continents.
Kratom has a real user community: people managing chronic pain, tapering off prescription opioids, and recreational users. Some users say it helps. For someone already dependent on opioids, kratom may be less harmful than illicit fentanyl. But that is a medical decision — one that belongs in a clinic with a doctor and a withdrawal plan, not in the checkout line at a gas station.
Because kratom is sold as a supplement rather than a drug, it skips the FDA approval process. Products vary widely in potency, can be contaminated, and have no required dosing standards. The American Kratom Association has lobbied to keep kratom unscheduled. Several states have passed a Kratom Consumer Protection Act that requires labeling and basic purity standards — a small step toward harm reduction, but it does not resolve the bigger safety questions.
Bovine colostrum — the first milk a cow produces after giving birth — is one of the fastest-growing supplement categories of 2025–2026, driven by wellness influencer endorsements. The marketing claims run from "immune support" to "gut repair" to better skin and athletic performance. The science is real, but narrow. The gap between what trials have actually shown and what brands claim is wide.
Colostrum is rich in antibodies (immunoglobulins), lactoferrin, growth factors (IGF-1, TGF-β), proline-rich peptides, and other immune signaling proteins. These compounds serve a clear job in newborn mammals: setting up gut immunity and supporting tissue growth in animals whose immune systems are not mature yet. The question for adult supplements is different: do these proteins survive your stomach acid intact, and do they produce real effects once they get past it?
The strongest evidence for colostrum in adults is in athletes during heavy training. A 2016 systematic review and meta-analysis of 5 randomized trials (152 participants) by Jones and colleagues found colostrum supplementation cut the incidence of upper respiratory symptom days by about 44% and episodes by 38% over 8–12 weeks of training — a population with known immune suppression during heavy loads. Separate studies suggest colostrum can reduce the gut "leakiness" that endurance athletes get during long, hot sessions. These are real findings, but in a narrow population.
For most colostrum buyers — non-athletes, generally healthy — the evidence is thin. There are no large randomized trials showing better general immunity, anti-aging effects, skin improvement, or the other broad wellness claims that show up in marketing. The IGF-1 in colostrum is mostly broken down in your stomach and does not reach the bloodstream in meaningful amounts. The antibody dose from a serving is a small fraction of what your gut already meets from food every day.
Quality bovine colostrum costs $40–$80 per month. At today's evidence levels, that is hard to justify for most healthy adults. If you are training hard and keep getting upper respiratory infections, an 8–12 week trial is reasonable. Otherwise, the immune and gut benefits colostrum is sold for are better supported by basics: enough sleep, a fiber-rich diet, and regular exercise.
Vitamin C has a reputation as the safest vitamin to give kids — it dissolves in water, the body flushes the extra, and true deficiency (scurvy) really can happen in picky eaters. All true. What gets left out: the safe upper limits for children are much lower than for adults, and household routines like "I take 1,000 mg, so I give my kid 500" can cause real problems.
The NIH sets Tolerable Upper Intake Levels (ULs) for vitamin C by age: 1–3 years, 400 mg/day; 4–8 years, 650 mg/day; 9–13 years, 1,200 mg/day; 14–18 years, 1,800 mg/day. The actual RDA is much lower — 15 mg/day for toddlers up to 75 mg/day for teens — and is easy to hit with food. A single orange gives about 70 mg. The limits exist because going over them causes diarrhea, nausea, and stomach cramps, and very high long-term doses can raise the risk of oxalate kidney stones because the body converts excess vitamin C to oxalate.
The most common reason parents add vitamin C is to prevent colds. The Cochrane review by Hemilä and Chalker (2013) pooled 29 trial comparisons with more than 11,000 participants. Regular vitamin C did not lower how often people got colds in the general population. It did slightly shorten cold duration — about 14% in children, or roughly a day off a typical week-long cold. Starting vitamin C after symptoms appeared did not show a clear benefit. The "immune boost" story driving most kid vitamin C use is not well supported above what kids already eat.
One genuinely useful role for vitamin C is helping kids absorb iron from plant foods. Pairing 25–75 mg of vitamin C with iron-rich plant foods (lentils, beans, fortified cereal) can roughly double non-heme iron absorption. That matters for vegetarian kids or kids with iron-deficiency anemia. You can do this with food alone — a small glass of orange juice with a bowl of fortified cereal — no supplement needed.
Kids eating a varied diet with any fruit and vegetables almost always meet the vitamin C target. A supplement is reasonable for very picky eaters with restricted diets. If you do supplement, use a kid-sized dose: 25–50 mg for toddlers, 50–100 mg for school-age children. Skip adult-dose products. Chewable tablets are easier to dose accurately than gummies.
Boron does not have a Recommended Dietary Allowance. There is no formally defined enzyme job for it — nothing as clean as, say, zinc's role in catalysis. And yet, a steady stream of human studies points to real roles in bone health, sex hormone balance, and cognition. Western diets often run low.
A 1987 USDA study (Nielsen and colleagues) found that giving postmenopausal women on a low-boron diet 3 mg/day raised serum estradiol and testosterone to levels similar to estrogen replacement therapy. A 2010 pilot study by Naghii in 8 healthy men gave 10 mg/day for 1 week: free testosterone rose, estradiol dropped, and the inflammatory markers hsCRP and TNF-alpha fell. A 2015 clinical study confirmed higher free testosterone and lower sex hormone binding globulin (SHBG) — lower SHBG means more usable testosterone in circulation. Effects are most consistent in people who started with low boron intake.
Boron seems to support bone by reducing urinary loss of calcium and magnesium and by helping the body use vitamin D. Animals deprived of boron lose bone strength. In humans, NHANES data link adequate boron intake to better bone mineral density. The vitamin-D and magnesium connections make it interesting as part of a bone-health stack, though randomized human trials are smaller than for calcium and vitamin D.
USDA Human Nutrition Research Center work found that very low dietary boron (0.25 mg/day) hurt performance on tasks of attention, hand-eye coordination, and short-term memory compared with an adequate intake (3.25 mg/day). EEG patterns also changed: less theta activity (linked to drowsiness) and more alpha and beta activity (linked to alert focus).
The best food sources are fruit (avocado, prunes, raisins, apples), legumes, and nuts. Typical Western intake is 0.5–3 mg/day — below the doses (3–10 mg/day) used in trials. Boron supplements are cheap. The IOM sets the Tolerable Upper Intake Level at 20 mg/day for adults. No notable toxicity has been seen at the 3–10 mg range. Avoid in pregnancy and breastfeeding because of limited safety data.
Cognitive decline with age is common but not inevitable, and not uniform. On average, working memory, processing speed, and word recall start to dip in the fifth decade. A handful of supplements have real human evidence for slowing or modifying parts of that decline — with important caveats about effect size and which people benefit most.
DHA (docosahexaenoic acid) is the dominant structural fat in brain gray matter and at the synapses where neurons communicate. Brain DHA falls with age, and people with higher blood DHA do better on cognitive tests in many observational studies. The MIDAS trial (Yurko-Mauro and colleagues, 2010) randomized 485 healthy adults aged 55+ with age-related memory complaints to 900 mg/day of algal DHA or placebo for 24 weeks. The DHA group showed measurably better learning and episodic memory. Higher baseline DHA also tracks with lower dementia risk in large prospective cohorts. Dose: 900–1,000 mg/day of DHA, from algal oil to avoid mercury concerns associated with some fish oils.
Elevated homocysteine — an amino acid the body normally clears with B6, B9 (folate), and B12 — is a well-established independent risk factor for cognitive decline and dementia. The VITACOG trial by Smith and colleagues (PMID 20838622) gave 168 older adults with mild cognitive impairment a daily B-vitamin combination for 2 years; participants who started with elevated homocysteine had roughly half the rate of brain shrinkage compared to placebo. B12 deficiency is common after age 60 because stomach acid drops. Blood testing before supplementing is ideal; 500–1,000 mcg/day of B12 is low-risk.
Phosphatidylserine (PS) is a phospholipid in the membranes of every brain cell. PS in the brain falls with age. Trials in age-associated memory impairment — the body of evidence behind the FDA's qualified health claim — show that 100–400 mg/day of PS modestly improves memory, attention, and word recall. The effect size is small (roughly 10–15% over placebo on standardized memory tests) but consistent across studies.
Lion's mane mushroom (Hericium erinaceus) raises Nerve Growth Factor (NGF), a protein that helps neurons survive and grow. In the 2009 Mori RCT, adults with mild cognitive impairment who took 3 g/day of dry powder for 16 weeks scored better on a Japanese cognitive test than placebo, with scores drifting back down after they stopped. A 2023 Australian trial found gains in immediate and delayed word recall in healthy adults. Most trials are small. Dose: 500–1,000 mg/day of a fruiting-body extract standardized for beta-glucans.
Ginkgo biloba, marketed for memory for decades, did not reduce dementia in the large GEM trial (3,069 older adults, ~6 years on 240 mg/day). Prevagen (apoaequorin, a jellyfish protein) has no plausible mechanism for crossing the blood-brain barrier and did not beat placebo in independent testing — the FTC and the New York Attorney General sued the maker for deceptive marketing. Both are among the most popular brain supplements in the US. Neither belongs ahead of the four above.
Green tea, the drink, is one of the most studied plant compounds in nutrition science, and it has a strong safety record. Green tea extract (GTE) — the concentrated capsule or tablet form delivering 400–1,000 mg of catechins (mostly EGCG, epigallocatechin gallate) per dose — is a different story. At those concentrated doses, GTE has caused acute liver injury, liver failure requiring transplant, and death in published case reports. The U.S. Pharmacopeia (USP) Expert Panel and the European Food Safety Authority (EFSA) have both flagged GTE as a hepatotoxicity risk above certain doses.
A cup of brewed green tea has about 50–100 mg of catechins. A typical GTE supplement has 400–1,000 mg per serving — the equivalent of drinking 4–10 strong cups all at once. At high doses, EGCG generates reactive oxygen species in liver cells in a dose-dependent way. The EFSA Panel on Food Additives and Nutrient Sources concluded in 2018 that GTE doses providing 800 mg/day or more of EGCG raise safety concerns. The 2020 USP comprehensive systematic review found published liver injury cases tied to EGCG intakes ranging from 140 mg/day to about 1,000 mg/day, with wide person-to-person variability that is likely partly genetic.
Hepatology journals have documented many cases of acute hepatitis tied to GTE weight-loss supplements, including previously healthy young adults who needed liver transplant. The pattern is consistent: use of a commercial GTE product (often a fat-loss formula), jaundice within weeks, biopsy-confirmed hepatocellular injury, and resolution after stopping. The U.S. Drug-Induced Liver Injury Network (DILIN) consistently lists green tea extract among the most common single-ingredient supplement causes of liver injury referred for evaluation. The toxicity is idiosyncratic — most users show no harm — but the people who do react can deteriorate quickly.
Risk factors for GTE-related liver injury include taking it on an empty stomach (which sharply raises peak EGCG in the blood), higher doses (>800 mg EGCG/day), female sex, and likely some variants in drug-metabolizing enzymes. Stacking GTE with other compounds that can stress the liver — high-dose niacin, kava, certain herbal extracts — substantially raises risk. People with pre-existing liver disease should avoid GTE altogether.
If you want the cardiovascular or metabolic benefits attributed to green tea polyphenols, the beverage is much safer than the extract: tea's natural matrix slows absorption and keeps blood EGCG well below toxic levels. The evidence for GTE as a weight-loss aid is modest and does not justify the liver risk. Take it with food, not on an empty stomach. Never exceed 400 mg of EGCG per day from supplements, and stop and seek medical care immediately if you notice jaundice, dark urine, or right-upper-quadrant pain.
Turkesterone is an ecdysteroid — a steroid-like compound found in plants and insects — that became a breakout supplement trend on TikTok and fitness forums starting around 2021. Influencers claimed it produced steroid-like muscle gains without steroid side effects. The hype was extraordinary. As of 2026, no published human resistance-training trial has tested turkesterone against placebo with muscle or strength outcomes. The only human turkesterone study to date used acute (single-dose) measurements in 11 men and found no change in IGF-1 or resting metabolic rate.
The excitement around turkesterone traces to rodent and insect studies showing ecdysteroids can activate anabolic signaling pathways — specifically, stimulation of the estrogen receptor beta (ERβ) pathway and protein synthesis. A 2019 German study (Isenmann et al., Archives of Toxicology, PMID 31123801) actually tested the related compound ecdysterone — not turkesterone — in 46 men over 10 weeks of resistance training. It found significantly higher muscle-mass and bench-press gains in the ecdysterone groups. On that basis, the authors recommended ecdysterone be added to the WADA prohibited list. Crucially, this study used ecdysterone, not turkesterone, and the result has not been independently replicated.
The first peer-reviewed human study of turkesterone specifically was published by Harris et al. in 2024 (Muscles, PMID 40757520). Eleven healthy men received single doses of turkesterone or placebo with measurements at baseline, 3 hours, and 24 hours post-ingestion. There were no statistically significant changes in serum IGF-1 (a key anabolic marker), resting metabolic rate, or lipid and carbohydrate metabolism. The authors concluded the data “fail to fully support turkesterone as a potent anabolic supplement.” This is an acute pharmacology study, not a resistance-training trial — meaning even the most fundamental claim, that chronic turkesterone improves muscle outcomes, has never been tested in humans.
Turkesterone faces a fundamental pharmacological problem: its oral bioavailability is extremely poor. Ecdysteroids are poorly absorbed in the human gut and rapidly metabolized. Plasma concentrations achieved with typical supplement doses are a small fraction of the concentrations used in cell culture experiments showing anabolic activity. Supplement companies sell “complexed” or “cyclodextrin” turkesterone at premium prices claiming enhanced absorption — but no human pharmacokinetic data has shown that these formulations produce meaningfully higher blood levels.
Turkesterone supplements typically cost $40–$80 per month. The mechanism is speculative in humans, oral bioavailability is poor, the one published human study found no acute biochemical effect, and no chronic placebo-controlled training trial exists. The 2019 Isenmann study often cited in marketing was actually for the related compound ecdysterone — not turkesterone — and has not been replicated. For muscle building, the evidence-based options remain: creatine monohydrate, adequate protein (1.6–2.2 g/kg/day), progressive resistance training, and adequate sleep.
Antibiotics are among the most valuable medical tools in pediatric care, but they disrupt the gut microbiome. Antibiotic-associated diarrhea (AAD) affects roughly 11–40% of children taking antibiotics, with the rate depending on the antibiotic class and the child’s age. Whether giving probiotics during and after a course can reduce this disruption has been tested in dozens of trials — more consistently than for most supplements children are offered.
Lactobacillus rhamnosus GG (LGG) is the best-studied probiotic strain for preventing pediatric AAD. The most current Cochrane review (Guo et al., 2019; PMID 31039287) pooled 33 trials with 6,352 children and found probiotics cut the risk of AAD from 19% to 8%, a 55% relative reduction (RR 0.45, 95% CI 0.36–0.56). The benefit was much larger when at least 5 billion CFU/day were used: number needed to treat (NNT) of 6, versus 9 overall. LGG and Saccharomyces boulardii were the strains with the strongest individual evidence.
Saccharomyces boulardii is a yeast, not a bacterium, so antibiotics do not kill it. That makes it practical during an antibiotic course — timing relative to each dose is not critical. Pediatric trials show S. boulardii (250–500 mg/day) reduces AAD by roughly 40–50%, in line with LGG. Some pediatric guidelines (including the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, ESPGHAN) specifically endorse LGG and S. boulardii as the strains with the strongest evidence.
Start the probiotic at the same time as the antibiotic, not after symptoms appear. Continue for at least 1–2 weeks after the antibiotic course ends. For bacterial strains like LGG, space the dose at least 2 hours apart from the antibiotic so the antibiotic is less likely to kill it. S. boulardii can be taken at the same time as the antibiotic. Effective trial doses: LGG at 5–10 billion CFU/day; S. boulardii at 250–500 mg/day.
Across the 2019 Cochrane review (24 trials reporting safety data), no serious adverse events were attributed to probiotics in otherwise healthy children. Probiotics are not appropriate for severely ill, immunocompromised, or central-line-dependent children, where rare bloodstream infections from probiotic strains have been reported.
Beyond AAD prevention, broader microbiome disruption from antibiotic courses in children can persist for weeks to months. Fermented foods — yogurt with live cultures, kefir — provide a wider mix of microbes than single-strain capsules. A diet high in prebiotic fiber (fruits, vegetables, legumes) supports regrowth of beneficial species. These dietary steps complement the probiotic course.
Vitamin D research has a paradox. Observational studies strongly link low vitamin D levels to almost every major chronic disease — heart disease, cancer, diabetes, dementia, autoimmune conditions, and depression. Yet the large randomized trials designed to test whether supplements prevent these outcomes have been mostly disappointing. The reason is not that vitamin D doesn’t work. It’s that most trials were designed in ways that almost guarantee a null result.
The largest and most cited vitamin D trial is VITAL (Manson 2019, PMID 30415629): 25,871 adults, 2,000 IU/day of vitamin D3 vs. placebo, about 5.3 years of follow-up. VITAL found no significant drop in heart disease or cancer in the overall group. But the average baseline 25(OH)D level was already 30.8 ng/mL — right at the threshold most clinicians call “sufficient.” Giving extra vitamin D to people who are not low has no clear reason to help. When researchers looked only at participants with baseline deficiency, some outcomes did improve. VITAL was a population trial, not a deficiency-correction trial — and the difference matters.
Many early vitamin D trials used 400–800 IU/day. We now know those doses barely move serum 25(OH)D in adults who start out low. The blood levels linked to benefit in observational studies often sit above 40–60 ng/mL, which usually takes 2,000–5,000 IU/day in real-world dosing. Pooled meta-analyses, including the cancer-mortality analysis by Keum et al. 2019 (Annals of Oncology, PMID 31504112), find clearer effects when trials actually push serum levels into the target range.
Cancer and heart disease take decades to develop. A 2–3 year supplement trial is usually too short to see a change in cancer rates or heart attacks — even when the underlying biology is real. VITAL’s 5-year follow-up is among the longest, and that may still be too brief for outcomes with a 10–20 year lag. Notably, the VITAL extended follow-up (Bischoff-Ferrari 2022, PMID 35139361) found a 22% drop in autoimmune disease incidence with longer follow-up — an effect the original 5-year analysis missed.
When trials correct these design flaws — enrolling deficient people, using doses that actually raise serum levels, and following participants long enough — the picture improves. The D2d trial (Pittas 2019, PMID 31173679) found that vitamin D in prediabetic adults with baseline 25(OH)D below 12 ng/mL cut progression to type 2 diabetes by 62%. Recent meta-analyses on falls and fractures show benefit only when baseline deficiency is corrected. The big-trial “vitamin D doesn’t work” headline is misleading. The biology is still plausible; most trials are just poorly built to detect it. Bottom line: test, then treat. Don’t supplement blind, and don’t dismiss vitamin D based on null trials in already-replete people.
Saffron (Crocus sativus) is best known as an expensive cooking spice. It is far less known as one of the most clinically supported natural antidepressants. The randomized-trial evidence behind it outperforms most herbal remedies and stands up well against pharmaceutical antidepressants in mild-to-moderate depression. The gap between how strong the evidence is and how few people have heard of it is striking.
The Hausenblas et al. 2013 meta-analysis (Journal of Integrative Medicine, PMID 24299602) was the first to pool the early trial data: 5 placebo-controlled and active-controlled studies showing saffron extract significantly outperformed placebo and matched fluoxetine and imipramine. Larger and more recent reviews have built on it. Marx et al. 2019 (Nutrition Reviews, PMID 31504123) pooled 23 RCTs and found saffron beat placebo by a large effect size (Hedges’ g around −0.99 for depression scores) and matched standard antidepressants head-to-head. Saffron also caused fewer side effects than SSRIs or tricyclics. These effect sizes are bigger than those of most other “mood” supplements and similar in size to the effect SSRIs show over placebo.
Saffron’s active compounds are safranal and crocin — the carotenoid pigments that give the spice its color and aroma. Lab studies suggest these compounds slow serotonin reuptake (similar to how SSRIs work), tone down NMDA-receptor activity, and lower oxidative stress in the brain. The multi-target action may help explain why a botanical can match single-mechanism drugs in head-to-head trials. Saffron has also been linked to higher brain-derived neurotrophic factor (BDNF), a protein associated with antidepressant response.
Clinical trials consistently use 30 mg/day of a saffron extract standardized to safranal — either 30 mg once daily or 15 mg twice daily. You can’t reach this dose from cooking: heat destroys most of the active compounds, and recipes use only a few threads. Standardized capsules are needed. Onset of effect in trials is usually 4–6 weeks, similar to prescription antidepressants.
The current evidence supports saffron as a reasonable option for mild-to-moderate depression, especially for people who prefer a non-drug option, who had significant SSRI side effects (such as sexual dysfunction), or who can’t access psychiatric care. It is not a stand-alone treatment for severe depression, suicidal ideation, bipolar disorder, or psychosis. If you take an SSRI, MAOI, or other serotonergic medication, talk to your doctor before adding saffron — in theory, combining serotonergic agents could increase the risk of serotonin syndrome. Don’t stop a prescribed antidepressant without medical guidance.
Travel puts your body through specific stressors: time-zone shifts that disrupt your sleep clock, exposure to new germs, different food and water, and changes in activity. Unlike most of the supplement market, a few travel uses have strong, specific clinical evidence. This guide covers the picks with the best evidence-to-cost ratio.
Melatonin is the most evidence-backed supplement for jet lag. The Herxheimer & Petrie 2002 Cochrane review (10 trials, PMID 12076414) concluded that melatonin is “remarkably effective” at preventing or reducing jet lag when taken at the destination’s bedtime, in doses of 0.5–5 mg. Lower doses (0.5–1 mg) shift the body clock as well as higher doses, with less morning grogginess. Timing matters more than dose: take it at local bedtime for the first 3–4 nights after arrival. Eastward travel (clock advance) is harder than westward and benefits more from melatonin. Don’t take it on the plane — take it at your destination’s bedtime.
Traveler’s diarrhea hits 20–50% of visitors to high-risk regions. McFarland’s 2007 meta-analysis (12 trials, Travel Medicine and Infectious Disease, PMID 17298912) found probiotics reduced TD risk overall, with a relative risk of about 0.85 (roughly a 15% reduction). The strongest single-strain data is for Saccharomyces boulardii, with Lactobacillus rhamnosus GG also supported. The studied protocol starts 2–5 days before travel and continues during the trip. The absolute risk reduction is modest, so probiotics complement — not replace — standard food and water hygiene.
Crowded planes and airports raise upper-respiratory infection risk. Hemilä’s 2017 meta-analysis (JRSM Open, PMID 28515951) found zinc acetate lozenges (75–100 mg total elemental zinc per day, divided across the day) cut common-cold duration by about 33% when started within 24 hours of symptom onset. The form matters: zinc acetate had stronger and more consistent evidence than zinc gluconate. For prevention, evidence is weaker, and high-dose lozenges should not be used continuously — chronic high zinc intake (above ~40 mg/day elemental for weeks) can cause copper deficiency.
Winter trips and indoor itineraries can lower sun exposure. Keeping vitamin D in the sufficient range (1,000–2,000 IU/day) is well tolerated and modestly reduces acute respiratory infection risk in deficient people, per the Martineau et al. 2017 individual-participant-data meta-analysis (BMJ, PMID 28202713). It’s a sensible baseline, not a dramatic intervention.
Activated charcoal for “food safety” doesn’t neutralize bacterial toxins and can block absorption of medications you’re actually relying on. Oregano oil capsules have no human trial evidence for travel infections. “Immune booster” mushroom blends have no travel-specific data. For high-altitude trips, the evidence-based option is prescription acetazolamide; ginkgo and other supplements are inconsistent in trials. If you’re going above 2,500 m, talk to your doctor before relying on a supplement.
Raw desiccated thyroid glandular supplements are made from freeze-dried or dried animal thyroid tissue, usually from cattle or pigs. They are sold over the counter for “energy,” “metabolism,” and “thyroid support.” Unlike prescription desiccated thyroid (such as Armour Thyroid or Nature-Throid), OTC glandulars are not regulated as drugs, not standardized for hormone content, and not subject to medical oversight. The problem: independent lab testing has shown that many of these “supplements” do contain real thyroid hormone — thyroxine (T4) and triiodothyronine (T3) — in unpredictable amounts.
Kang and colleagues tested 10 over-the-counter thyroid health supplements (Thyroid, 2013, PMID 23972023) and detected measurable T4 and/or T3 in 9 of 10 products. T3 doses ranged up to 25 mcg per recommended daily serving — close to a prescription T3 dose, and far higher than dietary-supplement law allows. T3 is potent: prescription liothyronine is dosed in micrograms precisely because small dose differences produce real physiological effects. Supplement manufacturers do not have to do potency testing the way drug makers do, so the actual dose in any given bottle can vary widely from batch to batch.
Too much thyroid hormone causes thyrotoxicosis (drug-induced hyperthyroidism). Symptoms include a fast or irregular heartbeat, atrial fibrillation (a dangerous arrhythmia that raises stroke risk), tremor, anxiety, insomnia, weight loss, heat intolerance, and bone loss. These effects can occur even in people with normal baseline thyroid function. Case reports in clinical literature describe thyrotoxicosis, atrial fibrillation, and adrenal-thyroid cross-effects from OTC glandulars, including a series of patients with elevated free T3 and suppressed TSH from products they did not realize contained active hormone (Poppe et al., European Thyroid Journal, 2019). The American Thyroid Association and the American Association of Clinical Endocrinology both explicitly warn against using these products outside medical supervision.
Bovine glandular tissue raises a separate concern: prion contamination (the agent of bovine spongiform encephalopathy, “mad cow”). The FDA and Health Canada both restrict bovine-derived ingredients from specified risk materials in the human food and supplement supply, and both warn that imported glandular products may not meet these standards. For consumers, there is no easy way to verify a product’s sourcing.
The biggest driver is frustration with standard thyroid care. People with fatigue, weight changes, brain fog, or hair loss often have a “normal” TSH and are told nothing is wrong. Some functional-medicine and naturopathic practitioners then suggest glandulars as an “all-natural” alternative. The frustration is real; the solution is not. A proper thyroid workup includes TSH, free T4, free T3, and thyroid antibodies (TPO and TgAb), interpreted alongside symptoms. If treatment is needed, levothyroxine (T4) and, in selected cases, prescription liothyronine (T3) or natural desiccated thyroid (NDT) provide standardized, monitored doses.
The FDA has issued warning letters to companies selling thyroid glandulars that make drug claims. But products labeled only for “thyroid support” without explicit hormone claims sit in a gray zone the law has not closed. Until it does, the risk falls on the consumer. Bottom line: don’t take OTC thyroid glandulars. If you want desiccated thyroid, get it by prescription with proper monitoring. If your symptoms are real but standard testing is normal, push for a fuller workup — not an unregulated bottle.
Lion’s mane (Hericium erinaceus) sits in an unusual spot in the supplement world. It has genuinely interesting biology and a small but real human-trial record in older adults with cognitive impairment. It also has a social-media reputation that vastly oversells its effects in healthy young adults. The honest read of the evidence depends on knowing which population a study used — and not mistaking lab and rodent findings for proof of human benefit.
Lion’s mane contains compounds called hericenones (in the fruiting body) and erinacines (in the mycelium). In cell culture and rodent studies, these compounds boost Nerve Growth Factor (NGF) and Brain-Derived Neurotrophic Factor (BDNF) — proteins that help nerve cells survive, grow, and form connections. This is real, interesting biology. The catch: most online discussions skip the next step and treat the lab data as proof of focus or memory benefits in healthy adults. That step has not been done.
The most cited human trial is Mori et al. 2009 (Phytotherapy Research, PMID 18844328): 30 Japanese adults aged 50–80 with mild cognitive impairment (MCI), 3 g/day of lion’s mane dry powder for 16 weeks. The supplemented group scored significantly higher on a cognitive function scale. Notably, scores fell again after participants stopped taking it — consistent with a real but reversible effect, not a permanent change. The Docherty et al. 2023 pilot trial (Nutrients, PMID 36904192) tested 1.8 g/day in 41 healthy adults aged 18–45. After 28 days, the supplement group showed faster Stroop-test performance and a small drop in subjective stress. The trial was small and needs replication, but it’s the best healthy-young-adult data so far. Saitsu et al. 2019 (Biomedical Research, PMID 31413233) reported similar small cognitive gains in older Japanese adults.
Lion’s mane has a huge online following with reports of sharper focus and less brain fog. The anecdotal record is hard to interpret. Cognitive interventions show large placebo responses, people often change diet, sleep, or caffeine intake at the same time, and any mild anxiety-reducing effect can feel like “sharper focus.” None of that means the mushroom is fake. It means the strength of online enthusiasm is well beyond what the controlled trials currently support.
Lion’s mane is a reasonable addition to a brain-health routine for people over 50 with cognitive concerns. The safety profile is good. Typical doses are 500–1,000 mg/day of standardized extract or 1–3 g/day of fruiting-body powder. Don’t expect dramatic focus or productivity gains within hours — in trials, effects appear over weeks. The evidence for MCI is solid; the evidence for healthy young adults is preliminary. For acute cognitive performance, caffeine, creatine, and L-theanine still have far stronger trial support.
Docosahexaenoic acid (DHA) is a long-chain omega-3 fatty acid. It makes up about 15–20% of the fatty acid in brain gray matter and keeps building up through childhood and the teen years. The brain uses DHA in nerve-cell membranes and in the myelin sheath — the fatty insulation around nerve fibers that lets signals travel quickly. That makes adequate DHA important for skills that depend on fast neural processing, like reading, attention, and learning.
Blood DHA levels in children track closely with how much oily fish they eat. The UK National Diet and Nutrition Survey shows that the average child aged 11–18 eats well below the recommended one portion of oily fish per week, and a large share eat none at all in a typical week. Children on plant-based diets are at higher risk: the body can convert plant ALA (from flax, chia, walnuts) into DHA, but conversion is inefficient — usually under 5% in adults, and even less in some children.
The DOLAB I trial (Richardson et al. 2012, PLoS One, PMID 22970171) randomized 362 UK children aged 7–9 with below-average reading ability to 600 mg/day algal DHA or placebo for 16 weeks. In the pre-specified subgroup of children whose baseline reading was in the lowest 20%, DHA produced a statistically significant improvement on a standardized reading test. The whole-group effect was smaller and not statistically significant. DOLAB II partially replicated this pattern. Older work by Richardson & Montgomery 2005 (the Oxford-Durham study, Pediatrics, PMID 15867020) found EPA/DHA improved reading and behavior in children with developmental coordination disorder. Taken together, the data suggests DHA helps the children who are struggling the most, with smaller average effects in unselected populations.
Bloch & Qawasmi’s 2011 meta-analysis (Journal of the American Academy of Child & Adolescent Psychiatry, PMID 21961774) pooled 10 trials and found omega-3 supplementation produced a modest but significant improvement in ADHD symptoms (Cohen’s d ~ 0.31). Effects were larger when EPA dose was higher. This is meaningfully smaller than the effect of stimulant medication, but the safety profile is excellent and the data is consistent.
Children aged 4–12 with low fish intake can reasonably take 250–500 mg DHA per day; for ADHD or reading concerns, 600 mg/day is the dose used in trials. Algal oil DHA is identical in structure to fish-oil DHA and is the preferred form for vegetarian or vegan kids, or for families who don’t want fish-derived products. Flavored liquid fish oils improve compliance for younger children. If a child reliably eats two servings of oily fish (salmon, mackerel, sardines) per week, a supplement is usually unnecessary. Fish-oil supplements at these doses are well tolerated; the main side effect is fishy burps, which is reduced by refrigerating the bottle and taking it with meals.
The “appeal to nature” is one of the most powerful biases in supplement marketing. The word “natural” is used as a stand-in for “safe,” “effective,” and “not like a pharmaceutical drug.” None of those meanings hold up. Some of the most toxic substances ever measured are entirely natural — botulinum toxin, ricin, aflatoxin, deadly nightshade. Some of the safest medicines used today are synthetic. The word “natural” on a supplement label tells you nothing about safety or whether the product works.
Aristolochic acid: Found in Aristolochia plants used in traditional herbal medicine. It is a potent kidney toxin and a known human carcinogen (IARC Group 1). The Belgian “Chinese herbs nephropathy” outbreak (Vanherweghem et al. 1993, The Lancet, PMID 8094488) caused kidney failure in young women using a slimming preparation; many later developed urothelial cancer (Nortier et al. 2000, NEJM, PMID 10874060).
Comfrey (Symphytum officinale): Sold for centuries as a wound-healing herb. Comfrey contains pyrrolizidine alkaloids that cause hepatic veno-occlusive disease — a serious and sometimes fatal liver injury. The U.S. FDA asked manufacturers to remove oral comfrey products from the market in 2001, and several other regulators followed.
Pennyroyal: Used historically as a folk abortifacient. Pennyroyal oil causes severe liver and kidney injury and has caused deaths even at modest doses.
Ephedra (ma huang): A natural source of the stimulant ephedrine. Banned by the U.S. FDA in 2004 as a dietary-supplement ingredient after Haller & Benowitz 2000 (NEJM, PMID 11122588) linked it to strokes, heart attacks, and sudden cardiac death.
The DILIN registry — the U.S. NIH Drug-Induced Liver Injury Network — reports that herbal and dietary supplements account for a growing share of acute liver injury cases that lead to transplant or death. Navarro et al. 2014 (Hepatology, PMID 25043597) found supplement-related liver injury in DILIN rose from 7% of cases in 2004–2007 to 20% in 2010–2013. The U.S. CDC estimates roughly 23,000 emergency-department visits per year are attributable to dietary-supplement adverse events (Geller et al. 2015, NEJM, PMID 26465985), most often from cardiovascular effects of weight-loss and energy products in young adults.
Many drugs come from nature: penicillin from mold, aspirin from willow bark, digoxin from foxglove, morphine from poppy, paclitaxel from yew. The line between “natural” and “pharmaceutical” isn’t a scientific category. It’s a regulatory and marketing category. The questions that actually matter are: Does it work? Is it safe at the dose being used? Has it been tested in humans? Does it interact with my other medications? “Natural” answers none of those.
The 16th-century physician Paracelsus put it simply: any substance can be toxic at some dose. Vitamin A is essential, but excess causes liver damage and severe birth defects. Iron is essential, but an overdose causes organ failure. Even oxygen, at high partial pressures, can cause seizures and lung damage. On the other side, synthetic medicines like statins, metformin, and aspirin have decades of safety data in hundreds of millions of people. Safety depends on the dose and the biology, not on whether something came from a plant.
When you’re looking at a supplement, ignore the word “natural.” Ask instead: What is the human trial evidence? What dose was studied, and is that what’s in the bottle? Has it been linked to liver, kidney, or heart problems? Does it interact with anything I take, especially blood thinners, antidepressants, immunosuppressants, or chemotherapy? If you can’t answer those questions, “all-natural” on the front of the package isn’t a substitute.
Iron deficiency is the most common nutrient deficiency in the world, affecting an estimated 2 billion people. The standard treatment is ferrous sulfate. It works, but the side effects — constipation, nausea, abdominal cramps, dark stools, and a metallic taste — cause many patients to stop before their anemia is corrected. Lactoferrin is a different option. It is an iron-binding protein naturally found in breast milk, tears, and saliva. In trials, bovine (cow) lactoferrin can improve iron status with much fewer gut symptoms and at a much smaller actual iron dose.
Lactoferrin does not flood the body with iron the way ferrous sulfate does. Instead, it shifts how the body handles the iron it already has. It binds iron tightly, helps regulate hepcidin (the hormone that controls iron release from stores), and modulates inflammation. Chronic inflammation drives hepcidin up, locks iron away from red-blood-cell production, and causes the “anemia of inflammation” that often does not improve with standard iron pills. By calming this signal, lactoferrin can free up iron the body already has.
The most cited evidence comes from a series of Italian trials in pregnant women with iron-deficiency anemia. Paesano et al. 2010 (International Journal of Immunopathology and Pharmacology, PMID 20525393) compared 100 mg/day of bovine lactoferrin to ferrous sulfate (about 100–105 mg of elemental iron daily). Lactoferrin produced equal or greater rises in hemoglobin and serum ferritin, with much less GI distress. Because bovine lactoferrin contains only a small amount of bound iron (roughly 1–2 mg per 100 mg of protein), patients took a small fraction of the elemental iron used in the comparator group. A 2023 meta-analysis by Lepanto et al. (Frontiers in Pharmacology) pooled multiple RCTs and confirmed significant improvements in hemoglobin, ferritin, and serum iron with bovine lactoferrin and consistently fewer adverse events than standard iron salts. Effects in non-pregnant adults and children are smaller and more variable, so the data is strongest in pregnancy.
The biggest practical advantage is tolerability. Iron therapy fails most often because patients stop taking it. Lactoferrin also avoids some of the gut-side effects linked to high-dose ferrous iron, including oxidative stress on intestinal cells and shifts in the gut microbiome. Because it has antimicrobial properties, it may be especially useful where iron deficiency overlaps with gut infections.
Lactoferrin is most compelling for pregnant women (high iron needs and poor tolerance of standard iron), patients who stopped ferrous sulfate because of side effects, and people with chronic inflammatory conditions where hepcidin is elevated. It is more expensive than ferrous sulfate ($20–$40 per month versus a few dollars), but the math changes if it lets a patient stay on therapy long enough to actually correct the anemia. Typical doses in trials are 100–300 mg of bovine lactoferrin per day, taken on an empty stomach. Lactoferrin is dairy-derived and is not appropriate for people with severe dairy-protein allergy. Anyone treating significant anemia should still work with a clinician to confirm the diagnosis, identify the cause, and recheck blood work.
The joint-supplement market is enormous, with multi-billion-dollar U.S. sales each year, driven by osteoarthritis, sports injuries, and age-related wear. It is also one of the most uneven supplement categories. Products with serious clinical support sit on the same pharmacy shelf as products with almost no human data. This guide ranks the most common joint supplements by clinical evidence quality.
Undenatured Type II Collagen (UC-II): Don’t confuse this with hydrolyzed collagen peptides (below). UC-II is intact, native collagen given in tiny doses (40 mg/day). It is thought to work through “oral tolerance” — teaching gut-associated immune cells to stop attacking the body’s own joint collagen. Lugo et al. 2016 (Nutrition Journal, PMID 26822714) randomized 191 adults with knee OA to UC-II vs glucosamine+chondroitin vs placebo for 180 days. UC-II produced larger reductions in WOMAC pain than glucosamine+chondroitin and outperformed placebo significantly.
Boswellia serrata extract (AKBA): Boswellic acids inhibit 5-lipoxygenase (5-LOX), an enzyme that drives joint inflammation. Sengupta et al. 2008 (5-Loxin trial, Arthritis Research & Therapy, PMID 18667059) tested an AKBA-enriched Boswellia extract (100–250 mg/day) in 75 patients with knee OA over 90 days; both doses produced significant improvements in pain and function within 7 days. Yu et al. 2020 (Phytotherapy Research) meta-analyzed 7 RCTs and confirmed benefit on WOMAC pain and function scores.
Glucosamine sulfate (not hydrochloride): The GAIT trial (Clegg et al. 2006, NEJM, PMID 16495392; n=1,583) found glucosamine HCl plus chondroitin did not beat placebo overall, but the moderate-to-severe pain subgroup showed benefit. European trials using prescription-grade crystalline glucosamine sulfate at 1,500 mg/day (Reginster et al. 2001 and the long-term follow-up) more consistently show pain reduction. The form matters: HCl appears less effective than crystalline sulfate, which explains much of the conflicting literature.
Hydrolyzed collagen peptides: 10 g/day supplies amino acids and bioactive peptides that stimulate cartilage and tendon collagen synthesis. Multiple RCTs in athletes and OA patients show modest but significant reductions in joint pain (e.g., Zdzieblik et al. 2017, Applied Physiology, Nutrition, and Metabolism). Smaller effect than UC-II at the per-gram level, but the data are consistent.
Chondroitin sulfate: GAIT found no average benefit, but European trials with pharmaceutical-grade chondroitin (800–1,200 mg/day) show more consistent results. The 2015 OARSI guidelines list pharmaceutical chondroitin as “appropriate” for symptomatic relief in knee OA. Source quality and the sulfation pattern of the chondroitin polymer matter; most retail products use low-grade bovine material of variable quality.
Turmeric/curcumin (high-bioavailability forms): Standardized, bioavailability-enhanced curcumin (Meriva, BCM-95, Theracurmin — not plain turmeric powder) reduces inflammatory biomarkers and OA pain in multiple RCTs at 1,000–1,500 mg/day. Daily et al. 2016 (Journal of Medicinal Food, PMID 27533649) meta-analyzed 8 RCTs and reported curcumin produced pain reductions comparable to NSAIDs in some head-to-head trials. Use enhanced-absorption forms; raw turmeric powder is barely absorbed.
MSM (methylsulfonylmethane): A few small trials show modest benefit. Larger and pooled analyses are inconsistent, and effect sizes are small. Oral hyaluronic acid: Oral HA is largely broken down by stomach acid before it can reach the joint. Intra-articular HA injections (a medical procedure) have stronger evidence; the supplement form does not. Save your money for the tiers above.
Calcium is the most abundant mineral in the body. About 99% of it is stored in bones and teeth. The U.S. Recommended Dietary Allowance is 1,000–1,200 mg/day for most adults. National survey data show that a large share of U.S. adults — especially women over 50 — fall short on diet alone. But blanket supplementation has become controversial. Several meta-analyses raised concerns about cardiovascular risk in supplement users. The question is no longer “should I take calcium?” but “who actually needs it, how much, and in what form?”
Calcium supplementation has the clearest evidence in: postmenopausal women not meeting dietary calcium goals, people with documented osteoporosis or osteopenia, patients on long-term corticosteroid therapy, and people with malabsorption (celiac, IBD, post-bariatric surgery). The Women’s Health Initiative (Jackson et al. 2006, NEJM, PMID 16481635) randomized 36,282 postmenopausal women to 1,000 mg calcium carbonate plus 400 IU vitamin D3 daily or placebo. The intention-to-treat hip-fracture reduction was modest (about 12%) and not significant. In adherent participants, the reduction was about 29% and statistically significant. For adults who already eat enough dairy, leafy greens, and fortified foods, supplements offer little extra bone benefit.
Bolland et al. 2010 (BMJ, PMID 20671013) pooled 11 trials of calcium-only supplements (without vitamin D) and reported about a 27% relative increase in myocardial infarction (heart attack) in supplement users. A 2011 follow-up that added WHI data found a smaller but still elevated risk when calcium was given without vitamin D. The proposed mechanism is a brief rise in serum calcium after a supplement dose, which may promote arterial calcification over time — a spike that does not happen with dietary calcium, which is absorbed slowly across meals. Other large analyses (Chung et al. 2016 for the U.S. National Osteoporosis Foundation, Annals of Internal Medicine, PMID 27776363) did not find a significant CV signal at intakes within recommended ranges. Current consensus, including the NOF/ASPC guidelines, is: get calcium from food first, supplement only to fill the gap, and keep total intake below about 2,000–2,500 mg/day (the IOM tolerable upper intake for adults).
Calcium carbonate is the cheapest and most concentrated form, with 40% elemental calcium by weight. It needs stomach acid to dissolve, so it should be taken with food. Calcium citrate contains 21% elemental calcium but is well absorbed regardless of stomach acid. That makes citrate the better choice for adults over 50 (who often produce less acid), people on proton-pump inhibitors, and anyone who gets GI discomfort with carbonate. Either form works if you split doses: don’t take more than 500 mg of elemental calcium at one sitting — absorption efficiency drops above that point.
Vitamin D is needed to absorb calcium from the gut. Without enough vitamin D, only about 10–15% of dietary calcium is absorbed; with sufficient vitamin D it climbs to 30–40%. This is why almost every successful calcium fracture trial co-administered vitamin D. Vitamin K2 (menaquinones, especially MK-7) is a more recent addition. K2 activates osteocalcin, which helps deposit calcium in bone, and matrix Gla protein, which helps keep calcium out of arterial walls. The Rotterdam Study (Geleijnse et al. 2004, Journal of Nutrition, PMID 15514282) found higher dietary menaquinone intake associated with lower coronary heart disease and aortic calcification. Trial-level evidence for supplemental K2 on hard cardiovascular outcomes is still maturing, but the mechanism makes pairing calcium with D3 and K2 a reasonable choice.
Calcium competes for absorption with iron, zinc, and magnesium. Take calcium at least 2 hours apart from iron supplements, and at least 4 hours apart from thyroid medication (levothyroxine). Calcium also reduces absorption of tetracyclines and fluoroquinolone antibiotics. The practical recipe for most adults: aim for 800–1,000 mg from diet, supplement only the remaining gap in split doses of 500 mg or less, pair with 1,000–2,000 IU vitamin D3, and consider 90–180 mcg vitamin K2 (MK-7) per day.
Age-related macular degeneration (AMD) is a leading cause of severe vision loss in older adults in wealthy countries. The macula is the small central spot in the retina that handles sharp, detailed vision. It packs in two yellow pigments: lutein and zeaxanthin. They act like built-in sunglasses, soaking up some blue light and quenching free radicals. The amount of pigment in the macula (called macular pigment optical density, or MPOD) drops with age. The big AREDS2 trial put a specific lutein/zeaxanthin dose to the test for slowing AMD.
The Age-Related Eye Disease Study 2 (AREDS2), run by the U.S. National Eye Institute, enrolled 4,203 adults aged 50 to 85 who were at risk of advanced AMD. In the main analysis, adding 10 mg lutein and 2 mg zeaxanthin to the original AREDS formula did not hit statistical significance for the whole group (HR 0.90, 98.7% CI 0.76–1.07; p=0.12). Two findings still made the lutein/zeaxanthin combo the new standard. First, in a pre-planned secondary analysis, swapping out beta-carotene for lutein and zeaxanthin lowered progression to advanced AMD by about 18% (HR 0.82). Second, in participants whose dietary intake of lutein/zeaxanthin was in the lowest 20% at baseline, supplementation cut progression by roughly 26% versus the no-L/Z arms. Beta-carotene also raised lung cancer risk in former smokers (23 vs 11 cases), making the swap both safer and as effective. The current AREDS2 formulation (lutein 10 mg, zeaxanthin 2 mg, vitamin C 500 mg, vitamin E 400 IU, zinc 80 mg, copper 2 mg) is the standard of care for intermediate AMD.
Lutein and zeaxanthin absorb blue light (about 400–500 nm) before it reaches the photoreceptors. That cuts light-driven oxidative damage to the retinal pigment epithelium. With most people now spending hours in front of screens, this filtering job has gotten more attention. Studies that measure MPOD show that taking 10–20 mg lutein per day raises pigment density within 2–4 months. Higher MPOD lines up with better contrast sensitivity and less glare disability. Blue-light-blocking glasses don’t have strong evidence; the body’s built-in pigment filter does.
The richest dietary sources of lutein and zeaxanthin are cooked dark leafy greens (kale and spinach can deliver 10–20 mg per cooked cup) and egg yolks. Egg-yolk lutein is highly bioavailable because of its fat matrix. Most U.S. adults eat only 1–2 mg per day — well below the 10 mg used in AREDS2. Reaching that target through food alone is possible but takes a daily plan that includes greens or eggs. For people with early AMD findings on an eye exam (such as drusen) or a strong family history, supplementing at the AREDS2 dose is well supported. Lutein and zeaxanthin are fat-soluble, so take them with a meal that contains some fat.
Observational data from the Nurses’ Health Study and Health Professionals Follow-up Study link higher lutein and zeaxanthin intake to lower advanced AMD risk over decades of follow-up. Lutein also accumulates in brain tissue, and small trials in older adults (Stringham & Hammond’s line of MPOD/cognition work; the Renzi LAMA-style trials) show modest improvements in processing speed and working memory with 10–12 mg/day lutein. The eye benefit is the strongest evidence; the brain story is promising but earlier-stage.
Spirulina (Arthrospira platensis) is a blue-green cyanobacterium that has been eaten for centuries and is now sold as one of the most nutrient-dense foods on the planet. By dry weight it is high in protein (roughly 60–70%), iron, B vitamins, and phycocyanin — a blue pigment with antioxidant activity. The gap between what spirulina actually delivers and what its marketing promises is large, and the safety story is rarely on the front of the bag.
Per gram, spirulina is dense. But a typical serving is 3–5 grams — about a teaspoon. At 3 grams you get roughly 2 grams of protein (less than one bite of chicken), about 2 mg of iron (around 11% of the U.S. adult RDA for men), and small amounts of B vitamins. The "superfood" claim leans on per-gram comparisons that fall apart at real serving sizes. Spirulina’s iron is meaningful for vegans who take higher daily doses (10–15 g), but for most people the practical nutrient delivery is modest. The phycocyanin content does have real antioxidant and anti-inflammatory activity in cell and animal studies.
One of the most stubborn claims about spirulina is that it’s a B12 source for vegans. It is not. Spirulina contains mostly pseudovitamin B12 — corrinoid analogs that don’t work as B12 in human cells. Watanabe and colleagues (1999, Journal of Agricultural and Food Chemistry; PMID 10552882) characterized the cobamides in commercial spirulina tablets and found that the bulk (about 83%) was inactive pseudovitamin B12. Worse, these analogs may compete with true B12 for absorption and intrinsic-factor binding, so they could blunt B12 status rather than build it. Vegans who lean on spirulina for B12 are at real risk of deficiency. True B12 (cyanocobalamin or methylcobalamin) is still required.
Spirulina is grown in alkaline ponds that can concentrate heavy metals (lead, mercury, arsenic, cadmium). Because spirulina pulls minerals out of its growth medium, contamination depends entirely on water quality and manufacturing controls. A 2013 analysis in the Saudi Journal of Biological Sciences found that several commercial spirulina products had heavy metal levels that exceeded safe daily intake at standard servings. Wild-harvested or open-pond products can also be contaminated with cyanotoxins (microcystins) from co-occurring blue-green algae — the U.S. FDA and Health Canada both flag this risk. Products from controlled, certified facilities (organic, third-party tested) carry far lower risk.
The strongest clinical signal for spirulina is in lipids. A 2018 meta-analysis (Huang et al., Clinical Nutrition; 12 RCTs) reported significant reductions in total and LDL cholesterol and triglycerides, with a small bump in HDL. There is preliminary evidence for blood pressure and blood glucose effects in type 2 diabetes, though trial quality is mixed. For immune function and athletic performance — two heavily marketed claims — the data come from small, unreplicated trials. Spirulina from a reputable manufacturer is not harmful, but it is not the superfood the bag suggests.
Alpha-lipoic acid (ALA) is a small sulfur-containing molecule. It works as a cofactor in the energy-making reactions of mitochondria and as an antioxidant that operates in both the watery and fatty parts of the cell — an unusual feature. The body makes a little on its own. Supplemental ALA at 300–600 mg/day has the most clinical evidence for diabetic peripheral neuropathy. In Germany, prescription ALA (Thioctacid) has been used as a standard neuropathy treatment for decades.
The ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) program built the clinical foundation. ALADIN I (Ziegler et al., Diabetologia, 1995) randomized 328 adults with type 2 diabetes and symptomatic neuropathy. Intravenous ALA at 600 mg/day for 3 weeks reduced neuropathic symptoms (pain, burning, tingling, numbness) versus placebo. The SYDNEY 2 trial (Ziegler et al., Diabetes Care, 2006; PMID 17065669) tested oral ALA at 600, 1,200, or 1,800 mg/day for 5 weeks in 181 patients and showed a clinically meaningful drop in symptoms at all three doses, with the best risk-to-benefit ratio at 600 mg/day. A 2012 meta-analysis (Mijnhout et al., International Journal of Endocrinology; PMID 22331979) pooled the available trials and concluded that 600 mg/day IV ALA over 3 weeks produces a significant and clinically relevant reduction in neuropathic pain (Grade A recommendation); the evidence for oral ALA over 3–5 weeks is supportive but less definitive.
Alpha-lipoic acid comes as two mirror-image forms: R-lipoic acid (the natural, biologically active form) and S-lipoic acid. Most supplements contain a 50/50 racemic mix. R-ALA is the form used in mitochondrial reactions and is roughly 40–50% more bioavailable than racemic ALA in pharmacokinetic studies. Stabilized R-ALA (often as sodium R-lipoate) is sold but costs more. Note that the trials that built the neuropathy evidence used racemic ALA at 600 mg/day. R-ALA may have theoretical advantages, but racemic ALA at trial-validated doses is well supported.
ALA boosts glucose uptake by activating AMPK and helping move GLUT4 transporters to the cell surface. Multiple trials have shown small but statistically significant drops in fasting blood glucose and HbA1c at 300–600 mg/day in type 2 diabetes. This is useful, but it also means ALA can interact with insulin and oral diabetes medications and could trigger hypoglycemia. People on metformin, sulfonylureas, or insulin should start at the low end of the dose range and check their blood sugar more often.
The evidence-based oral dose for neuropathy is 600 mg/day on an empty stomach (food cuts ALA absorption by about 30%). Doses above 600 mg/day didn’t add benefit in SYDNEY 2 and increased GI side effects (nausea, stomach upset). ALA can also recycle other antioxidants (vitamins C and E, glutathione, CoQ10) and binds certain metals, giving it a broad biochemical footprint. For people without diabetes, ALA at 300–600 mg/day is sometimes used for general antioxidant support, but the evidence is much weaker outside the neuropathy setting.
Beta-alanine is one of the few sports supplements with a clear, well-understood mechanism and strong institutional backing. The International Society of Sports Nutrition (ISSN) issued a position stand in 2015 (Trexler et al., PMID 26175657) classifying beta-alanine as safe and effective for boosting exercise capacity in high-intensity activities lasting 1–4 minutes. The mechanism is indirect but powerful: beta-alanine is the rate-limiting precursor to carnosine, a dipeptide that buffers hydrogen ions in working muscle. That buffer delays the acidosis that forces athletes to slow down during intense effort.
During hard exercise, fast ATP breakdown and glycolysis dump hydrogen ions into the muscle. The pH drops — that’s the “burn.” Carnosine (β-alanyl-L-histidine) is one of the main intracellular buffers in skeletal muscle. Supplementing with beta-alanine raises muscle carnosine by roughly 40–80% over 4–12 weeks, confirmed by muscle biopsy and MRS (magnetic resonance spectroscopy). More carnosine means more buffering capacity and longer time before acidosis-driven fatigue.
The most distinctive side effect is a tingling or prickling feeling in the skin (paresthesia), usually on the face, neck, and hands within 15–30 minutes of taking it. It happens because beta-alanine activates Mas-related G-protein coupled receptors (MrgprD) on sensory nerves under the skin. The effect is dose-related and harmless — it is not an allergic reaction and has no link to the supplement’s effectiveness. Sustained-release formulations cut the tingling, and splitting the daily dose into smaller servings (about 1.6 g per dose, per the ISSN stand) helps too. The tingling often eases over weeks of use as receptors adapt.
Beta-alanine helps most in activities dominated by anaerobic glycolysis: 400–1500 m running, competitive rowing, high-rep resistance training, combat sports, and repeated sprints. A 2012 meta-analysis in Amino Acids (Hobson et al., PMID 22270875; 15 studies, 360 participants, 23 exercise tests) found a median performance improvement of about 2.85% for exercise lasting 60–240 seconds, with smaller effects for shorter or much longer events. For purely aerobic endurance (marathon running, long-distance cycling) or maximal single-effort strength (one-rep max), beta-alanine provides little to no benefit.
The ISSN-recommended protocol is 4–6 g/day for at least 2–4 weeks, with up to 12 weeks needed to fully load muscle carnosine. Loading is essential — unlike caffeine, beta-alanine does not produce acute effects, and a single dose before training is useless. Timing relative to training does not matter; what matters is consistent daily intake. Once loaded, carnosine stays elevated for several weeks after stopping, decaying at roughly 2% per week. Beta-alanine can be combined with creatine (different mechanisms), and the pair may be helpful for high-intensity performance.
Choline was officially recognized as an essential nutrient by the U.S. Institute of Medicine in 1998. It is also one of the least discussed and most under-consumed nutrients in the American diet. Analyses of NHANES data (Wallace & Fulgoni, Nutrients, 2017) show that roughly 90% of U.S. adults fall short of the Adequate Intake (AI) of 550 mg/day for men and 425 mg/day for women. Unlike better-known shortfalls (vitamin D, iron), choline insufficiency rarely causes obvious acute symptoms — it quietly contributes to fatty liver, impaired methylation, and suboptimal brain function over time.
Choline has three core jobs. First, it is the building block for phosphatidylcholine, the main phospholipid in cell membranes and a key part of VLDL particles that move fat out of the liver. Without enough choline, fat builds up in the liver. Choline deficiency is a recognized cause of non-alcoholic fatty liver disease. Second, choline is the precursor to acetylcholine, a neurotransmitter critical for memory, attention, and muscle control. Third, choline (via betaine) feeds methyl groups into the same one-carbon metabolism cycle as folate and B12.
People who carry MTHFR variants (especially C677T — about 10–15% of many populations as homozygotes and up to 40% as heterozygotes) have impaired folate metabolism and lean more heavily on choline-derived methyl groups. Research from da Costa, Zeisel, and colleagues (American Journal of Clinical Nutrition, 2006) shows people with MTHFR variants are more vulnerable to organ dysfunction during choline depletion. For these individuals, hitting or exceeding the choline AI is not optional — it is a needed backup pathway when folate recycling is compromised.
Choline needs go up sharply in pregnancy (the AI rises to 450 mg/day, though many researchers argue the true requirement is higher). Choline supports neural tube closure, hippocampal development, and lifelong cognitive function. A 2018 randomized feeding trial (Caudill et al., FASEB Journal; PMID 29217669; 26 women in their third trimester randomized to 480 vs 930 mg choline/day) showed that infants whose mothers took the higher dose had significantly faster information-processing speed at 4, 7, 10, and 13 months of age. Despite this, most prenatal vitamins contain zero choline or trivial amounts (10–55 mg), and choline is rarely discussed in routine prenatal care.
Dietary choline comes mainly from eggs (~147 mg per large egg), liver (~356 mg per 3 oz), and soybeans. For supplementation, the two best-studied forms are CDP-choline (citicoline) and alpha-GPC. CDP-choline supplies choline plus cytidine (which converts to uridine, a nucleotide used in synaptic membrane synthesis); it has trial evidence for cognitive support at 500–2,000 mg/day. Alpha-GPC is about 40% choline by weight (the highest of the supplemental forms) and crosses the blood-brain barrier readily; it has evidence for cognitive support in older adults and is used clinically in Europe for cognitive decline. Both are well absorbed and well tolerated. For simple choline repletion, alpha-GPC at 300–600 mg/day is cost-effective; for nootropic goals, CDP-choline at 250–500 mg/day adds the cytidine benefit.
Tart cherry (Prunus cerasus), and the Montmorency variety in particular, has become one of the more credible natural recovery aids in sports nutrition. Unlike many "natural anti-inflammatory" supplements that lean on cell-culture data, Montmorency tart cherry concentrate has been tested in well-designed human exercise-recovery trials — in marathon runners, strength athletes, and resistance-training protocols — with consistent positive results for muscle soreness, inflammation markers, and oxidative stress.
Howatson and colleagues (2010, Scandinavian Journal of Medicine & Science in Sports; PMID 19883392) gave 20 recreational marathon runners Montmorency tart cherry juice or placebo for 5 days before, the day of, and for 48 hours after a marathon. The cherry group recovered isometric muscle strength faster, had significantly lower inflammation (IL-6, CRP, uric acid), and showed less oxidative stress (lower TBARS at 48 h, higher total antioxidant status). Bowtell et al. (2011, Medicine & Science in Sports & Exercise; PMID 21233776) tested Montmorency cherry concentrate in 10 well-trained men doing intensive single-leg knee-extension exercise (10 sets of 10 reps at 80% 1RM). Maximal voluntary contraction recovered faster at 24 and 48 h with cherry, and oxidative damage (protein carbonyls) was lower.
Tart cherries are rich in anthocyanins (cyanidin and peonidin glycosides) and other polyphenols that inhibit cyclooxygenase-1 and -2 (COX-1, COX-2) — the same enzymes targeted by ibuprofen and aspirin, though much less potently. Cell-based work by Seeram and colleagues at Oregon Health & Science University placed cherry anthocyanin anti-inflammatory activity in the same general range as a standard ibuprofen dose. The advantage over NSAIDs for athletes is that cherry anthocyanins do not appear to blunt the adaptive response to training the way chronic NSAID use can.
An unexpected line of research is sleep. Montmorency cherries are one of the few natural food sources of melatonin (roughly 13 ng/g). Howatson et al. (2012, European Journal of Nutrition; PMID 22038497) gave 20 healthy adults 30 mL of tart cherry juice concentrate twice daily for 7 days; total urinary melatonin rose significantly, and total sleep time and sleep efficiency improved versus placebo. A separate pilot in older adults with insomnia (Pigeon et al., 2010, Journal of Medicinal Food; PMID 20438325; n = 15, crossover) showed a significant reduction in wakefulness after sleep onset versus placebo, although other sleep measures (latency, total sleep time, efficiency) did not separate significantly. The sleep effect is real but modest compared with exogenous melatonin.
The effective dose in the trials is about 30 mL of Montmorency concentrate twice daily, or 8–12 oz of juice twice daily, starting 4–5 days before the bout and continuing 2–3 days after. Capsulated powdered tart cherry extract (480–1,000 mg/day) has also shown effects, but with fewer trials. Pre-loading matters: a single post-exercise dose does not reproduce the multi-day protocol. Tart cherry combines well with sleep, protein, and other recovery basics, and does not interact with common medications at typical doses.
The pediatric supplement aisle has exploded with gummy vitamins, probiotic pouches, and "brain-boosting" omega-3 products. The American Academy of Pediatrics (AAP) is clear: most children eating a reasonably varied diet do not need a multivitamin. But specific nutrient gaps are common in specific groups, and a small set of supplements has real evidence in kids. The challenge is sorting the few that matter from the many sold on parental anxiety.
Vitamin D is the one supplement with near-universal pediatric endorsement. The AAP recommends 400 IU/day for all infants from birth (breast milk supplies very little — roughly 25–78 IU per liter) and 600 IU/day for children over age 1 (Wagner & Greer, AAP Clinical Report, Pediatrics, 2008; reaffirmed). NHANES data show roughly 15% of U.S. children are vitamin D deficient (<20 ng/mL) and another 30–40% are insufficient (20–29 ng/mL), with higher rates in children with darker skin, in northern latitudes, and with limited outdoor time. Deficiency is linked to impaired bone mineralization and more frequent respiratory infections. Vitamin D3 (cholecalciferol) drops for infants and chewable tablets for older children are inexpensive and well tolerated.
DHA (docosahexaenoic acid) is a structural part of developing brain tissue. It accumulates rapidly during the first two years of life and continues through adolescence. Children who eat fatty fish 2+ times per week generally have adequate omega-3 status, but most U.S. children fall well short. The DOLAB trial (Richardson et al., PLOS ONE, 2012; PMID 22970149) randomized 362 healthy 7–9-year-olds underperforming in reading to 600 mg/day DHA from algal oil or placebo for 16 weeks. The full-sample reading effect was not significant, but the pre-planned subgroup of 224 children whose initial reading scored at or below the 20th centile showed a meaningful improvement, and parent-rated ADHD-type behaviors improved across the active group. A 10-trial meta-analysis (Bloch & Qawasmi, Journal of the American Academy of Child & Adolescent Psychiatry, 2011; PMID 21961774; 699 children) found a small but significant effect of omega-3 supplementation on ADHD symptoms, with EPA dose correlating to efficacy. Practical dose: 250–600 mg DHA/day for children over age 2.
Iron deficiency is the most common nutritional deficiency in children worldwide. Symptoms include fatigue, poor concentration, impaired cognitive development, and more frequent infections. The AAP (Baker & Greer, AAP Clinical Report, Pediatrics, 2010; PMID 20923825) recommends universal screening for iron deficiency at 12 months. Supplementation is warranted in children with confirmed deficiency or those with very restricted diets that lack iron-rich foods (red meat, fortified cereals, legumes). The recommended pediatric form is ferrous sulfate liquid, dosed by weight — roughly 3–6 mg elemental iron/kg/day for treatment, 1–2 mg/kg/day for prevention. Iron should not be given to children without documented deficiency: iron overload carries its own risks.
Several supplement categories sold to kids lack evidence or carry real risk. Melatonin use in children has skyrocketed; the AAP recommends it only as a short-term tool under physician guidance, and the long-term effects on developing hormonal systems are unknown. Herbal "immune boosters" (elderberry, echinacea) for children have minimal evidence and few pediatric dosing studies. Gummy multivitamins often add 2–4 grams of sugar per serving. Independent commercial testing services (e.g., ConsumerLab) have reported many children's gummy products that do not meet label claims for active vitamin content.
A basic children's multivitamin is reasonable for kids with truly restrictive diets (severe picky eating, vegan diets, multiple food allergies), chronic GI conditions affecting absorption, or documented failure to thrive. Choose a product that provides about 100% of the Daily Value (not megadoses) for vitamin D, iron, zinc, and iodine — the four nutrients most often inadequate in restricted pediatric diets. Avoid products with excessive vitamin A (retinol), which can reach toxic levels in kids more quickly than in adults. For most children eating a varied diet, targeted supplementation (vitamin D ± omega-3) is more appropriate than a broad multivitamin.
Quercetin is a flavonoid found in onions, apples, berries, and capers. It has been studied for decades as an antioxidant. Its more recent twist is in a different field: senolytic therapy, which selectively clears senescent (worn-out, dysfunctional) cells that accumulate with age and drive chronic inflammation. This dual identity — a familiar plant compound that also has senolytic activity in combination — has made quercetin one of the most studied flavonoids in both nutrition and aging research.
Quercetin’s effects on the immune system are modulatory rather than “boosting.” In cell and animal studies it inhibits NF-κB signaling, lowers production of pro-inflammatory cytokines (IL-6, TNF-α), and stabilizes mast cells (cutting histamine release). A 2010 community RCT (Heinz et al., Pharmacological Research; PMID 20478383) randomized 1,002 adults aged 18–85 to placebo, 500 mg/day, or 1,000 mg/day quercetin for 12 weeks and tracked upper respiratory tract infections (URTIs). The whole-cohort URTI rate was not significantly reduced. A pre-specified subgroup of subjects aged 40+ who self-rated as physically fit (n = 325) on 1,000 mg/day showed a 36% drop in URTI severity and a 31% drop in total sick days vs placebo. So the picture is "modulator with conditions," not "cold preventer."
The breakthrough that pulled quercetin from flavonoid curiosity to aging-research focus came from Zhu et al. (Aging Cell, 2015; PMID 25754370). Their group at the Mayo Clinic showed that the combination of dasatinib (a leukemia drug) plus quercetin (D+Q) selectively kills senescent cells in vitro and in vivo. Senescent cells stop dividing but resist apoptosis, secreting a stew of inflammatory proteins (the senescence-associated secretory phenotype, or SASP) that drives age-related disease. In mouse models, intermittent D+Q improved physical function and extended healthspan. The first human pilot followed in 2019 (Justice et al., EBioMedicine; PMID 30616998): 14 patients with idiopathic pulmonary fibrosis received intermittent D+Q (dasatinib 100 mg/day, quercetin 1,250 mg/day, 3 days per week for 3 weeks) and showed clinically meaningful improvements in 6-minute walk distance, gait speed, and chair-stand time. The work is early but real.
During the COVID-19 pandemic, quercetin drew attention as a possible zinc ionophore — a molecule that helps move zinc into cells, which would in theory raise intracellular zinc and inhibit viral RNA-dependent RNA polymerase. Cell-culture work (e.g., Dabbagh-Bazarbachi et al., 2014) showed quercetin can act as a zinc ionophore in vitro. Translation to humans is a big leap: the larger clinical trials of quercetin ± zinc for COVID-19 prevention or treatment have been mixed and largely null. The mechanism is interesting; the clinical benefit is unproven.
Quercetin’s main limitation is poor oral bioavailability — only about 2–5% of an oral dose reaches the systemic circulation in active form due to fast metabolism, glucuronidation, and limited solubility. That is why effective trial doses are typically 500–1,000 mg/day, and why enhanced-absorption formulations (quercetin phytosome, quercetin with bromelain or vitamin C) exist. For the senolytic protocol, researchers use intermittent dosing (e.g., 3 consecutive days per month) rather than daily, on the principle that senolysis needs brief high exposure rather than sustained low levels. For everyday immune or antioxidant use, 500–1,000 mg/day with food — ideally an enhanced-absorption form — is the standard.
HMB (β-hydroxy-β-methylbutyrate) is a metabolite of the branched-chain amino acid leucine. The body makes only about 0.2–0.4 grams per day from normal protein intake. Where leucine is the main amino-acid signal that turns on muscle protein synthesis, HMB appears to work on the other side of the equation: it slows muscle protein breakdown via inhibition of the ubiquitin–proteasome pathway. That anti-catabolic role is what makes HMB especially relevant for older adults, who experience faster breakdown and a blunted anabolic response to protein — the hallmarks of sarcopenia.
The largest published meta-analysis to date (Bear et al., American Journal of Clinical Nutrition, 2019; PMID 30982854) pooled 15 RCTs and 2,137 participants across mixed clinical conditions. HMB or HMB-containing supplements produced small but real improvements in skeletal muscle mass (SMD 0.25; 95% CI −0.00 to 0.50) and a clearer effect on muscle strength (SMD 0.31; 95% CI 0.12–0.50). For older adults specifically, Lin et al. (European Geriatric Medicine, 2020; PMID 33034021) pooled 9 RCTs and 448 participants and reported a significant positive effect on fat-free mass (SMD 0.37; 95% CI 0.16–0.58), with the strongest effect when HMB was given as the sole intervention (rather than added to a structured exercise program). Effects are most consistent in frail or bed-rested older adults — the situations where muscle loss is most aggressive.
A common question is why not simply take leucine, since the body converts leucine to HMB. The answer is efficiency and mechanism. Only about 5% of ingested leucine is converted to HMB — you would need roughly 60 grams of leucine daily to generate 3 grams of HMB, an impractical amount that would far exceed protein needs. More importantly, leucine’s primary effect is stimulating mTOR-driven muscle protein synthesis (the anabolic signal), while HMB’s primary effect is slowing muscle protein breakdown (the anti-catabolic signal). These are different pathways. In older adults with “anabolic resistance” (a blunted mTOR response to protein), the anti-catabolic action of HMB may be more achievable than trying to overcome the blunted anabolic response with ever-higher leucine doses.
The benefit is population-specific. In young, well-fed athletes, HMB shows little or no effect — their muscle protein turnover is already well-regulated. The clearer benefit is in adults over 60, especially those who are sedentary, recovering from surgery or hospitalization, frail, or eating below the recommended protein target. Deutz et al. (Clinical Nutrition, 2013; PMID 23514626) randomized older adults (mean age in the 60s; 19 evaluable in the per-protocol analysis) to HMB 3 g/day or placebo around 10 days of complete bed rest. The placebo group lost about 2 kg of lean body mass; the HMB group preserved lean mass, with no significant change. For older adults starting a resistance training program, HMB combined with exercise typically produces greater gains in lean mass and strength than exercise alone.
The established effective dose is 3 g/day of calcium HMB (the most studied form), divided into three 1-gram doses with meals. HMB-free acid (HMB-FA) is a newer form with faster pharmacokinetics — peak blood levels at about 30 minutes vs. 2 hours for calcium HMB — and is sometimes given as a single 3 g daily dose. HMB is not a substitute for adequate protein (1.0–1.2 g/kg/day minimum for older adults, per ESPEN guidance). Loading is not required, but consistent daily use for at least 4–6 weeks is needed to see measurable effects on lean mass. HMB has an excellent safety profile; no significant adverse effects have been reported in published trials.
In Germany, St. John’s Wort (Hypericum perforatum) is widely prescribed for mild-to-moderate depression. That is not folk practice — it is guideline-driven medicine built on more than 35 randomized trials and large Cochrane reviews. The most recent Cochrane meta-analysis (Linde et al., Cochrane Database of Systematic Reviews, 2008; PMID 18843608; 29 trials, 5,489 patients) concluded that standardized Hypericum extracts are superior to placebo and as effective as standard antidepressants for major depression, with fewer adverse events than older tricyclics or SSRIs. A more recent meta-analysis comparing St. John’s Wort with SSRIs specifically (Ng et al., Journal of Affective Disorders, 2017; PMID 28064110; 27 trials, 3,808 patients) reported comparable response and remission rates and significantly fewer dropouts due to adverse events.
The therapeutic effect is attributed to hyperforin and, to a smaller degree, hypericin. Hyperforin inhibits reuptake of serotonin, norepinephrine, dopamine, GABA, and glutamate at roughly comparable potency — an unusually broad neurochemical profile. Clinically studied extracts are standardized to either 3–6% hyperforin (such as WS 5570 and LI 160) or 0.3% hypericin, with the hyperforin-standardized extracts having the stronger evidence base for depression. Extracts without standardization or with hyperforin below 3% have produced the null results that surface in some U.S.-based trials.
Effective clinical doses are 600–1,800 mg/day of standardized extract, most commonly 300 mg three times daily. Onset is 2–4 weeks, similar to SSRIs. For severe depression, St. John’s Wort is not a substitute. The Hypericum Depression Trial Study Group (JAMA, 2002; PMID 11926934) randomized 340 outpatients with major depression of at least moderate severity to St. John’s Wort, sertraline, or placebo for 8 weeks; neither active arm separated from placebo on the primary outcomes. The lesson is that severity of presentation strongly moderates response — both for SSRIs and for the herb.
Hyperforin is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, which together metabolize and transport roughly 50% of prescription drugs. Borrelli & Izzo (AAPS Journal, 2009; PMID 19859815) catalog the clinically significant interactions: oral contraceptive failure (breakthrough bleeding and unintended pregnancies have been reported), reduced cyclosporine and tacrolimus levels (with documented transplant rejections), reduced antiretroviral exposure (indinavir, nevirapine), reduced anticancer exposure (irinotecan, imatinib), reduced warfarin effect (raising thrombosis risk), and serotonin syndrome when combined with SSRIs or SNRIs. The herb should never be combined with MAOIs and requires a 2-week washout before starting any new antidepressant. Photosensitivity is the most common direct side effect at high doses. The U.S. FDA, the European Medicines Agency, and Health Canada all advise patients to disclose St. John’s Wort use to any clinician prescribing other medication.
St. John’s Wort is best positioned as a first-line option for mild-to-moderate depression in patients who (a) are not on interacting medications, (b) have not responded to or tolerated SSRIs, or (c) prefer a botanical with a robust evidence base. It is not appropriate for bipolar depression (can trigger mania), severe or psychotic depression, or pregnancy. Use a hyperforin-standardized extract from a reputable manufacturer; the unstandardized products on U.S. shelves are often the source of negative trial results.
Niacinamide (nicotinamide), the amide form of vitamin B3, has been studied for osteoarthritis since the 1950s, when William Kaufman documented functional joint improvements in hundreds of patients taking 900–4,000 mg/day. Kaufman's observational work was dismissed for decades, but a small controlled trial by Jonas and colleagues (1996, PMID 8841834) randomized 72 patients with osteoarthritis to 3,000 mg/day niacinamide or placebo for 12 weeks. Global arthritis impact improved by 29% (95% CI 6–46; p=0.04) on niacinamide while worsening by about 10% on placebo, anti-inflammatory drug use dropped 13%, and joint mobility improved by 4.5° over controls. The effect size is comparable to or exceeds what glucosamine has shown in head-to-head indirect comparisons, though Jonas was a single small pilot trial and has not been replicated at scale.
Unlike NSAIDs (COX inhibition) or glucosamine (cartilage substrate provision), niacinamide appears to act as a precursor to NAD+, supporting chondrocyte mitochondrial function and suppressing inflammatory cytokines (IL-1, TNF-α). High-dose niacinamide has also been shown to inhibit osteoarthritis-associated nitric oxide synthase activity in cartilage explants. This places it mechanistically closer to emerging NAD+ boosters (NR, NMN) than to classical joint supplements.
Critical point: this is niacinamide, not niacin. Niacin (nicotinic acid) causes the flushing reaction and carries liver toxicity at high doses; niacinamide does not flush and has a much better safety profile, though doses above 3,000 mg/day should be monitored for liver enzymes. The Jonas protocol uses 500 mg six times daily — divided dosing matters because plasma half-life is short (about 4 hours).
Niacinamide has not become mainstream for osteoarthritis because that single 72-patient RCT has not been replicated at scale — a pattern common to generic, unpatentable molecules. But the mechanistic rationale is strong, the cost is trivial (about $5/month), and the safety margin at 3,000 mg/day is wide as long as liver enzymes are checked periodically. For patients who have failed glucosamine/chondroitin or wish to complement them, niacinamide is a reasonable evidence-informed addition with a distinct mechanism.
L-Carnitine is a quaternary ammonium compound synthesized from lysine and methionine that shuttles long-chain fatty acids into mitochondria for beta-oxidation. Without it, cells cannot efficiently burn fat for energy. The tissues with the highest energy demand — heart, skeletal muscle, and sperm — are most dependent on adequate carnitine status, which is exactly where the supplementation evidence is strongest.
A 2013 systematic review and meta-analysis in Mayo Clinic Proceedings (DiNicolantonio et al., PMID 23597877) pooled 13 controlled trials with 3,629 patients in the setting of acute myocardial infarction. L-carnitine (typically 2–6 g/day) was associated with a 27% reduction in all-cause mortality (RR 0.78, 95% CI 0.60–1.00), a 65% reduction in ventricular arrhythmias (RR 0.35, 95% CI 0.21–0.58), and a 40% reduction in new anginal symptoms (RR 0.60, 95% CI 0.50–0.72). The same meta-analysis found no benefit for incident heart failure or reinfarction, so the signal is concentrated on early electrical and mortality outcomes rather than every cardiac endpoint. Mechanism likely involves restoring fatty acid oxidation in ischemic myocardium, where carnitine levels drop sharply. Despite these findings, carnitine has not entered routine post-MI care — a gap that remains difficult to explain given the safety and cost profile.
Cochrane reviews of antioxidants for male subfertility consistently identify carnitine (often combined with acetyl-L-carnitine) as one of the strongest-performing interventions, with significant improvements in sperm motility, concentration, and morphology at doses of 2–3 g/day over 3–6 months. Live birth rate data are weaker due to trial design, but pregnancy rates improve in partners of treated men. Epididymal fluid normally contains carnitine at 2,000× serum concentrations — a clue to its functional importance in sperm maturation.
Gut bacteria metabolize dietary carnitine to trimethylamine, which the liver oxidizes to TMAO — a metabolite linked observationally to atherosclerosis. This generated headlines suggesting carnitine is cardiotoxic, but controlled trial data continue to show cardioprotective outcomes, suggesting the TMAO hypothesis is not the dominant effect in supplementation contexts. Patients with existing kidney disease should still use carnitine cautiously.
L-carnitine tartrate is the most bioavailable oral form for muscle and cardiac outcomes. Acetyl-L-carnitine (ALCAR) crosses the blood-brain barrier and has separate evidence for diabetic neuropathy and age-related cognitive decline. Propionyl-L-carnitine has specific evidence in peripheral arterial disease. The three forms are not interchangeable.
Alpha-ketoglutarate (AKG) is a central TCA cycle intermediate that participates in energy production, amino acid metabolism, collagen synthesis, and epigenetic regulation as a cofactor for DNA and histone demethylases. Human plasma AKG declines roughly 10-fold between age 40 and age 80 — one of the more dramatic age-associated biochemical changes reported. Restoring youthful levels became a testable longevity hypothesis around 2020.
A 2020 study in Cell Metabolism (Asadi Shahmirzadi et al., PMID 32877690) showed that Calcium AKG (CaAKG) supplementation starting at middle age in C57BL/6 mice extended median lifespan in females (the published survival curves correspond to roughly a 10–12% extension) and, more importantly, compressed morbidity: a frailty index fell across multiple aging parameters even when raw lifespan gains were modest. The authors proposed that CaAKG suppresses chronic inflammation in part by inducing IL-10, lowering systemic TNF-α and IL-6.
A 2021 retrospective open-label analysis in Aging (Demidenko et al., PMID 34847066) examined 42 adults taking Rejuvant® (a formulation of CaAKG plus retinyl palmitate and vitamin D3) for an average of 7 months. Participants showed an average decrease in biological age of 8 years on the TruAge DNA methylation test (p ≈ 6.5×10−12). Caveats are large: no placebo arm, retrospective selection, and epigenetic age is a biomarker rather than a hard outcome. But the signal generated enough interest to motivate placebo-controlled replication, which is now in progress.
Common human doses are 1,000–3,000 mg/day of Ca-AKG, typically taken with food. The calcium content is modest but should be counted toward total intake. AKG is not patentable; most products are identical commodity Ca-AKG, and price variation reflects marketing rather than chemistry. AKG is well-tolerated in published trials, but anyone with hypercalcemia or on calcium-restricted diets should discuss use with a clinician.
Ca-AKG is one of the more promising longevity interventions with a plausible mechanism and encouraging early human data, but controlled trials with hard endpoints are still in progress. Treat it as an evidence-accumulating supplement, not a proven longevity therapy. Its best use case is in adults over 50 targeting metabolic and inflammatory markers of aging, alongside exercise, sleep, and protein intake — which still outperform any supplement.
Soy isoflavones — mainly genistein and daidzein — are plant compounds (phytoestrogens) that bind more strongly to one of the two estrogen receptors (ERβ) than the other. Population studies have long noted that East Asian women report dramatically fewer menopausal hot flashes than Western women, and average soy intake differs by roughly 10-fold. The obvious hypothesis — that taking soy isoflavones would close that gap — has been tested in dozens of trials with mixed results. Understanding why the results are mixed is the key to using soy effectively.
Specific gut bacteria convert daidzein into equol, a more bioactive metabolite with higher affinity for ERβ. Only about 25–30% of Western adults harbor the bacteria that produce equol, compared with 50–60% of East Asian adults. The Taku 2012 meta-analysis (Menopause; PMID 22433977) and subsequent equol-producer subgroup analyses found that the hot flash reduction from soy isoflavones is consistently larger in equol producers — often roughly two-fold larger — helping to explain the geographic gap in trial outcomes and why a one-size-fits-all dose often disappoints.
Beyond vasomotor symptoms, soy isoflavones at 40–80 mg/day over 6–12 months produce modest but consistent improvements in arterial stiffness, LDL cholesterol (about 5–8% lower), and lumbar-spine bone mineral density in postmenopausal women. The bone effect is smaller than bisphosphonates but clinically meaningful for mild osteopenia. Cognitive benefits remain inconsistent.
The idea that soy promotes breast cancer comes from rodent studies using isolated genistein at far-higher-than-dietary doses. In human epidemiology, the relationship is inverted: women with the highest soy intake have lower breast cancer incidence and, importantly, lower recurrence after diagnosis (Messina 2016 Nutrients; PMID 27886135). The American Cancer Society now affirms that moderate dietary soy is safe for breast cancer survivors. Isolated high-dose isoflavone supplements (>100 mg/day) have weaker long-term safety evidence than food-based soy.
Soy isoflavones are a reasonable non-hormonal option for women with mild-to-moderate hot flashes who prefer not to use or cannot tolerate HRT. Equol testing is available and can predict responder status, though many clinicians simply run an empirical 3-month trial at 50–80 mg/day of a standardized extract. Effects develop gradually over 6–12 weeks — not overnight.
Inositol is a sugar alcohol with nine stereoisomers. Two of them — myo-inositol (MI) and D-chiro-inositol (DCI) — serve as second messengers for insulin signaling. Women with polycystic ovary syndrome (PCOS) have disrupted tissue ratios of MI to DCI, with ovarian DCI deficiency contributing to hyperandrogenism and ovulatory dysfunction. Correcting this ratio is one of the better-supported nutritional interventions in reproductive endocrinology.
Healthy plasma MI:DCI is roughly 40:1. In PCOS, the ratio is distorted due to elevated epimerase activity in ovarian tissue. The Nordio & Proietti 2012 RCT (European Review for Medical and Pharmacological Sciences; PMID 22774396) randomized 50 overweight women with PCOS to MI alone vs MI + DCI for 6 months and showed that the MI + DCI combination outperformed MI alone on metabolic and ovarian outcomes. Subsequent ratio-finding work by the same group and the 2015 Italian consensus recommended a 40:1 MI:DCI ratio (typically 2,000 mg MI + 50 mg DCI twice daily) as the most physiological. Products delivering DCI alone, or only MI, tended to over- or under-correct the imbalance.
The 2017 Unfer meta-analysis in Endocrine Connections (PMID 29042448) pooled 9 RCTs (247 cases, 249 controls) and found significant decreases in fasting insulin and HOMA-IR with MI alone or with DCI, plus a non-significant trend toward lower testosterone. Subsequent meta-analyses (e.g., Pundir et al., BJOG 2018; PMID 28759180) reported improvements in ovulation rate and clinical pregnancy with inositols compared with placebo or metformin in PCOS, with lower side-effect burden than metformin. Metabolic improvements typically appear by 3 months; fertility improvements often need 3–6 months of consistent use.
Myo-inositol at 4 g/day has shown benefit for gestational diabetes prevention in high-risk women, and at 12–18 g/day has shown efficacy comparable to SSRIs for panic disorder in small controlled trials. These higher doses are safe but cause osmotic GI symptoms (loose stools, bloating) in some users.
Inositol is one of the better-tolerated supplements in the reproductive space, with GI upset being the main side effect at high doses. It can be combined with metformin safely and often works at least as well as metformin alone for ovulatory restoration with fewer side effects. Women planning conception should pair it with adequate folate intake.
Chondroitin sulfate is a sulfated glycosaminoglycan that, alongside collagen and aggrecan, forms the structural scaffold of articular cartilage. Oral chondroitin has been controversial in the US but remains a first-line osteoarthritis treatment in European guidelines (ESCEO, EULAR) — a gap that is driven largely by product quality and study design, not by irreconcilable evidence.
Unlike NSAIDs, chondroitin has shown disease-modifying effects in several MRI and radiographic trials. The 2017 CONCEPT trial (Reginster et al., PMID 28939627) randomized 604 patients with symptomatic knee OA to pharmaceutical-grade chondroitin sulfate 800 mg/day, celecoxib 200 mg/day, or placebo over 6 months. Both active treatments outperformed placebo on pain and function, with chondroitin showing similar efficacy to celecoxib. Longer trials (about 2 years) have shown slowing of joint-space narrowing — a structural endpoint — with chondroitin that is not seen with NSAIDs.
Much of the negative chondroitin literature, including parts of the GAIT trial, used low-purity or low-molecular-weight product that is functionally different from pharmaceutical-grade chondroitin sulfate. The US supplement market carries wide quality variation — some products contain 50% or less of labeled content. Europe registers a prescription-grade form (chondroitin sulfate sodium, 800 mg daily) that consistently outperforms supplement-grade material in head-to-head trials.
The MOVES trial (Hochberg et al., 2016; PMID 25589511) randomized 606 patients with Kellgren-Lawrence grade 2–3 knee OA and moderate-to-severe pain to glucosamine hydrochloride 1,500 mg/day + chondroitin sulfate 1,200 mg/day or celecoxib 200 mg/day for 6 months. WOMAC pain reductions were essentially identical (about 50% in both arms; non-inferiority confirmed). The combination is more commonly used than either alone, though the incremental benefit of combining versus single-agent is modest.
Chondroitin is well-tolerated, with rare GI upset. Onset is slow — most trials show meaningful improvement by 2–3 months, with maximal benefit at 6 months. It is not appropriate for acute flares. Patients with end-stage OA (bone-on-bone) are unlikely to respond meaningfully; the intervention is most useful in mild-to-moderate OA where cartilage remains.
Glucosamine exists in two main supplement forms: glucosamine sulfate (GS) and glucosamine hydrochloride (GH). The form distinction has generated strong opinions, mainly because European guidelines favor glucosamine sulfate while most US retail bottles contain glucosamine hydrochloride. The underlying chemistry and clinical data suggest the form difference is real but often misunderstood.
Both salts dissociate in the stomach and release free glucosamine into circulation. The practical difference is the elemental glucosamine per gram: glucosamine sulfate is usually stabilized with potassium chloride or sodium chloride, so a 1,500 mg dose of "glucosamine sulfate" actually delivers about 1,178 mg of free glucosamine. Glucosamine hydrochloride is more concentrated: 1,500 mg of the HCl salt delivers about 1,250 mg of free glucosamine. If you match doses on elemental glucosamine, bioavailability is equivalent.
Two long-term European trials — Reginster 2001 (Lancet; PMID 11214126; n=212, 3 years, 1,500 mg/day) and Pavelka 2002 (Archives of Internal Medicine; PMID 12374520; n=202, 3 years) — showed that glucosamine sulfate reduced joint-space narrowing in knee OA. Similar trials with glucosamine hydrochloride — notably portions of the US GAIT study (Clegg 2006; PMID 16495392) — were negative on the primary outcome. The difference is most likely not the sulfate ion itself, but the prescription-grade European formulation (the Rotta crystalline glucosamine sulfate) used in the sulfate studies, versus mixed-quality supplement-grade HCl used elsewhere.
Some researchers argue that the sulfate ion itself provides substrate for proteoglycan synthesis, but human pharmacokinetic studies show that oral sulfate contributes only minimally to joint-tissue sulfate pools. Dietary sulfur amino acids (methionine, cysteine) dwarf any contribution from glucosamine sulfate. The clinical edge of sulfate products is better explained by formulation quality and consistent dosing than by a unique sulfate mechanism.
If you can access a stabilized, pharmaceutical-grade crystalline glucosamine sulfate (common in Europe), that has the strongest trial record. In the US, a reputable glucosamine HCl product delivering about 1,500 mg of elemental glucosamine is a reasonable alternative. Avoid multi-ingredient "joint complex" products with sub-therapeutic glucosamine doses — they deliver less than half the studied amount and produce correspondingly smaller effects.
Melatonin is one of the most over-dosed supplements in America. A 2023 analysis in JAMA (Cohen et al.; PMID 37097362) tested 25 melatonin gummy products from US retailers and found that 22 of 25 (88%) contained quantities of melatonin that did not match the label, with measured melatonin ranging from 74% to 347% of the declared dose. At the same time, the typical retail dose (3–10 mg) is 10–100× higher than what the pineal gland naturally produces at night. MIT sleep researcher Richard Wurtman's dose-response work in the 1990s and Zhdanova's follow-up trials showed that low, physiologic doses (about 0.1–0.3 mg) reliably restore endogenous melatonin levels and improve sleep onset, while much higher doses can desensitize receptors and produce a worse next-day profile.
In Wurtman's controlled trials at MIT, 0.3 mg produced peak plasma melatonin within physiologic range and improved sleep latency. At 3 mg, plasma melatonin exceeded normal nighttime levels by 10× and remained elevated well into morning — blunting next-night endogenous production and producing a morning hangover effect. Higher doses did not produce better sleep; they produced persistent receptor saturation and worse circadian alignment.
There are specific contexts where 1–5 mg is appropriate: jet lag travel, shift work sleep disorder, and certain pediatric neurodevelopmental conditions under clinical supervision. For routine sleep onset issues in healthy adults, 0.3 mg is a better starting dose with a cleaner next-morning profile.
Melatonin is a circadian signal, not a sedative. Its effect on sleep onset is modest (about 7–10 minutes in healthy adults); its effect on circadian phase-shifting is substantial. For sleep onset, timing is 30–60 minutes before bedtime. For advancing a delayed sleep phase (night owls), taking 0.5 mg 4–6 hours before desired bedtime shifts the circadian clock earlier with each successive night.
Immediate-release melatonin addresses sleep onset. Patients whose primary complaint is sleep maintenance (waking at 3am and unable to return to sleep) often do better with a low-dose extended-release formulation, as blood melatonin falls rapidly with immediate-release products. Prolonged-release melatonin 2 mg is approved as a prescription product for insomnia in adults over 55 in Europe (Circadin), where endogenous melatonin declines with age.
Melatonin is remarkably safe acutely, but chronic high-dose use in children has been associated with delayed puberty signals in animal models and remains incompletely studied long-term. For adult sleep onset, start with 0.3 mg 30 minutes before desired sleep. Increase only if no effect after two weeks. Most users never need more.
Most probiotic trials use generic multi-strain products and produce correspondingly generic outcomes. A handful of specific strains, however, have well-characterized clinical effects tied to documented mechanisms. Lactobacillus gasseri — particularly strains SBT2055 and BNR17 — is one of the better-documented examples, with controlled trials in adiposity reduction and gynecological health.
The headline study is Kadooka 2010 (European Journal of Clinical Nutrition; PMID 20216555). Eighty-seven adults with obese tendencies (BMI 24.2–30.7) were randomized to a fermented milk containing L. gasseri SBT2055 (about 2×1010 CFU/day, from FM at 108 CFU/g × 200 g/day) or matched placebo fermented milk for 12 weeks. The active group showed a 4.6% reduction in abdominal visceral fat area, plus significant reductions in body weight (1.4%), BMI (1.5%), waist (1.8%), and hip (1.5%). A 2013 follow-up RCT in the British Journal of Nutrition (Kadooka et al.; PMID 23614897) tested lower CFU doses (106 and 107 CFU/g) in 210 healthy Japanese adults with large visceral fat areas and reported similar — in fact slightly larger — visceral fat reductions (about 8% in both lower-dose groups), confirming dose responsiveness rather than ceiling. In both trials, effects attenuated after stopping the product, suggesting ongoing microbiota modulation rather than permanent change.
L. gasseri produces conjugated linoleic acid (CLA) and expresses bile salt hydrolase, which together alter lipid absorption and fecal fat excretion. It also reduces intestinal inflammation markers (serum LPS, TNF-α) that contribute to metabolic dysfunction in obesity. The effect size is modest — comparable to a well-executed diet intervention sustained for 8 weeks — but the safety and cost profile are favorable.
L. gasseri is one of the dominant species in healthy vaginal microbiota, and strain-specific oral or vaginal formulations (often combined with L. rhamnosus) have shown benefit in recurrent bacterial vaginosis (BV) and urinary tract infections. Systematic reviews of probiotics for urogenital infections in women have reported about a 50% reduction in BV recurrence at 3–6 months when L. gasseri- or L. rhamnosus-containing products are used adjunctively or after standard antibiotic therapy.
Not all L. gasseri strains reproduce the weight or urogenital effects seen in these trials. The studied strains include SBT2055 (weight), BNR17 (visceral fat / insulin sensitivity), and LA-14 / LN-101 (urogenital). Buying a generic "L. gasseri probiotic" without strain identification may miss the effect entirely. Reputable products name the specific strain on the label.
Desiccated beef liver capsules have exploded in popularity in fitness and "ancestral" communities, marketed as a concentrated source of bioavailable vitamin A, B12, iron, choline, and copper. The marketing is not wrong about nutrient density — on a per-calorie basis, liver is one of the most nutrient-dense foods. The real questions are whether the capsule delivery vehicle and realistic dosing preserve those advantages, and whether the supposed benefits go beyond what a standard multivitamin provides.
A typical 6-capsule serving of freeze-dried beef liver (about 3 g of powder, roughly equivalent to 15 g of fresh liver) provides approximately: vitamin A 3,000–5,000 IU as preformed retinol, vitamin B12 15–20 µg, riboflavin 0.5 mg, iron 1–2 mg (heme iron), copper 1–2 mg, and choline 100–150 mg. That is a meaningful contribution for B12 and copper, but the iron dose is too small to correct deficiency, and the choline is roughly one-fifth of the adult adequate intake.
Unlike multivitamins that often use beta-carotene, liver provides preformed retinol — directly usable by the body without requiring conversion. Beta-carotene-to-retinol conversion is variable in humans, and common polymorphisms in the BCO1 (also known as BCMO1) gene reduce conversion efficiency by 50% or more in carriers (Lietz et al. 2012, Journal of Nutrition; PMID 22113863). For people with poor carotenoid conversion, retinol from liver or egg yolk is functionally more useful than plant-source provitamin A.
Chronic intake above 10,000 IU/day of preformed retinol is associated with bone demineralization and hepatotoxicity (Penniston & Tanumihardjo 2006, American Journal of Clinical Nutrition; PMID 16469975). People who combine liver capsules with vitamin A-fortified foods and a multivitamin can easily exceed the tolerable upper intake. Pregnancy is the highest-risk context: preformed retinol is teratogenic above roughly 10,000 IU/day, so conventional advice is to avoid liver and high-retinol products in pregnancy. Conservative use is 1–3 capsules/day rather than the 6–8 some products suggest.
A well-formulated multivitamin delivers similar or greater amounts of the same nutrients at lower cost and with more consistent dosing. Liver's real advantage is the food matrix — nutrients bound to endogenous proteins that the body evolved to process. Whether freeze-dried powder in a capsule preserves this advantage over tablet-form synthetic nutrients is plausible but not rigorously tested. Eating a few ounces of fresh liver once every 1–2 weeks accomplishes the same nutritional goal for most people at negligible cost.
Bergamot (Citrus bergamia) is a hybrid citrus fruit grown almost only in the Calabria region of southern Italy. Its peel is rich in unusual flavonoids — especially brutieridin and melitidin — that act like very mild plant statins by partially blocking HMG-CoA reductase, the enzyme that makes cholesterol. Italian researchers have built a steady evidence base for standardized bergamot extract (often labeled BPF, for Bergamot Polyphenolic Fraction) over the last 15 years.
The most useful summary is a 2019 systematic review by Lamiquiz-Moneo and colleagues in Critical Reviews in Food Science and Nutrition (PMID 31670973). It pooled 12 human studies. Across those trials, total cholesterol fell by 12–31%, LDL by 8–41%, and triglycerides by 12–40%. Most studies also showed a small rise in HDL. Doses ranged from about 500 to 1,500 mg/day of standardized bergamot extract, usually for 30–180 days. The reviewers note the trials were heterogeneous and quality was modest, so the headline numbers should be read as a plausible range, not a fixed effect size.
Brutieridin and melitidin compete with HMG-CoA reductase, but per molecule they are far weaker than prescription statins. Bergamot likely works through several pathways at once: light HMG-CoA reductase blockade, AMPK activation (helpful for glucose and fat metabolism), increased PON1 activity (which protects HDL from oxidation), and reduced new fat-making in the liver. The combined effect is meaningful even though no single mechanism is strong on its own.
The clearest add-on data come from Gliozzi and colleagues in International Journal of Cardiology, 2013 (PMID 24239156). Seventy-seven adults with mixed high cholesterol were randomized to placebo, rosuvastatin 10 mg, rosuvastatin 20 mg, BPF 1,000 mg, or BPF 1,000 mg + rosuvastatin 10 mg for 30 days. Adding BPF to the low-dose statin produced larger drops in LDL and oxidized-LDL markers than rosuvastatin alone. That makes bergamot a reasonable option for people who get muscle pain on higher statin doses and want to stay on the lowest effective dose. As a stand-alone, it is reasonable for adults with mild-to-moderate high cholesterol who do not yet need a prescription. It should not replace a statin in someone with established heart disease.
Look for products standardized to about 40% polyphenols or to a defined BPF fraction. Generic “bergamot extract” with no standardization can be inconsistent. Bergamot is well tolerated; mild stomach upset is the most common report. Because it lowers lipids, recheck a lipid panel at 8–12 weeks, and tell any prescriber who is also adjusting cholesterol medications.
Vitamin B12 comes in four forms used in supplements: cyanocobalamin (the cheap, stable, lab-made form), hydroxocobalamin (the form bacteria actually make), and the two coenzyme forms the body uses in cells — methylcobalamin and adenosylcobalamin. Marketing has built up the idea that “active” methylcobalamin is the only correct choice. The clinical evidence is more mixed than that.
All four forms are absorbed through the intrinsic-factor pathway. At very high oral doses, about 1% of the dose also crosses the gut wall by simple diffusion, which is why 1,000 µg pills work even in pernicious anemia. Once inside cells, the body converts B12 between the methyl and adenosyl coenzyme forms as needed. Cyanocobalamin must first have its cyanide group removed, a small extra step that is fine in healthy adults but can be slower in heavy smokers, since the cyanide-detox system is already busy with cigarette smoke.
Hydroxocobalamin is the standard B12 injection in much of Europe. It binds plasma proteins more tightly than cyanocobalamin and is cleared from the body more slowly, so injections can be spaced further apart. It is the gold-standard injection for pernicious anemia and is also approved as an antidote for cyanide poisoning. Oral hydroxocobalamin is less common in the US but is clinically interchangeable with methylcobalamin for most everyday supplementation.
For diabetic peripheral neuropathy, several randomized trials and meta-analyses have tested high-dose methylcobalamin (typically 1,500–5,000 µg/day) and reported small improvements in nerve-conduction tests and pain scores compared with placebo or cyanocobalamin. The effect size is modest and the trial quality is mixed (Sun 2018, Diabetes Research and Clinical Practice; PMID 29626491). For ordinary B12 deficiency, all four forms work; making sure you absorb and store enough B12 matters more than which form you pick.
MTHFR gene variants affect folate metabolism, not B12 metabolism. The popular advice that MTHFR carriers must use methylcobalamin is not strongly supported. What does help MTHFR-variant individuals is using methylfolate (5-MTHF) instead of synthetic folic acid. The B12 form choice is secondary.
For routine supplementation, any of the four forms at 500–1,000 µg/day is enough. For documented deficiency, methyl- or hydroxocobalamin at 1,000–2,000 µg/day is reasonable. For diabetic neuropathy, high-dose methylcobalamin has slightly better evidence. Do not lose sleep over the choice — B12 form selection is one of the lower-stakes decisions in supplementation.
Thiamine (vitamin B1) is water-soluble and uses two specific transporters — THTR1 and THTR2 — to enter cells. Above about 5 mg in a single dose, those transporters saturate and most extra thiamine is excreted in urine. Two lipid-modified versions of thiamine, TTFD (thiamine tetrahydrofurfuryl disulfide, often labeled “allithiamine”) and benfotiamine, get around this limit because they cross cell membranes by simple diffusion, then get converted back to thiamine inside the cell.
TTFD was developed in Japan in the 1960s after researchers noticed that garlic and rice-bran extracts produced a longer-lasting thiamine effect than ordinary thiamine alone. The lipid-soluble disulfide form passes through cell membranes, including the blood–brain barrier, and is broken down inside cells to release free thiamine. In tissue and blood measurements, TTFD raises intracellular thiamine to levels that ordinary oral thiamine cannot reach (Lonsdale 2006; PMID 16550223).
TTFD has been studied in conditions where the brain has trouble using thiamine: pyruvate dehydrogenase deficiency, subacute necrotizing encephalomyelopathy (Leigh syndrome), and a range of fatigue syndromes. Reports are mostly case series and small open-label studies, with randomized evidence still limited. Wider clinical use in dysautonomia, POTS, and migraine has run ahead of the formal trial data, so claims should be treated cautiously.
Benfotiamine (S-benzoylthiamine O-monophosphate) is another fat-soluble thiamine derivative. It is best studied for painful diabetic neuropathy. The BENDIP randomized trial (Stracke 2008, Experimental and Clinical Endocrinology & Diabetes; PMID 18473286) tested benfotiamine 300–600 mg/day over 6 weeks and reported modest symptom improvement on the TSS pain score. Unlike TTFD, benfotiamine does not enter the brain efficiently — it acts mainly in peripheral nerves and tissues (Volvert 2008, BMC Pharmacology; PMID 18549472).
TTFD is usually taken at 50–200 mg/day with a meal that contains some fat. Some users report a short-lived rough patch — worse fatigue or anxiety for 1–3 weeks — in the first weeks of use, which clinicians who use TTFD describe as a “paradoxical reaction.” Starting at 10–25 mg and slowly working up usually avoids this. TTFD is well tolerated long term but has a noticeable sulfur odor that some people dislike.
5-Aminolevulinic acid (5-ALA) is a small amino-acid-like molecule that the body makes inside mitochondria from glycine and succinyl-CoA. It is the first building block of heme, the iron-containing pigment in hemoglobin, myoglobin, and the cytochromes that carry electrons in the cell's energy chain. In recent years, 5-ALA paired with iron (sodium ferrous citrate, or SFC) has been studied as a way to nudge mitochondrial function in people with prediabetes and type 2 diabetes.
The most-cited human trial is Higashikawa 2013 in Nutrition (PMID 23759263). It randomized 212 mildly hyperglycemic adults (fasting glucose 105–125 mg/dL or HbA1c 6.1–7.1%) to one of three 5-ALA + iron doses or placebo for 12 weeks. The highest-dose arm (15 mg ALA-P + 1.8 mg iron daily) lowered fasting plasma glucose by about 2.3 mg/dL (95% CI 0.24–4.42; p=0.029) and improved 2-hour oral glucose tolerance by about 14.2 mg/dL versus placebo. Importantly, HbA1c, fasting insulin, and HOMA-IR did not change. The effect on glucose handling is real but small; this is a fasting-glucose and post-meal effect, not an HbA1c effect.
5-ALA pushes more building blocks into the heme pathway, which supports cytochrome c oxidase (Complex IV) and other mitochondrial cytochromes. More efficient electron transport may improve insulin sensitivity in tissues where mitochondrial function is sluggish, such as skeletal muscle and pancreatic beta cells. The iron must be co-supplied because making heme uses iron stoichiometrically; without it, prolonged 5-ALA could deplete iron stores.
A 2016 Bahraini pilot trial (Al-Saber 2016, Journal of Diabetes Research; PMID 27738640) tested 5-ALA + SFC up to 200 mg/day in 53 adults with uncontrolled type 2 diabetes. It was primarily a safety study and showed the combination was well tolerated alongside standard antidiabetic drugs. 5-ALA is also the active compound in photodynamic therapy for actinic keratosis and certain cancers, where it accumulates in abnormal cells and is activated by light. Oral supplement doses are far lower than those used for photodynamic therapy.
At supplement doses of 25–100 mg/day, 5-ALA is generally well tolerated. Mild stomach upset is the most common report. Temporary photosensitivity has been described at higher doses. People with porphyria or hereditary hemochromatosis should avoid 5-ALA because of effects on the heme pathway and iron handling. Anyone already taking iron should keep total intake within recommended limits.
CoQ10 cycles between two forms in the body: ubiquinone (the oxidized form) and ubiquinol (the reduced form). Both are sold as supplements, and ubiquinol products usually cost about two to three times as much. The marketing claim is that ubiquinol is “pre-converted” and therefore more useful. The reality depends on who is taking it.
Both forms are absorbed by passive diffusion in the small intestine and packaged into chylomicrons, the same fat-carrying particles your gut uses for dietary fat. That is why taking either form on an empty stomach gives much lower blood levels than taking it with a meal. In healthy adults under 50, the body absorbs ubiquinone efficiently and the liver reduces most of it to ubiquinol, which is the dominant form circulating in plasma no matter which form you swallow.
The age and statin contexts matter. In adults over 60–70, the enzymes that reduce ubiquinone are slower, and several studies have shown that at the same dose, ubiquinol gives somewhat higher total plasma CoQ10 in older adults than ubiquinone (Hosoe 2007, Regulatory Toxicology and Pharmacology; PMID 16919858). In statin-treated patients with muscle symptoms, small trials (Langsjoen 2008; PMID 18373549) reported improvement at ubiquinol 100–200 mg/day. The Q-SYMBIO trial, which showed mortality and hospitalization benefit in chronic heart failure, used ubiquinone at 100 mg three times daily (300 mg/day total) (Mortensen 2014, JACC: Heart Failure; PMID 25282031). More recent heart-failure work increasingly tests ubiquinol at 200 mg/day.
For healthy adults under 50 taking CoQ10 for general mitochondrial support or for migraine prevention at 100–400 mg/day, ubiquinone gives the same plasma levels at lower cost. There is no clinically meaningful advantage to ubiquinol in this group.
Ubiquinol re-oxidizes back to ubiquinone in air, so it has to be packaged in well-sealed softgels under inert gas to stay reduced. Cheap ubiquinol products may already be partly oxidized when you open the bottle, which erases any form advantage. Buy from manufacturers that publish stability data or third-party testing.
Under 50 and healthy: ubiquinone is the cost-effective choice. Over 60, on a statin with muscle symptoms, or in heart failure under medical care: ubiquinol is the more defensible choice. In both cases, take with the fattiest meal of the day, and expect plasma levels to settle over 2–3 weeks.
Leucine is one of three branched-chain amino acids (the others are isoleucine and valine), but it has a special job: it is the main signal that turns on muscle protein synthesis through the mTORC1 pathway. After a meal, plasma leucine has to climb above a certain level — the “leucine threshold” — to flip that switch. How much protein and what kind you eat matters because both control whether the threshold is crossed.
Work by Stuart Phillips, Luc van Loon and others has converged on roughly 2.5–3 g of leucine per meal as enough to maximally stimulate muscle protein synthesis in younger adults. That is roughly 20–25 g of high-quality animal protein (whey, eggs, lean meat) or about 35–40 g of typical plant protein. Older adults show “anabolic resistance”: they need about 40% more leucine and protein per meal to get the same muscle-protein-synthesis response — closer to 4 g of leucine, often delivered as roughly 30–40 g of high-quality protein (Phillips 2014, Sports Medicine; PMID 25355187).
Adding 2–3 g of free leucine to a sub-threshold meal (under about 20 g of protein) restores a full muscle-protein-synthesis response in older adults (Wall 2013, Clinical Nutrition; PMID 23043721). That is useful for people with poor appetite, early satiety, or plant-heavy diets where reaching the leucine threshold each meal is harder. Adding leucine to a meal that already has 30–40 g of high-quality protein does not help — the threshold has already been crossed.
BCAA supplements typically deliver leucine, isoleucine, and valine in a 2:1:1 ratio. For muscle protein synthesis, leucine does the work and the other two contribute little. So a BCAA blend is, in effect, a leucine product with two extras and a higher price. If you want a leucine effect, buy leucine. (BCAAs may have a separate, weaker role in central fatigue during long endurance sessions, which is a different application.)
Leucine alone cannot build muscle without all nine essential amino acids being available as raw material. In a fed state with normal protein intake, those amino acids are in the bloodstream already, so this does not matter. In a fasted or under-fueled state, supplementing leucine can briefly turn on mTORC1 without supplying the building blocks for new protein, which is inefficient. Essential amino acid (EAA) blends sidestep that limitation (Churchward-Venne 2012, Journal of Physiology; PMID 22451437).
Add 2–3 g of leucine to meals that fall short of about 20 g of high-quality protein. Use 3–5 g around training if your post-workout protein is delayed. Stay below about 10 g/day — very high single doses of leucine compete with isoleucine and valine for the same transporters and could create imbalances.
Vinpocetine is a chemically modified version of vincamine, a compound from the lesser periwinkle plant (Vinca minor). It has been sold as a prescription drug for cognitive impairment in Hungary, Russia, and other Eastern European markets (under names like Cavinton) since the 1970s, and at the same time as an over-the-counter nootropic in the United States. In 2016 and again in 2019, the US FDA stated that vinpocetine does not legally qualify as a dietary ingredient and should not be sold as a supplement, especially because of risks during pregnancy. The product is still widely available, which leaves shoppers in a confusing regulatory gray zone.
Under the Dietary Supplement Health and Education Act (DSHEA, 1994), supplements may contain ingredients that were already on the market as foods or supplements before that date. Vinpocetine was first developed and sold as a pharmaceutical, not as a food. In 2016 the FDA published a tentative conclusion that vinpocetine never qualified as a dietary ingredient, and in November 2019 the agency confirmed that finding and warned women of childbearing age in particular not to use vinpocetine supplements (FDA, “FDA statement on warning for women of childbearing age about possible safety risks of dietary supplements containing vinpocetine,” June 2019). Enforcement has been uneven, and many products remain on store shelves.
The FDA’s 2019 warning was driven by a National Toxicology Program / NIH review (NTP, 2019) of vinpocetine's reproductive toxicology. In pregnant rats and rabbits, vinpocetine at exposures comparable to typical human supplement doses caused fetal loss and reduced fetal weight. On that basis, FDA stated that vinpocetine should not be used by women who are pregnant or could become pregnant. Most consumer-facing labels do not display this warning prominently. Health Canada has also not approved vinpocetine as a Natural Health Product, and several products have been refused entry under the Natural and Non-prescription Health Products Directorate.
The 2003 Cochrane review on vinpocetine for cognitive impairment and dementia (Szatmari & Whitehouse 2003; PMID 12535455) concluded that the evidence in dementia was inconclusive, with most trials small, short, and methodologically weak. Later reviews of vinpocetine in vascular cognitive impairment have reported small improvements in cognitive test scores and cerebral blood flow at 15–30 mg/day (typically split into three doses), with mechanisms thought to include PDE1 inhibition, sodium-channel modulation, and mild cerebral vasodilation. In healthy adults without cognitive impairment, effects on memory and attention have been small and inconsistent.
Vinpocetine has mild antiplatelet activity, so it may add to bleeding risk when combined with warfarin, direct oral anticoagulants, aspirin, NSAIDs, or fish oil at high doses. It is metabolized by CYP3A4 and CYP2C19, so strong inhibitors and inducers of those enzymes can alter blood levels. There are scattered case reports in the FDA Adverse Event Reporting System (FAERS) of agranulocytosis, gastrointestinal upset, and palpitations associated with vinpocetine-containing supplements, although causation is hard to establish from spontaneous reports alone.
Vinpocetine is more like a medication than a typical supplement ingredient. Anyone considering it should treat it that way: avoid in pregnancy or if pregnancy is possible, avoid in people with bleeding disorders or on anticoagulants, and discuss with a clinician before taking it long term. Its narrow clinical role (mainly vascular cognitive impairment in older adults under medical supervision in countries where it is licensed) does not justify routine over-the-counter use by healthy adults seeking memory enhancement.
Most popular prebiotic fibers — inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS) — are fermented quickly by gut bacteria, which can produce a lot of gas, bloating, and urgency in people with sensitive guts or IBS. Acacia fiber (also called gum arabic, from Acacia senegal or Acacia seyal) is a complex arabinogalactan polysaccharide that is fermented more slowly and further along the colon, so it tends to deliver prebiotic benefits with less of the rapid gas.
The cleanest dose-response data come from Calame and colleagues in the British Journal of Nutrition, 2008 (PMID 18466655). Healthy adults took 5, 10, 20, or 40 g/day of acacia fiber, 10 g/day of inulin, or water for 4 weeks. Acacia at the optimal 10 g/day dose raised stool Bifidobacteria and Lactobacillus counts at least as much as inulin, with no significant tolerability complaints reported. Studies in IBS populations have suggested that acacia is among the better-tolerated fibers because of its slower fermentation profile, which is why it shows up on many low-FODMAP-friendly food lists.
Acacia is moderately soluble and forms a soft, viscous gel in the gut. For chronic constipation, 10–20 g/day generally improves stool frequency and softens stool consistency over 2–3 weeks (Min 2012, World Journal of Gastroenterology; PMID 22912550). Unlike stimulant laxatives, fiber-based regimens do not lose effect with daily use.
A small Sudanese trial in healthy adult women (Babiker 2012, Nutrition Journal; PMID 23241359) reported modest reductions in body mass index and body-fat percentage with 30 g/day of gum arabic over 6 weeks. Larger and longer trials are needed; treat acacia as a small dietary nudge rather than a weight-loss drug. The likely mechanism is delayed gastric emptying plus increased short-chain fatty acid (especially butyrate) production, which signals fullness through gut hormones.
Start with about 5 g/day mixed into water, coffee, or food — it is essentially tasteless and dissolves clear. Build up to 10–20 g/day over a couple of weeks to keep any transient bloating to a minimum. Acacia does not have known clinically important drug interactions, but, like any fiber, take it at least 2 hours apart from medications where exact timing of absorption matters (such as thyroid hormone or certain antibiotics).
Fucoxanthin is an orange carotenoid pigment found almost exclusively in brown seaweeds such as Undaria pinnatifida (wakame) and Laminaria (kombu). It got attention around 2005 after a Japanese animal study showed that fucoxanthin increased UCP1 expression in white fat — in effect making white fat behave a bit like the calorie-burning brown fat of newborns (Maeda 2005, Biochemical and Biophysical Research Communications; PMID 15896707). The mechanism is appealing, and supplement marketing ran with it. The human evidence is much thinner than the marketing.
The single most-cited human trial is Abidov 2010 in Diabetes, Obesity and Metabolism (PMID 19840063). It was a 16-week double-blind randomized study of 151 obese, non-diabetic premenopausal women, most with non-alcoholic fatty liver disease (NAFLD). The active arm received Xanthigen, a proprietary product containing brown-seaweed extract (with 2.4 mg/day of fucoxanthin) plus 300 mg/day of pomegranate seed oil. Participants on Xanthigen lost about 5.5 kg over 16 weeks compared with placebo. Important caveats: the study was sponsored by the product's developer, the active treatment was a combination, not fucoxanthin alone, and the trial has not been independently replicated.
Rodent studies showing strong fat-loss effects use doses that, scaled to a human, would mean grams of fucoxanthin per day — far above any commercial supplement. In humans, oral fucoxanthin is poorly absorbed (about 0.1–1% of the dose), and most of what reaches the bloodstream is the metabolite fucoxanthinol. Standard supplement doses of 1–4 mg fucoxanthin produce blood levels that may be too low to meaningfully turn on UCP1 in human fat tissue.
The more replicable human findings are modest: small reductions in liver fat in NAFLD, slight improvements in fasting insulin, and some antioxidant and anti-inflammatory activity. These are real but small. For weight loss specifically, the evidence is thinner than for the proven tools (calorie management, exercise, and, where appropriate, GLP-1 receptor agonists like semaglutide for people who qualify medically).
Fucoxanthin itself is generally well tolerated. The bigger concern is the source: brown seaweeds can contain large amounts of iodine and, depending on harvest area, traces of arsenic. Excess iodine can disturb thyroid function in susceptible people. Choose products that are standardized for both fucoxanthin content and tested for iodine and heavy metals, and avoid combining with thyroid medication without clinical supervision.
Ferulic acid is a hydroxycinnamic acid — a small plant phenol — found in meaningful amounts in whole grains (especially brown rice and wheat bran), coffee, and many vegetables. It is one of the most abundant plant antioxidants in a typical Western diet. Supplemental ferulic acid has gained popularity as a longevity and skin-health ingredient, but the evidence for taking it as a pill is weaker than the evidence for using it on the skin.
The best-replicated human application is topical. Duke University dermatology researchers (Lin 2005, Journal of Investigative Dermatology; PMID 16185284) showed that adding 0.5% ferulic acid to a topical solution of 15% L-ascorbic acid (vitamin C) and 1% α-tocopherol (vitamin E) stabilized the formula and roughly doubled photoprotection (from about 4-fold to about 8-fold) against simulated solar UV. The “C+E+ferulic” combination has been a dermatology standard ever since. This is a cosmeceutical use; the evidence does not automatically transfer to oral pills.
Oral ferulic acid is well absorbed (roughly 50% of the dose) but is rapidly conjugated to glucuronide and sulfate metabolites and cleared, so circulating free ferulic acid is short-lived. Those metabolites still have some antioxidant activity. Doses in human trials usually run 250–1,000 mg/day, with modest reductions in oxidative-stress markers (such as malondialdehyde and 8-OHdG) and small improvements in endothelial function in small studies.
Bumrungpert and colleagues (Bumrungpert 2018, Nutrients; PMID 29865227) randomized 48 hyperlipidemic adults to 1,000 mg/day ferulic acid or placebo for 6 weeks. The treatment group showed reductions in total cholesterol, LDL, and triglycerides, and improvements in oxidative-stress and inflammatory markers. Effect sizes were modest and the trial was small, so the result needs replication before treating ferulic acid as a stand-alone lipid therapy.
Ferulic acid is a reasonable supporting ingredient in a broader polyphenol strategy alongside compounds like quercetin, rosmarinic acid, or resveratrol. It is unlikely to deliver dramatic effects on its own. For skin, topical C+E+ferulic combinations have far better evidence than oral supplementation. For systemic effects, dietary intake from coffee, whole grains, and polyphenol-rich produce is the foundation, and supplementation is at best additive.
Honokiol is a small plant compound (a "lignan") found in the bark of the magnolia tree (Magnolia officinalis). Magnolia bark has been used in traditional Chinese and Japanese medicine for centuries to ease anxiety, support sleep, and calm digestive complaints. Modern lab work shows that honokiol — together with its sister compound magnolol — turns up the volume on GABA-A receptors, the brain's main "calming" switches. That helps explain its mild relaxing effect, and it does so at a site different from where benzodiazepines like Xanax or Valium bind.
Patch-clamp studies on rat and recombinant human GABA-A receptors show honokiol acts as a positive allosteric modulator: it does not turn the receptor on by itself, but it makes the receptor respond more strongly when the brain's own GABA arrives (Alexeev 2012; PMID 22445602; DOI 10.1016/j.neuropharm.2012.03.002). The effect is broad across receptor subtypes, with extra strength at δ-containing extra-synaptic receptors. This is mechanistically different from the benzodiazepine site, so honokiol can produce calming effects without typical benzodiazepine memory loss or breathing suppression — though that does not mean it is risk-free, especially when combined with other sedatives.
Most human studies use a standardised magnolia + phellodendron blend (Relora®), not pure honokiol, so the data describe the combination rather than honokiol alone. A 6-week randomised trial in 40 mildly anxious overweight premenopausal women found that 750 mg/day of the blend reduced short-term ("state") anxiety scores compared with placebo, but did not change long-standing trait anxiety, salivary cortisol, sleep, or appetite (Kalman 2008; PMID 18426577; DOI 10.1186/1475-2891-7-11). A 4-week trial in 56 moderately stressed men and women using the same blend reported an 18% drop in salivary cortisol and improvements in tension, fatigue, and overall mood (Talbott 2013; PMID 23924268; DOI 10.1186/1550-2783-10-37). The two trials disagree on the cortisol question, which is why most clinicians treat the cortisol claim cautiously.
In rodent studies, honokiol shortens the time it takes to fall asleep and increases non-REM sleep, but matched human sleep trials are sparse. Lab-dish and animal cancer work shows honokiol blocks NF-κB signalling and triggers cancer-cell death, which is why it appears in oncology pre-clinical pipelines — but no human cancer trial has yet shown a clinical benefit. People with cancer should not substitute honokiol for evidence-based treatment.
Typical magnolia bark extract dosing is 250–500 mg one or two times daily, providing roughly 10–20 mg of honokiol per dose. Effects begin within about 30–60 minutes and last 4–6 hours. Because honokiol amplifies GABA, combining it with alcohol, benzodiazepines, opioids, or other sedatives can produce excessive drowsiness and should be avoided. Magnolia bark has not been tested for safety in pregnancy or breastfeeding and should be skipped in those situations. Stop magnolia bark at least 2 weeks before surgery because of the additive sedation risk.
Kaempferol is a flavonoid — a class of plant pigment compounds — found in good amounts in kale, spinach, broccoli, capers, endive, tea, and saffron. Over the past decade it has attracted longevity-research attention because lab studies show it can switch on autophagy, the cell's waste-recycling system that slows with age, and nudge signalling pathways (SIRT1, AMPK, NRF2) that regulate stress resistance.
In cell and rodent models, kaempferol turns on autophagy by quieting mTORC1 and activating TFEB (the master switch for lysosome production). A 2010 paper showed kaempferol — but not quercetin, myricetin, or resveratrol — protected dopamine neurons from a Parkinson-like toxin specifically through this autophagy mechanism (Filomeni 2010; PMID 20594614; DOI 10.1016/j.neurobiolaging.2010.05.021). Mammalian data also include reduced beta-amyloid build-up in Alzheimer mouse models, lower fat-tissue inflammation, and improved glucose handling. Lifespan extension has been reported in worms (C. elegans), but the size of the effect varies and has not been replicated in mammals.
The longest-running data come from a Finnish cohort of about 10,000 adults followed for years. People in the top quartile of kaempferol intake had a 30% lower rate of stroke and other cerebrovascular disease than people in the bottom quartile (RR 0.70, 95% CI 0.56–0.86; Knekt 2002; PMID 12198000; DOI 10.1093/ajcn/76.3.560). Other epidemiology suggests links to lower ovarian and pancreatic cancer rates, but those signals are smaller and less consistent. Observational data cannot prove cause-and-effect — people who eat more kaempferol-rich vegetables also tend to eat better diets overall — but the direction of effect across populations is encouraging.
Like most flavonoids, kaempferol is poorly absorbed when swallowed. Only about 1–3% of an oral dose reaches blood as free kaempferol because the gut wall and liver quickly attach sulfate or glucuronide groups, which the body then sweeps out (Calderón-Montaño 2011; PMID 21428901; DOI 10.2174/138955711795305335). The food matrix and your individual gut microbiota change absorption further. Phytosome or liposomal formulations report several-fold higher plasma levels than plain kaempferol powder, but head-to-head outcome trials are still missing.
Typical supplement labels list 50–200 mg/day of kaempferol or kaempferol-rich plant extracts (saffron, ginkgo, kale concentrate). A regular dietary intake of 5–10 mg/day is realistic from 1–2 servings of kaempferol-rich vegetables. Kaempferol mildly inhibits CYP3A4 and CYP2C9 in lab studies, which means caution if you take drugs with a narrow safe range (warfarin, some chemotherapies, ciclosporin). Because the strongest human signals are tied to whole-food intake rather than pills, the most defensible use of kaempferol is as part of a polyphenol-rich diet, with supplementation an optional add-on rather than a substitute.
Pine pollen — mostly from Chinese red pine (Pinus massoniana) and Scots pine (Pinus sylvestris) — has been sold as a natural testosterone booster since the early 2010s. The marketing rests on two true facts: pine pollen contains tiny amounts of plant steroids that look like human androgens, and Asian traditional medicine has used pine pollen in tonic blends for centuries. Neither fact supports the leap to "raises your testosterone."
Older analytical work on Scots pine pollen detected testosterone, epitestosterone, and androstenedione at the level of fractions of a microgram per gram of dry pollen. A typical 2–5 g daily scoop would therefore deliver less than 5 µg of testosterone — roughly one-thousandth to one-ten-thousandth of the 4–7 mg an adult man's testes make every day. Even if every microgram were absorbed orally (it isn't — oral testosterone is very poorly bioavailable because of liver first-pass metabolism), the math does not produce a hormonal effect. No randomised trial has shown a meaningful change in serum testosterone with pine pollen.
Pine pollen is nutrient-dense: amino acids, several B vitamins, trace minerals, and plant polyphenols including rutin, quercetin, and kaempferol. Recent in-vitro work on a polysaccharide extract from Korean red pine pollen showed it can activate immune-cell signalling (NF-κB) at the lab-dish level (Jang 2023; PMID 38213288; DOI 10.4014/jmb.2309.09026) — a finding consistent with general "plant nutrient" effects but a long way from a clinical claim. Treat pine pollen as a moderately useful botanical food, not a hormone.
Pine pollen is a recognised seasonal aeroallergen, and people with tree-pollen allergies can react to swallowed or inhaled pine pollen products. Alcohol-tincture products extract less of the protein allergens than raw powder, but neither form is allergy-tested or standardised. If you have hay fever in spring, start very low or skip pine pollen entirely.
If you enjoy pine pollen as a food-form polyphenol blend and aren't allergic, it's a reasonable addition. If your goal is more testosterone, the evidence-supported levers are different: regular resistance training, 7–9 hours of sleep, treating low body weight or excess body fat, fixing a vitamin D deficiency if you have one, and treating a true zinc deficiency if you have one. Pine pollen does not replace any of those.
As NAD+ (nicotinamide adenine dinucleotide) has gone mainstream in longevity talk, a predictable thing has happened: companies are now selling NAD+ itself in capsules, sublingual lozenges, and patches. The pitch — take the exact molecule you want to raise, skip the precursor — sounds obvious. In reality, oral NAD+ is the one form of the molecule you specifically should not buy.
NAD+ is a large, charged dinucleotide (molecular weight about 663 daltons), well above the ~500-dalton ceiling that small molecules typically need to slip across the gut wall on their own. In the gut and bloodstream, NAD+ is rapidly chopped up by enzymes (CD38, CD73, and others) into smaller pieces — mainly nicotinamide (NAM) and ribose. The practical result: pay for NAD+, absorb nicotinamide at about the same efficiency as taking nicotinamide directly, at a much higher cost (Rajman 2018; PMID 29514064; DOI 10.1016/j.cmet.2018.02.011).
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are smaller and use dedicated cellular doorways. NR is taken into cells through nucleoside transporters (ENT1, ENT2) and quickly phosphorylated to NMN inside the cell. NMN is then turned into NAD+ by enzymes called NMNATs. The first dose-finding trial in humans showed that single oral doses of 100, 300, or 1,000 mg of NR produced clear, dose-dependent rises in blood NAD+ metabolites (Trammell 2016; PMID 27721479; DOI 10.1038/ncomms12948). NMN has its own transporter story (Slc12a8 was proposed in some tissues but is contested in others) and also produces measurable NAD+ increases at practical oral doses (Yoshino 2018; PMID 29249689; DOI 10.1016/j.cmet.2017.11.002). Direct oral NAD+ has not matched these results.
IV NAD+ bypasses the gut problem and does raise blood NAD+, but the rise is rapid, short-lived, and the cost per session is high; long-term outcome data are sparse. Sublingual NAD+ lozenges sit between the two: they avoid the stomach but still meet the same plasma- and tissue-degrading enzymes. Published pharmacokinetic data for sublingual NAD+ are weaker than for sublingual NMN.
A 300 mg daily dose of oral NAD+ typically retails for about $2–4/day; the same dose of NMN or NR, which actually moves NAD+ metabolites in blood, runs roughly $1–2/day. The premium pricing of direct NAD+ products is not matched by performance.
If your goal is to raise NAD+ with an oral supplement, choose NR or NMN at 250–1,000 mg/day. Direct oral NAD+ is not a useful upgrade. Reserve IV NAD+ for specific clinical contexts (under medical supervision) where the cost and rapid clearance are acceptable trade-offs.
Folic acid is the synthetic, oxidised form of folate used in food fortification and most multivitamins since the US fortification rule took effect in 1998. L-methylfolate (also called 5-MTHF or 5-methyltetrahydrofolate) is the natural, ready-to-use form your body actually puts to work in methylation reactions. Which one you should swallow depends on what you're using it for — and on your MTHFR gene status.
Folic acid is not directly usable. Your body has to reduce it in two steps with the enzyme dihydrofolate reductase (DHFR) before it becomes 5-MTHF. Human DHFR is fairly slow at this job. At doses above about 400 µg a day, unmetabolised folic acid (UMFA) starts to show up in blood. UMFA itself isn't usable, and there is ongoing debate about whether long-term high UMFA interferes with the natural folate-receptor system. The cautious position has pushed many clinicians toward the natural 5-MTHF form when supplementing above food-fortification levels (Scaglione & Panzavolta 2014; PMID 24494987; DOI 10.3109/00498254.2013.845705).
MTHFR (methylenetetrahydrofolate reductase) is the enzyme that converts 5,10-methylene-THF into 5-MTHF. The common C677T variant cuts enzyme activity by roughly 35% in heterozygous (CT) carriers and roughly 70% in homozygous (TT) carriers. About 30% of people of European ancestry are heterozygous and 10% homozygous; rates vary by population. Homozygous TT carriers tend to have higher fasting homocysteine on standard folic-acid supplementation, and that gap closes faster with 5-MTHF. So for MTHFR TT carriers, methylated folate has a measurable pharmacological advantage.
The neural-tube-defect prevention evidence that drove folate recommendations was built on folic acid trials, and folic acid remains the evidence-grade choice for women with normal MTHFR status who are planning pregnancy or in early pregnancy. For women with known MTHFR variants, prior neural tube defects, or recurrent miscarriage, 5-MTHF at 400–800 µg/day is a defensible substitute and is supported by European reviews comparing the two forms (Obeid 2013; PMID 23482308; DOI 10.1515/jpm-2012-0256). The total folate intake from fortified food + supplement matters more than the form for most healthy women.
L-methylfolate is approved by the FDA in the US as a "medical food" (Deplin®) for use alongside antidepressants in major depressive disorder that hasn't responded to an SSRI. The mechanism is donation of methyl groups for neurotransmitter synthesis. In two sequential parallel-comparison trials, L-methylfolate at 15 mg/day (but not 7.5 mg/day) significantly improved depression scores versus placebo when added to ongoing SSRI treatment, with a number needed to treat of about six (Papakostas 2012; PMID 23212058; DOI 10.1176/appi.ajp.2012.11071114). A 2014 follow-up suggested the response is greater in patients with MTHFR variants or markers of inflammation. This is a specific clinical use, not a general recommendation.
For most adults with normal MTHFR status who just want to cover dietary gaps: 400 µg/day of folic acid is fine. For MTHFR variant carriers, women planning pregnancy after a prior loss, or anyone using folate as part of treatment for SSRI-resistant depression: 5-MTHF at 400–800 µg/day (or 7.5–15 mg/day for depression, under clinician supervision). Avoid chronic high-dose folic acid (>1,000 µg/day) without a specific reason — the long-term safety of persistent UMFA isn't fully settled.
L-theanine is an amino acid found mostly in tea leaves (Camellia sinensis) and a few mushroom species. On its own, it produces mild relaxation without making you sleepy. Combined with caffeine, it produces one of the most reproducible "calm focus" effects in nutritional pharmacology — faster, more accurate attention with less of the caffeine jitter, at predictable doses.
The two foundational trials both came out in 2008. Haskell and colleagues compared 250 mg L-theanine, 150 mg caffeine, and the combination in a placebo-controlled crossover. The combination — not either compound alone — produced faster simple reaction time, faster numeric working-memory reaction time, better sentence-verification accuracy, less mental fatigue, and lower headache ratings (Haskell 2008; PMID 18006208; DOI 10.1016/j.biopsycho.2007.09.008). Owen and colleagues used a smaller dose — 100 mg L-theanine + 50 mg caffeine — and found the combination improved both speed and accuracy on attention-switching and reduced distractibility on memory tasks (Owen 2008; PMID 18681988; DOI 10.1179/147683008X301513). A 2010 study replicated the attention-switching benefit at 97 mg theanine + 40 mg caffeine (Einöther 2010; PMID 20079786; DOI 10.1016/j.appet.2010.01.003).
Across these trials the ratio of theanine to caffeine sits between roughly 1.7:1 and 2.4:1 — the popular "2:1" rule of thumb is a fair shorthand. Lower ratios feel more like caffeine alone; very high ratios (4:1 and above) lose the alertness benefit.
L-theanine modestly increases alpha-wave activity on EEG (associated with relaxed, attentive states), boosts GABA tone, and modulates glutamate transmission. Caffeine works mainly by blocking adenosine receptors, which raises alertness and reduces perceived fatigue. The combination tends to produce caffeine's alertness without the full sympathetic-nervous-system activation that drives jitter and anxiety. Theanine also blunts caffeine's tendency to disrupt sleep when caffeine is taken later in the day.
Peak effects start about 30–45 minutes after ingestion and last roughly 3–4 hours. For focused work or study: 200 mg theanine + 100 mg caffeine, taken 30 minutes before. For an afternoon nudge without disturbing sleep: 100 mg theanine + 50 mg caffeine, ideally before 2 pm. Brewed tea already contains roughly a 2:1 theanine-to-caffeine ratio, which is why a cup of green tea typically reads as "calm focus" while the same caffeine dose from coffee can read as "jittery."
L-theanine on its own is also studied as a mild anxiolytic at 200–400 mg, without benzodiazepine-type sedation or dependence. It is well tolerated and doesn't have significant drug interactions of its own, but the caffeine half of the combination retains all the usual interactions: caution with beta-blockers, fluoroquinolone antibiotics, theophylline, and anticoagulants. Pregnant and breastfeeding people should follow the same caffeine cap as for coffee or tea (typically ≤ 200 mg/day). People who tolerate caffeine poorly can take theanine alone.
Barley grass and wheatgrass powders are staples of the "green superfood" aisle, sold as concentrated sources of chlorophyll, enzymes, and "alkaline" minerals. The marketing tends to mash together what is true about fresh juiced grass with what is true about dried powder, and what is proven with what is extrapolated.
A 10 g scoop of quality barley grass or wheatgrass powder delivers roughly 3–4 g of protein, 1–2 g of fibre, 20–30% of the daily value for vitamin K, 10–15% of vitamin A (as beta-carotene), modest amounts of iron, magnesium, and B vitamins, plus polyphenols and chlorophyll. That is a respectable nutritional contribution — broadly comparable to a serving of dark leafy greens in concentrated form. A review of barley grass identifies the same sets of vitamins, minerals, antioxidants, and bioflavonoids (saponarin and lutonarin in particular) that drive the modest anti-inflammatory and antioxidant effects seen in lab studies (Lahouar 2015; PMID 26477798; DOI 10.1142/S0192415X15500743). The honest comparison is to a salad, not to a multivitamin.
Chlorophyll is marketed as "alkalinising" and "oxygenating." Neither is supported by physiology — your blood pH is held in a narrow range by the lungs and kidneys, regardless of what you eat, and intact dietary chlorophyll does not enter the bloodstream in a meaningful amount. Chlorophyll does have one real effect inside the gut: it binds dietary mutagens like aflatoxin so they leave in stool rather than entering circulation. A randomised trial in adults at high risk of liver cancer in Qidong, China, showed 100 mg of chlorophyllin three times a day for 4 months reduced a urinary biomarker of aflatoxin–DNA damage by about 55% versus placebo (Egner 2001; PMID 11724948; DOI 10.1073/pnas.251536898). That benefit is real but specific to people with high carcinogen exposure, and a typical greens powder serving delivers far less chlorophyll than the trial dose.
Fresh grass juice contains enzymes that some marketers credit with therapeutic effects. Drying largely inactivates those enzymes, and what little survives is broken down by stomach acid before reaching the small intestine. The nutritional value of dried grass powder comes from vitamins, minerals, fibre, polyphenols, and chlorophyll — not from enzymes.
Nutritionally the two are similar. Barley grass tends to run slightly higher in vitamin B1 and chlorophyll; wheatgrass tends to run slightly higher in vitamin C and selenium. Both are typically gluten-free when harvested before grain formation, but cross-contamination during processing is common, so look for explicit gluten-free certification if you have coeliac disease or a wheat allergy.
Treat grass powders as a convenience food for hitting your vegetable intake, not as a therapeutic supplement with a specific clinical effect. At $1–2 per scoop, an actual serving of spinach, kale, or a smoothie tends to give you more nutrients per dollar. The defensible marketing line is "a convenient way to add greens to your diet" — which is true. "Alkalising, oxygenating, enzyme-rich superfood" is mostly copy.
Oat beta-glucan is a soluble fibre from the cell walls of the oat plant (Avena sativa). It is one of the few food components for which the US Food and Drug Administration has authorised a heart-health claim: that 3 grams a day of soluble fibre from oats, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease (codified at 21 CFR 101.81; final rule first published in the Federal Register, January 23, 1997, 62 FR 3584). That authorisation rests on decades of consistent randomised-trial evidence showing modest but reliable LDL cholesterol reduction at practical doses.
A 2014 meta-analysis of 28 randomised controlled trials found that 3 g/day or more of oat beta-glucan reduced LDL cholesterol by 0.25 mmol/L (~10 mg/dL) and total cholesterol by 0.30 mmol/L (~12 mg/dL) versus control diets, with no change in HDL or triglycerides (Whitehead 2014; PMID 25411276; DOI 10.3945/ajcn.114.086108). A larger 2016 systematic review of 58 trials at a median dose of 3.5 g/day found similar effects: LDL −0.19 mmol/L, non-HDL −0.20 mmol/L, and apolipoprotein B −0.03 g/L (Ho 2016; PMID 27724985; DOI 10.1017/S000711451600341X). LDL drops are larger (15–20 mg/dL) in people who start with high cholesterol. The effect is smaller than a statin (which typically lowers LDL 30–50%), but larger than most other dietary changes you can make on your own.
Beta-glucan forms a thick, viscous gel in the small intestine that traps bile acids and stops them from being reabsorbed. The liver then has to pull cholesterol out of the bloodstream to make new bile acids, which is what lowers blood LDL. The mechanism is similar to prescription bile-acid sequestrants like cholestyramine but much gentler on the gut. Fibre that escapes the small intestine is fermented in the colon into short-chain fatty acids, which appear to nudge liver cholesterol production down further.
Not every "oats with beta-glucan" product gives the same effect. The cholesterol-lowering action depends on how thick a gel the beta-glucan forms in the gut, which depends on its molecular weight. Minimally processed rolled or steel-cut oats and quality concentrated beta-glucan extracts retain high molecular weight. Heavily processed products — extruded cereals, some snack bars — can have beta-glucan that has been broken down enough that the same 3 g number on the label produces less of a clinical effect. Products that specify molecular weight on the label are preferable when the goal is cholesterol management.
Beta-glucan also flattens the rise in blood glucose after a meal, mildly improves insulin sensitivity, and increases satiety. These benefits are additive to the cardiovascular effect, and the same 3 g/day dose addresses all of them.
3 g/day is the target. That equals roughly 70 g of rolled oats (about a generous half-cup of dry oats, or 1.5 cups cooked), or a single scoop of a concentrated beta-glucan supplement. Take it with a meal for best viscosity. Expect 6–8 weeks before the effect shows up on a lipid panel. Side effects are limited mostly to transient gas or bloating, which usually resolves as you continue.
Melanotan II is a lab-made copy of part of alpha-melanocyte stimulating hormone (α-MSH), the body's natural pigment-stimulating hormone. It was first synthesised at the University of Arizona in the 1980s as an investigational drug. It has never been approved for human use anywhere in the world. Despite that, melanotan II is sold through online peptide suppliers and at the back of gyms as an injectable for tanning, libido, and "fat loss." The safety record explains why no regulator has approved it — and why the UK Medicines and Healthcare products Regulatory Agency (MHRA), Australia's TGA, and most European authorities have publicly warned consumers off it.
Melanotan II is a non-selective agonist at the melanocortin receptor family (MC1R, MC3R, MC4R, MC5R). Activation of MC1R on pigment cells (melanocytes) drives melanin production, which is what produces a tan without UV exposure. Activation of MC3R and MC4R in the brain produces the often-marketed "extras": rapid-onset erections (priapism is a documented adverse event), increased libido, appetite suppression, and nausea (Habbema 2017; PMID 28266027; DOI 10.1111/ijd.13585). The same melanocortin pathway has produced two narrowly approved relatives: afamelanotide (Scenesse®), approved by the FDA and EMA only for adults with erythropoietic protoporphyria as an implantable, dose-controlled drug; and bremelanotide (Vyleesi®), FDA-approved in 2019 for premenopausal hypoactive sexual desire disorder, with a defined safety database (Clayton 2022; PMID 35147466; DOI 10.1089/jwh.2021.0191). Melanotan II is neither of those.
Case reports across dermatology, nephrology, neurology, and toxicology journals describe a striking range of harms following melanotan II self-injection.
Adverse-event signals reported across these papers and pharmacovigilance reviews also include priapism (sustained painful erections), facial flushing, nausea (the most common acute side effect), and persistent focal hyperpigmentation. None of these have been studied in a controlled trial of melanotan II at the doses people actually use.
Because melanotan II is sold outside any regulatory framework, what's in the vial is not what's on the label. Independent mass-spectrometry analyses of black-market peptide products have repeatedly found wide differences in actual peptide content, bacterial endotoxin contamination, and in some cases the wrong compound entirely (Habbema 2017 review; PMID 28266027). Self-injection outside a medical setting also adds the standard risks of non-sterile injection: injection-site abscesses, cellulitis, and bloodstream infection.
In the United States, melanotan II is not FDA-approved for any indication and may not be legally marketed for human use; FDA has issued warning letters to sellers. In the United Kingdom, the MHRA has repeatedly warned that melanotan II is not licensed and is illegal to supply, and Trading Standards has prosecuted sellers. The Therapeutic Goods Administration in Australia classifies it as a prohibited import. The European Medicines Agency has not authorised it. Possession-for-personal-use sits in a legal grey zone in some countries, but distribution is generally illegal. Crucially, doctors do not have an approved framework to monitor people using melanotan II, and there is no antidote — care is supportive only.
For pigmentation: sunless tanners with dihydroxyacetone (DHA) and bronzing cosmetics produce a cosmetic tan with no systemic exposure. For libido or erectile function: licensed options exist — PDE5 inhibitors (sildenafil, tadalafil) for erectile dysfunction, and bremelanotide for premenopausal HSDD in women, both with documented safety monitoring (Clayton 2022; PMID 35147466). For people with erythropoietic protoporphyria: the related compound afamelanotide is medically supervised and licensed for that condition. The appeal of melanotan II is understandable; the risk profile is not.
Caffeine is the most widely used psychoactive substance in the world and also the most thoroughly studied ergogenic aid in sports science. Hundreds of randomised trials and several meta-analyses agree that a one-off dose of caffeine before exercise reliably improves endurance, strength, and certain cognitive tasks. The interesting questions today aren't whether it works but how much, when, and for whom.
A 2019 umbrella review in the British Journal of Sports Medicine pulled together 11 prior systematic reviews containing 21 meta-analyses, with mostly moderate or high methodological quality. The consistent finding: caffeine produces ergogenic effects on aerobic endurance, muscular strength, muscular endurance, anaerobic power, and jumping performance, with the largest and most reliable effect on aerobic endurance (Grgic 2019; PMID 30926628; DOI 10.1136/bjsports-2018-100278). The 2021 International Society of Sports Nutrition position stand sets the practical dose as 3–6 mg per kg of body mass, taken about 60 minutes before exercise, with the minimum effective dose possibly as low as 2 mg/kg and very high doses (~9 mg/kg) producing more side effects without more benefit (Guest 2021; PMID 33388079; DOI 10.1186/s12970-020-00383-4).
The CYP1A2 gene polymorphism rs762551 sorts people into fast and slow caffeine metabolisers. In a randomised crossover of 101 male athletes doing a 10-km cycling time trial, fast metabolisers (AA genotype) shaved 4.8% off their time at 2 mg/kg and 6.8% at 4 mg/kg of caffeine, while slow metabolisers (CC genotype) actually rode 13.7% slower at the 4 mg/kg dose (Guest 2018; PMID 29509641; DOI 10.1249/MSS.0000000000001596). Follow-up studies have shown smaller or less consistent gene effects in different sports, so this isn't a hard rule. A broader review confirms that beyond CYP1A2, individual differences in adenosine A2A receptor variants, habitual intake, and sleep status all shape an athlete's response (Nehlig 2018; PMID 29514871; DOI 10.1124/pr.117.014407). For most athletes, caffeine is still ergogenic; for the smaller group who feel worse on it, lowering the dose or skipping it is reasonable.
Peak blood levels of caffeine arrive about 45–60 minutes after a capsule of anhydrous caffeine and slightly later from coffee, because food and other coffee compounds slow absorption. The standard pre-competition protocol is 3–6 mg/kg taken about 60 minutes before. Caffeinated chewing gum is absorbed across the cheek lining within 15–20 minutes, useful for late-race top-ups. Brewed coffee works but delivers a much more variable dose (typically 70–200 mg per cup depending on bean, grind, and brew method).
Above about 6 mg/kg the performance curve flattens while side effects accelerate: anxiety, fast heart rate, GI upset, and disrupted sleep if taken within 6 hours of bed. The FDA describes 400 mg/day as the upper end of intake "not generally associated with negative effects" for healthy non-pregnant adults (FDA Consumer Update on caffeine). Pregnant or breastfeeding people are advised to cap intake at 200 mg/day or less by ACOG and EFSA. Pure powdered caffeine has caused fatal accidental overdoses — FDA banned its bulk consumer sale in 2018 — so avoid it. Combining caffeine with other stimulants (synephrine, yohimbine, the now-banned DMAA) sharply raises cardiovascular risk and should be avoided.
For most athletes, 3–4 mg/kg taken 60 minutes before training or competition delivers most of the benefit with manageable side effects. For cognition or office work, 100–200 mg pairs well with about twice as much L-theanine to smooth out jitter. Cycling caffeine (1–2 weeks off every few months) restores some sensitivity but isn't strictly required for the acute ergogenic effect.
Oral rehydration therapy (ORT) is arguably the most consequential public-health intervention of the 20th century. A systematic review for the Child Health Epidemiology Reference Group estimated that oral rehydration solution (ORS) can prevent about 93% of deaths from diarrhoea in children under five (Munos 2010; PMID 20348131; DOI 10.1093/ije/dyq025). Modern flavoured sports drinks borrow the same concept but use a much lower sodium concentration, which is why they don't replace ORS when illness or heavy sweat loss is the problem.
In the small intestine the SGLT1 transporter pulls sodium and glucose across the gut wall together, and water follows by osmosis. Too little glucose and the pump stalls; too much and the lumen becomes hypertonic, which pulls water out of the body and can worsen diarrhoea. The WHO reduced-osmolarity formula adopted in 2002 is balanced for this cotransport: 75 mmol/L sodium, 75 mmol/L glucose, 65 mmol/L chloride, 20 mmol/L potassium, and 10 mmol/L citrate (total osmolarity ~245 mOsm/L).
Most commercial sports drinks contain only 10–25 mmol/L sodium — roughly a quarter of the WHO formula — and 6–8% carbohydrate for taste and fuelling. That ratio is fine for working muscles during exercise, but it isn't enough sodium to maximise rehydration after heavy losses. For endurance events over two hours in the heat, or any GI illness, true ORS-style products (Pedialyte, Hydralyte, DripDrop, WHO-style sachets) deliver more sodium and rehydrate faster.
A Cochrane review in children compared the reduced-osmolarity ORS to the original WHO formula. Pooling 8 trials (1,491 children) for the primary outcome, reduced-osmolarity ORS lowered the odds of needing unscheduled IV fluids (OR 0.59, 95% CI 0.45–0.79), reduced stool output, and reduced vomiting, with no excess hyponatraemia (Hahn 2002; PMID 11869639; DOI 10.1002/14651858.CD002847). A separate Cochrane review of polymer-based (rice or wheat) ORS, which slowly releases glucose, found further small reductions in stool output and IV-fluid need versus glucose ORS (Gregorio 2016; PMID 27959472; DOI 10.1002/14651858.CD006519.pub3). In athletes, urine markers track exercise-induced fluid loss reasonably well, but laboratory studies generally show that drinks with more sodium are retained longer post-exercise than water or low-sodium sports drinks (Hahn & Waldréus 2013; PMID 23994895).
For daily hydration: plain water is enough. For 60+ minutes of hard exercise in the heat or 90+ minutes of moderate exercise: a sports drink with 6–8% carbohydrate and ~20–30 mmol/L sodium covers fuelling and modest fluid balance. For diarrhoea, vomiting, hot-weather dehydration, or post-event fluid replacement after heavy sweat loss: use a true ORS-style product or WHO-style sachet, where the higher sodium (45–75 mmol/L range) is what drives rehydration.
Severe dehydration — lethargy, no urine for 8 hours, cool mottled skin, or rapid breathing in a child — needs medical care, not home rehydration. Electrolyte sachets that deliver more than 1,000 mg sodium per packet are designed for athletic loss and can raise blood pressure if used daily. People with diabetes should read the carbohydrate label on ORS products: some deliver the equivalent of a soft drink's sugar load.
Sarcopenia — the age-related loss of muscle mass, strength, and function — is one of the most consequential and most preventable drivers of disability after about age 65. Protein supplementation has moved from a bodybuilder topic to a routine part of geriatric care, and the current expert consensus supports daily intakes well above the standard RDA.
The US RDA for protein, 0.8 g/kg/day, was derived from short-term nitrogen-balance studies in younger adults and assumes excellent protein quality. The international PROT-AGE Study Group recommends at least 1.0–1.2 g/kg/day for healthy older adults, 1.2 g/kg/day or more for those who exercise, and 1.2–1.5 g/kg/day for older adults with acute or chronic disease — with the exception of severe kidney disease (eGFR <30 not on dialysis), where intakes are limited (Bauer 2013; PMID 23867520; DOI 10.1016/j.jamda.2013.05.021). The European Working Group on Sarcopenia in Older People (EWGSOP2) endorses similar targets and now defines sarcopenia primarily by low muscle strength, with low quantity used for confirmation (Cruz-Jentoft 2019; PMID 30312372; DOI 10.1093/ageing/afy169).
Aging muscle develops "anabolic resistance" — older adults need more leucine per meal than younger adults to switch on muscle protein synthesis. Stable-isotope work in older men has placed the per-meal leucine threshold at roughly 2.5–3 g, which corresponds to about 25–40 g of high-quality protein per meal. Distributing protein across three or four meals so each one hits this threshold is more effective than loading the daily total into dinner.
Whey is the most studied protein in sarcopenia trials; it has the highest leucine content (~10–11% of amino acids) and absorbs quickly, which suits the per-meal leucine-threshold approach. Casein digests more slowly and gives a longer amino-acid release, which is why it's often used at bedtime. Plant proteins (soy, pea) can do the job but usually need 20–30% more grams to match the leucine load, and a blend (e.g., pea + rice) is preferred over a single source.
Protein supplementation alone produces small effects; combined with progressive resistance training the effect is meaningful. A meta-analysis of 49 RCTs (1,863 healthy adults) found that adding protein supplementation to resistance training significantly increased fat-free mass (mean +0.30 kg vs control), 1-rep-max strength, and muscle fibre cross-sectional area, with the benefit shrinking as participant age rose; benefits plateaued at total intakes above ~1.6 g/kg/day (Morton 2018; PMID 28698222; DOI 10.1136/bjsports-2017-097608). Training provides the mechanical signal; protein supplies the building blocks. Neither alone delivers what the combination does.
In older adults with normal kidney function, intakes up to ~1.5 g/kg/day have not been shown to harm kidney function in trials. In moderate-to-severe chronic kidney disease (eGFR <30 mL/min/1.73 m², not on dialysis) protein is restricted, with targets individualised by a renal dietitian. For everyone else over 65 on sustained high-protein intake, an annual basic metabolic panel including eGFR is a reasonable baseline check.
Most of the world's adults have reduced lactase activity. Estimated worldwide prevalence of lactose malabsorption is around 60–65%, with regional rates ranging from under 10% in Northern European populations to over 90% in much of East Asia and West Africa (Catanzaro 2021; PMID 33887513; DOI 10.1016/j.nutres.2021.02.003). For people who have symptoms with dairy, lactase enzyme supplementation is one of the few cases where a supplement directly substitutes for a missing human enzyme.
Lactase (lactase-phlorizin hydrolase, β-galactosidase) breaks lactose into glucose and galactose so they can be absorbed in the small intestine. Without enough lactase, lactose reaches the colon, where bacteria ferment it into hydrogen, methane, and short-chain fatty acids and pull in water by osmosis. The result — bloating, gas, cramps, and watery diarrhoea within 30 minutes to a few hours of dairy — is what most people mean by "lactose intolerance" (Misselwitz 2019; PMID 31427404; DOI 10.1136/gutjnl-2019-318404). Lactase products either pre-digest the lactose in milk before drinking or supply the enzyme alongside the meal so digestion can happen in the gut.
Enzyme supplementation reliably lowers post-dairy breath hydrogen (an objective marker of lactose malabsorption) and tends to reduce symptom scores in trials, with effect rising as the dose rises. The clinical benefit varies between people because the response depends on residual lactase, transit time, the gut microbiome, and the lactose load consumed; placebo effects are also large in this condition (Misselwitz 2019; PMID 31427404). Reviews of lactose-intolerance management consistently list exogenous lactase as a reasonable option for symptom control alongside dose reduction, lactose-free milk, and probiotic strategies (Catanzaro 2021; PMID 33887513).
Take a lactase tablet or drops with the first bite or sip of dairy. For mild intolerance, 3,000–6,000 FCC units (food chemical codex) per meal is usually enough; for higher loads or more severe cases, 9,000 FCC units is typical. The enzyme only digests lactose — it doesn't help non-lactose reactions like a milk-protein (casein) allergy or A1 β-casein sensitivity. People who react to butter, hard aged cheeses, or yoghurt — all of which contain little lactose — almost certainly have a different problem; lactase won't fix it.
Pre-hydrolysed lactose-free milk is often cheaper than repeated enzyme use. Aged cheeses (cheddar, parmesan, gruyère, manchego) are naturally low-lactose because most of it is removed in whey or fermented out. Yoghurt with live cultures partly self-digests its lactose and is tolerated by many people with low lactase. Some probiotic strains (e.g., Lactobacillus delbrueckii) and prebiotic carbohydrates may also reduce symptoms over time, though strain selection matters (Oak & Jha 2019, Crit Rev Food Sci Nutr).
Thiamine (vitamin B1) is a cofactor for three enzymes critical to glucose metabolism: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, and transketolase. Without enough thiamine, cells can't fully oxidise carbohydrate, and the brain — which runs almost entirely on glucose — is hit first. Frank deficiency is uncommon in the general population but common enough in alcohol use disorder, after bariatric surgery, in long-standing hyperemesis, and during refeeding to be a recognised medical priority.
Acute thiamine deficiency can cause Wernicke's encephalopathy, classically characterised by confusion, gait ataxia, and eye-movement abnormalities (ophthalmoplegia or nystagmus); untreated, it can progress to the largely irreversible amnestic Korsakoff syndrome. UK Royal College of Physicians and NICE guidance recommend giving parenteral thiamine (typical regimen: Pabrinex IV, equivalent to ~500 mg thiamine three times daily for 2–3 days, then maintenance) to anyone with suspected Wernicke's and to high-risk decompensating drinkers, because oral absorption is too slow and too low to rescue the acute presentation. A Cochrane review of randomised data on thiamine for Wernicke-Korsakoff in people with alcohol use disorder concluded that the available trial evidence is insufficient to dictate optimal dose, frequency, route, or duration — current dosing is largely consensus-based, but the case for early high-dose parenteral treatment is uncontested clinically (Day 2013; PMID 23818100; DOI 10.1002/14651858.CD004033.pub3).
Standard thiamine mononitrate and thiamine HCl are absorbed via a saturable, carrier-mediated process in the small intestine; absorption flattens at around 4–5 mg per dose, and most of an additional load is excreted unchanged. Fat-soluble derivatives — benfotiamine, sulbutiamine, fursultiamine, and TTFD — cross the gut by passive diffusion and produce substantially higher blood and tissue thiamine levels than equivalent oral thiamine HCl, although the size of that gap depends on the specific derivative and tissue.
The BENDIP randomised, double-blind, placebo-controlled trial randomised 165 patients with symmetrical distal diabetic polyneuropathy to benfotiamine 600 mg/day, 300 mg/day, or placebo. After 6 weeks, the Neuropathy Symptom Score improved more with benfotiamine than placebo (per-protocol p=0.033), with the larger effect at the 600 mg/day dose; the symptom labelled "pain" responded best (Stracke 2008; PMID 18473286; DOI 10.1055/s-2008-1065351). Mechanistically, benfotiamine activates transketolase and is thought to reduce flux through the polyol, hexosamine, and advanced-glycation pathways implicated in diabetic complications.
Loop diuretics (furosemide, bumetanide) increase urinary thiamine loss and low thiamine status has been documented in a meaningful fraction of heart failure patients; small trials of supplementation have shown improvements in surrogate measures, but no large outcome trial has demonstrated mortality or hospitalisation benefit. The signal is enough to make routine thiamine sufficiency reasonable in this population, not to justify aggressive megadoses.
Thiamine is water-soluble and has no established tolerable upper intake level — excess is excreted in urine. For at-risk groups (chronic heavy alcohol use, long-term loop diuretics, post-bariatric, Crohn's, hyperemesis), 50–100 mg/day oral thiamine HCl is a typical maintenance dose. Benfotiamine 150–300 mg twice daily is the research-backed range for diabetic neuropathy. Sulbutiamine is sold off-label for fatigue in some countries but has much thinner evidence. Suspected Wernicke's remains a parenteral-treatment situation; do not rely on oral supplements.
Riboflavin (vitamin B2) at pharmacologic doses is one of the few supplements that show up in headache-society guidelines as a probable migraine preventive. The effect is moderate, takes about three months to develop, and only helps a subset of patients — but the safety profile is so clean that many neurologists try it before committing to a prescription prophylactic.
People with migraine show signs of mild mitochondrial dysfunction: reduced ATP turnover and higher lactate on magnetic-resonance spectroscopy in some studies, and a higher prevalence of certain mitochondrial DNA variants. Riboflavin is the precursor to flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN), cofactors in oxidative phosphorylation. The 400 mg/day dose is roughly 300 times the RDA and is intended to push flavin-dependent enzyme activity higher, not to correct dietary deficiency.
The pivotal 1998 randomised controlled trial by Schoenen and colleagues randomised 55 migraine patients to 400 mg/day riboflavin or placebo for 3 months. Riboflavin was significantly better than placebo at reducing attack frequency (p=0.005) and headache days (p=0.012). The "responder" rate — patients whose attacks fell by at least 50% — was 59% on riboflavin versus 15% on placebo, giving a number-needed-to-treat of about 2.3 (Schoenen 1998; PMID 9484373; DOI 10.1212/wnl.50.2.466).
A systematic review of 11 clinical trials published over the next two decades reported a consistent positive effect in adults at 400 mg/day, with mixed and weaker effects in children and adolescents and no benefit when riboflavin was added to placebo-controlled combination products (Thompson 2017; PMID 28485121; DOI 10.1111/jcpt.12548). The American Academy of Neurology and American Headache Society guideline classifies riboflavin as Level B (probably effective) for episodic migraine prevention — the same tier as magnesium, feverfew (MIG-99), and several NSAIDs. Butterbur (Petasites) was Level A in that 2012 guideline, but the AHS later withdrew its recommendation because of unregulated pyrrolizidine-alkaloid hepatotoxicity in commercial products. Coenzyme Q10 sits at Level C (possibly effective) (Holland 2012; PMID 22529203; DOI 10.1212/WNL.0b013e3182535d0c).
Expect to give it 2–3 full months before judging the response. The only common side effect is bright fluorescent-yellow urine from excretion of excess riboflavin — harmless but startling. There are essentially no drug interactions and no dose-related toxicity, and the 400 mg/day dose is well above the RDA (1.3 mg) so it's only practical via supplementation. Riboflavin is sometimes used in combination with 400–600 mg magnesium and 100–300 mg coenzyme Q10 as a "mitochondrial trio," but the trial evidence for the combination is weaker than for the single agents and additivity hasn't been formally established.
Only about 5–10% of US adults meet the Adequate Intake for fibre — 25 g/day for adult women and 38 g/day for adult men (Institute of Medicine 2005). That gap is one of the largest dietary deficits in Western populations and tracks with higher rates of colon cancer, cardiovascular disease, type 2 diabetes, and all-cause mortality. A fibre supplement can help close the gap, but not all fibres do the same job.
Soluble, viscous fibres (psyllium, oat β-glucan, pectin) dissolve in water to form a gel, which slows nutrient absorption, blunts post-meal glucose spikes, lowers LDL cholesterol, and feeds gut microbes. Insoluble fibres (cellulose, wheat bran) add bulk to stool and speed transit through the colon. Whole foods contain both; supplements usually emphasise one. Psyllium and oat β-glucan are the canonical choices for cholesterol and bowel regularity; wheat dextrin and partially hydrolysed guar are gentler everyday options; inulin and fructo-oligosaccharides (FOS) are strong prebiotics but ferment quickly and cause gas in many users; methylcellulose (a synthetic) bulks stool with minimal fermentation.
A 2019 series of systematic reviews and meta-analyses commissioned by WHO pooled 185 prospective cohort studies and 58 randomised controlled trials, totalling roughly 135 million person-years, to map the dose-response between dietary fibre intake and disease outcomes. Comparing the highest fibre consumers with the lowest, the analysis found a 15–30% lower risk of all-cause mortality, cardiovascular mortality, incident coronary heart disease, stroke, type 2 diabetes, and colorectal cancer. Risk reduction across the critical outcomes was greatest at intakes of about 25–29 g/day, and the dose-response curves suggested further benefit at higher intakes (Reynolds 2019; PMID 30638909; DOI 10.1016/S0140-6736(18)31809-9). Trial data showed corresponding drops in body weight, systolic blood pressure, and total cholesterol with higher fibre intakes.
Psyllium has the strongest dossier of any supplemental fibre. A meta-analysis of 35 RCTs showed that psyllium taken before meals lowered fasting blood glucose by 37 mg/dL and HbA1c by about 1 percentage point in patients with type 2 diabetes, with a dose-response that scaled with baseline glycaemic control (Gibb 2015; PMID 26561625; DOI 10.3945/ajcn.115.106989). Psyllium also has FDA-authorised health claims for lowering risk of coronary heart disease (via LDL reduction) at ~7 g/day soluble fibre, and oat β-glucan has an analogous claim at 3 g/day (21 CFR 101.81). For weight, a meta-analysis of 62 RCTs (3,877 participants) of viscous fibre showed modest but statistically significant reductions in body weight (−0.33 kg), BMI (−0.28 kg/m²), and waist circumference (−0.63 cm) without explicit calorie restriction (Jovanovski 2020; PMID 31897475; DOI 10.1093/ajcn/nqz292).
Start low (around 5 g/day of supplemental fibre) and titrate up by 5 g every few days to give the gut microbiome and motility time to adjust. Take with plenty of water — bulk-forming fibres without fluid can paradoxically worsen constipation or, rarely, cause an obstructive bezoar. Separate fibre supplements from oral medications by about 2 hours to avoid binding interference, especially with thyroid hormone, lithium, and some antibiotics. Food-based fibre (legumes, whole grains, vegetables, fruit, nuts) remains the ideal; supplements are a useful bridge while dietary patterns change.
Sodium bicarbonate — the same baking soda that's in most kitchens — is not the first supplement most athletes think of, but it's one of the most thoroughly studied. The Australian Institute of Sport rates it an "A" supplement (strong evidence in specific situations), and the International Society of Sports Nutrition issued a position stand in 2021 endorsing it for high-intensity exercise.
During hard anaerobic work, hydrogen ion (H+) accumulates inside muscle, dropping intracellular pH and slowing key glycolytic enzymes. Bicarbonate raises blood buffering capacity, which helps muscle dump H+ and lactate into the blood and keeps the muscle pH from falling as far. A meta-analysis in Sports Medicine covering 38 studies and 137 performance estimates found a mean 1.7% increase in performance with single doses of 0.3 g/kg body mass in short maximal efforts (Carr 2011; PMID 21923200; DOI 10.2165/11591440-000000000-00000). An umbrella review of meta-analyses on the topic concluded that the evidence for bicarbonate is moderate-quality for ergogenic effects on Wingate-style anaerobic power, Yo-Yo intermittent running performance, and 30-second to 8-minute high-intensity exercise (Grgic 2021; PMID 34794476; DOI 10.1186/s12970-021-00469-7).
The ISSN position stand recommends 0.2–0.5 g/kg body mass, with 0.3 g/kg as the optimal single dose; higher doses don't add benefit but do worsen side effects. Standard timing is 60–180 minutes before exercise, adjusted to the individual's GI response. Multi-day protocols, where 0.4–0.5 g/kg/day is split across three meals for 3–7 days before competition, can be effective and reduce same-day GI risk (Grgic 2021 ISSN; PMID 34503527; DOI 10.1186/s12970-021-00458-w).
The biggest gains are seen in events that are hard, short, and limited by anaerobic glycolysis: 400–1,500 m running, 100–400 m swimming, 1–4 km cycling time trials, rowing 2,000 m, combat sports, and repeated sprints in team sports. Effects on muscle strength and pure repeated-sprint ability are less consistent, and there's little benefit for marathon-paced efforts — the bottleneck there isn't H+ accumulation.
The single biggest practical limitation is gut distress: belching, bloating, nausea, abdominal pain, and urgent diarrhoea, particularly with the 0.3 g/kg single dose. The position stand suggests using lower doses (0.2 g/kg), splitting across 30–60 minutes, taking it with a carbohydrate-rich meal, using enteric-coated or gelatin capsules, or switching to multi-day loading. Always test the protocol in training, never first on race day.
The ISSN review concludes that combining bicarbonate with creatine or beta-alanine may produce additive effects. Beta-alanine raises intracellular carnosine (an intramuscular buffer); bicarbonate raises extracellular buffering, so the two operate at different sites. Whether bicarbonate combined with caffeine or nitrate adds extra benefit is still unclear.
For healthy athletes, single-dose acute use at ergogenic doses is well tolerated. The sodium load is non-trivial — a 0.3 g/kg dose in a 70 kg athlete delivers about 1,600 mg of sodium — so it's not appropriate for people with uncontrolled hypertension, heart failure, severe kidney disease, or low-sodium-restricted diets. Long-term daily megadoses can cause metabolic alkalosis and hypokalaemia.
The current National Academies Adequate Intake for potassium is 3,400 mg/day for adult men and 2,600 mg/day for adult women. The most recent NHANES estimates put median US intake at roughly 2,400–2,800 mg/day for men and 1,800–2,300 mg/day for women — a shortfall in essentially the entire population. Raising potassium intake has one of the largest blood-pressure effects of any nutritional change for people with hypertension.
A WHO-commissioned BMJ meta-analysis pooled 22 randomised controlled trials (1,606 adult participants) and 11 cohort studies (127,038 adults). Higher potassium intake reduced systolic blood pressure by 3.49 mmHg (95% CI 1.82–5.15) and diastolic by 1.96 mmHg (95% CI 0.86–3.06) in adults with hypertension; the effect was not significant in normotensives. In observational data, higher potassium intake was associated with a 24% lower risk of stroke (RR 0.76, 95% CI 0.66–0.89), with no significant impact on renal function, blood lipids, or catecholamines (Aburto 2013; PMID 23558164; DOI 10.1136/bmj.f1378). The 2017 ACC/AHA hypertension guideline lists increasing dietary potassium to 3,500–5,000 mg/day as a non-pharmacologic Class IA recommendation for adults with elevated blood pressure (Whelton 2018; PMID 29133356).
The sodium-to-potassium ratio may matter more than either nutrient alone. The Filippini 2021 dose-response meta-analysis of 85 sodium-reduction trials found an approximately linear drop in blood pressure across the entire range of sodium intake studied, with no flattening at low intakes and steeper effects in hypertensive participants (Filippini 2021; PMID 33586450; DOI 10.1161/CIRCULATIONAHA.120.050371). Stacking lower sodium with higher potassium reproduces the DASH diet pattern, which lowered systolic BP by 8–14 mmHg in hypertensive adults in the original DASH-Sodium trial.
Over-the-counter potassium supplements in the US are limited to 99 mg per tablet by FDA labelling guidance (driven by historical concerns about ulceration and cardiac arrhythmia from concentrated KCl tablets), so they contribute little to closing a multi-thousand-milligram gap. Prescription potassium chloride and potassium citrate (used for nephrolithiasis or hypokalaemia) are dosed at 10–40 mEq (780–3,120 mg) and are monitored with serum potassium. People taking ACE inhibitors, ARBs, potassium-sparing diuretics (spironolactone, eplerenone, amiloride), trimethoprim, or those with chronic kidney disease must not self-supplement potassium — hyperkalaemia can cause fatal arrhythmia. Potassium-based salt substitutes are similarly not safe for these groups.
Food sources outperform pills in essentially every trial because they deliver potassium with magnesium, fibre, and polyphenols at a slow absorption rate. Practical high-potassium foods: a baked potato with skin (~900 mg), one cup of cooked beans (~600 mg), a banana (~420 mg), one cup of cooked spinach (~840 mg), tomato sauce, prunes, salmon, plain yoghurt, and avocado. Adding one of these to most meals closes the gap quickly without the safety concerns of supplements.
Calcium is cheap, familiar, and routinely over-supplemented. When it actually is indicated — postmenopausal women not meeting intake targets, long-term corticosteroid users, people treated for osteoporosis, certain pregnancy and lactation situations — the form and timing matter, and many people end up taking the version that fits their physiology worst.
Calcium carbonate is ~40% elemental calcium by weight, the cheapest and most concentrated common form. Because it's a basic salt, it needs stomach acid to ionise, so it should be taken with food. Calcium citrate is ~21% elemental calcium, more expensive, and absorbs comparably with or without food and without needing gastric acid — which is the practical reason it's preferred for people on a proton-pump inhibitor or H2 blocker, after gastric bypass, and in older adults with age-related hypochlorhydria. A controlled crossover study in 37 healthy adults using stable-isotope tracers found that, when both salts were taken with food, fractional absorption was essentially the same (~36% at a 300 mg load and ~28% at a 1,000 mg load) (Heaney 1999; PMID 10367025; DOI 10.1007/s001980050111). The form difference matters mainly when stomach acid is missing or the supplement is taken on an empty stomach.
Fractional calcium absorption drops sharply above ~500 mg per dose, so anyone taking more than 500–600 mg of supplemental calcium per day should split the dose. Calcium from food is delivered more slowly and isn't bound by this single-dose ceiling in the same way.
From about 2010 onward, several reanalyses of randomised trials raised concern that calcium supplements (but not dietary calcium) might modestly increase cardiovascular events. The National Osteoporosis Foundation and American Society for Preventive Cardiology convened a panel that reviewed the evidence with a Tufts University evidence-review team and concluded with moderate-quality evidence (B-level) that calcium intake from food or supplements has no relationship — beneficial or harmful — to cardiovascular disease, cerebrovascular disease, mortality, or all-cause mortality in generally healthy adults, provided total intake stays below the National Academy of Medicine tolerable upper intake of 2,000–2,500 mg/day (Kopecky 2016; PMID 27776362; DOI 10.7326/M16-1743). The hypothesis that pairing calcium with vitamin K2 (MK-7) directs calcium toward bone instead of vasculature is biologically plausible but has not yet been confirmed by hard endpoint trials.
Postmenopausal women whose dietary intake is below ~1,200 mg/day, long-term oral glucocorticoid users, people on osteoporosis-specific therapy, and certain pregnancy and lactation situations are the main indications. For most other adults consuming dairy or fortified plant milks plus leafy greens and nuts, the relevant gap is usually vitamin D status, magnesium, and protein — not added calcium. Stay below the upper-intake limit of 2,000–2,500 mg/day from food plus supplements combined.
Magnesium glycinate — also called magnesium bisglycinate or diglycinate — consists of one magnesium ion bound to two glycine molecules. It's become the default recommendation for sleep, mild anxiety, and daily supplementation because head-to-head data show better tolerability than magnesium oxide and it doesn't share the laxative effect of magnesium citrate.
Magnesium absorption depends on the amount that reaches the small intestine in a soluble, ionisable form. Mineral oxide formulations are poorly soluble at intestinal pH and dissolve incompletely; chelated forms (glycinate, lysinate, malate) are more soluble and may also be absorbed in part as an intact dipeptide. In a controlled stable-isotope study of 12 patients with prior ileal resection, magnesium diglycinate was tolerated better and produced an earlier and larger time-course of absorption than magnesium oxide; in the four patients with the worst MgO absorption, the diglycinate was about twice as well absorbed (23.5% vs 11.8%) (Schuette 1994; PMID 7815675; DOI 10.1177/0148607194018005430). In a randomised double-blind trial in 46 healthy adults comparing magnesium oxide, citrate, and amino-acid chelate at 300 mg/day for 60 days, organic forms (citrate and chelate) outperformed oxide on urinary, serum, and salivary magnesium markers (Walker 2003; PMID 14596323). The clinical headline: glycinate matches or exceeds oxide on absorption while being less likely to cause loose stools.
A systematic review of 18 trials of magnesium supplementation (often combined with B-vitamins) in groups vulnerable to anxiety (mild anxiety, premenstrual syndrome, postpartum, hypertension) found a generally positive but inconsistent effect on subjective anxiety, with study quality limiting how confident the conclusion can be (Boyle 2017; PMID 28445426; DOI 10.3390/nu9050429). Few of those trials specifically tested glycinate, so most of the published "anxiety and sleep" evidence applies to magnesium broadly rather than to one form.
Each 400 mg of elemental magnesium delivered as bisglycinate carries with it about 2–3 g of glycine. Glycine itself has small-trial evidence for improved sleep onset and subjective sleep quality, which is one reason glycinate is often picked for bedtime use. The combined effect hasn't been formally isolated against placebo, so treat it as a plausible side benefit rather than a primary mechanism.
Magnesium oxide is the cheapest and most concentrated form on drugstore shelves but is the least soluble; in healthy adults it absorbs poorly and most of an oral dose acts as an osmotic laxative (which is exactly why milk of magnesia is magnesium hydroxide and why magnesium citrate is used for bowel preparations). It works fine if a laxative is the goal; for actually raising body magnesium it's a poor choice.
Magnesium L-threonate has small trials suggesting better central nervous system penetration and may suit cognitive-aging applications. Magnesium malate has weak rationale for fibromyalgia or fatigue. Magnesium citrate is the standard for occasional constipation. Magnesium taurate has a cardiovascular rationale that hasn't been confirmed in outcome trials. For everyday sleep, mild anxiety, muscle cramps, and migraine prophylaxis, glycinate is a reasonable all-purpose choice.
200–400 mg of elemental magnesium per day, often taken in the evening. Read labels carefully: a product can list either "magnesium bisglycinate 1,000 mg" (the total compound, of which only ~140 mg is elemental magnesium) or "magnesium (as bisglycinate) 200 mg" (the elemental amount). The elemental amount is what counts. The Tolerable Upper Intake Level for supplemental magnesium in adults is 350 mg/day; doses above this can cause diarrhoea and, rarely in renal impairment, hypermagnesaemia.
Ginger root is one of the best-studied traditional remedies for nausea. Across pregnancy-related nausea, chemotherapy-induced nausea, postoperative nausea, and motion sickness, randomised trials show ginger lowering nausea scores by a clinically meaningful amount with a safety profile most prescription antiemetics cannot match.
The 2015 update of the Cochrane review on nausea and vomiting in early pregnancy (Matthews 2015; PMID 26348534; DOI 10.1002/14651858.CD007575.pub4) concluded that ginger products (typically 1–1.5 g/day) appear to improve nausea symptoms in some women, with effect sizes broadly in the same range as vitamin B6 (pyridoxine), although the body of evidence is limited by small trials and inconsistent vomiting outcomes. ACOG’s Practice Bulletin on nausea and vomiting in pregnancy lists ginger as a non-pharmacologic option that can be tried before or alongside vitamin B6 / doxylamine.
The Ryan 2012 URCC CCOP trial (PMID 21818642; DOI 10.1007/s00520-011-1236-3) randomised 576 patients to placebo, 0.5 g/day, 1.0 g/day, or 1.5 g/day of a standardised ginger extract added to standard 5-HT3 antiemetics, starting 3 days before chemotherapy. The 0.5 and 1.0 g/day doses produced the largest reductions in acute (day-1) nausea; 1.5 g/day did not show added benefit. Several oncology supportive-care guidelines list ginger as a reasonable adjunct (not monotherapy).
Gingerols (in fresh root) and shogaols (formed when ginger is dried or cooked) are the main active compounds. Proposed mechanisms include 5-HT3 receptor antagonism (the same target class as ondansetron), faster gastric emptying, and a mild anti-inflammatory effect. Standardised extracts such as Zintona and EV.EXT 77 specify gingerol content; whole-root powder varies a lot batch to batch.
1–1.5 g/day in 2–4 divided doses is the usual effective range across indications. Above ~2 g/day, heartburn and GI upset become more common. Ginger has a mild antiplatelet effect, so people on warfarin, DOACs, clopidogrel, or high-dose NSAIDs should discuss use with their clinician. Fresh ginger tea, candied ginger, or capsules all work — in pregnancy, capsules are usually better tolerated than strong-tasting forms during peak nausea.
Myo-inositol is a sugar alcohol that acts as a second messenger inside cells for insulin signalling. It is one of the few non-prescription products with consistent randomised evidence for restoring ovulation in polycystic ovary syndrome (PCOS), with effect sizes broadly comparable to metformin and a much friendlier side-effect profile.
Women with PCOS often show altered tissue distribution of myo-inositol and D-chiro-inositol, which contributes to insulin resistance and to higher ovarian androgen output. Supplementing myo-inositol appears to improve insulin signalling and is associated with lower LH, lower free testosterone, lower fasting insulin, and more regular cycles — usually over 8–12 weeks of use.
The Unfer 2017 meta-analysis of inositols in PCOS (PMID 29042448; DOI 10.1530/EC-17-0243) pooled randomised trials and reported consistent improvements in ovulation, androgen levels, and HOMA-IR. The Raffone 2010 head-to-head trial in Gynecological Endocrinology (PMID 20222840; DOI 10.3109/09513590903366996) compared myo-inositol 4 g/day + folic acid 400 mcg to metformin 1,500 mg/day in PCOS women and found ovulation rates were similar between groups, with fewer GI side effects in the inositol arm. Smaller IVF trials suggest that inositol supplementation in the months before assisted reproduction can improve oocyte quality and reduce gonadotrophin requirements, although the evidence base is heterogeneous and not conclusive on live-birth rates.
At much higher doses (12–18 g/day), myo-inositol has shown benefit in panic disorder and OCD in small crossover trials — the Palatnik 2001 trial vs fluvoxamine (PMID 11386498; DOI 10.1097/00004714-200106000-00014) is the best-known example. These doses can cause loose stools but are otherwise well tolerated. The evidence base is far smaller than for PCOS and these uses are not first-line.
The most-studied PCOS regimen is 2 g myo-inositol + 50 mg D-chiro-inositol twice daily with meals (the 40:1 MI:DCI ratio that mirrors physiologic plasma ratios). Hormonal and cycle effects begin at 4–8 weeks; fertility outcomes typically need 3–6 months. It can be combined safely with metformin. If conception is planned, pair with methylfolate or folic acid per usual prenatal guidance. Drug interactions are minimal.
Lactobacillus rhamnosus GG (LGG, ATCC 53103) was isolated in 1983 from a healthy human gut and has become one of the most-studied probiotic strains in the world. Unlike most "gut health" blends, its evidence base is strain-specific and concentrated in a small number of well-defined indications.
The strongest evidence is in acute infectious diarrhoea in children. The Szajewska 2019 systematic review and meta-analysis in Alimentary Pharmacology & Therapeutics (PMID 31025399; DOI 10.1111/apt.15267) pooled 18 RCTs (n=4,208 children) and found LGG shortened diarrhoea duration by about 0.85 days (95% CI −1.15 to −0.56) and reduced length of hospital stay, with larger effects in European trials and smaller effects in non-European cohorts. ESPGHAN’s 2014 acute-gastroenteritis position paper (Szajewska 2014; PMID 24614141; DOI 10.1097/MPG.0000000000000320) lists LGG (alongside S. boulardii) as a probiotic with strong recommendation for use as an adjunct to rehydration. Effects are largest when given early in illness.
The Goldenberg 2015 Cochrane review of probiotics for pediatric antibiotic-associated diarrhoea (AAD) (PMID 26695080; DOI 10.1002/14651858.CD004827.pub4) pooled 23 RCTs (n=3,938) and found probiotics roughly halved AAD risk (RR 0.46, 95% CI 0.35–0.61, NNT~10). Among individual strains, LGG and S. boulardii at 5–40 billion CFU/day had the best supporting data. Typical adult and pediatric protocols use 10⁹–10¹⁰ CFU/day starting with the antibiotic and continuing 1–2 weeks after.
Early trials suggested LGG in pregnancy and infancy might reduce eczema by age 2–4 in high-risk families. Replication has been mixed and current World Allergy Organization guidance concludes the overall evidence does not support a broad recommendation. Some benefit may exist in atopy-prone families, but the finding has not held up robustly.
LGG has weak or absent evidence for IBS-D (other strains work better), Crohn’s maintenance, weight loss, mood, and generic "gut health" in asymptomatic adults. Matching strain to indication matters — generic "probiotic" marketing obscures the fact that most clinical benefits are strain-specific.
Look for products labelled "Lactobacillus rhamnosus GG" with the ATCC 53103 designation — this is the specific researched strain. Typical dose 10⁹–10¹⁰ CFU/day. Refrigerate unless the product is specifically labelled shelf-stable. Culturelle and the Valio range deliver standardised LGG; cheaper generic "rhamnosus" products may use unrelated strains with little data. Avoid in severely immunocompromised patients and those with central venous catheters because of rare reports of bacteraemia.
Silexan is a standardised oral lavender oil preparation (sold as Lasea) licensed as a medicine for generalised anxiety disorder and subthreshold anxiety in several European countries. Among herbal anxiolytics, it is unusual for having been tested head-to-head against an SSRI and a benzodiazepine in registration-grade randomised trials — and for having held up in both comparisons.
The Kasper 2014 trial in the International Journal of Neuropsychopharmacology (PMID 24456909; DOI 10.1017/S1461145714000017) randomised 539 adults with generalised anxiety disorder (DSM-5, baseline HAM-A ≥ 18) to Silexan 160 mg/day, Silexan 80 mg/day, paroxetine 20 mg/day, or placebo for 10 weeks. Both Silexan doses produced significantly larger HAM-A reductions than placebo (p < 0.01); Silexan 160 mg/day reduced HAM-A by 14.1 ± 9.3 points versus 9.5 ± 9.0 with placebo and 11.3 ± 8.0 with paroxetine. Adverse-event rates with Silexan were comparable to placebo and lower than with paroxetine. The earlier Woelk & Schläfke 2010 trial in Phytomedicine (PMID 19962288; DOI 10.1016/j.phymed.2009.10.006) compared Silexan 80 mg/day to lorazepam 0.5 mg/day in GAD; HAM-A reductions were similar, with Silexan showing none of lorazepam’s sedation or dependency signals.
Silexan is roughly 36% linalool and 34% linalyl acetate — the two monoterpenes most consistently linked to lavender’s calming effects. It is steam-distilled from Lavandula angustifolia flowers under controlled conditions to fixed pharmacopoeial specifications. Generic lavender oil products vary widely in composition and cannot be assumed to reproduce Silexan’s trial outcomes.
Silexan inhibits voltage-dependent calcium channels in neurons and shows partial agonism at 5-HT1A receptors. Crucially, it does not act at GABA-A receptors, which is consistent with the absence of sedation, dependency, and withdrawal in trial data.
Typical dose is 80 mg once or twice daily, taken with or without food. Onset is usually around 2 weeks, with maximal effect by 6–8 weeks. The most common side effect is eructation with a lavender-like taste, in roughly 1–2% of patients. Available in the US as a supplement (e.g. Calm Aid) and in Europe as a licensed medicine (Lasea). Use in pregnancy is not recommended due to limited safety data; caution is advised in children. As with any anxiolytic, do not stop a prescribed SSRI to switch to Silexan without medical advice.
Enteric-coated peppermint oil is one of the few non-prescription products explicitly recommended in the American College of Gastroenterology 2021 IBS guideline (Lacy 2021; PMID 33315591; DOI 10.14309/ajg.0000000000001036) for global symptom relief in irritable bowel syndrome. The evidence base has grown steadily since the first peppermint-oil IBS trials in the 1970s.
The active compound, l-menthol, blocks L-type calcium channels in intestinal smooth muscle, producing local relaxation of the gut wall. Enteric coating is critical: uncoated peppermint oil is absorbed in the stomach, where it tends to relax the lower oesophageal sphincter (causing reflux) and never reaches the small or large intestine in meaningful amounts. Coated preparations release menthol along the small bowel and colon — where IBS symptoms originate.
The Alammar 2019 meta-analysis in BMC Complementary and Alternative Medicine (PMID 30654773; DOI 10.1186/s12906-018-2409-0) pooled 12 RCTs (n=835 IBS patients) and reported a risk ratio of 2.39 (95% CI 1.93–2.97) for global symptom improvement and 1.78 (95% CI 1.43–2.20) for reduction in abdominal pain versus placebo, with a number needed to treat of 3 for global symptoms and 4 for abdominal pain. The earlier Khanna 2014 systematic review (PMID 24100754; DOI 10.1097/MCG.0b013e3182a88357) reached a similar conclusion across 9 RCTs. Effects are seen across IBS subtypes.
Most trials used IBgard (180 mg, sustained-release, three times daily) or Colpermin (187 mg, enteric-coated, three times daily). Generic non-enteric peppermint capsules and peppermint tea do not reproduce these results. If you’re paying for the trial-grade effect, buy a trial-grade preparation.
The most common side effect is heartburn or reflux — uncommon with properly enteric-coated products but more likely with pre-existing GERD or hiatal hernia. Headache and a peppermint-tasting belch are occasional. Peppermint oil can lower blood pressure modestly and may add to antihypertensive effects in some people. Avoid in pregnancy due to limited safety data, and stop a few days before any planned upper-GI endoscopy if your gastroenterologist requests it.
Saccharomyces boulardii is unusual among probiotics: it is a yeast rather than a bacterium. That matters clinically because antibacterial antibiotics do not kill it, so it is one of the few probiotics that can be taken at the same time as a course of antibiotics. It also has some of the better randomised-trial evidence in the probiotic space.
The Szajewska & Kołodziej 2015 systematic review and meta-analysis in Alimentary Pharmacology & Therapeutics (PMID 26216624; DOI 10.1111/apt.13344) pooled 21 RCTs (n=4,780 children and adults). S. boulardii reduced the risk of antibiotic-associated diarrhoea from 18.7% to 8.5% (RR 0.47, 95% CI 0.38–0.57; NNT~10). The effect was consistent across paediatric (RR 0.43) and adult (RR 0.49) trials. Benefit is largest when supplementation starts on day 1 of antibiotics and continues a few days to a week beyond the antibiotic course.
For preventing recurrence of C. difficile infection, S. boulardii added to standard therapy (vancomycin or fidaxomicin) reduced recurrence rates in some trials but results have been heterogeneous. The McFarland 2010 adult-focused meta-analysis (PMID 20458757; DOI 10.3748/wjg.v16.i18.2202) and the Szajewska 2015 review found a signal for C. difficile reduction in children (2 RCTs, n=579, RR 0.25) but not in pooled adult data (9 RCTs, RR 0.80, not significant). Current US IDSA / SHEA guidelines do not recommend probiotics for primary C. difficile prevention as a standard of care; some clinicians still use S. boulardii as an adjunct in selected cases.
Smaller trials suggest S. boulardii can modestly reduce the incidence of traveller’s diarrhoea when started a few days before travel and continued throughout the trip. The effect is on top of (not a replacement for) standard food and water hygiene. A typical preventive regimen is 250–500 mg twice daily.
The specific strain matters: CNCM I-745 (sold as Florastor in the US and Ultra-Levure in much of Europe) is the strain with the largest evidence base. Typical dose is 250 mg one to two times daily. Unlike bacterial probiotics, it does not require refrigeration. Avoid in severely immunocompromised patients, neonates in intensive care, and patients with central venous catheters because of rare but serious case reports of Saccharomyces fungaemia in those settings.
Red yeast rice (RYR) is a fermented rice product that has been used in Chinese cuisine and traditional medicine for centuries. It contains naturally occurring monacolin K — chemically identical to the prescription statin lovastatin. That makes RYR a pharmacologically active product that behaves like a low-dose statin, even when it is sold from a supplement shelf.
The Banach 2019 international expert review in Atherosclerosis Supplements (PMID 31451336; DOI 10.1016/j.atherosclerosissup.2019.08.023) drew on the available RYR randomised trials and reported LDL-C reductions on the order of 15–25% with standardised RYR products containing monacolin K, broadly comparable to low- or low-to-moderate-intensity prescription statins. The earlier Gerards 2015 systematic review in Atherosclerosis (PMID 25897793; DOI 10.1016/j.atherosclerosis.2015.04.004) reached similar efficacy conclusions but flagged significant uncertainty about long-term safety and the heterogeneity of products tested. Several European cardiology positions list RYR with a defined monacolin content as a reasonable option for mild hypercholesterolaemia in patients who refuse or cannot tolerate prescription statins.
The catch: in the US, FDA considers RYR containing meaningful amounts of monacolin K to be an unapproved drug, not a supplement. Manufacturers therefore either sell products with very low or variable monacolin content, market overseas, or risk enforcement action. In June 2022 the EU lowered its allowed monacolin K dose in food supplements to under 3 mg/day, citing safety concerns. Independent testing has repeatedly found monacolin K content ranging from near zero to several mg per capsule across products marketed almost identically. Without third-party assay results, you do not know what dose you are actually taking.
Because the active compound is chemically a statin, the side-effect profile mirrors lovastatin: muscle pain or weakness in a minority of users, elevated liver enzymes in a smaller minority, rare rhabdomyolysis, and drug interactions through CYP3A4 (taking RYR alongside grapefruit, some macrolide antibiotics, or azole antifungals can substantially raise monacolin exposure). Pregnancy and breastfeeding are contraindicated. As with prescription statins, modest CoQ10 depletion is plausible.
Some RYR products contain citrinin, a nephrotoxic mycotoxin produced during certain Monascus fermentations. EU regulation caps citrinin in food supplements made from RYR at 100 mcg/kg; US regulation is weaker. Reputable brands disclose citrinin testing on the label or certificate of analysis.
If you can tolerate a prescription statin, the prescription is preferred — the dose is known, monitoring is built in, and the safety follow-up is more rigorous. RYR with defined monacolin K content is a reasonable option for patients who cannot or will not take a prescription statin, but the pharmacology, drug-interaction risk, and monitoring should be treated as if you were taking a statin, because pharmacologically you are.
Most probiotic claims are vague and strain-agnostic. Bifidobacterium infantis 35624 (now reclassified as Bifidobacterium longum subsp. longum 35624, sold as Align in the US) is an exception — its IBS evidence is strain-specific, placebo-controlled, and published in tier-1 gastroenterology journals.
The pivotal Whorwell 2006 dose-finding RCT in the American Journal of Gastroenterology (PMID 16863564; DOI 10.1111/j.1572-0241.2006.00734.x) compared three doses of B. infantis 35624 to placebo over 4 weeks in 362 women with IBS. The 1 × 10⁸ CFU/day dose produced statistically significant improvement in abdominal pain, bloating, bowel-habit dissatisfaction, and overall symptom relief. The lower (1 × 10⁶) and higher (1 × 10¹⁰) doses did not separate from placebo — a U-shaped dose response and a useful reminder that "more probiotic" is not always better.
The O’Mahony 2005 trial in Gastroenterology (PMID 15765388; DOI 10.1053/j.gastro.2004.11.050) showed that B. infantis 35624 (but not the comparator Lactobacillus salivarius) normalised the pro-inflammatory IL-10 / IL-12 cytokine ratio in IBS patients alongside symptom relief — a plausible mechanism linking gut microbial composition, low-grade mucosal immune activation, and IBS symptoms. Few probiotic strains have this kind of mechanism-and-outcome alignment in the same patient population.
The research dose for IBS is 1 × 10⁸ CFU/day of strain 35624. Commercial Align (Procter & Gamble) is the formulation that delivers this strain at this dose. Pharmacy-brand "Bifidobacterium infantis" products usually use unrelated strains that do not have the same data. If you are treating IBS, specify the 35624 strain on the label.
Onset of symptom improvement is typically 2–4 weeks of daily use. Across IBS as a class, the Ford 2014 meta-analysis in American Journal of Gastroenterology (PMID 25070051; DOI 10.1038/ajg.2014.202) found probiotics overall reduced the risk of persistent IBS symptoms (RR 0.79, 95% CI 0.70–0.89), but noted that which species and strain are most effective remains uncertain — B. infantis 35624 is one of the better-supported single strains within that average. Not all patients respond. If 8 weeks of consistent use shows no benefit, continuing is unlikely to help; switching to low-FODMAP, enteric-coated peppermint oil, or gut-directed psychological therapies is reasonable. Safety is excellent — mild bloating in the first few days is the most common adverse effect.
Alpha-glycerophosphocholine (Alpha-GPC, also called choline alphoscerate) is a choline-containing phospholipid found naturally in milk and produced inside the body from phosphatidylcholine. Among choline forms sold as supplements, it has the most clinical data — mostly for cognitive decline in older adults and, in much smaller trials, for explosive athletic performance.
Alpha-GPC is registered as a prescription drug in several European countries (e.g. Gliatilin, Delecit) for cognitive deficits, mostly in mixed Alzheimer’s / cerebrovascular populations. The ASCOMALVA trial (Amenta 2012; PMID 22959283; DOI 10.1016/j.jns.2012.07.003) randomised Alzheimer’s patients with co-existing ischaemic cerebrovascular injury to donepezil + Alpha-GPC 1,200 mg/day or donepezil + placebo. The 12-month interim analysis (91 of a planned 210 patients) showed less decline on MMSE, ADAS-cog, IADL, and caregiver-distress scales in the combination arm; longer-term follow-up reports from the same group continued to favour the combination. The finding is promising but limited to that specific population — Alpha-GPC is not established as monotherapy for Alzheimer’s disease.
The Bellar 2015 RCT in the Journal of the International Society of Sports Nutrition (PMID 26582972; DOI 10.1186/s12970-015-0103-x) gave 13 college-aged men 600 mg/day of Alpha-GPC for 6 days in a placebo-controlled crossover and found a significant increase in isometric mid-thigh pull peak force versus placebo (p=0.044), with a non-significant trend on upper-body isometric force. Smaller acute-dosing studies have reported transient growth-hormone increases. The overall evidence base is much smaller than for creatine or caffeine and not all studies have been positive (e.g. acute-ingestion trials of choline-containing supplement stacks have shown no effect on power or anaerobic capacity).
Alpha-GPC is a bioavailable choline source that crosses the blood–brain barrier. Per gram, it delivers about 40% choline by mass — in the same neighbourhood as choline bitartrate, with mechanistic claims (but not yet hard outcome data) of better CNS delivery than salt forms. For everyday choline intake, eggs, liver, and soybeans deliver more choline per dollar than any supplement.
Observational and mechanistic work has linked dietary choline (and gut-microbial conversion to trimethylamine N-oxide, TMAO) to higher cardiovascular event rates in some cohorts. The relationship is not yet causal and has not been replicated in randomised trials of choline supplementation. While that question is unresolved, it makes sense to match supplemental choline intake to actual need rather than mega-dose.
300–600 mg one to two times daily is typical, with meals to reduce mild GI effects. Avoid in pregnancy due to limited safety data. Anyone with bipolar disorder should know that some choline-related compounds have been associated with mood destabilisation in case reports — evidence is limited but worth flagging if you have a personal or family history.
Most garlic supplements are sold on the strength of allicin — the pungent compound produced when fresh garlic is crushed. Aged garlic extract (AGE; the original branded product is Kyolic) is made differently: sliced garlic is soaked in dilute ethanol for up to 20 months, yielding a near-odourless, stable extract with a different (and not necessarily weaker) pharmacology. AGE is one of the better-studied garlic products, with several randomised trials in cardiovascular risk reduction.
The Ried 2020 review and meta-analysis in Experimental and Therapeutic Medicine (PMID 32010325; DOI 10.3892/etm.2019.8374) pooled 12 trials (n=553 hypertensive participants) and reported an average systolic blood pressure reduction of 8.3 ± 1.9 mmHg, with diastolic BP reduced by 5.5 ± 1.9 mmHg in the subset of 8 trials (n=374) reporting it. That is in the same range as a single first-line antihypertensive at a low dose. Effects appear most consistent with standardised AGE products specifically and more variable with generic garlic powders.
Several small randomised trials have examined whether AGE slows atherosclerosis on imaging. The Budoff 2009 RCT in Preventive Medicine (PMID 19573556; DOI 10.1016/j.ypmed.2009.06.018) showed slower coronary artery calcium (CAC) progression over 1 year with AGE plus B vitamins and folic acid versus placebo. The Matsumoto 2016 trial in the Journal of Nutrition (PMID 26764322; DOI 10.3945/jn.114.202424) used coronary CT angiography in metabolic-syndrome patients and reported a reduction in low-attenuation (lipid-rich, higher-risk) plaque with AGE 2,400 mg/day. These are among the few supplement trials to use direct imaging endpoints, but cohorts have been small (~50–65 per arm) and the findings still need larger replication before being treated as definitive.
AGE produces modest LDL reductions (typically in the 5–10% range) and small reductions in hs-CRP in pooled data. These effects are smaller than statins but appear additive on top of standard therapy. S-allyl-cysteine is the most commonly proposed contributor, with effects on endothelial function and nitric oxide availability.
AGE is well tolerated, with minimal GI effects and no garlic odour — a practical advantage over fresh garlic for daily use. It has a mild antiplatelet effect, so use caution alongside warfarin, DOACs, or high-dose NSAIDs, and stop 1–2 weeks before scheduled surgery. CYP-enzyme drug interactions are weaker with AGE than with fresh garlic or allicin-yield extracts but still possible.
Standard AGE dose in trials is 1,200–2,400 mg/day, usually divided. Look for Kyolic-branded or otherwise standardised AGE products; generic "aged garlic" products vary widely in extraction process and active-compound content. The published efficacy was earned by specific standardised preparations — that is what to buy.
Astragalus membranaceus (Huang Qi) has been a staple of Traditional Chinese Medicine for over two thousand years, used in formulas for fatigue, frequent infections, and recovery from illness. The modern supplement market for astragalus is much larger than the Western clinical-trial evidence supporting it.
Most of astragalus's modern marketing rests on cycloastragenol — a saponin derivative shown in cell culture to activate telomerase in immune cells. The first commercial product, TA-65, was studied in a one-year open-label trial in 114 cytomegalovirus-positive subjects and reported a decline in the percentage of senescent cytotoxic T cells with no change in mean telomere length (Harley 2011; PMID 20822369). This was a small, industry-supported, non-randomised study and has not been replicated in large independent trials. Cell-senescence shifts of this kind have not been linked to clinical or longevity endpoints.
The strongest body of Western evidence is in oncology supportive care. A 2006 meta-analysis pooled 34 randomised trials of astragalus-based Chinese herbal decoctions combined with platinum-based chemotherapy in advanced non-small-cell lung cancer (n > 2,800). Combination therapy was associated with reduced risk of death at 12 months (RR 0.67) and improved tumour response and chemotherapy tolerability, but study quality was low to moderate, blinding was rare, and reporting bias was likely (McCulloch 2006; PMID 16421421; DOI 10.1200/JCO.2005.03.6392). Major oncology guidelines do not incorporate astragalus into standard care.
Laboratory studies consistently show immunomodulatory effects — enhanced macrophage and NK cell activity, cytokine modulation. The bidirectional nature of these effects explains traditional use for both immune weakness and autoimmune flare, but also creates uncertainty about safety in autoimmune disease and transplantation. Astragalus should be avoided in organ-transplant recipients on immunosuppressants and in people with active autoimmune disease without practitioner oversight.
Astragalus is generally well tolerated. Bulk-herb powders, standardised root extracts, and cycloastragenol-enriched products differ by orders of magnitude in active compound content; the same labelled "1,000 mg astragalus" can deliver vastly different pharmacology. Cycloastragenol products especially benefit from third-party testing for content. Some commercial extracts have been reported to induce CYP-450 enzymes, with potential interactions for narrow-therapeutic-window drugs.
A reasonable adjunct in a TCM framework under practitioner guidance. As a stand-alone longevity or immune supplement, the human evidence doesn't match the marketing. If using, start with standardised root extract at 500–1,500 mg/day and track objective outcomes rather than relying on general "feel."
Bacopa monnieri, known in Ayurveda as Brahmi, has been used for two millennia as a memory tonic. Unlike most traditional nootropics, it has been tested in multiple placebo-controlled trials in healthy adults and has produced small but reproducible cognitive benefits, especially for memory acquisition.
A 2014 meta-analysis pooled 9 randomised, placebo-controlled trials of Bacopa monnieri in 518 healthy adults. Bacopa significantly improved cognition in domains including the timed Trail Making Test (Test B) and timed simple reaction time, with effect sizes mostly small but consistent across trials. The authors noted study heterogeneity and suggested benefits emerge with sustained use rather than acute dosing (Kongkeaw 2014; PMID 24252493; DOI 10.1016/j.jep.2013.10.053). A separate systematic review reached similar conclusions about cognitive benefits with sustained dosing (Pase 2012; PMID 22747190). A randomised placebo-controlled trial in 98 healthy older adults using a standardised extract (CDRI 08) for 12 weeks showed improvement on the Acquisition and Delayed Recall scores of the Rey Auditory Verbal Learning Test (Morgan 2010; PMID 20590480; DOI 10.1089/acm.2009.0367).
Bacopa is unusual among cognitive supplements: the effect typically emerges only after 8–12 weeks of daily use, not at a single dose. This matches the proposed mechanism — modulation of BDNF and serotonergic signalling, with downstream effects on dendritic branching — which requires sustained exposure. People who stop after 2–4 weeks usually conclude incorrectly that it does nothing.
Trial evidence is anchored to extracts standardised to bacosides (typically 45–55%), most often the Indian CDRI 08 / KeenMind formulation. Traditional whole-leaf preparations and cheaper extracts with vague standardisation aren't interchangeable. Look for stated bacoside content, not just "Bacopa."
The most common side effect is mild GI upset (nausea, loose stools), worse on an empty stomach — take with food. Some users feel mildly sedated. Bacopa modulates thyroid hormone (raising T4 in some animal studies and small trials), so caution is reasonable in thyroid disease. Mild effects on CYP enzymes mean caution with narrow-therapeutic-index drugs (warfarin, phenytoin, certain immunosuppressants).
Standard research dose: 300 mg/day of an extract standardised to ~50% bacosides, taken for at least 12 weeks before judging response. Benefits in healthy adults typically plateau by 12–24 weeks; whether continued use sustains gains beyond that is untested but mechanistically plausible.
Bilberry (Vaccinium myrtillus) became famous via a WWII story of British pilots eating bilberry jam to improve night vision — a story that is almost certainly apocryphal. The modern evidence is narrower and more specific than the marketing suggests, but some applications do hold up.
Controlled trials in healthy adults since the 1990s have repeatedly tested bilberry on night vision and found no benefit. The anthocyanins in bilberry are antioxidants with effects on capillary stability and microcirculation, but they do not improve rod-cell dark adaptation in healthy eyes. Treat night-vision claims as legacy advertising, not science.
Several Japanese randomised trials have tested bilberry anthocyanin extracts on visual fatigue from prolonged screen work. Pooled effects show modest reductions in accommodation fatigue and subjective eye-strain scores, with most blinded crossover trials struggling to distinguish bilberry from placebo on objective measures (Yoshida 2013, Alternative Medicine Review; Chu 2011 review chapter in Herbal Medicine: Biomolecular and Clinical Aspects).
The more interesting evidence is in early diabetic retinopathy and other microvascular conditions. Anthocyanin-rich bilberry extracts reduce oxidative-stress markers and improve retinal microvascular endpoints in small randomised trials. The effects are modest and adjunctive, not a replacement for glucose control or guideline-directed retinopathy therapy.
A small randomised trial of a standardised Vaccinium myrtillus anthocyanin extract in normal-tension glaucoma reported improvement in mean deviation on Humphrey visual field testing over 24 months compared to placebo (Levy 2015, Current Eye Research). The trial was small (single centre, <100 participants) and the finding has not been replicated; treat as hypothesis-generating.
Bilberry has been studied in chronic venous insufficiency, haemorrhoids, and metabolic syndrome with modest effects on capillary fragility, microcirculation, and blood pressure. For these indications, other agents (diosmin, micronised purified flavonoid fraction, horse chestnut) have stronger evidence.
Bilberry supplements vary enormously in anthocyanin content. Standardised extracts typically specify 25% anthocyanosides (often delivering 80–160 mg anthocyanins per dose). Generic "bilberry fruit powder" usually has a small fraction of the active compounds at clinical-trial concentrations. Whatever effect bilberry provides is dose-dependent on the anthocyanin content, not the gram weight on the label.
Black cohosh (Actaea racemosa; older name Cimicifuga racemosa) is the most commonly used herbal supplement for menopausal symptoms in Western countries. It occupies an awkward place in the evidence landscape: effective enough in some trials to receive attention from menopause societies, but unreliable enough across studies and flagged often enough in case reports that regulators have mandated liver-warning labels.
A Cochrane review of 16 placebo-controlled trials (n=2,027) found no consistent benefit on the frequency or intensity of hot flushes — some trials showed modest improvement, others showed none, and pooling did not produce a robust effect (Leach 2012; PMID 22786509; DOI 10.1002/14651858.CD007244.pub2). The 2023 North American Menopause Society non-hormone therapy position statement does not recommend black cohosh for vasomotor symptoms, citing inconsistent efficacy and safety concerns (NAMS 2023). The German standardised iCR/Remifemin extract has the most consistent individual-trial record but doesn't reliably outperform placebo in pooled analyses.
Unlike soy isoflavones or red clover, black cohosh does not bind oestrogen receptors. Its mechanism is unclear and probably involves serotonergic and dopaminergic effects. This means it doesn't carry the theoretical endometrial-stimulation risk of phytoestrogens, but it also doesn't reliably address oestrogen-dependent symptoms like vaginal atrophy or bone loss.
Since the late 1990s, multiple post-marketing case reports have linked black cohosh products to acute hepatitis, with a small number progressing to transplantation. A structured causality reanalysis of 69 reported cases concluded that confounders (concomitant medication, comorbid liver disease, product mislabelling) made a definitive causal link difficult, with only a minority of cases meeting probable or highly probable causality (Teschke 2009; PMID 19010650). RCT-level data have not shown elevated liver enzyme rates. The EU regulator's position is that idiosyncratic hepatotoxicity is rare but plausible, and labels must warn users to discontinue with any signs of liver injury (fatigue, dark urine, jaundice, pale stools).
Typical dose is 20–40 mg twice daily of standardised iCR/Remifemin extract or equivalent (40–80 mg total). Evidence is strongest for use up to 6 months. Avoid in pregnancy and breastfeeding (insufficient data), and use with caution in breast-cancer survivors. Avoid combination with other hepatotoxic medications and consider checking liver enzymes at baseline and during use. Stop 2 weeks before elective surgery.
A reasonable option for mild-to-moderate vasomotor symptoms in people who cannot or prefer not to use HRT, SSRIs/SNRIs, or gabapentin, and who don't have liver risk factors. A 6-month review point is sensible: if symptoms aren't materially better, stop.
Bromelain is a protein-cleaving enzyme complex extracted from pineapple stem or fruit. It has been used for decades in European medicine for post-surgical swelling and sinusitis, with a modest but credible evidence base that has not fully translated into North American practice.
Bromelain has been studied in acute rhinosinusitis with mixed but mostly favourable trial results, including a paediatric RCT showing faster symptom resolution. The German Commission E monograph supports use of bromelain (80–320 mg/day in divided doses, 7–10 days) for acute sinusitis as an adjunct to standard care, and bromelain remains available in many European pharmacies as an OTC option.
Trials in oral, orthopaedic, and plastic surgery have generally shown that bromelain modestly reduces post-operative swelling, bruising, and pain compared to placebo, with consistent but small effect sizes (roughly 20–30% reduction in oedema scores in many trials). Bromelain is used routinely in some European surgical centres; in the US it is more commonly patient-initiated than physician-prescribed.
A clinical-studies review of bromelain in osteoarthritis concluded that doses of 540–1,890 mg/day produced clinically meaningful pain relief in mild-to-moderate knee OA, with effect size in some trials approaching that of standard NSAIDs but with better GI tolerability (Brien 2004, Evidence-Based Complementary and Alternative Medicine). Head-to-head trials with NSAIDs are limited.
Bromelain reduces several pro-inflammatory mediators, modulates fibrin breakdown, and has mild anti-platelet effects. A portion of orally ingested bromelain remains enzymatically active after absorption (Maurer 2001; PMID 11577981), which is unusual for an orally-dosed proteolytic enzyme and is part of the basis for systemic anti-inflammatory effects.
For systemic anti-inflammatory effect, take between meals on an empty stomach; with food, bromelain acts mostly as a digestive enzyme instead. Standard dose ranges from 500 GDU (~500 mg) two to three times daily for inflammatory indications. Main risks: mild anti-platelet effect (caution with warfarin, DOACs, antiplatelet drugs, and perioperatively); rare allergic reaction in people with pineapple, latex, or related allergies; occasional GI upset. Stop 1–2 weeks before elective surgery.
Cacao flavanols — the bitter polyphenols in dark chocolate and cocoa — have been studied for decades as putative cardiovascular protectants. In 2022, the COSMOS trial (n=21,442) provided the first large randomised, placebo-controlled evidence that a cocoa flavanol supplement reduces cardiovascular death. The result was modest and didn't hit the primary endpoint, but it shifted the evidence landscape.
Over a median of 3.6 years, participants randomised to 500 mg/day cocoa flavanols (including ~80 mg epicatechin) had a 10% reduction in the primary composite cardiovascular events outcome that did not reach statistical significance (HR 0.90, 95% CI 0.78–1.02). Cardiovascular death — a secondary endpoint — was reduced by 27% (HR 0.73, 95% CI 0.54–0.98). Sensitivity analyses adjusted for non-adherence pushed several outcomes toward stronger effects (Sesso 2022, COSMOS, American Journal of Clinical Nutrition; the trial registry record is NCT02422745).
Cacao flavanols, especially the catechin/epicatechin fraction, raise endothelial nitric-oxide signalling, improve flow-mediated dilation, modestly lower blood pressure, and have mild anti-platelet effects. A Cochrane review of 35 short-term trials concluded that cocoa products lower systolic BP by about 1.8 mmHg and diastolic by 1.8 mmHg in adults, with greater effects in hypertensives (Ried 2017; PMID 28439881; DOI 10.1002/14651858.CD008893.pub3). An earlier meta-analysis of cardiovascular surrogate endpoints reached similar conclusions on lipid and endothelial outcomes (Hooper 2012, American Journal of Clinical Nutrition).
COSMOS used a standardised cocoa flavanol supplement (500 mg flavanols, ~80 mg epicatechin per daily dose; the CocoaVia formulation). Commercial dark chocolate delivers a highly variable 50–500 mg flavanols per 100 g, and "Dutched" (alkalised) cocoa loses most of its flavanol content. Eating enough dark chocolate daily to match COSMOS would deliver several hundred kcal of sugar and fat — not a serious cardiovascular strategy.
If you want what was tested, the standardised cocoa flavanol supplement is the only direct match. If you prefer food, choose minimally processed dark chocolate (>70% cocoa, no "processed with alkali"). Real-world dietary intake almost certainly produces a smaller effect than the trial because flavanol content varies and absorption depends on processing.
Middle-aged and older adults with cardiovascular risk factors appear to be the population most likely to gain something. No major harms in COSMOS apart from mild GI upset and the calorie cost of any chocolate-based approach. Cocoa is not a statin substitute, but a reasonable adjunct for people not eligible for or not taking lipid-lowering therapy.
Chamomile (Matricaria chamomilla) has been used for sleep and anxiety for at least three millennia. The modern evidence is real but smaller than the marketing suggests. Chamomile works — mildly — and for the right person and the right indication, mildly is enough.
A double-blind RCT in 57 outpatients with mild-to-moderate generalised anxiety disorder showed that an oral chamomile extract titrated to 1,100 mg/day produced a significantly greater reduction in HAM-A anxiety scores than placebo over 8 weeks, with response and remission rates roughly comparable to low-dose anxiolytics (Amsterdam 2009; PMID 19593179). A larger long-term-management trial in 179 GAD patients used chamomile 1,500 mg/day for 12 weeks of open-label treatment followed by a randomised continuation phase. While long-term continuation didn't significantly delay relapse versus placebo, anxiety scores remained substantially below baseline (Mao 2016, Phytomedicine).
Smaller RCTs in adults with insomnia, postpartum mothers, and elderly residents have shown modest improvements in subjective sleep quality, sleep latency (around 10–15 minutes faster sleep onset in some trials), and daytime functioning. The tea form, with 2–3 g of dried flowers per cup, delivers a smaller active dose than the standardised capsule extracts used in anxiety trials, and probably works as much through ritual and behavioural activation as pharmacology.
Apigenin, a flavonoid concentrated in chamomile, binds weakly to the benzodiazepine site of the GABA-A receptor in animal studies and accounts for most of chamomile's anxiolytic and mild sedative effect. Chamomile also contains bisabolol and matricin (precursor to chamazulene) with anti-inflammatory effects relevant to GI use. Standardised extracts often specify apigenin content (typically 1.2%).
Chamomile is in the Asteraceae family. People with severe ragweed, chrysanthemum, or daisy allergies can cross-react, occasionally with anaphylaxis. Chamomile has mild anti-platelet and anticoagulant activity; use caution with warfarin, DOACs, and antiplatelet drugs and stop 1–2 weeks before elective surgery. Pregnancy data are limited; tea-strength is widely consumed but higher-dose extracts should be avoided during pregnancy.
For anxiety: 200–1,500 mg/day of a standardised extract, with the upper end matching the trial evidence. For sleep: a cup of strong chamomile tea 30–60 minutes before bed fits well as part of a sleep-hygiene routine rather than as an isolated drug. For mild post-prandial GI upset: traditional after-meal use has modest supporting evidence (Srivastava 2010 review).
Citicoline (CDP-choline) is a naturally-occurring intermediate in phosphatidylcholine synthesis. It is licensed as a prescription drug (Somazina, Ceraxon) in Europe, Japan, and Latin America for stroke recovery and vascular cognitive impairment. In the US it is sold as a dietary supplement with broader claims that outrun the evidence.
The ICTUS trial (n=2,298) randomised acute ischaemic stroke patients to citicoline 2,000 mg/day or placebo for 6 weeks. The primary composite endpoint at 90 days — recovery on the modified Rankin Scale, NIHSS, and Barthel Index — was not significantly different between groups (Davalos 2012; PMID 22691567; DOI 10.1016/S0140-6736(12)60813-7). After ICTUS, European stroke guidelines downgraded routine use; some pre-ICTUS meta-analyses had reported a small benefit in selected subgroups, but the trial weight has shifted against generalised use in acute stroke.
The IDEALE study and other trials have evaluated long-term oral citicoline (500–1,000 mg/day, often 9–12 months) in vascular cognitive impairment after stroke or due to small-vessel disease. Pooled effects are small but consistent for the MMSE and other cognitive scales (Alvarez-Sabin 2011, Stroke; Gareri 2015 review in Clinical Interventions in Aging). Effect sizes are modest and the safety profile is unusually clean.
Smaller trials in healthy adults have produced mixed results on attention and memory. The most consistent positive signal is on sustained-attention tasks; memory benefits in non-impaired adults are inconsistent. Citicoline supports phospholipid synthesis and cholinergic tone; it doesn't add capacity to a healthy brain in the way it appears to support a damaged one.
Typical supplement dose is 250–500 mg/day. Pharmaceutical doses for stroke and cognitive decline are 1,000–2,000 mg/day. Cognizin (a branded citicoline used in multiple trials) is the formulation with the most consistent label-accuracy testing. "CDP-choline" and "citicoline" name the same molecule.
Tolerability is excellent — mild GI upset is the most common complaint. There are no major drug-interaction signals. Citicoline can lower blood pressure modestly; use caution stacking with antihypertensives. Pregnancy data are limited.
L-citrulline is a non-essential amino acid that the body converts to L-arginine, the precursor to nitric oxide. Taking citrulline raises blood arginine and downstream NO signalling more reliably than taking arginine directly, because oral arginine is largely cleared by first-pass hepatic and intestinal metabolism. Citrulline malate adds malate (a Krebs-cycle intermediate) to the amino acid in a 2:1 or 1:1 ratio.
A meta-analysis of 12 acute-dose randomised crossover trials examined citrulline supplementation (with or without malate) on high-intensity strength and power performance. Pooled across studies (single-dose or short-term), citrulline produced a small but statistically significant improvement in performance (effect size ~0.20), with the largest effects in resistance-exercise volume and lower effects on single-effort maximal strength (Trexler 2019; PMID 30895562; DOI 10.1007/s40279-019-01088-8). The 6–8 g pre-workout dose used in many trials reduces fatigue in later sets more reliably than it boosts a single 1-rep maximum.
A review of cardiometabolic trials of L-citrulline reported modest reductions in resting and exercise systolic blood pressure (typically 2–5 mmHg), improvements in flow-mediated dilation, and limited but plausible effects on arterial stiffness in adults with hypertension or pre-hypertension; effects are larger and more consistent with chronic dosing (3–6 g/day for 8+ weeks) than with single doses (Allerton 2018; PMID 30029482; DOI 10.3390/nu10070921).
A small single-blind RCT in 24 men with mild erectile dysfunction tested L-citrulline 1.5 g/day for one month versus placebo. Erection hardness score improved from 3 to 4 in 12 of 24 participants on citrulline vs 2 of 24 on placebo, with no adverse events (Cormio 2011; PMID 21195829; DOI 10.1016/j.urology.2010.08.028). The effect is smaller than that of PDE5 inhibitors, but the safety profile is excellent.
Performance: 6–8 g citrulline malate (roughly 4–5 g pure L-citrulline) about 30–60 minutes pre-workout. Vascular and ED applications: 3–6 g pure L-citrulline daily, often split. Pure L-citrulline is cheaper per effective dose than citrulline malate but lacks the small malate contribution.
Very well tolerated; no established UL for supplemental citrulline. Mild GI symptoms at >10 g/day. Use caution stacking with PDE5 inhibitors (additive hypotension) or antihypertensives. Pregnancy data are limited.
Cod liver oil has been given to children since the 19th century, originally for rickets. It fell from favour as standalone vitamin D and concentrated fish-oil products became available, then had a minor revival in the COVID-19 era when interest in vitamin D status surged. It has real advantages over separate supplements but also non-trivial risks — particularly around pre-formed vitamin A.
A 5 mL teaspoon of standard cod liver oil typically provides 400–500 mg of EPA+DHA combined, 400–1,000 IU vitamin A as retinol, and 400–1,200 IU vitamin D — depending on brand and concentration. The density is useful: one supplement covers three evidence-based deficiencies common in northern-latitude populations. Brand labels vary widely; read the per-serving values, not the front-of-pack claims.
The pre-formed retinol in cod liver oil adds up quickly. A landmark cohort study reported that women consuming >10,000 IU/day of pre-formed vitamin A in early pregnancy had ~5-fold higher risk of cranial-neural-crest birth defects compared with those consuming ≤5,000 IU/day (Rothman 1995, NEJM; PMID 7477116; DOI 10.1056/NEJM199511233332101). The Institute of Medicine subsequently set a Tolerable Upper Intake Level for adults of 3,000 µg RAE/day (~10,000 IU) for pre-formed vitamin A. A teaspoon of standard cod liver oil daily fits within that limit; a tablespoon every day will, for many products, breach it. Pregnant women should pick a vitamin-A-free fish oil plus a separate vitamin D supplement, not cod liver oil.
Per dollar of EPA+DHA, high-quality cod liver oil is competitive with generic fish oil but is less concentrated. For high-dose EPA+DHA goals (e.g. 2–4 g/day for cardiovascular indications), dedicated fish-oil capsules or icosapent ethyl (prescription) deliver more per pill. For general supplementation in northern-latitude winters — modest omega-3, fat-soluble vitamins, traditional palatability — cod liver oil has a reasonable case.
Arctic cod from Norwegian or Icelandic waters is the traditional source and tends to have the best sustainability and contaminant profile. Third-party testing for mercury, PCBs, dioxins, and oxidation (peroxide value, anisidine value, TOTOX) matters — rancid fish oil is pro-inflammatory and unpleasant. Heavily flavoured products (lemon, orange) can mask early rancidity, so prefer transparent brands.
The 1930s demonstration that cod liver oil prevented rickets is one of the oldest proven nutritional interventions. Population-level observational data during respiratory-virus seasons (including pandemic influenza work cited by Cannell 2006 in Epidemiology and Infection) suggest plausibly modest infection-rate effects mediated by vitamin D, but randomised trials of cod liver oil specifically for respiratory infection have not produced conclusive benefit. Bottom line: a sensible supplement in vitamin-D-poor latitudes if dosed within the vitamin A UL, but not a magic preventive.
D-mannose is a simple sugar related to glucose. It is absorbed in the upper GI tract and largely excreted unchanged in urine, where it competitively blocks E. coli adhesion to uroepithelial cells — the critical first step of urinary tract infection. The mechanism is elegant. For a decade the clinical evidence looked promising too. In 2024, a large, well-powered trial in UK primary care reversed that picture.
Hayward et al. randomised 598 women with recurrent UTI in UK primary care to 2 g D-mannose daily or placebo for 6 months. The primary outcome was the proportion of women with a clinically suspected UTI requiring antibiotics. Result: no significant difference between D-mannose and placebo (51.0% vs 55.7%). Secondary outcomes, including severity and symptom duration, also did not differ meaningfully. Because MERIT was larger, blinded, and placebo-controlled in a real-world primary-care population, its finding supersedes most of the earlier literature.
A 2014 Serbian RCT (Kranjcec et al., n=308) had reported UTI recurrence of 14.6% with D-mannose vs 60.8% with no prophylaxis and 20.4% with nitrofurantoin — the trial that drove the original enthusiasm. Several small open-label and observational studies added supportive signals. But these trials were smaller, often unblinded, and frequently compared against no-treatment rather than placebo. Observational and non-randomised data in UTI is particularly prone to regression-to-the-mean because recurrence naturally fluctuates.
Type 1 fimbriae on uropathogenic E. coli bind mannose residues on uroepithelial glycoproteins; exogenous D-mannose saturates those fimbriae and allows bacteria to be flushed with urine. In vitro and in urothelial organoid work, the effect is robust. What MERIT suggests is that the plausible in vitro effect does not translate to a reliable clinical benefit at 2 g/day in women with a pattern of recurrence that primary care sees.
Not first-line evidence-based prevention. A reasonable option to trial for women who prefer to avoid antibiotics, tolerate the cost, and understand the evidence is now negative in the best trial. It is very safe (mild GI upset, osmotic diarrhoea at high doses). It may still help some individuals — personal response varies — but expectation management is important.
Cranberry extract standardised to ≥36 mg proanthocyanidins has a 2023 Cochrane review showing roughly 25% reduction in recurrent UTIs in women. Vaginal oestrogen in postmenopausal women has strong evidence. Methenamine hippurate (prescription) is non-inferior to low-dose antibiotic prophylaxis in the ALTAR trial (2022). Behavioural measures — hydration, post-coital voiding, avoiding spermicides — have modest but real effects.
D-mannose remains very safe. Main side effects are bloating and osmotic diarrhoea at doses above 3 g/day. Diabetics should note it contributes to carbohydrate load — though blood glucose effects are small because most is excreted unchanged. The safety profile is not in question; the efficacy is.
Hawthorn (Crataegus species) extracts have been used in European cardiology for over a century for mild heart failure and angina. The standardised extract WS 1442 is prescribed as a drug in Germany and several other EU countries with reimbursement. Its evidence base is more substantial than most supplement consumers realise.
The SPICE trial (n=2,681) randomised patients with NYHA class II/III heart failure to WS 1442 900 mg/day or placebo in addition to standard therapy. Over 2 years, the primary endpoint (cardiac death, MI, hospitalisation for heart failure) was not reduced overall, but prespecified subgroup analyses showed significant reductions in sudden cardiac death in patients with LVEF 25–35%. The interpretation is that hawthorn adds modest benefit on top of modern heart failure therapy in specific subgroups.
A 2008 Cochrane review of 14 earlier RCTs in mild-to-moderate heart failure (n=855) found hawthorn extract improved exercise tolerance (pressure-rate product) and reduced subjective symptoms (fatigue, dyspnoea) compared to placebo. Effect sizes were modest. These trials predated widespread ACE inhibitor and beta-blocker use, so the evidence applies most directly to an earlier era of heart failure management.
Hawthorn’s active compounds (oligomeric procyanidins, flavonoids) weakly inhibit phosphodiesterase-3, enhance endothelial function, and modulate ion channels. The net effect is mild positive inotropy without increased myocardial oxygen demand — pharmacologically sensible in heart failure.
Modern heart failure therapy (beta-blockers, ACE/ARB, mineralocorticoid antagonists, SGLT2 inhibitors, sacubitril/valsartan) provides very large mortality benefits. Hawthorn should never replace these. As an add-on for symptomatic relief in patients already on optimal therapy, the evidence is modest but supportive. WS 1442 at 900 mg/day is the tested dose.
Well tolerated in trials — main side effects are mild GI upset and occasional dizziness. Some additive effects with digoxin, nitrates, and antihypertensives; coordinate with prescribing clinician. Stop 2 weeks before surgery due to theoretical effects on cardiac electrophysiology.
Panax ginseng is one of the most commercially successful traditional medicines. Its marketing claims outstrip the evidence, but there are several specific applications where controlled trials have shown real effects — typically modest in size and requiring specific preparations.
A 2021 meta-analysis in the World Journal of Men’s Health reviewed 9 RCTs (n=587) in mild-to-moderate erectile dysfunction. Korean red ginseng 1,800–3,000 mg/day improved International Index of Erectile Function scores by roughly 4 points — smaller than PDE5 inhibitors but meaningful. Onset takes 4–8 weeks; effect is not acute.
Ginseng’s effects on cognition in healthy adults are subtle. Several small trials have shown modest improvements in working memory and reduced mental fatigue. A 2018 meta-analysis concluded effect sizes were small and replication inconsistent. For frank chronic fatigue syndrome, the evidence is slightly better but still modest.
American ginseng (Panax quinquefolius) — a different species — has the better evidence for cold prevention, particularly the CVT-E002 (Cold-fX) extract. Two RCTs showed ~25% reduction in cold incidence and severity over a winter season. Korean ginseng has weaker cold-prevention evidence.
Ginseng produces modest reductions in fasting glucose and HbA1c in type 2 diabetes in meta-analyses (HbA1c reduction ~0.2%). Effects are smaller than metformin but safe for add-on use. The metabolic evidence is better for American ginseng and fermented Korean ginseng than for raw Panax.
"Red" ginseng is steamed and dried, concentrating certain ginsenosides (Rg3, Rh2). "White" ginseng is simply dried. Fermented ginseng has enhanced absorption of the key ginsenoside metabolites. Label specifics matter: look for ginsenoside content (typically 3–7% total). Avoid energy shots or "ginseng" drinks with negligible standardised content.
Mild stimulant effects can disrupt sleep in some users — take in the morning. Possible additive effects with anticoagulants and hypoglycaemic drugs. Traditional practice uses ginseng in cycles (2–3 weeks on, 1 week off), though there is no strong pharmacological rationale for cycling. Contraindicated with MAOIs.
Methylsulfonylmethane (MSM) is a naturally occurring organosulfur compound. Unlike glucosamine and chondroitin, which have loud supporters and loud detractors, MSM has quietly accumulated a small but credible body of evidence for osteoarthritis symptoms, often flying under the marketing radar.
A 2017 meta-analysis in Journal of the American College of Nutrition reviewed 7 RCTs of MSM in knee osteoarthritis. MSM 3–6 g/day reduced WOMAC pain and function scores significantly compared to placebo, with effect sizes in the small-to-moderate range. The largest individual trial (Debbi et al., 2011) found MSM 3.4 g/day reduced pain scores by 25% over 12 weeks.
Several smaller trials have tested MSM for exercise-induced muscle soreness and recovery. At 3 g/day, MSM modestly reduced delayed-onset muscle soreness and inflammatory markers after strenuous exercise. Effect sizes are small; runners and weight trainers who report dramatic effects are likely partially placebo.
MSM donates methyl and sulfur groups to metabolism, modulates pro-inflammatory cytokines (TNF-α, IL-6), and may support glutathione synthesis. It is one of several sulphur-containing compounds (along with NAC and taurine) with broad low-level effects rather than a single precise mechanism.
Combination products dominate the osteoarthritis supplement shelf. Head-to-head trials of MSM alone vs combination products suggest MSM contributes independently, but whether the combination is more effective than any single ingredient is unclear. If budget is limited, any of the three alone has about the same modest effect.
3–6 g/day divided into 2–3 doses. Onset of effect typically 2–4 weeks. Main side effects are mild GI upset, rare headache, and a "sulphur" aftertaste at higher doses. No known drug interactions. MSM is well tolerated at these doses for years in trials.
Digestive enzyme supplements are one of the fastest-growing categories in GI wellness marketing. The pharmacological rationale is simple: pancreatic insufficiency cripples digestion and enzyme replacement restores it. The practical question is how often a healthy adult actually has pancreatic insufficiency. The answer is: much less than the supplement aisle implies.
Pancreatic enzyme replacement therapy (PERT, typically porcine pancreatin products) is a mainstay for cystic fibrosis, chronic pancreatitis, pancreatic cancer, and post-pancreatic surgery. These conditions cause true enzyme deficiency, with fat malabsorption diagnosed by stool elastase <200 mcg/g or objective fat absorption testing. In these settings, prescription pancreatin is highly effective and non-negotiable.
The evidence for OTC digestive enzymes in functional GI symptoms is weak. A 2019 review in Expert Review of Gastroenterology & Hepatology concluded most studies were small, poorly controlled, or of short duration. Effects are inconsistent and often do not separate from placebo. The exception is lactase for documented lactose intolerance and alpha-galactosidase (Beano) for FODMAP bloating, both of which target specific substrates.
For specific enzyme deficiencies, targeted products work. DPP-IV enzymes for gluten cross-contamination (not celiac disease). Alpha-galactosidase for beans and cruciferous vegetables. Lactase for dairy. Bromelain and papain for inflammation-associated dyspepsia. Generic broad-spectrum "digestive enzyme" blends work less reliably because they do not match the specific substrate.
Enzyme activity degrades with heat, humidity, and time. Products labeled with IU or FCC units for each enzyme are more informative than gross-weight labels. Acid-stable enteric coatings matter — many enzymes are destroyed in gastric acid without protection. Cheap "enzyme formulas" often contain primarily protein filler with token enzyme activity.
Individuals with objective evidence of specific enzyme deficiency; adults over 70 with documented digestive symptoms (age-related pancreatic exocrine function decline is real but modest); patients with malabsorption on workup. Most healthy adults with generic "bloating" are better served addressing diet, stress, meal timing, and microbiome than dumping enzyme powders on every meal.
Glutathione is the body’s master antioxidant — a tripeptide of glutamate, cysteine, and glycine present in every cell. Supplement marketing for "liposomal" or "reduced" glutathione implies that you can raise intracellular glutathione by swallowing it. The evidence is more equivocal than the marketing.
Oral glutathione is mostly hydrolysed in the gut by gamma-glutamyl transpeptidase and peptidases, leaving glutamate, cysteine, and glycine. Early studies showed essentially no rise in plasma intact glutathione from oral dosing. Newer studies with sublingual or liposomal forms have shown modest increases in plasma glutathione (10–30%), but translation to tissue glutathione remains uncertain.
The more pharmacologically defensible approach is supplying the rate-limiting precursors: cysteine (as NAC) and glycine. The GlyNAC approach (glycine + N-acetylcysteine) has shown in several trials to restore glutathione levels in older adults and to improve markers of oxidative stress, mitochondrial function, and insulin sensitivity. This works because the body makes its own glutathione; giving precursors is cheaper and more efficient than trying to deliver the finished product.
IV glutathione has been used in specific medical contexts (paracetamol overdose, selected toxicities) with clear effect. Oral glutathione for Parkinson’s disease has been studied with mixed results. For vague "detox," "anti-aging," or "immune support" claims that drive most retail sales, the evidence does not meaningfully support premium pricing.
Liposomal formulations can improve absorption of some drugs and nutrients, but independent testing of liposomal glutathione products shows variable actual liposomal content — many are essentially ordinary glutathione with lecithin added. Third-party testing and particle-size characterisation are uncommon in the supplement market.
For raising body glutathione: NAC 600–1,200 mg/day + glycine 3–5 g/day is cheaper and more evidence-based than premium liposomal glutathione. For a specific medical indication, discuss with a clinician; IV may be appropriate. For general health, a diet rich in cruciferous vegetables (sulforaphane) and adequate dietary cysteine (eggs, whey, poultry) supports endogenous glutathione economically.
Ginkgo biloba is one of the top-selling supplements in the world and one of the most-studied herbal extracts in modern medicine. The question is not whether it has been studied but what the studies have actually shown — and the answer is more modest than two decades of marketing have suggested.
The Ginkgo Evaluation of Memory (GEM) study — the largest trial of ginkgo ever conducted — randomised 3,069 older adults to EGb 761 240 mg/day or placebo over a median 6.1 years. Primary endpoint: incidence of dementia. Result: no benefit. Ginkgo did not reduce dementia incidence, cognitive decline, or Alzheimer’s diagnosis compared to placebo. This result fundamentally shifted the evidence base against ginkgo for dementia prevention in healthy older adults.
For patients who already have mild cognitive impairment or symptomatic dementia, the evidence is slightly more favourable. A 2015 Cochrane review found EGb 761 240 mg/day produced small improvements in cognition and activities of daily living in dementia patients compared to placebo over 22–26 weeks. Effect sizes are smaller than acetylcholinesterase inhibitors.
Ginkgo has been tested extensively in tinnitus, with meta-analyses producing mixed or negative results. For intermittent claudication (peripheral arterial disease), a 2013 Cochrane review found ginkgo extended pain-free walking distance modestly compared to placebo — meaningful but smaller than exercise therapy.
Almost all positive evidence refers specifically to EGb 761 (Tanakan, Tebonin) — a proprietary extract standardised to 24% flavonoid glycosides and 6% terpene lactones, with ginkgolic acids <5 ppm. Generic ginkgo products vary enormously in specification and cannot be assumed to replicate trial results.
Ginkgo has clinically meaningful antiplatelet effects. Case reports document post-surgical bleeding, subdural haematoma, and interactions with warfarin, DOACs, and aspirin. Stop 2 weeks before surgery. Also interacts with anticonvulsants (may lower seizure threshold) and with SSRIs through MAO modulation. At appropriate doses in healthy users, ginkgo is generally safe; the interactions matter more than the isolated toxicity.
Dietary nitrate — primarily from beetroot, leafy greens, and targeted supplements — has moved from folk remedy to performance standard in endurance sports science. The mechanism (nitrate → nitrite → nitric oxide) is well characterised and the performance and cardiovascular data are consistent.
A 2020 meta-analysis in Journal of the International Society of Sports Nutrition analysed 80 trials of dietary nitrate in endurance performance. Acute supplementation (6–12 mmol nitrate, 2–3 hours pre-exercise) improved time-trial performance in events lasting 4–30 minutes by an average of 1–3%. Effects are larger in recreationally trained individuals than in elite athletes (whose baseline NO availability is already high).
Nitrate is reduced to nitrite by oral bacteria (making antibacterial mouthwash and chewing gum inadvertent performance-killers) and then to nitric oxide in hypoxic tissues. NO enhances mitochondrial efficiency, muscle fibre function, and vasodilation. The combined effect is reduced oxygen cost for a given workload.
Dietary nitrate’s effect on blood pressure is one of its best-supported outcomes. A 2013 meta-analysis in Journal of Nutrition found daily beetroot juice or nitrate supplementation (typically 8 mmol/day) lowered systolic BP by 4–5 mmHg and diastolic by ~2 mmHg. This is comparable to some low-dose antihypertensives and is driven by NO-mediated vasodilation.
Performance doses: 6–12 mmol nitrate (400–800 mg) 2–3 hours before exercise. One 500 mL beetroot juice shot or 2–3 beetroots provide this. Concentrated shots (Beet It Sport, BeetElite) standardise the dose. Leafy greens (spinach, rocket, Swiss chard) deliver similar nitrate per meal but slower to titrate.
Do not use antibacterial mouthwash or chewing gum on the day of nitrate supplementation — oral bacteria are required for conversion. Beetroot turns urine and stool red (beeturia) in roughly 10–15% of people — harmless but startling. People on nitrate medications (GTN spray, isosorbide) should coordinate to avoid additive hypotension.
5-hydroxytryptophan (5-HTP) is a precursor to serotonin, derived from the seeds of Griffonia simplicifolia. It was intensively studied in the 1970s as a potential antidepressant and sleep aid. The pharmaceutical industry later moved to SSRIs. The reasons for that move — not just commercial — remain relevant for anyone considering 5-HTP today.
Early trials of 5-HTP in depression were small, mostly non-blinded, and mixed. A 2002 Cochrane review of 5-HTP and tryptophan for depression concluded the evidence was insufficient to establish efficacy and raised safety concerns. Modern controlled trials of 5-HTP in depression are largely absent. For sleep onset and quality, evidence is also thin — small trials with inconsistent outcomes.
In 1989, an epidemic of eosinophilia-myalgia syndrome (EMS) killed 37 people and sickened 1,500+ in the US. The outbreak was traced to L-tryptophan from a specific Japanese manufacturer with a contaminated production process. 5-HTP preparations have since been associated with "peak X" contamination that may cause similar syndromes, though incidence is low. This raised durable questions about product purity in this category.
5-HTP raises brain serotonin through a direct precursor path. Combining it with SSRIs, SNRIs, MAOIs, tramadol, triptans, or other serotonergic agents can precipitate serotonin syndrome — a potentially fatal condition characterised by hyperthermia, autonomic instability, altered mental status, and neuromuscular hyperactivity. Because 5-HTP is available OTC, this risk is often underappreciated.
SSRIs raise synaptic serotonin through reuptake blockade rather than precursor loading. This is more specific, produces a more predictable pharmacokinetic profile, and is less susceptible to peripheral conversion (which depletes peripheral tryptophan and can cause GI distress and weight changes). SSRIs are not without problems, but they’re a better-characterised tool for depression treatment.
5-HTP is not a first-line recommendation for depression, anxiety, or insomnia in any major guideline. People who insist on trying it should use a pharmaceutical-grade product, start low (50 mg), not combine with any serotonergic medication, and involve a clinician for any clinically meaningful depression.
Cinnamon has been one of the most popular supplements for blood sugar control for 15 years. The evidence for a real glucose-lowering effect is consistent but small; the effect size is routinely exaggerated in marketing; and the choice between Ceylon and cassia cinnamon matters for safety at daily doses.
A 2019 systematic review in Diabetic Medicine analysed 18 RCTs of cinnamon in type 2 diabetes and prediabetes. Cinnamon reduced fasting glucose by ~5–10 mg/dL and HbA1c by ~0.2 percentage points on average. These are real but modest effects — a fraction of what metformin produces, and comparable to what dietary fibre or basic exercise achieves.
Cassia cinnamon (Cinnamomum cassia, common supermarket cinnamon) is high in coumarin — a natural compound with hepatotoxic and mild anticoagulant effects. The European Food Safety Authority sets a tolerable daily coumarin intake of 0.1 mg/kg body weight. Regular cassia cinnamon at 1 teaspoon/day can exceed this for a small adult. Ceylon cinnamon (Cinnamomum verum) has roughly 1% of the coumarin content — much safer for daily use.
Cinnamon’s proposed mechanisms include insulin-mimetic activity through hydroxycinnamaldehyde, inhibition of alpha-glucosidase (slowing carbohydrate digestion), and modulation of GLUT4 translocation. Effects are mild, not unlike many polyphenol-rich foods in modest quantities.
Supplement marketing often cites older trials that showed larger effects (some around 1% HbA1c reduction). Those trials tended to be small, short, and in cohorts with very poor baseline control. When larger, better-designed trials in better-controlled diabetic populations were done, effect sizes shrank.
If you want to use cinnamon, use Ceylon, dose 1–2 g/day with meals, and do not expect pharmaceutical effect. It is not a substitute for glucose-lowering medications or lifestyle changes. It can be a reasonable tea-time ritual with mild benefit. Marketing of "cinnamon + berberine" products generally leans on berberine (which has modest legitimate effects) more than on cinnamon.
Astaxanthin is a carotenoid produced by the microalga Haematococcus pluvialis and responsible for the pink colour of salmon, shrimp, and flamingos that consume them. It is one of the most potent antioxidants tested in vitro, but clinical applications have been narrower than its marketing suggests.
A 2018 RCT in Nutrients found that 4–12 mg/day astaxanthin for 16 weeks improved skin elasticity, reduced wrinkle depth, and reduced UV-induced erythema compared to placebo. Effect sizes are small but consistent across several Japanese trials. Astaxanthin is not a replacement for sunscreen; it acts as a low-dose systemic photoprotectant.
Small Japanese trials have shown modest improvements in eye strain, accommodation, and subjective visual fatigue in heavy screen users with 4–12 mg/day astaxanthin over 4 weeks. Mechanism plausibly involves its accumulation in retinal and ciliary tissues.
Astaxanthin produces modest reductions in triglycerides and increases in HDL in small trials. It does not affect LDL meaningfully. Effects on blood pressure are inconsistent. This is not a cardiovascular-prevention tool on the scale of omega-3 or statins; it may be a minor adjunct.
Despite popularity in endurance circles, head-to-head trials have not found consistent performance or recovery benefits from astaxanthin. A 2011 study in cyclists showed improved time-trial performance with 4 mg/day over 4 weeks, but replication has been mixed.
4–12 mg/day is the typical effective range. Products sourced from Haematococcus pluvialis (microalgae) have consistent astaxanthin content. Synthetic astaxanthin (used in salmon farming) is a different isomer mixture and has less human evidence. Read labels; generic "carotenoid" products may contain very little astaxanthin.
Astaxanthin is well tolerated. It may have mild cholesterol-, BP-, and glucose-lowering effects to watch for with corresponding medications. Can tint skin faintly orange at high doses over long periods (harmless, reversible).
Cordyceps supplements promise endurance, energy, and libido, powered by traditional Chinese medicine claims and a compelling biological story (the fungus that infects insects in the Himalayas). The reality is that most commercial cordyceps is a lab-grown biomass with weaker evidence than the marketing implies.
Traditional cordyceps is Cordyceps sinensis (now reclassified as Ophiocordyceps sinensis), harvested from high-altitude caterpillars. Wild sinensis costs $20,000–100,000 per kilogram, making commercial use infeasible at scale. Essentially all supplements use Cordyceps militaris grown on grain, which is a different species with different chemistry.
Small trials have tested CS-4 (a fermented Cordyceps sinensis mycelium preparation) on exercise performance. A 2017 RCT in healthy older adults showed CS-4 improved VO2 max and ventilatory threshold modestly over 12 weeks. Results in younger athletes have been inconsistent. The evidence base is thin and largely industry-funded.
Cordyceps has been used traditionally for kidney support and has been studied in chronic kidney disease with mixed results. Some small trials suggest modest improvements in eGFR, but replication is limited. For immune function, claims largely rely on in vitro and animal studies.
Cordycepin (3’-deoxyadenosine) and adenosine are proposed actives. Standardisation is rare in the supplement space. Dosing ranges from 1–3 g/day of whole mushroom powder to 500–1,000 mg/day of concentrated extract. Without compound standardisation, dose comparisons across products are meaningless.
Independent testing of commercial cordyceps products has found substantial variation in fungal species content (some products contain non-Cordyceps fillers), heavy metal contamination from low-quality grain substrates, and actual cordycepin content ranging from 0 to high values. Third-party tested products from established mushroom companies (e.g. those disclosing lab results) are more reliable.
Cordyceps is a reasonable experimental supplement for someone already covering basics (sleep, exercise, diet, protein) and wanting to test an adaptogen-style intervention. It is not an evidence-based first choice for endurance or energy. Expect individual variability and track objective markers (training response, VO2, daily energy) rather than relying on subjective reports.
Maca (Lepidium meyenii) is a root vegetable from the Peruvian Andes, marketed as an aphrodisiac, fertility enhancer, and energy booster. It has a strong traditional reputation, a consumer following that has driven export demand, and a clinical evidence base that is smaller and more equivocal than its profile suggests.
A 2010 systematic review in BMC Complementary and Alternative Medicine analysed 4 RCTs of maca on sexual dysfunction. Evidence was limited but suggested modest benefit in SSRI-induced sexual dysfunction and in menopausal sexual dysfunction. Effect sizes were small and trials were small. Follow-up trials have been inconsistent.
Small trials have shown maca increases sperm count and motility in healthy men over 3–4 months. Effect sizes are modest, studies small, and female fertility evidence essentially absent. For documented infertility, maca is not a substitute for reproductive endocrinology evaluation.
Despite marketing suggesting "hormone balancing," controlled studies generally show maca does not alter serum testosterone, estrogen, FSH, LH, or cortisol meaningfully. Its mechanism likely involves non-hormonal pathways (possibly related to macaenes and macamides, unique alkaloids).
Subjective energy claims are popular but poorly supported. Small cycling and endurance trials have shown minimal to no performance improvements. If energy benefit occurs, it is modest and mostly subjective.
Maca is sold as yellow, red, and black varieties with different marketing claims (red for female hormone balance, black for male fertility, etc.). Evidence for variety-specific effects is weak. Peruvian-sourced, traditionally processed (gelatinised or cooked) maca is generally considered better tolerated than raw powder. Dose is typically 1.5–3 g/day.
Maca is generally safe at culinary-to-supplement doses, with main side effects being mild GI upset. Mild goitrogenic potential (like most cruciferous vegetables) — caution with thyroid conditions at high doses. Hormone-sensitive conditions warrant caution despite lack of clear hormonal activity.
When the FDA banned ephedra in 2004 following deaths linked to weight-loss and pre-workout supplements, the industry pivoted to bitter orange (Citrus aurantium), marketed as a "safe, natural" thermogenic. The primary alkaloid, p-synephrine, is structurally similar to ephedrine, and in combination with caffeine it reproduces many of ephedra’s cardiovascular effects.
p-synephrine is a trace amine that weakly stimulates beta-3 adrenergic receptors, with some activity at alpha-1 and beta-1. In isolation at modest doses it has a more limited cardiovascular effect than ephedrine. But synephrine is rarely alone: most weight-loss and pre-workout products combine it with caffeine (often >200 mg), other stimulants (octopamine, hordenine, yohimbine), and sometimes adulterants. These combinations amplify cardiac effects substantially.
Published case reports document myocardial infarction, ischaemic stroke, ventricular arrhythmia, and sudden cardiac death in otherwise healthy users of bitter orange/caffeine combinations. The FDA MedWatch database contains dozens of serious adverse event reports. A 2012 systematic review in Fitoterapia documented cardiac deaths linked to such products.
Meta-analyses show bitter orange, alone or with caffeine, produces weight loss of around 1–2 kg more than placebo over 6–12 weeks. Effect sizes are modest and unlikely to justify the cardiovascular risk.
Synephrine is banned in competitive sports by WADA. Some products tested positive for octopamine (also banned). Athletes subject to drug testing should avoid any product containing bitter orange extract. For consumers, the FDA has issued multiple warning letters but does not require bitter orange to carry warnings as ephedra did.
Anyone with hypertension, coronary disease, arrhythmia, anxiety disorders, or on MAOIs should avoid synephrine-containing products completely. Pregnancy is an absolute contraindication. People with any cardiac risk factors — family history of early MI, smoking, diabetes — should not use these products.
For weight loss: caloric restriction, protein-first meals, exercise, medical weight-loss medications (GLP-1 agonists) for eligible patients. For performance: caffeine at 3–6 mg/kg has predictable ergogenic benefit without the same cardiac risk. The evidence-based pre-workout is coffee.
Yohimbe (Pausinystalia yohimbe) is an African tree whose bark contains yohimbine — a potent alpha-2 adrenergic antagonist. Prescription yohimbine exists as a historical erectile dysfunction drug; bulk bark extracts sold as libido, weight-loss, and pre-workout supplements are a different matter. The toxicity profile has earned yohimbe bark a permanent seat at the top of poison control call lists for botanical supplements.
A 2015 analysis of poison control calls in Drug Testing and Analysis reviewed 238 yohimbe-related cases. Severe adverse events included hypertensive crisis (systolic BP >180 mmHg), tachyarrhythmia (heart rate >140 bpm), syncope, seizures, and rhabdomyolysis. ICU admission occurred in roughly 10% of serious cases.
Yohimbine content in commercial yohimbe bark products varies from 0 to >100 mg per dose — sometimes without any indication on the label. A 2015 analysis of 49 yohimbe-containing supplements in Drug Testing and Analysis found labels frequently misrepresented actual yohimbine content, with some products containing 3–5 times the label claim. Consumers titrating dose based on labels have no reliable information.
Yohimbine interacts severely with MAOIs (risk of hypertensive crisis), SSRIs/SNRIs (risk of anxiety/panic, serotonin interactions), tricyclics, and other sympathomimetics (additive cardiac toxicity). It can destabilise blood pressure in hypertensive patients and precipitate panic attacks in anxiety-prone individuals.
Prescription yohimbine at regulated doses (5.4 mg three times daily) has modest ED evidence. Bulk bark products aimed at libido or weight loss typically contain much higher doses in uncontrolled combinations with caffeine and other stimulants. The proposed alpha-2 antagonist fat-loss mechanism is real but clinically trivial in most users.
Anyone with cardiovascular disease, hypertension, anxiety or panic disorders, pregnancy, liver or kidney disease, bipolar disorder, or on psychiatric medications. Effectively, most of the population.
If yohimbine is medically indicated, a prescription product at a defined dose under medical supervision is the only responsible route. Over-the-counter yohimbe bark products fail the most basic criteria of predictable dosing and acceptable risk-benefit and should be avoided.
SARMs (Selective Androgen Receptor Modulators) are a class of compounds that activate androgen receptors in muscle and bone while, in theory, minimising activity in prostate and other tissues. Several have been in clinical development for cachexia, sarcopenia, and osteoporosis. None are FDA-approved for any indication. Yet ostarine, andarine, ligandrol, and others are widely sold online as "research chemicals" with predictable adverse events and regulatory action.
A 2020 JAMA Internal Medicine case series documented drug-induced liver injury (DILI) in young healthy men using ostarine, ligandrol, and related SARMs. Presentations included cholestatic hepatitis with bilirubin >20 mg/dL, some requiring hospitalisation. Unlike classical anabolic steroid hepatotoxicity, SARM DILI can occur at recreational doses over 8–12 weeks.
SARMs potently suppress endogenous testosterone production in men. Recovery after cycles is variable; some users develop persistent hypogonadism requiring testosterone replacement. Women using SARMs can develop voice deepening, clitoral hypertrophy, and menstrual irregularities, some of which are irreversible.
SARMs lower HDL cholesterol significantly (often 20–40% reductions) and raise LDL. Clinical trials of enobosarm (ostarine) showed consistent adverse lipid changes even at low doses. Reversal typically occurs after discontinuation but the cumulative exposure effect of stacking cycles is unknown.
Independent testing of SARM products consistently shows: mislabelled compounds, undeclared anabolic steroids, undeclared selective estrogen receptor modulators, heavy metals, and label doses divergent from actual. A 2017 JAMA analysis found only 52% of purchased SARM products contained the labelled compound. Buyers do not know what they are taking.
All SARMs are banned by WADA, NCAA, military testing programs, and most professional sports organisations. Positive tests have ended many careers; ostarine is a particularly common positive because of food and supplement contamination even in athletes who did not intentionally use it.
SARMs are not legal to sell for human consumption in the US, EU, UK, Canada, or Australia. Vendors sidestep this with "research chemicals" labels that would not survive a regulatory challenge but that allow grey-market sales. The FDA has issued warning letters, some companies have been fined, and state attorneys general have filed consumer-protection cases.
Some SARMs are in Phase 3 trials for specific medical indications (cachexia, sarcopenia). If approved, use would be under medical supervision with monitoring, not as recreational anabolics. Self-medication with unapproved SARMs at unknown purity is fundamentally different from regulated medical use.
DMAA (1,3-dimethylamylamine), DMHA (1,5-dimethylhexylamine), DMBA, and an ongoing rotation of "novel" stimulant amines are the chemical successors to ephedra in the pre-workout and weight-loss supplement space. Each new compound is marketed until regulators catch up, then replaced with a slightly different molecule. The pattern reflects regulatory arbitrage, not innovation.
DMAA was implicated in the deaths of US military personnel during physical training in 2011–2012. Case reports documented myocardial infarction and haemorrhagic stroke in young healthy soldiers using DMAA-containing supplements (Jack3d, OxyElite Pro). The FDA issued warning letters in 2013 and DMAA was removed from the US supplement market — but not reliably from every product labelled as such.
After DMAA was pushed out, DMHA appeared, followed by octodrine, phenylethylamine derivatives, and 1,3-DMBA. Each has a similar pharmacology: potent sympathomimetic with unclear therapeutic index and rapidly accumulating adverse event reports. The FDA has issued warning letters for DMHA. Each replacement is slightly restructured to evade regulation while preserving the stimulant effect — and the cardiovascular risk.
These compounds are typically combined with high-dose caffeine (300–400 mg), yohimbine, synephrine, and sometimes clenbuterol analogues or undeclared amphetamine-class substances. The summed effect is a substantial sympathomimetic load with unpredictable individual response, particularly in people with undiagnosed cardiac conditions.
Independent analysis of pre-workout supplements regularly finds: undeclared pharmaceutical stimulants (amphetamines, ephedrine), compounds banned in sport, mislabeled ingredient content, and heavy metal contamination. A 2019 JAMA Network Open analysis found dozens of pre-workout products contained unapproved stimulants.
Red flags on labels: proprietary blends that do not list individual ingredient doses; compounds ending in "-amine" that sound pharmaceutical; websites that are not the brand’s official site; claims of "stronger than banned" products; dramatic energy/focus claims that resemble ADHD medication effects; user forum mentions of "feeling tweaky" or needing cardiac medications after use.
Pure caffeine (3–6 mg/kg, up to 400 mg/day), creatine monohydrate, beta-alanine, citrulline malate, and beetroot/nitrate are the evidence-based pre-workout stack. None of them require novel stimulant chemistry. Stick to products that list individual ingredient doses, are third-party tested (NSF Certified for Sport, Informed-Sport), and have simple ingredient panels.
Tianeptine is a prescription antidepressant in parts of Europe, Asia, and Latin America. In the US it has never been approved as a medication but is not a controlled substance, creating a regulatory loophole. Products marketed as "nootropics," "mood enhancers," or "research chemicals" — with brand names like Za Za and Tianaa — have been implicated in a growing number of hospitalisations and deaths.
At therapeutic antidepressant doses (12.5 mg 2–3 times daily), tianeptine acts through glutamate modulation. At supranormal doses (50–500+ mg/day), its activity at mu-opioid and delta-opioid receptors dominates. Users seeking euphoria escalate rapidly; tolerance develops; withdrawal resembles opioid withdrawal with anxiety, sweating, tachycardia, and severe dysphoria. Physical dependence is well documented.
CDC analysis of poison control data found tianeptine exposure cases in the US rose from 11 in 2014 to over 150 per year by the early 2020s. Kentucky, Florida, Georgia, Tennessee, Alabama, and Michigan have each scheduled tianeptine as a controlled substance in response to local epidemics. Several states have reported overdose deaths, sometimes in combination with other substances.
Tianeptine products are sold in gas stations, head shops, and online with friendly packaging that obscures the pharmacology. Buyers frequently do not know they are taking an opioid-like substance with dependence potential. Hospital presentations involve patients seeking help for "supplement withdrawal" without realising they are opioid-dependent.
Acute toxicity can include respiratory depression, cardiac arrhythmia, seizures, and coma. Withdrawal typically starts within 12 hours of last use and peaks at 36–72 hours. Buprenorphine can treat both acute intoxication (in overdose) and withdrawal; naloxone has variable effectiveness.
FDA has issued warning letters to multiple tianeptine distributors and there have been seizures. The DEA has considered federal scheduling. Until federal action is complete, tianeptine remains legally available in many US states despite clear evidence of abuse potential.
Treat this as an opioid use disorder, not a supplement problem. Contact SAMHSA’s helpline (1-800-662-4357) or an addiction medicine physician. Abrupt discontinuation from high-dose daily use causes significant withdrawal; medically supervised tapering or buprenorphine induction is often required.
In the history of global health, oral rehydration therapy (ORT) is arguably the most cost-effective medical intervention ever developed. Before its widespread adoption, acute diarrhoeal disease killed an estimated 5 million children per year globally. ORT reduced that toll dramatically — and the formulation continues to be improved and distributed at a cost of pennies per dose.
During the Bangladesh war of independence, cholera swept refugee camps and intravenous saline was scarce. Physicians Dilip Mahalanabis and David Nalin demonstrated that an oral sodium-glucose solution could replace IV fluids for all but the most severe cases — at a cost of less than $0.10 per patient. The observation was published, refined, and eventually operationalised as the WHO/UNICEF oral rehydration salt sachets now distributed worldwide.
Original WHO-ORS (1975) had 90 mmol/L sodium and 111 mmol/L glucose. The reduced-osmolarity formula adopted in 2002 (75/75 respectively) showed in meta-analysis better stool output reduction and lower rates of IV fluid fallback in children with non-cholera diarrhoea. This has been the standard since.
Modern applications of WHO-style ORS extend to elderly patients with viral gastroenteritis, post-operative dehydration, moderate heat illness, long-haul air travel, hangover recovery, and endurance athletic events. The underlying physiology (SGLT1 cotransport) is the same.
Pedialyte, Hydralyte, LMNT, DripDrop, and prescription ORS packets (Electrolyte Solution) approximate the WHO formula with varying degrees of accuracy. Pedialyte is closest to the reduced-osmolarity WHO formula. Sports drinks are not equivalent: sodium content is roughly a quarter of ORS and glucose content is often higher than optimal for rehydration.
WHO home-prep formula: 1 litre of clean water, 6 teaspoons sugar, 1/2 teaspoon salt. This approximates the original ORS for emergency use when packets are unavailable. Commercial packets are more consistent and include additional components (potassium, citrate) that matter for children and severe cases.
For any patient with signs of severe dehydration (sunken eyes, lethargy, no urine for 8 hours, altered consciousness, cool mottled skin), for infants with severe vomiting, or for cholera-like high-volume watery diarrhoea, IV rehydration in a healthcare setting is required. ORT works for moderate dehydration; severe dehydration needs parenteral fluids.
Human breastmilk is a near-complete food for the first six months of life with a single, clinically important exception: vitamin D. Average breastmilk content sits around 25–78 IU/L, far below an infant's daily requirement. The American Academy of Pediatrics (AAP) has recommended 400 IU/day of supplemental vitamin D for all breastfed and partially breastfed infants since 2008, beginning in the first few days of life and continuing until the child reliably consumes 1,000 mL/day of fortified formula or, after weaning, the equivalent intake from fortified cow's milk.
The 2008 AAP clinical report responded to a documented resurgence of nutritional rickets in U.S. breastfed infants. Wagner and Greer's pediatric review summarized case series from across the southern U.S., Canada, and the U.K. showing rickets in exclusively breastfed, dark-skinned infants whose mothers were themselves vitamin D insufficient. Skin synthesis from sun exposure cannot be relied on for infants — AAP advises keeping babies under six months out of direct sun, and sunscreen blocks cutaneous vitamin D production.
U.S. infant formula is fortified to deliver about 400 IU vitamin D per litre. An infant taking less than ~1 L/day of formula falls short of the AAP target and should also receive supplementary drops — this is commonly missed. Health Canada uses the same 400 IU recommendation; the Canadian Paediatric Society advises supplementation for all breastfed infants and recommends 800 IU/day during winter months above 55°N latitude.
The Hollis 2015 trial in Pediatrics showed that giving the lactating mother 6,400 IU/day raised breastmilk vitamin D enough to keep her exclusively breastfed infant at 25(OH)D levels equivalent to direct infant supplementation with 400 IU. This is now an accepted alternative for families who prefer to dose the mother rather than the baby, but the AAP still positions direct infant supplementation as the default first-line strategy because adherence is more easily verified.
Liquid vitamin D drops are typically formulated so that one drop = 400 IU. Dispense onto a clean nipple, the corner of a pacifier, or directly into the corner of the mouth. Never use a tablespoon or measure with a household spoon — pediatric vitamin D overdose poisonings have been traced to 10x dosing errors with concentrated 5,000–15,000 IU/drop products marketed to adults. Use only products explicitly labelled for infants.
Routine 25(OH)D testing in healthy term infants is not recommended by AAP, the Endocrine Society, or USPSTF. Test only when there are clinical features of rickets (bowed legs, delayed gross motor milestones, frontal bossing) or in children with malabsorption, chronic kidney disease, anticonvulsant use, or prolonged inadequate intake.
Reviewed against 5 peer-reviewed sources.
Iron is the most common single-nutrient deficiency worldwide, and infants 6–24 months are the most vulnerable group. Iron deficiency in this window is linked to lower scores on tests of cognitive and motor development that, in some long-term cohort studies, do not fully reverse with later iron repletion. The supply side — how iron is delivered through breastmilk versus formula — is therefore one of the most consequential decisions in early infant nutrition.
Breastmilk contains roughly 0.3–0.4 mg/L of iron. About 50% is absorbed because of lactoferrin and the absence of competing minerals — one of the highest absorption fractions of any food. Healthy term infants are born with iron stores that, in combination with breastmilk, typically last about six months. After that, the supply gap widens and complementary foods become essential.
U.S. iron-fortified formulas contain 10–13 mg/L of iron, of which about 4–10% is absorbed because formula iron faces inhibitors (calcium, casein) without the support of lactoferrin. The total amount delivered is still substantially higher than breastmilk. Low-iron formulas (<6 mg/L) are no longer recommended in any U.S. or Canadian guideline; AAP issued a 1999 statement explicitly opposing them.
The AAP recommends that exclusively or partially breastfed infants begin 1 mg/kg/day of supplemental iron at 4 months, continuing until appropriate iron-rich complementary foods are reliably introduced (typically 6 months). This is one of the more contested AAP guidelines internationally — the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) does not endorse universal supplementation for term breastfed infants in well-nourished populations, citing higher iron status and lower endemic deficiency in Europe. Pediatricians in the U.S. typically follow AAP; in Europe, watchful waiting is the more common approach.
Preterm infants miss the third-trimester iron transfer and have substantially higher needs. AAP recommends 2 mg/kg/day starting at 1 month for preterm infants; ESPGHAN broadly agrees. Low-birth-weight infants, infants of mothers with iron deficiency anemia in pregnancy, and infants who experience early (<1 minute) cord clamping are also at higher risk and should be supplemented.
Pediatric ferrous sulphate drops remain first-line. Ferrous bisglycinate (chelated iron) shows comparable efficacy with less GI upset in adult trials, but pediatric data are sparser. Whichever form is used, give once daily on an empty stomach when possible, with a vitamin C source (a few mL of orange juice in older infants), and at least one hour from milk feeds, calcium, and antibiotics.
The AAP recommends universal screening for iron deficiency anemia at 12 months using hemoglobin plus a confirmatory ferritin or reticulocyte hemoglobin (CHr). USPSTF rates the same screening as "I" (insufficient evidence) but does not contradict the AAP position.
Reviewed against 6 peer-reviewed sources.
Fluoride is unique among supplements aimed at children because the U.S. Public Health Service first recommended community water fluoridation 80 years ago and the case for it has been re-evaluated continuously since. For most children in fluoridated U.S. metropolitan areas, dietary fluoride supplements are not necessary. But roughly a quarter of U.S. households — primarily rural well-water users — do not have access to fluoridated water, and for those children, the American Academy of Pediatric Dentistry (AAPD) and AAP still recommend prescription fluoride supplementation in specific dose-by-age windows.
The AAPD/AAP fluoride supplementation schedule (last revised 2023) bases dose on the child's age and the fluoride concentration in their primary drinking-water source. For water below 0.3 ppm fluoride, supplementation is 0.25 mg/day from age 6 months to 3 years, 0.5 mg/day from 3 to 6 years, and 1.0 mg/day from 6 to 16 years. For water in the 0.3–0.6 ppm range, the doses begin at age 3. For water at >0.6 ppm, no supplementation is recommended at any age.
Pediatricians should not prescribe fluoride drops without first knowing the household water's fluoride content. Municipal supplies report on annual Consumer Confidence Reports; private wells must be tested independently. The CDC's "My Water's Fluoride" tool covers many U.S. states. Without a tested value, dose recommendations are guesses.
The AAPD revised its toothpaste guidance in 2014 to recommend a smear (rice-grain) of fluoride toothpaste from first tooth eruption and a pea-sized amount from age 3, twice daily. This delivers a topical fluoride dose that, in cariogenic children, may be more important than supplementation. Children younger than 6 swallow a meaningful fraction of toothpaste, which is one reason supplementation timing should account for total daily intake.
Excess fluoride in the tooth-development years (roughly birth to 8) causes dental fluorosis, ranging from faint white streaks to brown mottling. The 2010 update of the supplementation schedule reduced the previous 0–6 month fluoride recommendation (0.25 mg/day) to none, and pushed the start of supplementation to 6 months — specifically to lower fluorosis risk in deciduous tooth enamel.
Some pediatric dentists deviate from the standard schedule based on individual caries risk. A child in a non-fluoridated area with active caries, recent restorations, or visible plaque may benefit from fluoride varnish applications (every 3–6 months) rather than daily drops. The U.S. Preventive Services Task Force gives an "A" recommendation to fluoride varnish for primary teeth in all children younger than 5.
Reviewed against 5 peer-reviewed sources.
Choline is one of the most under-appreciated nutrients in pregnancy. The Adequate Intake (AI) for pregnancy is 450 mg/day; for lactation, 550 mg/day. NHANES data consistently show that more than 90% of pregnant women in the United States fall below the AI, and most prenatal vitamins contain little or no choline. Yet randomized controlled trials in late pregnancy now show measurable differences in offspring attention, processing speed, and visuospatial memory tied to maternal choline intake.
Choline is the precursor for phosphatidylcholine (a major component of cell membranes, especially in brain and liver), acetylcholine (a key neurotransmitter), and betaine (a methyl donor that intersects with folate and B12 metabolism). The fetal brain undergoes rapid dendritic and synaptic growth in the third trimester, drawing heavily on maternal choline supply. Choline crosses the placenta against a concentration gradient, raising fetal plasma choline three- to fourfold above maternal levels — an active prioritization that depletes the mother if intake is insufficient.
Two double-blind RCTs from the Caudill group at Cornell tested 480 vs 930 mg/day choline in the third trimester. The 2018 study (FASEB Journal) measured infant information processing speed at 4, 7, 10, and 13 months — the higher-dose group consistently outperformed. The 2021 follow-up at age 7 (Bahnfleth et al., FASEB Journal) found that children whose mothers received 930 mg/day showed superior sustained attention compared to controls. Effect sizes were moderate but the studies are unusual in pediatric nutrition for showing maintained benefit several years post-exposure.
Choline is bulky — 450 mg in tablet form is a meaningful fraction of a multivitamin's total mass. To keep prenatal supplements small enough for women with morning sickness to swallow, manufacturers have historically left choline out. A 2018 American Medical Association policy statement called on prenatal vitamin makers to include choline at evidence-based levels. As of 2026, only a minority of prenatal products provide >100 mg.
Three large eggs (~440 mg) get most pregnant women to the AI in a single meal. Beef liver, salmon, chicken, and dairy contribute meaningfully; legumes and cruciferous vegetables contribute modest amounts. Vegan diets without supplementation reliably fall below 200 mg/day. For women who don't reach 450 mg from food, a stand-alone choline bitartrate or sunflower-lecithin supplement of 250–500 mg/day fills the gap.
The U.S. Tolerable Upper Intake Level (UL) for choline is 3,500 mg/day. At very high single doses (>7.5 g) some adults experience fishy body odor, hypotension, or sweating. None of the prenatal trials at 930 mg/day reported safety concerns. Choline interacts with folate metabolism — women on high-dose folate (e.g., MTHFR genotype management) should still meet the choline AI rather than rely on folate alone for methylation.
Reviewed against 6 peer-reviewed sources.
Vitamin K prophylaxis at birth is one of the most studied and effective neonatal interventions in modern medicine. A single 0.5–1 mg intramuscular dose has been the standard since the 1960s, virtually eliminating a once-fatal disease called Vitamin K Deficiency Bleeding (VKDB) of the newborn. Despite that record, refusal of the injection has risen in some U.S. communities, and pediatric hospitals have reported clusters of late-onset VKDB — including infant deaths and permanent neurological disability — that would not have occurred had the injection been given.
Vitamin K is a clotting cofactor; without it, factors II, VII, IX, and X cannot be activated. Newborns are vitamin K deficient by default: vitamin K crosses the placenta poorly, breastmilk contains very little, and the infant gut has not yet been colonized with K-producing bacteria. This deficiency window is widest for exclusively breastfed infants and lasts for the first several months.
Early VKDB (first 24 hours) is uncommon and almost exclusively associated with maternal anticonvulsant or anticoagulant use. Classic VKDB (2–7 days) presents as bleeding from the umbilical stump, mucous membranes, or circumcision sites. Late VKDB (2 weeks to 6 months) is the most dangerous form — about half of cases present with intracranial hemorrhage. Without prophylaxis, the AAP estimates late VKDB rates of 4.4–7.2 per 100,000 live births; with IM prophylaxis, the rate is essentially zero.
In 1990, a single observational paper by Golding et al. in BMJ reported a possible association between IM vitamin K and childhood leukemia. Subsequent and much larger case-control studies (Roman 2002, Fear 2003, Parker 1998 among others) found no such association, and the original signal was attributed to confounding by injection use in higher-risk newborns. The AAP, AAFP, and ACOG explicitly endorse IM vitamin K as safe; the leukemia hypothesis is considered refuted.
Some parents request oral vitamin K. Multiple oral protocols exist (most commonly 2 mg at birth, 2 mg at 1 week, 2 mg at 4 weeks for breastfed infants). All oral regimens have lower late-VKDB protection than a single IM dose. Denmark and the Netherlands have used oral protocols, but late-VKDB cases have been documented even with full adherence. The AAP recommends IM prophylaxis as first-line and considers oral acceptable only when parents refuse IM, with explicit informed consent about the residual risk.
A 2013 CDC MMWR report described five Nashville-area infants with late VKDB and intracranial hemorrhage between February 2013 and September 2013. All had refused vitamin K injection at birth. Three of the five required emergency neurosurgery. The cluster was widely cited as evidence that refusal is not a low-stakes choice. Similar clusters have since been reported from Oregon, Iowa, and the U.K.
The IM injection delivers a single dose of phytonadione (vitamin K1) within the first hour of life, preventing all three forms of VKDB with near-100% efficacy and no demonstrated long-term harms. Refusing the injection is a position with consequences that current evidence does not justify.
Reviewed against 6 peer-reviewed sources.
Prenatal multivitamins are a $1.6-billion U.S. market and almost every brand claims to provide "complete" prenatal nutrition. The reality, when measured against the American College of Obstetricians and Gynecologists' (ACOG) committee opinions and the National Academies' Dietary Reference Intakes, is that most over-the-counter prenatals are missing or under-dosing several key nutrients. This is what to actually look for on the label.
The single most consequential prenatal nutrient. The U.S. Public Health Service recommends 400 mcg/day of folic acid for all women capable of pregnancy and 600 mcg/day during pregnancy itself. Neural tube closure occurs by day 28 post-conception, before most women know they are pregnant. Either folic acid or methylated folate (5-MTHF / L-methylfolate) is acceptable; women with two MTHFR C677T variants may prefer 5-MTHF.
The Institute of Medicine's RDA for pregnancy is 27 mg/day. Most multivitamins meet this; the question is whether you tolerate the form. Ferrous bisglycinate causes less constipation than ferrous sulphate but is more expensive. Take with vitamin C and away from calcium, dairy, and thyroid medication.
The American Thyroid Association recommends 150 mcg/day of iodine for all pregnant and lactating U.S. women, but the AAP's 2014 review found that fewer than 50% of prenatal vitamins on the U.S. market contain it. Iodine deficiency in pregnancy is the leading global cause of preventable cognitive impairment in offspring. Check the label and verify "potassium iodide" or "iodine" appears with at least 150 mcg.
Almost universally absent from over-the-counter prenatals or present at token doses (e.g., 25–55 mg). The 2017 AMA resolution called on manufacturers to add choline at evidence-based levels; only a few prenatals (Needed, FullWell, Ritual Essential, ChlorPhos) do so as of 2026. If your prenatal lacks choline, eat eggs daily or add a stand-alone choline supplement.
ACOG and the FAO recommend at least 200 mg DHA/day in pregnancy and lactation. Many prenatals omit DHA or sell it as a separate softgel. Algal DHA is plant-based and lower in mercury than fish oil; either is acceptable.
The IOM RDA is 600 IU/day; the Endocrine Society recommends 1,500–2,000 IU/day for pregnant women. Most U.S. women enter pregnancy with insufficient 25(OH)D levels. Check baseline levels and supplement to a target of 30–50 ng/mL.
The pregnancy RDA is 1,000 mg/day, but calcium and iron compete for absorption, so prenatals typically provide 200–300 mg with the expectation that most calcium will come from food. If you don't consume dairy, fortified plant milks, or cooked greens daily, take a separate calcium supplement at a different time of day.
Pre-formed vitamin A (retinol or retinyl palmitate) above 10,000 IU/day is teratogenic. Look for vitamin A as beta-carotene only, or as retinol below 5,000 IU. This is a non-negotiable safety check — high-dose retinol multivitamins should never be taken in early pregnancy.
Herbal additions in prenatals (e.g., chasteberry, red raspberry leaf, ginger) are not evidence-based and the safety of most botanicals in pregnancy is poorly characterized. Choose a prenatal without herbal additions and add ginger only as needed for nausea.
Reviewed against 7 peer-reviewed sources.
The fatty-acid composition of breastmilk is among the most diet-dependent variables in human nutrition. Most macronutrients in breastmilk — protein, lactose, total fat — remain remarkably stable even when the mother's intake varies. DHA is the exception. Maternal DHA intake directly determines breastmilk DHA content within 2–3 days, and breastmilk DHA in turn determines what reaches the infant brain during its highest period of structural growth.
A 2007 systematic review by Brenna and colleagues compiled DHA content from 65 breastmilk studies across 30 countries. The range was striking: 0.06% of total fatty acids in some U.S. and Canadian samples, more than 1.4% in coastal Japan and the Faroe Islands. The single best predictor was the mother's seafood intake. Where DHA-rich fish are not staple foods, breastmilk DHA falls to roughly one-fifth of what populations with fish-heavy diets deliver.
DHA accounts for about 30% of the structural fatty acids in the cerebral cortex and 50% in the retina. Synthesis from the parent fatty acid alpha-linolenic acid (ALA, found in flax and walnut) is inefficient in humans — less than 8% conversion to EPA and less than 4% to DHA in adult women, and even lower in men. Pregnancy and lactation are periods of high demand that the conversion pathway cannot reliably meet without dietary input.
Multiple RCTs have shown that DHA supplementation at 200–1,000 mg/day during lactation raises breastmilk DHA proportionally. The DIAMOND trial (Birch 2010, American Journal of Clinical Nutrition) compared infant formulas with and without DHA/ARA enrichment and found benefits to visual acuity at 12 months in supplemented infants — an outcome that maternal supplementation can replicate in breastfed infants by raising milk DHA. The 2018 Cochrane review by Middleton (relevant to pregnancy outcomes) found 11–42% reductions in preterm birth with maternal omega-3 supplementation.
The FAO and ACOG recommend at least 200 mg/day DHA during pregnancy and lactation. Two servings (8–12 oz) of low-mercury fatty fish per week (salmon, sardines, herring, anchovies, trout) approximate this. For mothers who do not eat fish, algal DHA supplements at 200–300 mg/day raise breastmilk DHA to comparable levels without mercury concern.
The FDA/EPA "Advice About Eating Fish" (last updated 2024) recommends 2–3 servings per week of "Best Choices" fish for pregnant and breastfeeding women. The "Best Choices" list explicitly excludes king mackerel, marlin, orange roughy, shark, swordfish, tilefish (Gulf), and bigeye tuna because of mercury content. Salmon, sardines, herring, anchovies, Atlantic and Pacific mackerel (not king), trout, and farmed catfish are all "Best Choices" and high in DHA.
Cod-liver oil delivers DHA but also large amounts of pre-formed vitamin A (retinol). Daily cod-liver-oil supplementation in pregnancy has caused vitamin A toxicity. Use refined fish oil or algal oil; avoid cod-liver oil as a DHA source during pregnancy.
Reviewed against 6 peer-reviewed sources.
Selective eating — what most parents call "picky" — is developmentally normal between roughly 2 and 6 years of age. Estimates from longitudinal studies put the prevalence of picky eating at 14–50% in this age group depending on definition. Pediatric guidelines (AAP, ESPGHAN) do not recommend a multivitamin for typically developing children eating a varied diet. They do recommend one in specific clinical situations — and the line between "this child needs a multivitamin" and "this child needs reassurance and a feeding plan" is one of the most common questions in pediatric primary care.
Several large cross-sectional studies (Feeding Infants and Toddlers Study, FITS 2016; ALSPAC cohort UK) have found that picky eaters as a group do not differ significantly from non-picky eaters in total energy intake or weight-for-age. Where they do differ is in micronutrient diversity: lower intake of iron, zinc, fibre, vitamin E, and vitamin D is most consistently reported. Severe selective eating with persistent food refusal is a separate concern and warrants evaluation for ARFID (Avoidant/Restrictive Food Intake Disorder), feeding therapy referral, and laboratory work-up.
The AAP's pediatric nutrition handbook lists indications: children with chronic disease (cystic fibrosis, IBD, chronic kidney disease), children on restrictive elimination diets (e.g., for severe food allergy), children with developmental disabilities affecting feeding, and children whose dietary recall consistently fails to meet recommended intakes for multiple nutrients. Routine "insurance" multivitamins for healthy children eating a wide range of foods are explicitly not recommended.
If a multivitamin is appropriate, the goal is filling intake gaps without exceeding upper limits. Look for products that deliver close to the RDA for vitamin D (600 IU), zinc (3–5 mg for ages 1–3, 5 mg for 4–8), iron only if deficiency is documented (most pediatric multis omit iron deliberately because of overdose risk), B12 (especially for vegan kids), and iodine. Avoid products providing >100% RDA for vitamin A as retinol — chronic excess in children can cause hepatic toxicity and intracranial hypertension.
Gummy multivitamins are the most popular pediatric format and the worst by most criteria: high sugar, frequently underdosed compared to label, and treated like candy by children. A daily chewable tablet or a powder mixed into yogurt delivers more reliable doses with less sugar. If gummies are the only format a child will accept, they are still better than nothing for documented deficiency — but the goal is to phase to a non-gummy form once the child can tolerate it.
Iron is the leading cause of pediatric supplement-related death. Most pediatric multivitamins for ages 4+ are intentionally formulated without iron to reduce overdose risk. If iron supplementation is indicated, give it as a separate, clearly labelled product with a child-resistant cap, stored out of reach.
Reviewed against 5 peer-reviewed sources.
Few topics in prenatal nutrition generate more confusion than the folate vs folic acid vs methylfolate distinction. The basic facts are unambiguous: periconceptional folate supplementation reduces neural tube defects (NTDs) by 50–70%. The newer wrinkle is the MTHFR genotype question, where social-media advice has run far ahead of the genetics evidence.
Folic acid is the synthetic, oxidized form added to fortified flour and most prenatals. It is converted in the liver to dihydrofolate, then tetrahydrofolate, then 5-methyltetrahydrofolate (5-MTHF), the active circulating form. Folate is the umbrella term for the family of compounds and includes naturally occurring food folates (mostly in leafy greens, legumes, citrus). Methylfolate (5-MTHF, sold as Metafolin or Quatrefolic) is the supplemental form that bypasses the conversion steps.
The most-studied MTHFR variant, C677T, reduces the activity of the methylenetetrahydrofolate reductase enzyme. Heterozygotes (CT) have ~65% activity, homozygotes (TT) ~30%. About 10–15% of people of European ancestry and up to 25% of people of Hispanic ancestry are TT. The variant is associated with mildly elevated homocysteine and a small increase in NTD risk in offspring — but the practical implication is smaller than the marketing suggests.
The 1991 MRC Vitamin Study and the Czech double-blind 1992 trial established that 4 mg/day folic acid prevents recurrent NTDs (relative risk 0.28). Subsequent studies confirmed that 400–800 mcg/day folic acid prevents first-occurrence NTDs in the general population. These trials used folic acid, not 5-MTHF, and were conducted across populations with the full range of MTHFR genotypes. The protective effect held.
Head-to-head trials of folic acid vs 5-MTHF have shown comparable increases in red blood cell folate. The Lamers 2006 trial in the American Journal of Clinical Nutrition found that 5-MTHF raised RBC folate slightly more efficiently per dose unit, particularly in TT homozygotes. There are no NTD-prevention trials showing 5-MTHF outperforms folic acid because the necessary trial size makes such studies impractical.
For most women planning pregnancy, 400–800 mcg/day of either folic acid or 5-MTHF is appropriate, beginning at least one month before conception and continuing through the first trimester. Women with a personal or family history of NTDs should receive 4 mg/day under medical supervision. Women known to be MTHFR TT homozygous can reasonably choose 5-MTHF, but the absolute clinical benefit over folic acid is small and unproven for NTD prevention.
Direct-to-consumer MTHFR testing has driven anxiety far beyond what the evidence supports. The American College of Medical Genetics (ACMG) explicitly recommends against routine MTHFR genotyping in the workup of recurrent pregnancy loss, thrombophilia, or general preconception care. The variant is too common and the clinical implications too modest to justify population-wide testing. Women whose providers have tested them and reported a TT result should still take folate — in either form — periconceptionally.
Since 1998, the U.S. has required folic acid fortification of enriched grain products. NTD rates fell 23–28% within years of the mandate. Women trying to avoid synthetic folic acid by eating only unfortified flour need to be much more deliberate about leafy greens and supplementation — the cushion that fortification provides is meaningful.
Reviewed against 7 peer-reviewed sources.
If pediatric probiotics have a poster child, it is Lactobacillus reuteri DSM 17938 for infant colic. Multiple randomized controlled trials, individual patient data meta-analyses, and a 2018 Cochrane review now support its use specifically in breastfed infants with colic, and the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Working Group on Probiotics has issued a conditional recommendation in support. The evidence is unusual in pediatric supplements: well-defined strain, consistent dose, replicated benefit, and a tractable safety profile.
The Wessel "rule of threes" defines colic as crying for >3 hours/day, >3 days/week, for >3 weeks in an otherwise healthy infant. Roman IV criteria simplify to "rule of fives" for diagnostic purposes. Colic affects 10–25% of infants and resolves spontaneously by 3–4 months in nearly all cases — meaning any colic intervention has a high placebo response and a built-in regression to the mean.
The first signal came from Savino 2007 (Pediatrics): 90 breastfed colicky infants randomized to L. reuteri DSM 17938 (10^8 CFU/day) or simethicone for 28 days; the probiotic group had reductions in daily crying time of 95 minutes vs 7 minutes for simethicone. Replication came from Indrio 2014 (JAMA Pediatrics) and Savino 2018, both showing similar effect sizes in breastfed infants. Sung 2014 (BMJ), an Australian trial, did not replicate the benefit and crucially included formula-fed infants. The 2018 Sung individual-patient-data meta-analysis pooled 345 infants from four RCTs and found a clear benefit in breastfed infants (mean reduction 25 minutes/day, NNT ~8) and no clear benefit in formula-fed infants.
The reasons for the breastfed-vs-formula difference remain debated. Possibilities include differences in infant gut microbiome composition that allow L. reuteri to colonize more effectively in breastfed infants; the natural presence of L. reuteri in breastmilk; or an interaction with milk fat globule membrane components. ESPGHAN's recommendation is therefore restricted to breastfed colicky infants.
The trial dose is 10^8 CFU/day (5 drops of the most common commercial product) given once daily for at least 21 days. Effect, if any, is typically apparent by 3 weeks. Don't add it to hot bottles — lactobacilli are heat-sensitive. Most commercial preparations require refrigeration after opening.
Beyond colic, L. reuteri DSM 17938 has been studied in functional constipation (mixed results), infant regurgitation (some benefit on episodes per day), and prevention of necrotizing enterocolitis in preterm infants (the Cochrane review for NEC prevention favors a different strain combination). For the average breastfed colicky infant, this is the clearest pediatric probiotic indication on the books.
L. reuteri DSM 17938 has a long safety record in trials of preterm and term infants. Bacteremia from L. reuteri has been reported in immunocompromised neonates; the strain is not recommended in central-line patients, severely immunocompromised infants, or those with short-bowel syndrome. For healthy term breastfed infants with colic, the safety profile is excellent.
Reviewed against 6 peer-reviewed sources.
Walk down any U.S. drugstore vitamin aisle in cold-and-flu season and the children's section is dominated by gummies promising "immune support." Most combine some mix of vitamin C, zinc, elderberry, echinacea, and occasionally vitamin D. The marketing implies these gummies will keep children from getting sick, recover them faster when they do, or "boost" the immune system in some unspecified way. The pediatric evidence is thinner than the packaging suggests — in some cases, considerably thinner.
The 2013 Hemilä Cochrane review — the gold standard reference, with 29 trials and 11,306 participants — concluded that regular vitamin C supplementation does not prevent colds in the general population. It does shorten cold duration in children by about 14% (one less day per cold for kids on continuous prophylaxis). Starting vitamin C after symptoms begin shows no consistent benefit. The doses studied (200–1,000 mg/day) are higher than what most children's gummies provide.
The largest pediatric trial — Taylor 2003 in JAMA, 524 children with upper respiratory infections — found that Echinacea purpurea did not reduce duration or severity of symptoms versus placebo. It did increase the rate of rash by 7.1% vs 2.7% in the placebo group. Health Canada and the U.K.'s MHRA have advised against echinacea use in children under 12 because of allergic reaction concerns. The 2014 Cochrane review (Karsch-Volk) found echinacea "may have a weak benefit" in adult cold prevention but found insufficient evidence for treatment effects, and explicitly noted that pediatric data did not support pediatric use.
Adult trials of elderberry have suggested a 2–3 day reduction in cold and flu symptom duration. The single high-quality pediatric trial (Macknin 2020 in Clinical Infectious Diseases) randomized 87 children with influenza to elderberry syrup or placebo within 48 hours of symptom onset; the elderberry group showed no benefit and a possibly longer duration of symptoms. Elderberry products in children's gummies typically contain doses well below those used in adult trials. Raw elderberries, leaves, and bark contain cyanogenic glycosides and must not be eaten by children.
The Cochrane review of zinc for the common cold concluded that zinc lozenges started within 24 hours of symptom onset reduce cold duration in adults. The pediatric data are weaker; the 2015 update found insufficient evidence for routine zinc use in children for cold prevention or treatment. Critically, the lozenge form (allowing direct contact with throat tissue) is what shows benefit. Gummies that bypass mouth-and-throat contact via swallowing are unlikely to deliver the lozenge mechanism, and the gummy doses are typically below the 75 mg/day threshold cited in adult lozenge trials.
Hand washing, influenza vaccination, age-appropriate respiratory virus vaccines (RSV monoclonal for infants), avoidance of secondhand smoke, daycare hygiene policies, breastfeeding for the first six months, and adequate vitamin D status. None of these are immunity gummies. A child who is severely deficient in vitamin D, iron, or zinc will benefit from correcting that specific deficiency — but a "kitchen-sink" gummy is not how pediatricians correct documented deficiencies.
A typical "immunity" gummy contains 2–5 g of added sugar per serving. Two or three gummies per day in a child during cold season can deliver more added sugar than a small candy bar over a month. The American Heart Association recommends <25 g/day added sugar for children 2–18 and zero added sugar before age 2. Daily gummies push children meaningfully toward those limits with no demonstrated benefit.
Reviewed against 6 peer-reviewed sources.
Coaches, parents, and pediatricians have been warning teen athletes off creatine for two decades on the basis of largely speculative concerns — kidney damage, dehydration, growth-plate disruption. None of these concerns have held up in the published literature. The International Society of Sports Nutrition (ISSN), in its updated 2017 position stand, explicitly states that creatine monohydrate is safe and effective for adolescent athletes when used at standard doses with proper supervision. That doesn't mean every 14-year-old should be loading creatine, but it does mean that the categorical "no" most parents have been told overstates what the evidence shows.
The most-cited concern was kidney injury. Multiple studies in healthy adolescent and young adult athletes (Jagim 2018, Kreider 2017 ISSN review, Ostojic 2010) measuring serum creatinine, cystatin C, and glomerular filtration rate at standard creatine doses (3–5 g/day maintenance) have found no clinically meaningful changes in renal function. Serum creatinine itself does rise modestly — this is a measurement artifact (creatine is the precursor to creatinine), not a sign of kidney injury. Pediatric nephrology case reports of acute kidney injury attributed to creatine almost universally involve other contributing factors: pre-existing kidney disease, NSAID use, severe dehydration during summer training, or contaminated multi-ingredient products.
The "creatine causes cramps and dehydration" claim originated from anecdotal football-camp reports in the late 1990s. Controlled trials (Greenwood 2003 in Journal of Athletic Training; Lopez 2009) have consistently found no increased risk of cramps, heat illness, or dehydration in creatine-supplemented athletes vs controls. Some data suggest creatine slightly increases body water content, which is osmotically protective rather than dehydrating.
No randomized controlled trial has ever demonstrated impaired growth or pubertal development from creatine supplementation in adolescents. The longest pediatric studies are in clinical populations (Duchenne muscular dystrophy, mitochondrial disease) using doses similar to or higher than athletic doses for one to several years — none reported growth disruption.
The performance benefits in adolescents are similar in magnitude to those in adults: improvements in repeated high-intensity efforts, modest gains in lean mass with resistance training, and small improvements in strength. The benefit is modest enough that for a young athlete still developing technique, sport-specific training and adequate dietary protein matter more than creatine.
The AAP's 2005 Use of Performance-Enhancing Substances policy strongly discouraged creatine in athletes under 18, framing it as the "performance-enhancing substance" gateway. The 2023 update softened this, acknowledging the safety data but still recommending against routine use in pre-competition adolescents because the modest performance gains do not justify potential cultural normalization of supplementation. The current ISSN position and AAP position therefore disagree on policy while broadly agreeing on safety.
Use creatine monohydrate — the only form with a robust safety record. Skip the loading phase; 3–5 g/day is sufficient. Hydrate adequately. Use NSF Certified for Sport or Informed-Sport tested products to avoid contamination with banned substances or other ingredients. Avoid multi-ingredient pre-workouts containing creatine, caffeine, and stimulant blends — the creatine itself is not the safety concern in those products.
Reviewed against 6 peer-reviewed sources.
Ashwagandha (Withania somnifera) is one of the fastest-growing supplement categories of the 2020s, and pediatric versions — gummies, syrups, "calm kids" formulas — have followed the adult market into U.S. retail. The marketing pitches stress relief and improved sleep for anxious children. The clinical literature in children, however, is so thin that the most accurate description is: there is essentially no pediatric evidence base.
Adult trials of standardized ashwagandha extracts (KSM-66 and Shoden are the most common) have shown reductions in self-reported stress and salivary cortisol vs placebo, with effect sizes that have varied considerably across replication. Sleep onset latency reductions of 10–20 minutes have been reported in some adult trials. The adult evidence is best characterized as "promising for stress and sleep, but smaller than the marketing implies." None of this evidence directly transfers to pediatric populations.
A PubMed search through April 2026 returns only a handful of pediatric ashwagandha studies. The most-cited is Choudhary 2017, an open-label study in 30 children aged 8–14 with deficient memory and concentration. The trial used 250 mg twice daily for 4 months and reported improvements in attention scores. It was not placebo-controlled, was small, and was sponsored by the extract manufacturer. There is no published RCT of ashwagandha for childhood anxiety.
Adult-to-pediatric extrapolation works in narrow circumstances: well-characterized pharmacokinetics, established safety profile, and a similar disease mechanism. Ashwagandha has none of these in children. The herb's main bioactives (withanolides) have not had pediatric pharmacokinetic studies. Long-term safety data in growing humans does not exist. Ashwagandha modulates the hypothalamic-pituitary-adrenal axis — the same axis that drives pubertal development — and the consequences of long-term modulation in adolescents are unstudied.
Multiple case reports and the 2018 Sharma trial have shown that ashwagandha increases thyroid hormone levels (T3, T4) and can shift subclinical hypothyroid patients into normal range. This is potentially useful in adults with subclinical hypothyroidism, but in children the same effect can produce iatrogenic hyperthyroidism, especially in adolescent girls who already have a higher background rate of thyroid disease. There are no pediatric trials measuring thyroid impact.
The U.S. Drug-Induced Liver Injury Network has reported a small but increasing series of ashwagandha hepatotoxicity cases in adults, mostly in 2019–2024. The American College of Gastroenterology now lists ashwagandha among herbal supplements associated with idiosyncratic liver injury. There are isolated pediatric case reports but no incidence data — a child's smaller body mass and developing liver may amplify rather than reduce this signal.
Pediatric anxiety has effective interventions: cognitive-behavioral therapy is first-line, with SSRIs and exposure therapy as established second-line options. Sleep hygiene, family-based interventions, and treatment of anxiety disorders are evidence-based. Ashwagandha for an anxious child is, in 2026, an unknown intervention substituting for known ones. There is no responsible evidence-based recommendation for it in this population.
Reviewed against 5 peer-reviewed sources.
Children's "detox" and "cleanse" supplements occupy one of the more troubling corners of the pediatric wellness market. Marketed for everything from autism to ADHD to "heavy-metal removal," these products typically combine binders (zeolite, activated charcoal, bentonite clay), chelators (cilantro extract, chlorella, EDTA derivatives), and assorted herbs. The premises behind them range from unsupported to dangerous. The American College of Medical Toxicology and the American Academy of Clinical Toxicology have issued explicit warnings against unsupervised pediatric chelation, and at least one child has died.
The shared marketing claim is that modern children carry a "toxic burden" of heavy metals, pesticides, glyphosate, vaccine ingredients, mold mycotoxins, or other contaminants that the body cannot eliminate without help. The wellness vocabulary then promises that the supplement will "pull" these toxins out, restoring health, behavior, focus, or immune function. None of this maps to clinical toxicology. The body's elimination systems — liver, kidneys, gut, lungs — do the actual work of removing endogenous waste and most xenobiotics. Healthy children do not have a "toxic burden" requiring removal.
In 2005, a 5-year-old autistic child died in a Pennsylvania physician's office during an IV chelation infusion. The chelating agent (disodium EDTA) caused severe hypocalcemia and cardiac arrest. The case is the most cited example of why off-label chelation in children is dangerous. The U.S. FDA subsequently issued warnings against over-the-counter chelating products, and several states have prosecuted practitioners offering chelation for autism.
Activated charcoal is a legitimate emergency-medicine treatment for certain acute oral poisonings, given in the hospital under specific timing and clinical criteria. As a daily "detox" supplement for children, it does no good and creates real harms: it adsorbs medications (including pediatric maintenance medications and contraceptives in adolescents), reduces nutrient absorption, and can cause constipation severe enough to require hospital care. Bentonite clay products marketed for children have caused lead poisoning — the U.S. FDA has issued specific warnings about clay products contaminated with lead.
A specific subset of "detox" products is marketed to parents of autistic children, often paired with the false claim that vaccines or environmental toxins caused the autism. These products waste family resources, delay evidence-based intervention (applied behavior analysis, speech therapy, occupational therapy, psychiatric care for co-morbid anxiety), and have no demonstrated effect on autism symptoms. The 2010 Cochrane review of chelation for autism found no benefit and significant safety concerns.
Children with confirmed elevated blood lead levels, mercury exposure, or other heavy-metal poisoning are managed by pediatric toxicologists or specialized clinics, not by supplement-store products. Treatment, when indicated, uses specific prescription chelators (succimer, dimercaprol, calcium-EDTA) under hospital supervision. The clinical decision is made on blood levels and symptoms; the agent is matched to the metal; the chelation is given with intensive monitoring.
If you are concerned your child has been exposed to lead (older home, well water, certain imported pottery, certain folk remedies), ask your pediatrician for a blood lead test. If concerned about mercury, the FDA fish advisories tell you which species to limit. If concerned about pesticide exposure, washing produce removes most surface residues. None of these legitimate concerns is addressed by a "detox" gummy.
Reviewed against 6 peer-reviewed sources.
Pediatric "greens powders" are an extension of a successful adult wellness category. The pitch is straightforward: your child won't eat broccoli, but they'll drink a fruity-flavored shake that supposedly delivers servings of greens, fruits, vegetables, "superfoods," probiotics, and digestive enzymes in a single scoop. The supporting evidence ranges from thin to nonexistent, and the practical effect — replacing actual produce with a flavored powder — is the opposite of building lifelong eating habits.
A typical 6–8 g pediatric greens scoop contains a "proprietary blend" of 30+ ingredients. The total weight constraint matters: 8 g divided across 30 ingredients leaves trace amounts of most. A serving of broccoli is about 90 g. The "broccoli powder" in a greens scoop is at most a few hundred milligrams, with a fraction of that being intact phytonutrients after spray-drying. There is no plausible biochemical pathway by which 100 mg of dehydrated broccoli powder delivers the nutritional value of a half-cup of fresh broccoli.
Most of the vitamins and minerals in a pediatric greens powder come from a synthetic vitamin premix similar to what is in a multivitamin. This is the part that meaningfully delivers nutrients. The "10 servings of greens" claim is essentially marketing built around a multivitamin core. A multivitamin tablet, taken with actual food, achieves the same nutritional outcome at a fraction of the cost.
To make a kale-spirulina-spinach blend palatable to children, manufacturers add fruit powders, monk fruit or stevia, and "natural flavors" (a regulatory term that allows nearly any flavoring derived from a plant or animal source, with no disclosure obligation). Some pediatric greens powders contain 4–8 g of added sugar per serving. This is not a nutritional improvement over a piece of fruit.
Probiotic content is usually in the 1–5 billion CFU range, with strain identification missing or vague (e.g., "Lactobacillus blend"). Pediatric probiotic evidence is strain-specific (see L. reuteri DSM 17938 for colic, S. boulardii and L. rhamnosus GG for antibiotic-associated diarrhea); a generic "Lactobacillus blend" cannot be meaningfully linked to any clinical evidence. Digestive enzyme content is similarly small and undocumented for pediatric use.
Greens-powder ingredients commonly include cereal grasses, algae (chlorella, spirulina), and kelp. These are well-documented bioaccumulators of heavy metals. The Clean Label Project's 2018 plant-protein report and follow-up testing have repeatedly found greens powders with detectable lead, cadmium, and arsenic. The doses per scoop are below acute toxicity thresholds but, when added to the daily exposure profile of growing children whose blood-brain barrier is still maturing, are not nutritionally trivial.
Repeated exposure (10–15 neutral exposures to a new food before children typically accept it), modeling by parents and siblings, age-appropriate cooking participation, and removal of the "clean plate" pressure are the evidence-based feeding strategies. None of these is replaced by a powder. If a child has documented nutrient deficiencies, a targeted multivitamin is a more transparent and cheaper solution than a greens product.
Reviewed against 5 peer-reviewed sources.
For three decades, iron has been the single most lethal supplement on U.S. household shelves to children under six. Between 1983 and 1991, the CDC documented at least 38 pediatric deaths from iron-supplement ingestion — a remarkable concentration of fatalities for a class of products marketed as "natural." The introduction of unit-dose blister packaging in 1997 reduced fatalities sharply but did not eliminate them, and the rise of high-dose iron pills marketed for adult deficiency, women's prenatal use, and "energy" has put dangerous quantities back within easy reach of small children.
Iron toxicity follows a predictable four-stage pattern. Stage 1 (0–6 hours): GI corrosive injury — vomiting, diarrhea, abdominal pain, hematemesis. Stage 2 (6–24 hours): apparent improvement, sometimes called the "honeymoon" phase, that masks ongoing systemic absorption. Stage 3 (24–72 hours): metabolic acidosis, multi-organ failure, shock. Stage 4 (2–6 weeks): late gastric outlet obstruction from corrosive scarring. Doses above 60 mg/kg of elemental iron are routinely fatal without treatment; doses above 20 mg/kg cause significant systemic toxicity.
A 12-kilogram toddler reaches the 20 mg/kg threshold at 240 mg of elemental iron — roughly four standard 65 mg ferrous sulfate tablets, or three of the higher-dose 90–105 mg adult iron pills. A bottle of 100 prenatal pills contains enough iron to kill several toddlers. The median fatal pediatric ingestion in the literature is 5–10 adult tablets.
Iron gummies marketed for children are typically formulated at 10–18 mg per gummy — lower than adult doses, but a child who swallows half a bottle (50 gummies at 18 mg = 900 mg elemental iron) crosses the lethal threshold for a 12-kg child. The candy-like form makes accidental large ingestions more likely, not less.
Treat every iron product as a poison: child-resistant cap on every bottle, original packaging, locked or out-of-reach storage, never in a kitchen counter pillbox. If ingestion is suspected, call Poison Control immediately (1-800-222-1222 in the U.S.; 911 if symptomatic). Do not induce vomiting; do not give activated charcoal at home (charcoal does not bind iron). Bring the bottle and any remaining tablets to the ED.
Emergency management of confirmed pediatric iron toxicity involves serum iron levels (peak at 4–6 hours post-ingestion), abdominal radiograph (iron tablets are often radiopaque and can guide whole-bowel irrigation), and IV deferoxamine chelation for severe cases. Survival is good with prompt recognition; the deaths in the historical record almost universally involved delayed presentation or unwitnessed ingestion.
In 1997, the FDA mandated unit-dose blister packaging for all iron products containing more than 30 mg per dosage unit. The rule was overturned by court ruling in 2003 on procedural grounds and has not been re-issued. Many high-dose iron supplements are now back in bulk-bottle form. Parents should not assume that "child-resistant" caps prevent toddler access — AAP-cited toddler-defeat rates for child-resistant closures are around 15%.
Many of the documented pediatric iron deaths involved iron prescribed for the mother's pregnancy or postpartum anemia, kept in a bedside cabinet. Pediatricians counseling women on iron supplementation should explicitly discuss storage, particularly when there are toddlers in the household.
Reviewed against 9 peer-reviewed/regulatory sources.
U.S. pediatric melatonin ingestions reported to poison control centers increased 530% between 2012 and 2021, becoming the most common substance reported for unintentional pediatric ingestion in 2020. The CDC's 2022 MMWR report attributed the rise to the explosion of melatonin gummies, the deregulated supply chain, and the use of melatonin as a routine sleep aid in children. Two pediatric deaths and 287 ICU admissions over the study period reframed melatonin as a substance that warrants the same household-storage seriousness as adult medication.
Lelak et al. analyzed 260,435 pediatric melatonin ingestions reported to U.S. poison centers from 2012 to 2021. Annual reports rose from 8,337 in 2012 to 52,563 in 2021. Children under five accounted for the majority. Of all reported cases, 27,795 required healthcare evaluation, 4,097 were hospitalized, 287 required ICU admission, and 2 children died (both with co-ingestants). The vast majority were unintentional ingestions of products kept in accessible household locations.
Melatonin moved from niche supplement to mass-market gummy in the late 2010s. By 2022, the U.S. melatonin gummy market had grown to over $300 million annually, with much of the volume sold for children. The 2022 Cohen study in JAMA tested 25 brands of melatonin gummies and found that 22 of 25 products had melatonin content that diverged from the label by >10%. Some products contained up to 347% of the labeled dose. One product labeled as melatonin contained no melatonin and instead delivered cannabidiol (CBD).
The pediatric "physiological" dose for sleep onset is 0.1–0.3 mg, the "pharmacologic" dose 1–3 mg, and "high" pediatric doses 3–5 mg. Most U.S. pediatric melatonin gummies are formulated at 1–5 mg per gummy. A 5-mg gummy is already a pharmacologic dose; a child who eats half a 60-gummy bottle has ingested 150 mg, well above any therapeutic range. Acute toxicity manifests as profound sedation, hypotension, hypothermia, GI upset, and rarely seizures.
The data on chronic melatonin use in children are limited. Concerns include theoretical effects on pubertal development (melatonin is involved in HPG axis regulation), tolerance with chronic use, and dependency on an external sleep cue rather than sleep-hygiene establishment. The American Academy of Sleep Medicine and the AAP both recommend that pediatric melatonin be used short-term and only after sleep hygiene interventions have failed, with pediatric input.
For most pediatric sleep problems, behavioral interventions outperform melatonin: consistent bedtimes, removal of screens 60–90 minutes before bed, dim ambient light in the hour before sleep, age-appropriate sleep durations, treatment of underlying sleep-disordered breathing (snoring, OSA). Children with autism spectrum disorder and certain neurodevelopmental conditions have the strongest evidence base for melatonin use; healthy children with garden-variety sleep resistance do not.
Treat melatonin gummies as a medication. Store in original container with child-resistant cap, in a locked or out-of-reach location, never in a bedside drawer or kitchen counter pillbox. Dispose of expired or unwanted product through a drug take-back program. If a child ingests an unknown quantity, call Poison Control (1-800-222-1222); most asymptomatic ingestions can be observed at home, but symptomatic children need ED evaluation.
In Canada, the U.K., the E.U., Australia, and Japan, melatonin is prescription-only or strictly regulated as a medication. In the U.S., it remains a dietary supplement. Multiple petitions to the FDA have requested at minimum childproof packaging, dose-labelling accuracy, and a maximum per-unit dose. As of 2026, no such regulations have been enacted.
Reviewed against 9 peer-reviewed/regulatory sources.
The 2023–2024 cinnamon-applesauce-pouch lead-poisoning outbreak was a watershed for U.S. pediatric food and supplement safety. Between October 2023 and early 2024, the CDC recorded over 500 confirmed and probable lead-exposure cases in children under six linked to lead-adulterated cinnamon in three pouch brands (WanaBana, Schnucks, Weis). Blood lead levels in some affected children reached >100 µg/dL — medical emergencies. The episode triggered FDA enforcement actions, congressional inquiry, and renewed scrutiny of how heavy metals reach children's foods and supplements.
FDA inquiry traced the lead source to deliberate adulteration of cinnamon at a single Ecuadorian processor — lead chromate added to cinnamon as a yellow-orange colorant and weight bulker, likely for fraud rather than accident. The contaminated cinnamon contained roughly 5,110 ppm lead (5.11% by weight). Each affected pouch delivered approximately 100× the FDA's interim reference level for lead in similar foods. The recall was issued November 2023 and subsequently expanded; the FDA suspended import of the implicated cinnamon source in early 2024.
Children absorb 40–70% of ingested lead vs ~10% in adults. Lead crosses the developing blood-brain barrier and competes with calcium for cellular machinery. There is no known safe lead exposure level in children. The CDC defines blood lead reference value at 3.5 µg/dL, with action recommended above 5 µg/dL. Permanent IQ reduction, learning disabilities, attention problems, and behavioral issues have been documented at chronic exposures previously considered subclinical.
The Clean Label Project's 2018 report found detectable lead in 100% of 15 best-selling children's vitamins tested, with 7 products exceeding the California Proposition 65 reproductive harm warning threshold (0.5 µg/day). Re-testing in 2024–2025 found that the picture has improved modestly but lead remains detectable in many pediatric vitamins, particularly those formulated with herb-derived ingredients (spirulina, chlorella, kelp).
The FDA's "Closer to Zero" initiative (2021–ongoing) targets reductions in lead, arsenic, cadmium, and mercury in foods commonly consumed by children. Interim action levels for lead in apple juice (10 ppb), grain-based snacks for infants and toddlers (20 ppb), root vegetables (10 ppb), and other foods were proposed in 2024. The agency has not, as of 2026, set similar enforceable limits for dietary supplements marketed to children.
For pediatric supplements, two third-party verification programs explicitly test for heavy metals: USP Verified Mark and NSF Certified for Sport (which is athlete-focused but has tighter contamination standards than most general programs). Products carrying these marks have demonstrated heavy-metal levels below set thresholds. The marks do not guarantee zero lead but represent a substantial filter compared to unverified products.
Skip pediatric supplements containing greens, algae, kelp, or "superfood" blends unless the brand publishes batch-level heavy-metal testing. Avoid imported folk remedies, traditional ceremonial powders, and imported pottery or glazed cookware (older lead-glazed ware is a documented exposure source). For children with known exposure or housing-age risk factors (homes built before 1978), request a blood lead level test from the pediatrician at age 1 and age 2; many states require it for Medicaid-enrolled children.
If your child consumed a recalled product, contact the pediatrician for a blood lead test even if symptom-free. Lead poisoning can be silent for months. The FDA recall page for cinnamon-applesauce pouches remains active for parents who need to identify lot numbers from products purchased in 2023–2024.
Reviewed against 9 peer-reviewed/regulatory sources.
Pregnancy is the period of human life with the highest stakes for a supplement-safety conversation, yet population data consistently show 20–60% of pregnant women use at least one herbal product. Many do so under the assumption that "natural" implies safe in pregnancy. The pharmacologic reality is that most herbal supplements have not been formally tested in pregnant women, several have well-documented teratogenic, abortifacient, or pre-term-labor-inducing effects, and U.S. supplement labeling does not require pregnancy warnings. This is the don't-take list and the why behind it.
Several herbs have either firm clinical evidence of harm in pregnancy or strong pharmacologic plausibility supported by case reports. Pennyroyal: hepatotoxic and abortifacient; deaths recorded. Black cohosh: stimulates uterine contractility; not for pregnancy except in some labor-induction protocols at term under midwifery supervision. Blue cohosh: cardiotoxic to fetus; multiple reports of newborn cardiac injury after late-pregnancy use. Pleurisy root: cardiac glycoside content. Comfrey: pyrrolizidine alkaloids cause hepatic veno-occlusive disease; not for any oral use, pregnant or not. Ephedra/Ma Huang: vasoconstrictive and stimulant; banned by FDA but still encountered in imported products. Yohimbe: cardiac and CNS effects; no pregnancy safety data. Saw palmetto: anti-androgenic; theoretical concern for male fetal development. Goldenseal: contains berberine, which displaces bilirubin from albumin and may cause neonatal jaundice or kernicterus.
St. John's Wort: serotonergic effects, drug interactions; limited human pregnancy data. Kava: hepatotoxic in adults; no pregnancy data; CDC has issued advisories. Ashwagandha: traditional use as an abortifacient in some Ayurvedic texts; modulates HPA axis; not safety-tested in pregnancy. Tribulus: animal data suggest teratogenicity. Dong quai: emmenagogue traditionally used to induce menstruation; abortifacient potential. Feverfew: traditionally used to expel placenta; emmenagogue properties. Senna at high doses: uterine stimulant; the AAP previously advised against repeat use in pregnancy though acceptable as occasional short-term laxative. Aloe vera oral: cathartic and uterine stimulant.
A small number of herbs have either reasonable safety data or long-tradition pregnancy use without documented harm. Ginger: ACOG-endorsed for pregnancy nausea at ~1 g/day. Cranberry: limited pregnancy data; appears safe at standard urinary-tract supplement doses. Red raspberry leaf: traditionally used in late pregnancy; small RCTs show no harm but no clear benefit either. Peppermint tea: standard culinary doses appear safe. Chamomile tea: standard dietary doses appear safe; concentrated extracts are not well-studied. Garlic: standard culinary doses safe; high-dose supplements may have antiplatelet effects.
Pregnant women are systematically excluded from the clinical trials that establish supplement safety. The FDA's pregnancy-labeling rule (PLLR) does not apply to dietary supplements. The result is that supplement labels often carry no pregnancy warning even for ingredients with strong contraindications. The American College of Obstetricians and Gynecologists, the National Center for Complementary and Integrative Health (NCCIH), and the LactMed database remain the most reliable resources; but for many herbs, the most accurate clinical statement is "we do not know."
Disclose all supplement use to your obstetric provider at every visit. Bring the actual bottles to the first prenatal appointment. The first trimester is the highest-risk window for organogenesis but no period of pregnancy is risk-free for unstudied compounds.
Many over-the-counter pregnancy and "fertility" supplements combine 10+ ingredients including herbs not on standard pregnancy-safety lists. Reading the full ingredient panel matters — "calming blend" or "sleep support" formulations frequently include ashwagandha, chamomile concentrate, valerian, kava, or skullcap, several of which fall in the avoid columns above.
Reviewed against 10 peer-reviewed/regulatory sources.
Adolescent emergency-department visits attributed to dietary supplement use rose sharply through the 2010s, with disproportionate harm concentrated in two product categories: weight-loss/fat-burner supplements (predominantly used by teenage girls) and stimulant-loaded pre-workout supplements (predominantly used by teenage boys). A 2017 study by Or et al. in the Journal of Adolescent Health found that adolescents using these categories were at meaningfully elevated risk of severe medical events. Consumer Reports, the FDA, and pediatric professional societies have issued repeated warnings; the supply side has continued to grow.
Adult pre-workout products typically combine caffeine (150–400 mg/serving), beta-alanine, citrulline, and varying mixes of "stimulant" or "nootropic" compounds. Doses sized for 200-pound adult lifters can be problematic when consumed by 130-pound 16-year-olds, and label warnings against use under 18 are routinely ignored. Cases of cardiac arrhythmia, hypertension, vomiting, syncope, and rhabdomyolysis in adolescents using pre-workouts are reported in the pediatric emergency-medicine literature.
Yohimbine in fat-burner products has been associated with ED visits for tachycardia, severe anxiety, and hypertensive crisis, particularly in adolescents with underlying anxiety disorders. Synephrine (bitter orange) is the most common ephedra replacement and has been implicated in cardiovascular events when stacked with caffeine. DMAA (1,3-dimethylamylamine) was banned by the FDA in 2013 after multiple deaths in U.S. military personnel; it nonetheless reappears in imported pre-workouts. DMHA (octodrine) followed a similar trajectory. Kratom, marketed for "energy" or "focus," carries opioid-receptor activity and addiction potential; pediatric exposures rose sharply through the early 2020s.
The Harvard School of Public Health's Strategic Training Initiative for the Prevention of Eating Disorders (STRIPED) has documented that adolescents using diet pills, laxatives, or diuretics for weight control are at elevated risk of subsequent eating-disorder diagnosis. A 2019 prospective cohort published in American Journal of Public Health found that adolescent girls using weight-loss supplements were over five times more likely to receive an eating-disorder diagnosis within three years. The supplements function both as a precursor to and an enabler of disordered eating. Several U.S. states (New York, California, Massachusetts) have considered or passed legislation restricting sales of weight-loss supplements to minors.
"Detox tea" and "skinny tea" products marketed to adolescent girls typically contain senna, cascara, or other stimulant laxatives, often without prominent labeling. Repeated use causes electrolyte abnormalities, dehydration, and dependence. Hospitalization for hypokalemia in teenage girls following these products has been documented in case series.
The FDA's Tainted Products Marketed as Dietary Supplements database lists thousands of products spiked with prescription pharmaceuticals: sibutramine (a withdrawn weight-loss drug), phenolphthalein (a withdrawn stimulant laxative), sildenafil and tadalafil (in "male enhancement" products that adolescents access), DNP (a discontinued industrial uncoupler causing fatal hyperthermia), and various designer steroids in muscle-building supplements. Adolescents purchasing these products through Amazon, eBay, or convenience-store outlets cannot reliably identify which are adulterated.
The AAP recommends that pediatricians screen for supplement use in adolescent annual visits, particularly inquiring about pre-workouts, weight-loss aids, and "energy" products. The conversation should be non-judgmental but explicit about the lack of regulatory oversight, frequency of contamination, and the specific risks (cardiac, eating-disorder pipeline) associated with these categories.
Audit the household supplement shelf with adolescents present and explicit about why specific products are being removed. Discuss what is being sold to them at gym counters, on TikTok, and at convenience stores. If your teen has been using a product and is symptomatic (palpitations, vomiting, dizziness, mood changes), preserve the bottle and seek medical evaluation. Most ED encounters resolve with supportive care; some, particularly DNP and certain DMAA exposures, do not.
Reviewed against 9 peer-reviewed/regulatory sources.
SupplementScore is a community effort. Clinicians, researchers, and developers make our data better every day — corrections, new evidence, or partnership all welcome.
Found something wrong? Tell us what's off and link a source — we triage every submission with a citation.